
<html lang="en"     class="pb-page"  data-request-id="b4f093f1-03a1-454f-9c3d-5a1151cb0c4b"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;article:article:10.1021/acs.jmedchem.0c01170;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;issue:issue:10.1021/jmcmar.2020.63.issue-22"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Identification of TNO155, an Allosteric SHP2 Inhibitor for the Treatment of Cancer" /></meta><meta name="dc.Creator" content="Matthew J.  LaMarche" /></meta><meta name="dc.Creator" content="Michael  Acker" /></meta><meta name="dc.Creator" content="Andreea  Argintaru" /></meta><meta name="dc.Creator" content="Daniel  Bauer" /></meta><meta name="dc.Creator" content="Julie  Boisclair" /></meta><meta name="dc.Creator" content="Homan  Chan" /></meta><meta name="dc.Creator" content="Christine Hiu-Tung  Chen" /></meta><meta name="dc.Creator" content="Ying-Nan  Chen" /></meta><meta name="dc.Creator" content="Zhouliang  Chen" /></meta><meta name="dc.Creator" content="Zhan  Deng" /></meta><meta name="dc.Creator" content="Michael  Dore" /></meta><meta name="dc.Creator" content="David  Dunstan" /></meta><meta name="dc.Creator" content="Jianmei  Fan" /></meta><meta name="dc.Creator" content="Peter  Fekkes" /></meta><meta name="dc.Creator" content="Brant  Firestone" /></meta><meta name="dc.Creator" content="Michelle  Fodor" /></meta><meta name="dc.Creator" content="Jorge  Garcia-Fortanet" /></meta><meta name="dc.Creator" content="Pascal D.  Fortin" /></meta><meta name="dc.Creator" content="Cary  Fridrich" /></meta><meta name="dc.Creator" content="John  Giraldes" /></meta><meta name="dc.Creator" content="Meir  Glick" /></meta><meta name="dc.Creator" content="Denise  Grunenfelder" /></meta><meta name="dc.Creator" content="Huia-Xiang  Hao" /></meta><meta name="dc.Creator" content="Martin  Hentemann" /></meta><meta name="dc.Creator" content="Samuel  Ho" /></meta><meta name="dc.Creator" content="Andriana  Jouk" /></meta><meta name="dc.Creator" content="Zhao B.  Kang" /></meta><meta name="dc.Creator" content="Rajesh  Karki" /></meta><meta name="dc.Creator" content="Mitsunori  Kato" /></meta><meta name="dc.Creator" content="Nick  Keen" /></meta><meta name="dc.Creator" content="Robert  Koenig" /></meta><meta name="dc.Creator" content="Laura R.  LaBonte" /></meta><meta name="dc.Creator" content="Jay  Larrow" /></meta><meta name="dc.Creator" content="Gang  Liu" /></meta><meta name="dc.Creator" content="Shumei  Liu" /></meta><meta name="dc.Creator" content="Dyuti  Majumdar" /></meta><meta name="dc.Creator" content="Simon  Mathieu" /></meta><meta name="dc.Creator" content="Matthew J.  Meyer" /></meta><meta name="dc.Creator" content="Morvarid  Mohseni" /></meta><meta name="dc.Creator" content="Rukundo  Ntaganda" /></meta><meta name="dc.Creator" content="Mark  Palermo" /></meta><meta name="dc.Creator" content="Lawrence  Perez" /></meta><meta name="dc.Creator" content="Minying  Pu" /></meta><meta name="dc.Creator" content="Timothy  Ramsey" /></meta><meta name="dc.Creator" content="John  Reilly" /></meta><meta name="dc.Creator" content="Patrick  Sarver" /></meta><meta name="dc.Creator" content="William R.  Sellers" /></meta><meta name="dc.Creator" content="Martin  Sendzik" /></meta><meta name="dc.Creator" content="Michael D.  Shultz" /></meta><meta name="dc.Creator" content="Joanna  Slisz" /></meta><meta name="dc.Creator" content="Kelly  Slocum" /></meta><meta name="dc.Creator" content="Troy  Smith" /></meta><meta name="dc.Creator" content="Stanley  Spence" /></meta><meta name="dc.Creator" content="Travis  Stams" /></meta><meta name="dc.Creator" content="Christopher  Straub" /></meta><meta name="dc.Creator" content="Victoriano  Tamez, Jr." /></meta><meta name="dc.Creator" content="Bakary-Barry  Toure" /></meta><meta name="dc.Creator" content="Christopher  Towler" /></meta><meta name="dc.Creator" content="Ping  Wang" /></meta><meta name="dc.Creator" content="Hongyun  Wang" /></meta><meta name="dc.Creator" content="Sarah L.  Williams" /></meta><meta name="dc.Creator" content="Fan  Yang" /></meta><meta name="dc.Creator" content="Bing  Yu" /></meta><meta name="dc.Creator" content="Ji-Hu  Zhang" /></meta><meta name="dc.Creator" content="Suzanne  Zhu" /></meta><meta name="dc.Description" content="SHP2 is a nonreceptor protein tyrosine phosphatase encoded by the PTPN11 gene and is involved in cell growth and differentiation via the MAPK signaling pathway. SHP2 also plays an important role in..." /></meta><meta name="Description" content="SHP2 is a nonreceptor protein tyrosine phosphatase encoded by the PTPN11 gene and is involved in cell growth and differentiation via the MAPK signaling pathway. SHP2 also plays an important role in..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="September 10, 2020" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c01170" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01170" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c01170" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01170" /></link>
        
    
    

<title>Identification of TNO155, an Allosteric SHP2 Inhibitor for the Treatment of Cancer | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c01170" /></meta><meta property="og:title" content="Identification of TNO155, an Allosteric SHP2 Inhibitor for the Treatment of Cancer" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01170/20201120/images/large/jm0c01170_0020.jpeg" /></meta><meta property="og:description" content="SHP2 is a nonreceptor protein tyrosine phosphatase encoded by the PTPN11 gene and is involved in cell growth and differentiation via the MAPK signaling pathway. SHP2 also plays an important role in the programed cell death pathway (PD-1/PD-L1). As an oncoprotein as well as a potential immunomodulator, controlling SHP2 activity is of high therapeutic interest. As part of our comprehensive program targeting SHP2, we identified multiple allosteric binding modes of inhibition and optimized numerous chemical scaffolds in parallel. In this drug annotation report, we detail the identification and optimization of the pyrazine class of allosteric SHP2 inhibitors. Structure and property based drug design enabled the identification of protein–ligand interactions, potent cellular inhibition, control of physicochemical, pharmaceutical and selectivity properties, and potent in vivo antitumor activity. These studies culminated in the discovery of TNO155, (3S,4S)-8-(6-amino-5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine (1), a highly potent, selective, orally efficacious, and first-in-class SHP2 inhibitor currently in clinical trials for cancer." /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta><meta name="twitter:description" content="SHP2 is a nonreceptor protein tyrosine phosphatase encoded by the PTPN11 gene and is involved in cell growth and differentiation via the MAPK signaling pathway. SHP2 also plays an important role in the programed cell death pathway (PD-1/PD-L1). As an oncoprotein as well as a potential immunomodulator, controlling SHP2 activity is of high therapeutic interest. As part of our comprehensive program targeting SHP2, we identified multiple allosteric binding modes of inhibition and optimized numerous chemical scaffolds in parallel. In this drug annotation report, we detail the identification and optimization of the pyrazine class of allosteric SHP2 inhibitors. Structure and property based drug design enabled the identification of protein–ligand interactions, potent cellular inhibition, control of physicochemical, pharmaceutical and selectivity properties, and potent in vivo antitumor activity. These studies culminated in the discovery of TNO155, (3S,4S)-8-(6-amino-5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine (1), a highly potent, selective, orally efficacious, and first-in-class SHP2 inhibitor currently in clinical trials for cancer." /></meta><meta name="twitter:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01170/20201120/images/large/jm0c01170_0020.jpeg" /></meta><meta name="twitter:title" content="Identification of TNO155, an Allosteric SHP2 Inhibitor for the Treatment of Cancer" /></meta>
        
            <meta property="og:type" content="Article" /></meta>
        

        
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c01170"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/ke1q~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-6ee29527b3d8ff00a106.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01170">
            
        





































    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-12/achre4.2021.54.issue-12/20210615/achre4.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-6/amrcda.2021.2.issue-6/20210625/amrcda.2021.2.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-6/aabmcb.2021.4.issue-6/20210621/aabmcb.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-6/aaembp.2021.3.issue-6/20210622/aaembp.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-6/aaemcq.2021.4.issue-6/20210628/aaemcq.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-25/aamick.2021.13.issue-25/20210630/aamick.2021.13.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-6/aanmf6.2021.4.issue-6/20210625/aanmf6.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-6/aapmcd.2021.3.issue-6/20210611/aapmcd.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-6/abseba.2021.7.issue-6/20210614/abseba.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-12/accacs.2021.11.issue-12/20210618/accacs.2021.11.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-6/acscii.2021.7.issue-6/20210623/acscii.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-6/acbcct.2021.16.issue-6/20210618/acbcct.2021.16.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-3/achsc5.2021.28.issue-3/20210524/achsc5.2021.28.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-12/acncdm.2021.12.issue-12/20210616/acncdm.2021.12.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-6/aesccq.2021.5.issue-6/20210617/aesccq.2021.5.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-6/aelccp.2021.6.issue-6/20210611/aelccp.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-6/aeecco.2021.1.issue-6/20210611/aeecco.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-6/aewcaa.2021.1.issue-6/20210611/aewcaa.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-5/afsthl.2021.1.issue-5/20210618/afsthl.2021.1.issue-5.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-6/aidcbc.2021.7.issue-6/20210611/aidcbc.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-6/amlccd.2021.10.issue-6/20210615/amlccd.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-6/amlcef.2021.3.issue-6/20210607/amlcef.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-6/amclct.2021.12.issue-6/20210610/amclct.2021.12.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-6/ancac3.2021.15.issue-6/20210622/ancac3.2021.15.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-25/acsodf.2021.6.issue-25/20210629/acsodf.2021.6.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-6/apchd5.2021.8.issue-6/20210616/apchd5.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-6/ascefj.2021.6.issue-6/20210625/ascefj.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-25/ascecg.2021.9.issue-25/20210628/ascecg.2021.9.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-6/asbcd6.2021.10.issue-6/20210618/asbcd6.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-25/ancham.2021.93.issue-25/20210629/ancham.2021.93.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-25/bichaw.2021.60.issue-25/20210629/bichaw.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-6/bcches.2021.32.issue-6/20210616/bcches.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-6/bomaf6.2021.22.issue-6/20210614/bomaf6.2021.22.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-24/cgeabj.2021.99.issue-24/20210628-01/cgeabj.2021.99.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-6/crtoec.2021.34.issue-6/20210621/crtoec.2021.34.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-12/chreay.2021.121.issue-12/20210623/chreay.2021.121.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-12/cmatex.2021.33.issue-12/20210622/cmatex.2021.33.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-6/cgdefu.2021.21.issue-6/20210602/cgdefu.2021.21.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-12/enfuem.2021.35.issue-12/20210617/enfuem.2021.35.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-12/esthag.2021.55.issue-12/20210615/esthag.2021.55.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-6/estlcu.2021.8.issue-6/20210608/estlcu.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-25/iecred.2021.60.issue-25/20210630/iecred.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-12/inocaj.2021.60.issue-12/20210621/inocaj.2021.60.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-6/jaaucr.2021.1.issue-6/20210628/jaaucr.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-25/jafcau.2021.69.issue-25/20210630/jafcau.2021.69.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-6/jceaax.2021.66.issue-6/20210610/jceaax.2021.66.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-6/jceda8.2021.98.issue-6/20210608/jceda8.2021.98.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-6/jcisd8.2021.61.issue-6/20210628/jcisd8.2021.61.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-6/jctcce.2021.17.issue-6/20210608/jctcce.2021.17.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/jmcmar.2021.64.issue-12/20210624/jmcmar.2021.64.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-6/jnprdf.2021.84.issue-6/20210625/jnprdf.2021.84.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-12/joceah.2021.86.issue-12/20210618/joceah.2021.86.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-24/jpcafh.2021.125.issue-24/20210624/jpcafh.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-24/jpcbfk.2021.125.issue-24/20210624/jpcbfk.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-24/jpccck.2021.125.issue-24/20210624/jpccck.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-24/jpclcd.2021.12.issue-24/20210624/jpclcd.2021.12.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-6/jprobs.2021.20.issue-6/20210604/jprobs.2021.20.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-25/jacsat.2021.143.issue-25/20210630/jacsat.2021.143.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-6/jamsef.2021.32.issue-6/20210602/jamsef.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-25/langd5.2021.37.issue-25/20210629/langd5.2021.37.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-12/mamobx.2021.54.issue-12/20210622/mamobx.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-6/mpohbp.2021.18.issue-6/20210607/mpohbp.2021.18.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-12/nalefd.2021.21.issue-12/20210623/nalefd.2021.21.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-12/orlef7.2021.23.issue-12/20210618/orlef7.2021.23.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-6/oprdfk.2021.25.issue-6/20210618/oprdfk.2021.25.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-12/orgnd7.2021.40.issue-12/20210628/orgnd7.2021.40.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c01170&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c01170&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c01170&amp;href=/doi/10.1021/acs.jmedchem.0c01170" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 22</span><span class="cit-fg-pageRange">, 13578-13594</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/22" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c00948" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Drug Annotation</span><a href="/doi/10.1021/acs.jmedchem.0c00620" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Identification of TNO155, an Allosteric SHP2 Inhibitor for the Treatment of Cancer</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Matthew J. LaMarche</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Matthew J. LaMarche</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Global Discovery Chemistry, Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#3f525e4b4b575a4811535e525e4d5c575a7f4c5e51505956115c5052"><span class="__cf_email__" data-cfemail="9ef3ffeaeaf6fbe9b0f2fff3ffecfdf6fbdeedfff0f1f8f7b0fdf1f3">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Matthew+J.++LaMarche">Matthew J. LaMarche</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-6588-2302" title="Orcid link">http://orcid.org/0000-0002-6588-2302</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Michael Acker</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Michael Acker</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology Disease Area, Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Michael++Acker">Michael Acker</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Andreea Argintaru</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Andreea Argintaru</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Global Discovery Chemistry, Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Andreea++Argintaru">Andreea Argintaru</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Daniel Bauer</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Daniel Bauer</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Preclinical Safety Novartis Institutes for Biomedical Research, Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Daniel++Bauer">Daniel Bauer</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Julie Boisclair</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Julie Boisclair</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Preclinical Safety Novartis Institutes for Biomedical Research, Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Julie++Boisclair">Julie Boisclair</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Homan Chan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Homan Chan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology Disease Area, Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Homan++Chan">Homan Chan</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Christine Hiu-Tung Chen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Christine Hiu-Tung Chen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Global Discovery Chemistry, Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Christine+Hiu-Tung++Chen">Christine Hiu-Tung Chen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ying-Nan Chen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ying-Nan Chen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology Disease Area, Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ying-Nan++Chen">Ying-Nan Chen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Zhouliang Chen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Zhouliang Chen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Global Discovery Chemistry, Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Zhouliang++Chen">Zhouliang Chen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Zhan Deng</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Zhan Deng</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Protein Structure Group, Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Zhan++Deng">Zhan Deng</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Michael Dore</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Michael Dore</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Global Discovery Chemistry, Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Michael++Dore">Michael Dore</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">David Dunstan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">David Dunstan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Global Discovery Chemistry, Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=David++Dunstan">David Dunstan</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jianmei Fan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jianmei Fan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Global Discovery Chemistry, Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jianmei++Fan">Jianmei Fan</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Peter Fekkes</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Peter Fekkes</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Protein Structure Group, Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Peter++Fekkes">Peter Fekkes</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Brant Firestone</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Brant Firestone</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology Disease Area, Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Brant++Firestone">Brant Firestone</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Michelle Fodor</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Michelle Fodor</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Protein Structure Group, Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Michelle++Fodor">Michelle Fodor</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jorge Garcia-Fortanet</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jorge Garcia-Fortanet</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Global Discovery Chemistry, Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jorge++Garcia-Fortanet">Jorge Garcia-Fortanet</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Pascal D. Fortin</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Pascal D. Fortin</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology Disease Area, Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Pascal+D.++Fortin">Pascal D. Fortin</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Cary Fridrich</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Cary Fridrich</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Global Discovery Chemistry, Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Cary++Fridrich">Cary Fridrich</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">John Giraldes</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">John Giraldes</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Global Discovery Chemistry, Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=John++Giraldes">John Giraldes</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Meir Glick</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Meir Glick</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Protein Structure Group, Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Meir++Glick">Meir Glick</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Denise Grunenfelder</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Denise Grunenfelder</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Global Discovery Chemistry, Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Denise++Grunenfelder">Denise Grunenfelder</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Huia-Xiang Hao</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Huia-Xiang Hao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology Disease Area, Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Huia-Xiang++Hao">Huia-Xiang Hao</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Martin Hentemann</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Martin Hentemann</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology Disease Area, Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Martin++Hentemann">Martin Hentemann</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Samuel Ho</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Samuel Ho</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Protein Structure Group, Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Samuel++Ho">Samuel Ho</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Andriana Jouk</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Andriana Jouk</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Global Discovery Chemistry, Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Andriana++Jouk">Andriana Jouk</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Zhao B. Kang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Zhao B. Kang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Protein Structure Group, Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Zhao+B.++Kang">Zhao B. Kang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Rajesh Karki</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Rajesh Karki</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Global Discovery Chemistry, Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Rajesh++Karki">Rajesh Karki</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Mitsunori Kato</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mitsunori Kato</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Global Discovery Chemistry, Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mitsunori++Kato">Mitsunori Kato</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Nick Keen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Nick Keen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology Disease Area, Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Nick++Keen">Nick Keen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Robert Koenig</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Robert Koenig</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Global Discovery Chemistry, Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Robert++Koenig">Robert Koenig</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Laura R. LaBonte</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Laura R. LaBonte</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Metabolism and Pharmacokinetics, Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Laura+R.++LaBonte">Laura R. LaBonte</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jay Larrow</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jay Larrow</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Global Discovery Chemistry, Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jay++Larrow">Jay Larrow</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Gang Liu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Gang Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Global Discovery Chemistry, Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Gang++Liu">Gang Liu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Shumei Liu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Shumei Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology Disease Area, Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Shumei++Liu">Shumei Liu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Dyuti Majumdar</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Dyuti Majumdar</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Global Discovery Chemistry, Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Dyuti++Majumdar">Dyuti Majumdar</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Simon Mathieu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Simon Mathieu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Global Discovery Chemistry, Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Simon++Mathieu">Simon Mathieu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Matthew J. Meyer</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Matthew J. Meyer</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology Disease Area, Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Matthew+J.++Meyer">Matthew J. Meyer</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Morvarid Mohseni</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Morvarid Mohseni</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology Disease Area, Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Morvarid++Mohseni">Morvarid Mohseni</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Rukundo Ntaganda</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Rukundo Ntaganda</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Global Discovery Chemistry, Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Rukundo++Ntaganda">Rukundo Ntaganda</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Mark Palermo</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mark Palermo</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Global Discovery Chemistry, Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mark++Palermo">Mark Palermo</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Lawrence Perez</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lawrence Perez</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Global Discovery Chemistry, Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lawrence++Perez">Lawrence Perez</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Minying Pu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Minying Pu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology Disease Area, Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Minying++Pu">Minying Pu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Timothy Ramsey</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Timothy Ramsey</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Global Discovery Chemistry, Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Timothy++Ramsey">Timothy Ramsey</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">John Reilly</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">John Reilly</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Global Discovery Chemistry, Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=John++Reilly">John Reilly</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Patrick Sarver</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Patrick Sarver</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Global Discovery Chemistry, Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Patrick++Sarver">Patrick Sarver</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">William R. Sellers</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">William R. Sellers</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology Disease Area, Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=William+R.++Sellers">William R. Sellers</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Martin Sendzik</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Martin Sendzik</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Global Discovery Chemistry, Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Martin++Sendzik">Martin Sendzik</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Michael D. Shultz</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Michael D. Shultz</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Global Discovery Chemistry, Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Michael+D.++Shultz">Michael D. Shultz</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-7920-955X" title="Orcid link">http://orcid.org/0000-0001-7920-955X</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Joanna Slisz</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Joanna Slisz</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology Disease Area, Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Joanna++Slisz">Joanna Slisz</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kelly Slocum</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kelly Slocum</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology Disease Area, Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kelly++Slocum">Kelly Slocum</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Troy Smith</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Troy Smith</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Global Discovery Chemistry, Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Troy++Smith">Troy Smith</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Stanley Spence</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Stanley Spence</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Preclinical Safety Novartis Institutes for Biomedical Research, Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Stanley++Spence">Stanley Spence</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Travis Stams</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Travis Stams</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Protein Structure Group, Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Travis++Stams">Travis Stams</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Christopher Straub</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Christopher Straub</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Global Discovery Chemistry, Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Christopher++Straub">Christopher Straub</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Victoriano Tamez Jr.</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Victoriano Tamez, Jr.</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Global Discovery Chemistry, Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Victoriano++Tamez%2C++Jr.">Victoriano Tamez, Jr.</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Bakary-Barry Toure</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Bakary-Barry Toure</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Global Discovery Chemistry, Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Bakary-Barry++Toure">Bakary-Barry Toure</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Christopher Towler</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Christopher Towler</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Chemical and Pharmaceutical Profiling, Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Christopher++Towler">Christopher Towler</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ping Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ping Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology Disease Area, Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ping++Wang">Ping Wang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hongyun Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hongyun Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology Disease Area, Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hongyun++Wang">Hongyun Wang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sarah L. Williams</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sarah L. Williams</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Global Discovery Chemistry, Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sarah+L.++Williams">Sarah L. Williams</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Fan Yang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Fan Yang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Global Discovery Chemistry, Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Fan++Yang">Fan Yang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Bing Yu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Bing Yu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Global Discovery Chemistry, Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Bing++Yu">Bing Yu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ji-Hu Zhang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ji-Hu Zhang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Protein Structure Group, Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ji-Hu++Zhang">Ji-Hu Zhang</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Suzanne Zhu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Suzanne Zhu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology Disease Area, Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Suzanne++Zhu">Suzanne Zhu</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01170&amp;href=/doi/10.1021%2Facs.jmedchem.0c01170" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 22</span><span class="cit-pageRange">, 13578–13594</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">September 10, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>7 July 2020</li><li><span class="item_label"><b>Published</b> online</span>10 September 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 25 November 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c01170" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01170</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 <span class="NLM_copyright-holder">American Chemical Society</span></strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D13578%26pageCount%3D17%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DMatthew%2BJ.%2BLaMarche%252C%2BMichael%2BAcker%252C%2BAndreea%2BArgintaru%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D22%26contentID%3Dacs.jmedchem.0c01170%26title%3DIdentification%2Bof%2BTNO155%252C%2Ban%2BAllosteric%2BSHP2%2BInhibitor%2Bfor%2Bthe%2BTreatment%2Bof%2BCancer%26numPages%3D17%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D13594%26publicationDate%3DNovember%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c01170"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">4930</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">11</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c01170" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Identification of TNO155, an Allosteric SHP2 Inhibitor for the Treatment of Cancer&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Matthew&quot;,&quot;last_name&quot;:&quot;J. LaMarche&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;Acker&quot;},{&quot;first_name&quot;:&quot;Andreea&quot;,&quot;last_name&quot;:&quot;Argintaru&quot;},{&quot;first_name&quot;:&quot;Daniel&quot;,&quot;last_name&quot;:&quot;Bauer&quot;},{&quot;first_name&quot;:&quot;Julie&quot;,&quot;last_name&quot;:&quot;Boisclair&quot;},{&quot;first_name&quot;:&quot;Homan&quot;,&quot;last_name&quot;:&quot;Chan&quot;},{&quot;first_name&quot;:&quot;Christine&quot;,&quot;last_name&quot;:&quot;Hiu-Tung Chen&quot;},{&quot;first_name&quot;:&quot;Ying-Nan&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Zhouliang&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Zhan&quot;,&quot;last_name&quot;:&quot;Deng&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;Dore&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;Dunstan&quot;},{&quot;first_name&quot;:&quot;Jianmei&quot;,&quot;last_name&quot;:&quot;Fan&quot;},{&quot;first_name&quot;:&quot;Peter&quot;,&quot;last_name&quot;:&quot;Fekkes&quot;},{&quot;first_name&quot;:&quot;Brant&quot;,&quot;last_name&quot;:&quot;Firestone&quot;},{&quot;first_name&quot;:&quot;Michelle&quot;,&quot;last_name&quot;:&quot;Fodor&quot;},{&quot;first_name&quot;:&quot;Jorge&quot;,&quot;last_name&quot;:&quot;Garcia-Fortanet&quot;},{&quot;first_name&quot;:&quot;Pascal&quot;,&quot;last_name&quot;:&quot;D. Fortin&quot;},{&quot;first_name&quot;:&quot;Cary&quot;,&quot;last_name&quot;:&quot;Fridrich&quot;},{&quot;first_name&quot;:&quot;John&quot;,&quot;last_name&quot;:&quot;Giraldes&quot;},{&quot;first_name&quot;:&quot;Meir&quot;,&quot;last_name&quot;:&quot;Glick&quot;},{&quot;first_name&quot;:&quot;Denise&quot;,&quot;last_name&quot;:&quot;Grunenfelder&quot;},{&quot;first_name&quot;:&quot;Huia-Xiang&quot;,&quot;last_name&quot;:&quot;Hao&quot;},{&quot;first_name&quot;:&quot;Martin&quot;,&quot;last_name&quot;:&quot;Hentemann&quot;},{&quot;first_name&quot;:&quot;Samuel&quot;,&quot;last_name&quot;:&quot;Ho&quot;},{&quot;first_name&quot;:&quot;Andriana&quot;,&quot;last_name&quot;:&quot;Jouk&quot;},{&quot;first_name&quot;:&quot;Zhao&quot;,&quot;last_name&quot;:&quot;B. Kang&quot;},{&quot;first_name&quot;:&quot;Rajesh&quot;,&quot;last_name&quot;:&quot;Karki&quot;},{&quot;first_name&quot;:&quot;Mitsunori&quot;,&quot;last_name&quot;:&quot;Kato&quot;},{&quot;first_name&quot;:&quot;Nick&quot;,&quot;last_name&quot;:&quot;Keen&quot;},{&quot;first_name&quot;:&quot;Robert&quot;,&quot;last_name&quot;:&quot;Koenig&quot;},{&quot;first_name&quot;:&quot;Laura&quot;,&quot;last_name&quot;:&quot;R. LaBonte&quot;},{&quot;first_name&quot;:&quot;Jay&quot;,&quot;last_name&quot;:&quot;Larrow&quot;},{&quot;first_name&quot;:&quot;Gang&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Shumei&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Dyuti&quot;,&quot;last_name&quot;:&quot;Majumdar&quot;},{&quot;first_name&quot;:&quot;Simon&quot;,&quot;last_name&quot;:&quot;Mathieu&quot;},{&quot;first_name&quot;:&quot;Matthew&quot;,&quot;last_name&quot;:&quot;J. Meyer&quot;},{&quot;first_name&quot;:&quot;Morvarid&quot;,&quot;last_name&quot;:&quot;Mohseni&quot;},{&quot;first_name&quot;:&quot;Rukundo&quot;,&quot;last_name&quot;:&quot;Ntaganda&quot;},{&quot;first_name&quot;:&quot;Mark&quot;,&quot;last_name&quot;:&quot;Palermo&quot;},{&quot;first_name&quot;:&quot;Lawrence&quot;,&quot;last_name&quot;:&quot;Perez&quot;},{&quot;first_name&quot;:&quot;Minying&quot;,&quot;last_name&quot;:&quot;Pu&quot;},{&quot;first_name&quot;:&quot;Timothy&quot;,&quot;last_name&quot;:&quot;Ramsey&quot;},{&quot;first_name&quot;:&quot;John&quot;,&quot;last_name&quot;:&quot;Reilly&quot;},{&quot;first_name&quot;:&quot;Patrick&quot;,&quot;last_name&quot;:&quot;Sarver&quot;},{&quot;first_name&quot;:&quot;William&quot;,&quot;last_name&quot;:&quot;R. Sellers&quot;},{&quot;first_name&quot;:&quot;Martin&quot;,&quot;last_name&quot;:&quot;Sendzik&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;D. Shultz&quot;},{&quot;first_name&quot;:&quot;Joanna&quot;,&quot;last_name&quot;:&quot;Slisz&quot;},{&quot;first_name&quot;:&quot;Kelly&quot;,&quot;last_name&quot;:&quot;Slocum&quot;},{&quot;first_name&quot;:&quot;Troy&quot;,&quot;last_name&quot;:&quot;Smith&quot;},{&quot;first_name&quot;:&quot;Stanley&quot;,&quot;last_name&quot;:&quot;Spence&quot;},{&quot;first_name&quot;:&quot;Travis&quot;,&quot;last_name&quot;:&quot;Stams&quot;},{&quot;first_name&quot;:&quot;Christopher&quot;,&quot;last_name&quot;:&quot;Straub&quot;},{&quot;first_name&quot;:&quot;Victoriano&quot;,&quot;last_name&quot;:&quot;Tamez&quot;},{&quot;first_name&quot;:&quot;Bakary-Barry&quot;,&quot;last_name&quot;:&quot;Toure&quot;},{&quot;first_name&quot;:&quot;Christopher&quot;,&quot;last_name&quot;:&quot;Towler&quot;},{&quot;first_name&quot;:&quot;Ping&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Hongyun&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Sarah&quot;,&quot;last_name&quot;:&quot;L. Williams&quot;},{&quot;first_name&quot;:&quot;Fan&quot;,&quot;last_name&quot;:&quot;Yang&quot;},{&quot;first_name&quot;:&quot;Bing&quot;,&quot;last_name&quot;:&quot;Yu&quot;},{&quot;first_name&quot;:&quot;Ji-Hu&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Suzanne&quot;,&quot;last_name&quot;:&quot;Zhu&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;09&quot;,&quot;day&quot;:&quot;10&quot;,&quot;issue&quot;:&quot;22&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;13578-13594&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c01170&quot;},&quot;abstract&quot;:&quot;SHP2 is a nonreceptor protein tyrosine phosphatase encoded by the PTPN11 gene and is involved in cell growth and differentiation via the MAPK signaling pathway. SHP2 also plays an important role in the programed cell death pathway (PD-1/PD-L1). As an oncoprotein as well as a potential immunomodulator, controlling SHP2 activity is of high therapeutic interest. As part of our comprehensive program targeting SHP2, we identified multiple allosteric binding modes of inhibition and optimized numerous chemical scaffolds in parallel. In this drug annotation report, we detail the identification and optimization of the pyrazine class of allosteric SHP2 inhibitors. Structure and property based drug design enabled the identification of protein–ligand interactions, potent cellular inhibition, control of physicochemical, pharmaceutical and selectivity properties, and potent in vivo antitumor activity. These studies culminated in the discovery of TNO155, (3S,4S)-8-(6-amino-5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01170&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01170" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01170&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01170" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01170&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01170" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01170&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01170&amp;href=/doi/10.1021/acs.jmedchem.0c01170" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c01170" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c01170" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (5 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01170&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c01170%26sid%3Dliteratum%253Aachs%26pmid%3D32910655%26genre%3Darticle%26aulast%3DLaMarche%26date%3D2020%26atitle%3DIdentification%2Bof%2BTNO155%252C%2Ban%2BAllosteric%2BSHP2%2BInhibitor%2Bfor%2Bthe%2BTreatment%2Bof%2BCancer%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D22%26spage%3D13578%26epage%3D13594%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291181" title="Amines">Amines</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/22" title="Go to Volume 63, Issue 22"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/jmcmar.2020.63.issue-22/20201125/jmcmar.2020.63.issue-22.largecover.jpg" alt="Go to Volume 63, Issue 22"/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01170/20201120/images/medium/jm0c01170_0020.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01170/20201120/images/large/jm0c01170_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01170&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">SHP2 is a nonreceptor protein tyrosine phosphatase encoded by the <i>PTPN11</i> gene and is involved in cell growth and differentiation via the MAPK signaling pathway. SHP2 also plays an important role in the programed cell death pathway (PD-1/PD-L1). As an oncoprotein as well as a potential immunomodulator, controlling SHP2 activity is of high therapeutic interest. As part of our comprehensive program targeting SHP2, we identified multiple allosteric binding modes of inhibition and optimized numerous chemical scaffolds in parallel. In this drug annotation report, we detail the identification and optimization of the pyrazine class of allosteric SHP2 inhibitors. Structure and property based drug design enabled the identification of protein–ligand interactions, potent cellular inhibition, control of physicochemical, pharmaceutical and selectivity properties, and potent <i>in vivo</i> antitumor activity. These studies culminated in the discovery of TNO155, (3<i>S</i>,4<i>S</i>)-8-(6-amino-5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine (<b>1</b>), a highly potent, selective, orally efficacious, and first-in-class SHP2 inhibitor currently in clinical trials for cancer.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_23366" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_23366" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">SHP2 phosphatase is encoded by the <i>PTPN11</i> gene, functions in the cytoplasm of cells downstream of multiple receptor-tyrosine kinases, and is involved in numerous oncogenic cell-signaling cascades such as RAS-ERK and JAK-STAT. SHP2 is the first reported oncogenic phosphatase, as germline or somatic mutations in <i>PTPN11</i> that cause hyperactivation of SHP2 have been identified in Noonan syndrome (50%),<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> juvenile myelomonocytic leukemia (JMML, 35%), myelodysplastic syndrome (10%), B-cell acute lymphoblastic leukemia (7%), acute myeloid leukemia (AML, 4%),<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> and in solid tumors including lung adenocarcinoma, colon cancer, neuroblastoma, melanoma, and hepatocellular carcinoma.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> In addition to being an oncogenic phosphatase, SHP2 operates downstream of other oncogenic drivers such as RTK amplification and RAS-GTP cycling. While the role of SHP2 in these growth and signaling pathways is still evolving,<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> the opportunity to control these important growth pathways via SHP2 inhibition warrants further investigation.</div><div class="NLM_p">Recently, the relationship of SHP2 and RAS was described by multiple groups. SHP2 directly dephosphorylates RAS which enhances its association with the effector protein RAF to activate downstream proliferative MEK/ERK signaling.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Emerging data implicate SHP2 and RTK dependency of KRAS mutant cancers, particularly KRAS<sup><i>G12C</i></sup>.<a onclick="showRef(event, 'ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref6 ref7">(6,7)</a> KRAS-mutant non-small-cell-lung cancer was found to be dependent on SHP2 activity <i>in vivo</i>.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Targeting both SHP2 and KRAS<sup><i>G12C</i></sup> attenuated the escape from drug-induced quiescence and enhanced antiproliferative and antitumor effects.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Additionally, mutant KRAS critically depends on SHP2 during carcinogenesis, as SHP2 plays a central role in oncogenic KRAS-driven tumors, and genetic deletion of <i>PTPN11</i> profoundly inhibited tumor development in mutant KRAS-driven murine models of pancreatic ductal adenocarcinoma and non-small-cell lung cancer.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> SHP2 disrupts SOS1-mediated RAS-GTP loading and promotes RAS-GTP-dependent oncogenic BRAF, NF1 loss and nucleotide-cycling oncogenic KRAS.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> These findings collectively support the investigation of SHP2 inhibition alone and in combination with other targeted therapies, such as KRAS inhibitors.</div><div class="NLM_p">In addition to the above cell-autonomous mechanisms, SHP2 participates in the programed cell death pathway (PD-1/PD-L1) and contributes to cancer immune evasion.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> SHP2 is a negative regulator of JAK-STAT signaling and the PD-1/SHP2/STAT1/T-bet signaling axis, which mediates the suppressive effects of PD-1 on Th1 immunity at tumor sites. Therefore, inhibition of PD-1 or SHP2 should be sufficient to restore robust Th1 immunity and T-cell activation, reversing immunosuppression in the tumor microenvironment. The T-cell costimulatory receptor CD28 is also a substrate for SHP2 dephosphorylation.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Given the clinical success of anti-PD-1 and PD-L1 antibody-based therapeutics,<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> investigating the inhibition of SHP2 with a small molecule modality for cancer immunotherapy is also of great interest.</div><div class="NLM_p">Structurally, SHP2 phosphatase contains two <i>N</i>-terminal Src homology 2 (SH2) domains, a PTP domain and a <i>C</i>-terminal tail. X-ray structures have demonstrated that SHP2 adopts an autoinhibited conformation in its basal state, where the <i>N</i>-terminal SH2 domain interacts with the PTP domain and blocks access to the catalytic site (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>A).<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Bis-phosphotyrosyl peptides (e.g., IRS-1, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) or proteins bind to the SH2 domains of SHP2 and activate the phosphatase,<a onclick="showRef(event, 'ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref16 ref17">(16,17)</a> which imparts cancer dependence.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> Activating mutations in SHP2 are oncogenic (<i>vide supra</i>) and predominantly occur at the <i>N</i>-SH2:PTP interface. X-ray crystallography combined with small-angle X-ray scattering and biochemical experiments elucidated structural and mechanistic features of cancer-associated SHP2 variants (e.g., E76Q, F285S, S502P, D61V, E76K, etc.) harboring mutations within the <i>N</i>-SH2:PTP interdomain autoinhibitory interface.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> The basal dephosphorylation activity of activating mutants against substrates such as 6,8-difluoro-4-methylumbelliferyl phosphate (DIFMUP,<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a>) is unique and varies with p-IRS-1 concentration.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01170/20201120/images/medium/jm0c01170_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01170/20201120/images/large/jm0c01170_0001.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. (A) Equilibrium of SHP2 in closed (blocked active site) and open (free active site) states via a diphosphotyrosyl peptide, where the N-terminal SH2 domain is shown in green, the C-terminal SH2 domain is shown in blue, and the PTP domain is shown in beige. (B) DIFMUP assay measuring phosphatase activity. Figure adapted with permission from   <cite><i>J. Med. Chem.</i></cite> <span class="NLM_year">2016</span>, <em>59</em>, 7773–7782.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01170/20201120/images/large/jm0c01170_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01170&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In view of the importance of SHP2 as both a cell-autonomous and immunomodulatory anticancer target, the discovery of SHP2 inhibitors has attracted wide interest in the scientific community. Like many phosphatases, early drug discovery efforts focused on the orthosteric site.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Unfortunately, many reported phosphatase active site inhibitors often suffer from low potency, low selectivity, and poor pharmaceutical properties. This is largely due to the highly conserved, polar, and charged environment of the phosphatase active site.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Alternatively, we and others have turned to allosteric modes of phosphatase inhibition and detection.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Previously, we reported a novel allosteric mechanism of SHP2 inhibition whereby small molecules bind and stabilize the inactive conformation of SHP2.<a onclick="showRef(event, 'ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref24 ref25">(24,25)</a> SHP836 (<b>2</b>, <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A) resulted from a high-throughput screen of 1.5 M compounds. We utilized a well-precedented, fluorescence-based phosphatase biochemical assay measuring dephosphorylation of 6,8-difluoro-4-methylumbelliferyl phosphate (DIFMUP assay, 0.5 μM 2P-IRS-1, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>B). We also evaluated the modulation of p-ERK and DUSP6 mRNA as downstream markers of MAPK pathway activity, and antiproliferation activity in the EGFR amplified human esophageal squamous cell carcinoma, KYSE-520. This model was also subcutaneously implanted into immunocompromised mice for <i>in vivo</i> efficacy evaluation. In the following, we describe the identification and optimization of the pyrazine class of SHP2 allosteric inhibitors, using structure and property based drug design. These studies culminated in the discovery of TNO155, (3<i>S</i>,4<i>S</i>)-8-(6-amino-5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine (<b>1</b>), the first allosteric small molecule SHP2 inhibitor to enter clinical studies.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01170/20201120/images/medium/jm0c01170_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01170/20201120/images/large/jm0c01170_0002.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) Pyrimidine HTS hit, <b>2</b>. (B) Cocrystal structure of <b>2</b> with SHP2 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EHP">5EHP</a>), 1.85 Å, in the closed, inactive conformation, where the <i>N</i>-terminal SH2 domain is shown in green, the <i>C</i>-terminal SH2 domain is shown in blue, and the PTP domain is shown in beige. Inset: allosteric binding pocket at the junction of three domains. (C) Allosteric tunnel binding site of <b>2</b> with key residues noted. Figure adapted with permission from   <cite><i>J. Med.
Chem.</i></cite> <span class="NLM_year">2016</span>, <em>59</em>, 7773–7782.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01170/20201120/images/large/jm0c01170_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01170&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_15528" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_15528" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The optimization of the aminopyrimidine screening hit (screening hit <b>2</b>, <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) began by holding the eastern piperazine group constant and probing the SAR of the western aryl ring. Removing the ortho-chlorine (e.g., <b>3</b>), transposing the chlorines (e.g., <b>4</b>), and replacing them with isosteric methyl groups (<b>5</b>) all reduced biochemical inhibition. Thus, the dihaloarene was required at this stage in our optimization, as the chlorines effectively filled a hydrophobic pocket formed by residues R111, T253, L254, Q257, and Q495 (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>C).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Initial SAR of the Western Arene<a class="ref internalNav" href="#tbl1-fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01170/20201120/images/medium/jm0c01170_0010.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01170/20201120/images/medium/jm0c01170_0011.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl1-fn1"><div class="footnote" id="tbl1-fn1"><sup><sup>a</sup></sup><p class="last">Figure adapted with permission from   <cite><i>J. Med. Chem.</i></cite> <span class="NLM_year">2016</span>, <em>59</em>, 7773–7782.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a></p></div></div><div></div></div><div class="NLM_p">Next, while holding the dichlorophenyl ring constant, we perturbed the eastern piperazine motif (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). This moiety occupies a polar region of the allosteric binding pocket (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>C: F113, H114, E249, E250, T218, etc.) and is also solvent (water) exposed. We hypothesized that extending the amine toward these polar residues would allow for new interactions and increase in phosphatase inhibition. Replacing the piperazine ring with a 4-aminopiperidine motif increased the biochemical activity 10-fold (e.g., <b>6</b>, IC<sub>50</sub> = 1.3 μM). Alkylation of the amino group reduced the inhibition (e.g., <b>7</b>, IC<sub>50</sub> = 6.5 μM); however activity was further improved by stabilizing the pseudo-equatorial amine conformation by adding a geminal methyl group to the piperidine ring (e.g., <b>8</b>, IC<sub>50</sub> = 0.26 μM). Importantly, compound <b>8</b> showed modulation of phospho-ERK (p-ERK) activity in the esophageal squamous cell carcinoma KYSE-520 (IC<sub>50</sub> = 1.98 μM).</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Initial SAR of the Eastern Amine Region<a class="ref internalNav" href="#tbl2-fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01170/20201120/images/medium/jm0c01170_0012.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01170/20201120/images/medium/jm0c01170_0013.gif" alt="" id="fx4" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl2-fn1"><div class="footnote" id="tbl2-fn1"><sup><sup>a</sup></sup><p class="last">Figure adapted with permission from   <cite><i>J. Med. Chem.</i></cite> <span class="NLM_year">2016</span>, <em>59</em>, 7773–7782.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a></p></div></div><div></div></div><div class="NLM_p">With initially optimized arene and amine fragments in hand, we then turned our attention to the central pyrimidine ring (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). At first, we maintained the aniline interaction with E250 and found that the 1,2,4-triazine retained biochemical inhibition (<b>9</b>, IC<sub>50</sub> = 0.30 μM). Recognizing that the N-1 nitrogen (see numbering on <b>9</b>) was tolerated <i>vis à vis</i> the triazine and maintained a trajectory toward R111, we removed the adjacent N-2 nitrogen. We hypothesized that increasing the basicity of the nitrogen would strengthen the interaction with R111. As expected, the measured p<i>K</i><sub>a</sub>’s of the protonated triazine and pyrazine rings were 4.7 and 2.9, respectively. As a result, the pyrazine ring significantly increased both biochemical inhibition (<b>10</b>, IC<sub>50</sub> = 0.07 μM) and p-ERK modulation in KYSE-520 cells (IC<sub>50</sub>= 0.250 μM). Furthermore, upon extended incubation (5 days), <b>10</b> showed inhibition of cell proliferation (KYSE-520 model) with an IC<sub>50</sub> of 1.4 μM. Removing the amine group (<b>11</b>) or increasing the steric hindrance around the amine (<b>12</b>) lessened inhibition, presumably due to disturbance of the E250 interaction (<i>vide infra</i>).</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Initial SAR of the Central Heterocycle<a class="ref internalNav" href="#tbl3-fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01170/20201120/images/medium/jm0c01170_0014.gif" alt="" id="fx5" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01170/20201120/images/medium/jm0c01170_0015.gif" alt="" id="fx6" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl3-fn1"><div class="footnote" id="tbl3-fn1"><sup><sup>a</sup></sup><p class="last">Figure adapted with permission from   <cite><i>J. Med. Chem.</i></cite> <span class="NLM_year">2016</span>, <em>59</em>, 7773–7782.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a></p></div></div><div></div></div><div class="NLM_p">SHP099 (<b>10</b>) was identified and characterized as a moderately potent SHP2 inhibitor in biochemical experiments (IC<sub>50</sub> = 0.070 μM) and in the esophageal cancer model, KYSE-520 (p-ERK IC<sub>50</sub> = 0.250 μM; antiproliferation IC<sub>50</sub> = 2.5 μM). High aqueous solubility, selectivity, and oral bioavailability enabled <i>in vivo</i> characterization of <b>10</b>, which proved efficacious in murine cancer xenograft models. <b>10</b> also increased CD8<sup>+</sup> IFN-γ<sup>+</sup> T cells in tumors, decreased the tumor burden in CT-26 tumor bearing mice, and synergized with PD-1 blockade in cancer xenograft models.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> However, <b>10</b> also proved phototoxic in the <i>in vitro</i> 3T3 NRU phototoxicity test (PIF, 219; IC<sub>50</sub> under irradiation = 4.5 μM) and <i>in vivo</i> in the oral murine photolocal lymph node assay (oral photo-LLNA),<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> demonstrating dose-dependent signs of phototoxicity at pharmacologically relevant exposure levels. This was likely due to the extended chromophore as indicated by the strong UV/vis absorbance (<i>E</i><sub>max</sub> 352 nm = 14 300 M<sup>–1</sup> cm<sup>–1</sup>). In addition, <b>10</b> caused vacuolation in hepatocytes and Kupffer cells within the liver after 2 weeks of daily treatment in rats due to phospholipidosis, which was confirmed by electron microscopy (see <a href="/doi/suppl/10.1021/acs.jmedchem.0c01170/suppl_file/jm0c01170_si_001.pdf" class="ext-link">Supporting Information</a>). <b>10</b> also bound and inhibited the hERG channel (IC<sub>50</sub> = 5.9 μM), adding an additional chemotype-based cardiovascular risk. We attributed these safety findings to the large Vd<sub>ss</sub> (7 L/kg, rat) and amine p<i>K</i><sub>a</sub> of 9.5, consistent with the amphiphilic, cationic nature of <b>10</b>. Taken together, the observed phototoxicity, phospholipidosis, and selectivity challenges in <b>10</b> presented opportunities for further profile enhancement.</div><div class="NLM_p">In addition to the initial safety concerns of <b>10</b>, the pathway inhibitory activity of <b>10</b> proved inferior in comparison to other clinically used RTK and MAPK pathway inhibitors. For example, the marketed EGFR inhibitor erlotinib (<b>13</b>, <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>) modulates p-ERK (IC<sub>50</sub> = 0.015 μM) and inhibits proliferation (IC<sub>50</sub> = 0.102 μM) at more than 10-fold lower concentrations in the KYSE-520 model in comparison to <b>10</b> (p-ERK IC<sub>50</sub> = 0.250 μM, antiproliferation IC<sub>50</sub> = 2.5 μM). Furthermore, impressive modulation of the MAPK pathway via downstream nodes of SHP2 has been achieved. RAF inhibitor LXH254 (<b>14</b>), trametinib (<b>15</b>, a MEK inhibitor), and clinically used ERK inhibitors all inhibit 50% cellular proliferation at concentrations less than 0.250 μM (A375 and KYSE-520, respectively), which collectively compare favorably to <b>10</b> (antiproliferation IC<sub>50</sub> = 2.5 μM). More recent inhibitors targeting mutant KRAS were reported<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> and follow a similar potency trend (e.g., AMG510, <b>16</b>, p-ERK IC<sub>50</sub> = 0.030 μM, antiproliferation IC<sub>50</sub> < 0.030 μM, NCI-H358 model; MRTX849, <b>17</b>, p-ERK IC<sub>50</sub> < 0.010 μM, antiproliferation IC<sub>50</sub> 0.100 μM, MIA-PaCa-2 model). Similar to the clinically used MAPK modulators above, we envisioned that near complete pathway suppression via SHP2 inhibition would be necessary for maximal clinical utility as a single agent. The opportunity to maximize efficacy while minimizing exposure would likely provide a more useful therapeutic index. Thus, further optimization of <b>10</b> for SHP2 inhibition was necessary while maintaining the desirable physicochemical properties and selectivity of <b>10</b> and avoiding untoward chemical scaffold-based toxicology such as phototoxicity, phospholipidosis, and hERG inhibition.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01170/20201120/images/medium/jm0c01170_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01170/20201120/images/large/jm0c01170_0003.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Select small molecule inhibitors of the RTK-RAS-MAPK pathway.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01170/20201120/images/large/jm0c01170_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01170&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">While developing the SAR for the pyrazine series, other high-throughput screening results influenced our strategy for potency optimization. For example, azabenzimidazole <b>18</b> (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>A) weakly inhibited SHP2 with a biochemical IC<sub>50</sub> of 47 μM and thermally stabilized the protein by 1.5 °C in a differential scanning fluorimetry (DSF) experiment. A cocrystal structure of <b>18</b> bound to SHP2 revealed a similar binding mode as <b>10</b> (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>B) as the azabenzimidazole ring system of <b>18</b> occupied a similar region of the protein tunnel as the pyrazine motif of <b>10</b>. The pyridine ring of <b>18</b> ordered R111 in an H-bond interaction, which in turn organized R111 in a π–cationic stacking interaction with the dichlorophenyl ring. This was quite reminiscent of the preorganization of R111 by the pyrazole N of <b>10</b>. Noticeably distinct from <b>10</b> was the thioether of <b>18</b>. This aryl-S-aryl bridge imparted a deviation of the central ring plane by approximately 65° as compared to <b>10</b> (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>C). Furthermore, the additional S atom in <b>18</b> displaced the dichlorophenyl ring by approximately 1.6 Å. Intrigued by this related yet perturbed binding mode, we transferred the thioether structural motif to the pyrazine series and determined the effects on biochemical inhibition.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01170/20201120/images/medium/jm0c01170_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01170/20201120/images/large/jm0c01170_0004.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (A) Aminopyrazine <b>10</b> and azabenzimidazole HTS hit <b>18</b>. (B) Cocrystal structure of <b>18</b> with SHP2, 2.05 Å, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6MDD">6MDD</a>, where R111 is shown in orange. (C) Binding conformation of <b>18</b> (blue) overlaid with binding conformation of <b>10</b> (gray), showing central ring deviation and western arene movement.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01170/20201120/images/large/jm0c01170_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01170&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The synthesis of thioether-based aminopyrazine analogs began with 3-bromo-6-chloropyrazin-2-amine, <b>19</b> (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). Copper-catalyzed coupling<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> with various arylthiols at elevated temperature (85 °C) afforded the thioethers (<b>20</b>) in acceptable yields. Nucleophilic aromatic substitution with 4-methylpiperidin-4-amine then afforded the final products (<b>21</b>). With electron deficient aryl thiols, however, the Cu-catalyzed thiol coupling resulted in poor yields. We therefore employed the methods of Mispelaere-Canivet et al.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> to furnish the pyrazine-alkyl-thioether <b>22</b>, which then underwent retro-Michael reaction<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> under basic conditions to give <b>23</b>. Pd-mediated thiol coupling then set the stage for amine nucleophilic aromatic substitution, affording <b>21</b>.<named-content content-type="anchor" rid="fig4" type="simple"></named-content><named-content content-type="anchor" rid="sch1" type="simple"></named-content></div><figure id="sch1" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01170/20201120/images/medium/jm0c01170_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01170/20201120/images/large/jm0c01170_0008.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Thioether-aminopyrazinyl-amines<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01170/20201120/images/large/jm0c01170_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01170&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) CuI, K<sub>3</sub>PO<sub>4</sub>, 1,10-phenathroline, dioxane, 85 °C; (b) DIPEA, 90 °C; (c) Xantphos, Pd(OAc)<sub>2</sub>, DIPEA, dioxane, 95 °C, 90%; (d) NaOEt, RT, THF, 100%; (e) Xantphos, Pd<sub>2</sub>(dba)<sub>3</sub>, DIPEA, dioxane, 105 °C, 91%.</p></p></figure><div class="NLM_p">Our initial dichlorothioether analog (<b>24</b>, <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>) was slightly more potent than <b>10</b> in the biochemical assay (IC<sub>50</sub> = 0.029 μM) and in the KYSE-520 model (pERK IC<sub>50</sub> = 0.195 μM). The hydrophobicity of the S linker, however, had a detrimental effect on the physicochemical properties (e.g., solubility = 0.007 mM; log <i>P</i> = 3.6, log <i>D</i> (7.4) = 1.1) and selectivity (hERG IC<sub>50</sub> = 2.8 μM) as compared to <b>10</b>. Although the UV/vis absorbance was still high (<i>E</i><sub>max</sub> 355 nm = 15 300 M<sup>–1</sup> cm<sup>–1</sup>), the 3T3 assay assessing phototoxicity was only weakly positive (PIF = 5.2; IC<sub>50</sub> under irradiation = 16.2 μM). Since the thioether in <b>18</b> displaced the phenyl ring by approximately 1.6 Å and overlaid with the <i>ortho</i>-chloro substituent in <b>10</b>, we next removed the <i>meta</i>-chloro substituent in <b>24</b>. Accordingly, the monochloride (<b>25</b>) retained activity (biochemical IC<sub>50</sub> = 0.070 μM, p-ERK IC<sub>50</sub> = 0.250 μM). This structural simplification also lowered the lipophilicity (<b>25</b>, log <i>P</i> = 2.4, log <i>D</i> (7.4) = 0.8) and increased the aqueous solubility (<b>25</b>, 0.16 mM) as compared to its dichloro counterpart <b>24</b> (solubility = 0.007 mM; log <i>P</i> = 3.6, log <i>D</i> (7.4) = 1.1). Furthermore, since <i>meta</i>-Cl removal was permissible with the retention of activity (e.g., <b>25</b>), replacement of the <i>meta</i>-C with N was attempted along with replacement of the <i>ortho</i>-Cl with CF<sub>3</sub> (e.g., <b>26</b>). This manipulation also retained activity (<b>26</b>, biochemical IC<sub>50</sub> = 0.067 μM, p-ERK IC<sub>50</sub> = 0.339 μM) while lowering lipophilicity (<b>26</b>, log <i>P</i> = 2.0, log <i>D</i> (7.4) = −0.5) and improving selectivity and lipophilic efficiency (hERG IC<sub>50</sub> = 17 μM, LipE = 5.0). Replacement of the S-linker with oxygen and carbon proved less fruitful (<b>27</b>, IC<sub>50</sub> = 64 μM; <b>28</b>, IC<sub>50</sub> = 9.9 μM) presumably due to the hydrophobic interaction of S with the pocket formed by R111, T153, L254, Q255, P491 and the presumed trajectory variance of the methylene linker. Unfortunately, despite its improved potency as compared to <b>10</b>, compound <b>24</b> did not modulate p-ERK in KYSE-520 tumors implanted in mice as xenografts due to poor physicochemical properties, high plasma protein binding, and an inability to achieve free exposures that surpassed the cellular p-ERK IC<sub>50</sub>.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. SAR of the Thioether Linker<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01170/20201120/images/medium/jm0c01170_0016.gif" alt="" id="fx7" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">N.D. = not determined. KYSE-520 cells were used for p-ERK and antiproliferation assays. Solubility was determined at pH 6.8. hERG inhibition was determined via Q-patch assay.</p></div></div><div></div></div><div class="NLM_p">The cocrystal structure of <b>24</b> and SHP2 (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7JVN">7JVN</a>) revealed similar binding interactions as observed previously with <b>10</b> and <b>18</b>. The dichlorophenyl ring participates in a cationic−π stacking interaction with R111, which was preorganized via hydrogen bond with the pyrazine N (acceptor). Similar to <b>10</b>, the pyrazine aniline also partakes in a hydrogen bond with E250. The 4-methylpiperidine-4-amine fragment is oriented toward polar residues at the end of the tunnel, making hydrogen bonds with E249, F113, and a structural water. Due to the quaternized primary amine at physiological pH, the 4-methylpiperidine-4-amine donates all three protons to neighboring residues or water (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>B). Interestingly, the structural water made further interactions with T108, E110, and T253. These distal interactions raised the possibility of extending the amine fragment in order to displace the structural water and make direct interactions with the protein (e.g., T108, E110, or T253).</div><figure id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01170/20201120/images/medium/jm0c01170_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01170/20201120/images/large/jm0c01170_0005.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (A) Cocrystal structure of <b>24</b> with SHP2, 1.92 Å, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7JVN">7JVN</a>, showing H-bonds from the aminopyrazine ring with R111 and E250. (B) Amine region of <b>24</b> making interactions with E249, F113, and water.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01170/20201120/images/large/jm0c01170_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01170&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Thus, we homologated the amine fragment of <b>24</b> by one atom by incorporating (4-methylpiperidine-4-yl)methanamine, resulting in <b>29</b> (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>, biochemical IC<sub>50</sub> = 0.017 μM, p-ERK IC<sub>50</sub> = 0.088 μM). This transformation improved the activity by approximately 2-fold over <b>24</b> and was similarly lipophilic (<b>29</b>, log <i>P</i> = 4.3, log <i>D</i> (7.4) = 2.5) and unselective (<b>29</b>, hERG IC<sub>50</sub> = 2.4 μM). Interestingly, the aryl–aryl analog (<b>30</b>) with the amine extension was less potent than <b>24</b> and <b>10</b>, suggesting cooperation between the thioether linker and the extended amine of <b>29</b>. As before, perturbing the <i>meta</i> and <i>ortho</i> substituents (relative to S) did not compromise potency (e.g., <b>31</b> and <b>32</b>, IC<sub>50</sub> = 0.022–0.029 μM) and the introduction of additional heteroatoms controlled the lipophilicity (<b>31</b>, log <i>P</i> = 1.0, log <i>D</i> (7.4) = −1.6). Incorporation of a N atom <i>para</i> to S, intended to interact with L492 (<i>vide infra</i>), was also tolerated (e.g., <b>33</b>, biochemical IC<sub>50</sub> = 0.023 μM, p-ERK IC<sub>50</sub> = 0.123 μM). This change also imparted lower hydrophobicity (log <i>P</i> = 1.97, log <i>D</i> (7.4)= −0.85), improved lipophilic efficiency (5.2), higher selectivity (<b>33</b>, hERG IC<sub>50</sub> > 30 μM) as compared to <b>29 (</b>log <i>P</i> = 4.3, log <i>D</i> (7.4)= 2.5, hERG IC<sub>50</sub> = 2.4 μM).</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Structure–Activity Relationships of the Western Ring<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01170/20201120/images/medium/jm0c01170_0017.gif" alt="" id="fx8" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">N.D. = not determined. KYSE-520 cells were used for p-ERK and antiproliferation assays. Solubility was determined at pH 6.8. hERG inhibition was determined via Qpatch assay.</p></div></div><div></div></div><div class="NLM_p">Since extension of the amine in the presence of the thioether resulted in a modest gain of potency (2- to 3-fold), we next probed conformational stabilization of the extended amine via cyclization (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>). Although a variety of bicyclic rings were probed (not shown), the 6,5 spirocyclic system (e.g., <b>34</b>–<b>38</b>, <b>1</b>) proved among the most potent. <i>S</i> and <i>R</i> amine antipodes were evaluated (e.g., compounds <b>34</b>, <b>35</b>) and resulted in a clear preference for the <i>S</i>-amine enantiomer (<b>34</b>, IC<sub>50</sub> = 0.012 μM; <b>35</b>, IC<sub>50</sub> = 0.166 μM). In addition, the <i>para</i>-pyridyl-<i>meta</i>-aniline analog (e.g., <b>36</b>) retained biochemical activity and the SAR did not significantly diverge from the acyclic series (e.g., <b>33</b>, <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>); however cell potency was significantly increased (<b>36</b>, p-ERK IC<sub>50</sub> = 0.024 μM; <b>33</b>, p-ERK IC<sub>50</sub> = 0.123 μM). Remarkably, removal of the amine from the pyrazine was possible without losing binding affinity, biochemical inhibition, and cellular potency (e.g., <b>37</b>). This result indicated that with increasing affinity derived from the western arene and eastern amine fragments, the interaction with E250 was less important for binding as compared to earlier compounds (e.g., <b>10</b> to <b>11</b>). The des-amino congener however was more potent in the hERG assay, and related compounds were phototoxic. In order to control the p<i>K</i><sub>a</sub> of the amine and avoid untoward lipophilic amine-related promiscuity and toxicity (e.g., hERG, phospholipidosis), incorporation of additional heteroatoms in the spirocyclic ring system was evaluated (e.g., <b>38</b>). While introduction of oxygen reduced the measured p<i>K</i><sub>a</sub> (<b>38</b>, p<i>K</i><sub>a</sub> = 7.6) compared to the carbon analog (e.g., <b>36</b>, p<i>K</i><sub>a</sub> = 9.6), a significant loss of cellular activity was observed (e.g., <b>36</b>, p-ERK IC<sub>50</sub> = 0.024 μM, antiproliferation IC<sub>50</sub> = 0.123 μM; <b>38</b>, p-ERK IC<sub>50</sub> = 0.099 μM, antiproliferation IC<sub>50</sub> = 0.665 μM) without loss of biochemical activity (<b>36</b>, IC<sub>50</sub> = 0.014 μM; <b>38</b>, IC<sub>50</sub> = 0.007 μM). In order to increase the cellular penetration and balance lipophilicity across the entire molecule, we incorporated an additional methyl group within the furan ring (e.g., <b>39</b>, <b>1</b>). This resulted in the retention of biochemical activity and improved cellular potency with a preference for the <i>S</i>,<i>S</i>-diastereomer (<b>1</b>, TNO155, biochemical IC<sub>50</sub> = 0.011 μM; p-ERK IC<sub>50</sub> = 0.011 μM; antiproliferation IC<sub>50</sub> = 0.100 μM). Compound <b>1</b> was highly soluble (0.736 mM), had moderate lipophilicity (log <i>D</i> (7.4) = 0.6), high lipophilic efficiency (>6), and no measurable hERG activity (IC<sub>50</sub> > 30 μM). Like our other allosteric tunnel inhibitors, compound <b>1</b> was completely selective over panels of phosphatases and kinases based on screening in commercial panels (see <a href="/doi/suppl/10.1021/acs.jmedchem.0c01170/suppl_file/jm0c01170_si_001.pdf" class="ext-link">Supporting Information</a>). This selectivity is a result of the allosteric mechanism of inhibition which occurs via the ligands binding to the tunnel site of SHP2. The tunnel site is unique to SHP2 and SHP1 phosphatases. Selectivity over SHP1 is likely achieved due to differences in tunnel site residues.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. SAR of the Amine Region<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01170/20201120/images/medium/jm0c01170_0018.gif" alt="" id="fx9" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>a</sup></sup><p class="last">N.D. = not determined. KYSE-520 cells were used for p-ERK and antiproliferation assays. Solubility was determined at pH 6.8. hERG inhibition was determined via Qpatch assay.</p></div></div><div></div></div><div class="NLM_p">The cocrystal structure of <b>1</b> bound to SHP2 was determined at 2.15 Å (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7JVM">7JVM</a>) and revealed several new interactions (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>). The extended amine indeed displaced the structural water and made new, direct interactions with residues S109, E110, and F113. Once again, R111 participates in a cationic−π stacking interaction with the chloropyridine ring and was preorganized via the pyrazine N via a hydrogen bond. As previously observed, the pyrazine-aniline interacts with E250 in a hydrogen bond. K492 moved toward the pyridine N of <b>1</b>, although a formal H-bond was not observed. The pyridine-aniline functional group interacts with the nearby water network (not shown), indirectly interacting with K492.</div><figure id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01170/20201120/images/medium/jm0c01170_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01170/20201120/images/large/jm0c01170_0006.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. (A) Cocrystal of <b>1</b> bound to SHP2, 2.15 Å, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7JVM">7JVM</a>. (B) Amine region interactions with S109, E110, F113, and H114.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01170/20201120/images/large/jm0c01170_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01170&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The synthesis of <b>1</b> began with an aldol reaction between the enolate of 1-(<i>tert</i>-butyl) 4-ethylpiperidine-1,4-dicarboxylate (e.g., <b>40</b>, <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>) and (<i>S</i>)-2-((<i>tert</i>-butyldimethylsilyl)oxy)propanal which furnished the alcohol, <b>41</b>. Borohydride reduction of the ester and deprotection revealed the triol <b>42</b>. Cyclization via the tosylate followed by Dess–Martin oxidation<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> afforded the ketone <b>44</b>. Asymmetric reduction via the Ellman method<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> then selectively furnished the (<i>S</i>)-amine <b>45</b>. Deprotection and S<sub>n</sub>Ar displacement of chloride using 3-((2-amino-3-chloropyridin-4-yl)thio)-6-chloropyrazin-2-amine then furnished <b>1</b>.</div><figure id="sch2" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01170/20201120/images/medium/jm0c01170_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01170/20201120/images/large/jm0c01170_0009.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of TNO155 (<b>1</b>)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01170/20201120/images/large/jm0c01170_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01170&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) diisopropylamine, <i>n</i>-BuLi, THF, 0 °C; (b) LiBH<sub>4</sub>, 0 °C, THF; (c) TBAF, THF, 65%, 3 steps; (d)TsCl, NaH, THF; (e) DMP, DCM, 0 °C, 45%, 2 steps; (f) Ti(OEt)<sub>4</sub>, <i>R</i>-2-methylpropane-2-sulfinamide, THF, LiBH<sub>4</sub>, 90 °C, 65%; (g) HCl, dioxane, 0 °C, 90%; (h) DIPEA, DMSO, 100 °C, 65%.</p></p></figure><div class="NLM_p">The <i>in vivo</i> characterization of <b>1</b> began with the evaluation of pharmacokinetics across four preclinical species (<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>: mouse, rat, dog, monkey) at low dose (0.2–1 mg/kg iv, 1–5 mg/kg po, suspension formulation). Moderate to low clearance and an early <i>T</i><sub>max</sub> (0.8–2.0 h) were observed in all species along with moderate plasma protein binding (61–81%) and moderate to high oral bioavailability (<i>F</i> = 60–100%). These observations were consistent with favorable physicochemical properties (high solubility, permeability) and low <i>in vitro</i> CL in microsomes and hepatocytes. Additionally, compound <b>1</b> is not an inhibitor of CYP3A4, 2D6, or 2C9; thus the risk of any drug–drug interactions when used in combination is minimized.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Pharmacokinetics of <b>1</b> across Preclinical Species</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">parameter</th><th class="colsep0 rowsep0" align="center">mouse (C57BL/6)</th><th class="colsep0 rowsep0" align="center">rat (SD)</th><th class="colsep0 rowsep0" align="center">dog (beagle)</th><th class="colsep0 rowsep0" align="center">monkey (cyno)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dose (mg/kg; iv/po)</td><td class="colsep0 rowsep0" align="left">1/5</td><td class="colsep0 rowsep0" align="left">1/5</td><td class="colsep0 rowsep0" align="left">0.2/1</td><td class="colsep0 rowsep0" align="left">0.3/1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">sex</td><td class="colsep0 rowsep0" align="left">M</td><td class="colsep0 rowsep0" align="left">M</td><td class="colsep0 rowsep0" align="left">M</td><td class="colsep0 rowsep0" align="left">M + F</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">number of animals (iv/po)</td><td class="colsep0 rowsep0" align="left">3/3</td><td class="colsep0 rowsep0" align="left">2/2</td><td class="colsep0 rowsep0" align="left">2/3</td><td class="colsep0 rowsep0" align="left">3/3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CL (mL min<sup>–1</sup> kg<sup>–1</sup>)</td><td class="colsep0 rowsep0" align="left">24</td><td class="colsep0 rowsep0" align="left">15</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>V</i><sub>ss</sub> (L/kg)</td><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">7</td><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>1/2term</sub>, iv (h)</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">8</td><td class="colsep0 rowsep0" align="left">9</td><td class="colsep0 rowsep0" align="left">9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC (nM·h)/dose (mg/kg) iv</td><td class="colsep0 rowsep0" align="left">1530</td><td class="colsep0 rowsep0" align="left">2407</td><td class="colsep0 rowsep0" align="left">10690</td><td class="colsep0 rowsep0" align="left">6438</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC (nM·h)/dose (mg/kg) po</td><td class="colsep0 rowsep0" align="left">1190</td><td class="colsep0 rowsep0" align="left">2483</td><td class="colsep0 rowsep0" align="left">15854</td><td class="colsep0 rowsep0" align="left">3848</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub> (nM)/dose (mg/kg) po</td><td class="colsep0 rowsep0" align="left">357</td><td class="colsep0 rowsep0" align="left">657</td><td class="colsep0 rowsep0" align="left">1207</td><td class="colsep0 rowsep0" align="left">286</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>max</sub> (h) po</td><td class="colsep0 rowsep0" align="left">0.8</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">oral BA, <i>F</i> (%)</td><td class="colsep0 rowsep0" align="left">78</td><td class="colsep0 rowsep0" align="left">100</td><td class="colsep0 rowsep0" align="left">>100</td><td class="colsep0 rowsep0" align="left">60</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">plasma protein binding (%)</td><td class="colsep0 rowsep0" align="left">76</td><td class="colsep0 rowsep0" align="left">81</td><td class="colsep0 rowsep0" align="left">64</td><td class="colsep0 rowsep0" align="left">61</td></tr></tbody></table></div></div><div class="NLM_p"><b>1</b> was next evaluated in the EGFR driven esophageal carcinoma xenograft model, KYSE-520. Mice implanted subcutaneously with KYSE520 esophageal cancer cells were assessed for <i>in vivo</i> PKPD (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>A). Once tumors reached approximately 300 mm<sup>3</sup>, a single oral dose of compound <b>1</b> was administered and plasma and tumor tissue were collected at the dose levels indicated. The expression level of the downstream PD biomarkers DUSP6 (mRNA) and pERK (protein) were measured by qRT-PCR and MSD, respectively. The dose-dependent tumor PD effect correlates with the free plasma concentration of <b>1</b>. After multiple doses over a 2-week time period (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>B), <b>1</b> showed a robust and dose-dependent antitumor effect, achieving stasis at 10–20 mg/kg BID, and did not cause body weight loss. These maximal antitumor effects were consistent with other molecules previously reported (e.g., <b>10</b>, erlotinib, etc.), yet achieved at lower doses. Importantly, compound <b>1</b> proved negative in the <i>in vitro</i> 3T3 NRU phototoxicity test (PIF = 1.5; IC<sub>50</sub> under irradiation, 666 μM).</div><figure id="fig7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01170/20201120/images/medium/jm0c01170_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01170/20201120/images/large/jm0c01170_0007.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. (A) Dose-dependent exposure, p-ERK and DUSP-6 mRNA modulation of <b>1</b> after oral administration in KYSE-520 tumor bearing nude mouse at 2.5, 10, and 10 mg/kg. (B) Dose-dependent efficacy of <b>1</b> after oral administration in KYSE-520 tumor bearing nude mouse at 2.5, 10, and 20 mg/kg BID and effect on body weight.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01170/20201120/images/large/jm0c01170_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01170&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">Discussion and Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_03375" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_03375" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Small molecule modulation of SHP2 is of considerable therapeutic interest given the importance of SHP2 in known oncogenic pathways and its emerging role in immuno-oncology. The discovery of the tunnel allosteric binding site offers a new method to stabilize SHP2 in the autoinhibited, inactive conformation.<a onclick="showRef(event, 'ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref23 ref24">(23,24)</a> In addition to the pyrazine scaffold, we recently reported the identification and optimization of alternative chemical scaffolds, including pyrimidinone and various fused, bicyclic systems.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> Widespread interest in these seminal publications and patent disclosures<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> has resulted in other groups subsequently reporting similar chemical matter with the same mode of action.<a onclick="showRef(event, 'ref36 ref37 ref38'); return false;" href="javascript:void(0);" class="ref ref36 ref37 ref38">(36−38)</a> We also discovered and probed a second allosteric binding site, which also stabilizes the autoinhibited conformation of SHP2, and proved that dual allosteric inhibition was possible.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a></div><div class="NLM_p last">The pyrazine class of allosteric SHP2 inhibitors evolved from a pyrimidine high-throughput screening hit. Optimization of this chemical template was achieved via structure-based drug design, structure–property design, and transposing of SAR results across chemical series. Overall, these activities facilitated the identification of pyrazines with improved potency, high lipophilic efficiency, high solubility and permeability, selectivity over the hERG channel, and the avoidance of scaffold-based toxicity which included phototoxicity and phospholipidosis. These studies culminated in the identification of TNO155 (<b>1</b>): a potent, selective, BCS class I, orally bioavailable, and efficacious SHP2 inhibitor exhibiting dose-dependent pathway inhibition and antitumor activity in xenograft models. We demonstrate that optimization of potency in the allosteric pocket simultaneously with physicochemical properties was possible and that untoward chemical-based toxicity is avoidable. The studies described herein illustrate that appropriate pharmacokinetic and pharmaceutical properties can be achieved by inhibitors binding to the allosteric tunnel site of SHP2. Additionally, the observed MAPK pathway modulation of <b>1</b> compared equally to other clinically used MAPK inhibitors. The potency, selectivity, BCS I classification, ADME properties, and low risk of drug–drug interactions together all enable combination clinical studies of <b>1</b> with other targeted therapies. In addition to single agent clinical studies, combination clinical trials with ribociclib, spartalizumab, MRTX849, and LTT462/dabrafenib with <b>1</b> are ongoing.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> Finally, this new investigational agent, TNO155 (<b>1</b>), will enable clinical interrogation of the multifaceted roles of SHP2 in cancer and related molecular pathologies.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_42304" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_42304" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Compound Synthesis and Characterization</h3><div class="NLM_p last">Compound purity was assessed by HPLC to confirm >95% purity. All solvents employed were commercially available anhydrous grade, and reagents were used as received unless otherwise noted. A Biotage Initiator Sixty system was used for microwave heating. Flash column chromatography was performed on either an Analogix Intelliflash 280 using Si 50 columns (32–63 μm, 230–400 mesh, 60 Å) or a Biotage SP1 system (32–63 μm particle size, KP-Sil, 60 Å pore size). Preparative high-pressure liquid chromatography (HPLC) was performed using a Waters 2525 pump with 2487 dual wavelength detector and 2767 sample manager. Columns were Waters C18 OBD 5 μm, either 50 mm × 100 mm Xbridge or 30 mm × 100 mm Sunfire. NMR spectra were recorded on a Bruker AV400 (Avance 400 MHz) or AV600 (Avance 600 MHz) instrument. Analytical LC–MS was conducted using an Agilent 1100 series with UV detection at 214 and 254 nm and an electrospray mode (ESI) coupled with a Waters ZQ single quad mass detector. One of two methods was used: method A, 5–95% acetonitrile/H<sub>2</sub>O with 5 mM ammonium formate with a 2 min run, 3 μL injection through an inertisil C8 3 cm × 5 mm × 3 μm; method B, 20–95% acetonitrile/H<sub>2</sub>O with 10 mM ammonium formate with a 2 min run, 3 μL injection through an inertisil C8 3 cm × 5 mm × 3 μm. Purity of all tested compounds was determined by LC/ESI-MS Data were recorded using an Agilent 6220 mass spectrometer with electrospray ionization source and Agilent 1200 liquid chromatography. The mass accuracy of the system has been found to be <5 ppm. HPLC separation was performed at 75 mL/min flow rate with the indicated gradient within 3.5 min with an initial hold of 10 s. 10 mM ammonia hydroxide or 0.1 M TFA was used as the modifier additive in the aqueous phase.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Synthesis of TNO155, (3<i>S</i>,4<i>S</i>)-8-(6-Amino-5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine (<b>1</b>)</h3><div id="sec4_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i17" class="anchor-spacer"></div><h4 class="article-section__title" id="_i17"> Step a</h4><div class="NLM_p last">To a −10 °C solution of diisopropylamine (23.4 mL, 166 mmol) in THF (220 mL) was added <i>n</i>BuLi (2.5 M in hexane, 64.1 mL, 160 mmol) dropwise. After stirring for 30 min at this temperature, 1-<i>tert</i>-butyl 4-ethylpiperidine-1,4-dicarboxylate (27.5 g, 107 mmol) in THF (50 mL) was added dropwise and the resulting mixture was stirred for 30 min at 0 °C. (<i>S</i>)-2-((<i>tert</i>-Butyldimethylsilyl)oxy)propanal (20.47 mL, 102 mmol) was added, and the mixture was stirred for 1 h at 0 °C and 1 h at RT. The reaction was diluted with sat. aq NaHCO<sub>3</sub>:H<sub>2</sub>O (1:4, 125 mL). EtOAc (50 mL) was added, and the phases were separated. The aqueous phase was further extracted with EtOAc (3 × 100 mL). The combined organic phases were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and the solvent was removed under reduced pressure. The resulting residue was used in next step without further purification. MS <i>m</i>/<i>z</i> 346.4 (M + H – Boc)<sup>+</sup>.</div></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i18" class="anchor-spacer"></div><h4 class="article-section__title" id="_i18"> Step b</h4><div class="NLM_p last">To a solution of crude 1-<i>tert</i>-butyl 4-ethyl 4-((2S)-2-((<i>tert</i>-butyldimethylsilyl)oxy)-1-hydroxypropyl)piperidine-1,4-dicarboxylate (95 g, 214 mmol) in THF (600 mL) was added portionwise LiBH<sub>4</sub> (7.0 g, 321 mmol), and the resulting mixture was stirred for 16 h at RT. After cooling to 0 °C, sat. aq NaHCO<sub>3</sub>:H<sub>2</sub>O (1:2, 150 mL) was added, and the resulting mixture was vigorously stirred until no more bubbling was observed. EtOAc (100 mL) was added, the mixture was filtered, the phases were separated, and the aqueous phase was further extracted with EtOAc (3 × 50 mL). The combined organic phases were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and the volatiles were removed under reduced pressure to give <i>tert</i>-butyl 4-((2<i>S</i>)-2-((<i>tert</i>-butyldimethylsilyl)oxy)-1-hydroxypropyl)-4-(2-hydroxyethyl)piperidine-1-carboxylate (64.8 g, 161 mmol) which was used in next step without further purification.</div></div><div id="sec4_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19"> Step c</h4><div class="NLM_p last">A solution of <i>tert</i>-butyl 4-((2<i>S</i>)-2-((<i>tert</i>-butyldimethylsilyl)oxy)-1-hydroxypropyl)-4-(2-hydroxyethyl)piperidine-1-carboxylate (64.8 g, 161 mmol) and TBAF (1 M in THF, 242 mL, 242 mmol) in THF (500 mL) was stirred for 2 h at RT. Sat. aq NaHCO<sub>3</sub>:H<sub>2</sub>O (1:2, 150 mL) were added, the phases were separated, and the aqueous phase was further extracted with EtOAc (3 × 100 mL). The combined organic phases were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and the volatiles were removed under reduced pressure. The resulting residue was purified by silica chromatography (20 to 100% gradient of EtOAc/heptane) to give <i>tert</i>-butyl 4-((2<i>S</i>)-1,2-dihydroxypropyl)-4-(2-hydroxyethyl)piperidine-1-carboxylate (39.25 g, 136 mmol) as a semisolid colorless oil.</div></div><div id="sec4_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> Step d</h4><div class="NLM_p last">To a 0 °C suspension of NaH (10.60 g, 424 mmol) in THF (600 mL) was added dropwise a solution of <i>tert</i>-butyl 4-((2<i>S</i>)-1,2-dihydroxypropyl)-4-(2-hydroxyethyl)piperidine-1-carboxylate (35.06 g, 121 mmol) and TsCl (23.10 g, 121 mmol) in THF (200 mL). The resulting mixture was stirred for 1 h at 0 °C. Sat. aq NH<sub>4</sub>Cl (∼5 mL) was added slowly at −20 °C, and the reaction was vigorously stirred until no more bubbling was observed. At this point, sat. aq NH<sub>4</sub>Cl (100 mL) was added followed by brine (100 mL), and the mixture was extracted with EtOAc (3 × 100 mL). The combined organic phases were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and the solvent was removed under reduced pressure to give (3<i>S</i>)-<i>tert</i>-butyl 4-hydroxy-3-methyl-2-oxa-8-azaspiro[4.5]decane-8-carboxylate (32.19 g, 119 mmol) which was used in the next step without further purification. MS <i>m</i>/<i>z</i> 171.1 (M – Boc)<sup>−</sup>.</div></div><div id="sec4_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> Step e</h4><div class="NLM_p last">A solution of (3<i>S</i>)-<i>tert</i>-butyl 4-hydroxy-3-methyl-2-oxa-8-azaspiro[4.5]decane-8-carboxylate (32.19 g, 119 mmol) and Dess–Martin periodinane (67.4 g, 154 mmol) in DCM (300 mL) was stirred for 2 h at 0 °C. After warming to RT, the volatiles were removed under reduced pressure and the resulting residue was purified by silica chromatography (0 to 40% gradient of EtOAc/heptane) to give (<i>S</i>)-<i>tert</i>-butyl 3-methyl-4-oxo-2-oxa-8-azaspiro[4.5]decane-8-carboxylate (27.68 g, 92 mmol) as a pale yellow oil. <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ ppm 4.09 (d, <i>J</i> = 9.60 Hz, 1 H), 3.66–3.86 (m, 4 H), 3.03 (ddd, <i>J</i> = 13.77, 9.73, 3.79 Hz, 1 H), 2.90 (ddd, <i>J</i> = 13.64, 10.23, 3.41 Hz, 1 H), 1.68 (ddd, <i>J</i> = 13.83, 9.92, 4.29 Hz, 1 H), 1.41–1.59 (m, 2 H), 1.30–1.40 (m, 10 H), 1.20–1.25 (m, 3 H).</div></div><div id="sec4_2_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> Step f</h4><div class="NLM_p">A solution of (3<i>S</i>)-<i>tert</i>-butyl 3-methyl-4-oxo-2-oxa-8-azaspiro[4.5]decane-8-carboxylate (22.52 g, 84 mmol), titanium(IV) ethoxide (70.1 mL, 334 mmol), and (<i>R</i>)-2-methylpropane-2-sulfinamide (21 g, 173 mmol) in THF (300 mL) was stirred for 21 h at 90 °C. After cooling to −4 °C, MeOH (30 mL) was added, followed by dropwise addition (maintaining reaction temperature below 2 °C) of lithium borohydride (1.82 g, 84 mmol), and the resulting mixture was stirred for 1 h at −4 °C. Sat. aq NH<sub>4</sub>Cl was slowly added to quench the excess of borohydride (gelatin-type formed) followed by addition of EtOAc (500 mL). The resulting mixture was vigorously stirred for 15 min at RT and then filtered through a pad of Celite followed by an EtOAc (500 mL) wash. The volatiles were removed under reduced pressure and the resulting residue was purified by silica chromatography (0 to 100% gradient of EtOAc/heptane) to give (3<i>S</i>,4<i>S</i>)-<i>tert</i>-butyl 4-((<i>R</i>)-1,1-dimethylethylsulfinamido)-3-methyl-2-oxa-8-azaspiro[4.5]decane-8-carboxylate as a 95:5 diastereomeric mixture (minor diastereomer (3<i>R</i>,4<i>S</i>)-<i>tert</i>-butyl 4-((<i>R</i>)-1,1-dimethylethylsulfinamido)-3-methyl-2-oxa-8-azaspiro[4.5]decane-8-carboxylate).</div><div class="NLM_p last">The diastereomers were separated by chiral SFC as follows: column LC-4 30 mm × 250 mm, flow rate 100 g/min, mobil phase 30% MeOH in CO<sub>2</sub>, detection 225 nm, <i>t</i><sub>R</sub> = 0.95 min (minor diastereomer <i>t</i><sub>R</sub> = 0.55 min) to give (3<i>S</i>,4<i>S</i>)-<i>tert</i>-butyl 4-((<i>R</i>)-1,1-dimethylethylsulfinamido)-3-methyl-2-oxa-8-azaspiro[4.5]decane-8-carboxylate (19 g, 50.68 mmol). MS <i>m</i>/<i>z</i> 375.2.</div></div><div id="sec4_2_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> Step g</h4><div class="NLM_p last">A mixture of (3<i>S</i>,4<i>S</i>)-<i>tert</i>-butyl 4-((<i>R</i>)-1,1-dimethylethylsulfinamido)-3-methyl-2-oxa-8-azaspiro[4.5]decane-8-carboxylate (51 mg, 0.136 mmol) and HCl (4 M in dioxane, 340 μL, 1.362 mmol) in MeOH (5 mL) was stirred for 1 h at 40 °C. After cooling to RT, the volatiles were removed under reduced pressure to give (3<i>S</i>,4<i>S</i>)-3-methyl-2-oxa-8-azaspiro[4.5]decane-4-amine which was used in next step without further purification. MS <i>m</i>/<i>z</i> 171.1 (M + H)<sup>+</sup>.</div></div><div id="sec4_2_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> Step h</h4><div class="NLM_p last">A mixture of (3<i>S</i>,4<i>S</i>)-3-methyl-2-oxa-8-azaspiro[4.5]decane-4-amine crude, 3-((2-amino-3-chloropyridin-4-yl)thio)-6-chloropyrazin-2-amine (<b>20</b>: 35.5 mg, 0.123 mmol), and DIPEA (193 μL, 1.11 mmol) in DMSO (600 μL) was stirred for 16 h at 100 °C. After cooling to RT, the volatiles were removed under reduced pressure and the resulting residue was purified by HPLC (gradient elution 15–40% acetonitrile in water, 5 mM NH<sub>4</sub>OH modifier) to give (3<i>S</i>,4<i>S</i>)-8-(6-amino-5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine (<b>1</b>: 11 mg, 0.026 mmol). <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ ppm 7.67–7.47 (m, 2 H), 5.91 (d, <i>J</i> = 5.5 Hz, 1 H), 4.22 (qd, <i>J</i> = 6.4, 4.8 Hz, 1 H), 4.03 (ddt, <i>J</i> = 13.5, 8.9, 4.7 Hz, 2 H), 3.86 (d, <i>J</i> = 8.7 Hz, 1 H), 3.71 (d, <i>J</i> = 8.7 Hz, 1 H), 3.37 (td, <i>J</i> = 9.9, 4.9 Hz, 1 H), 3.29–3.23 (m, 1 H), 3.00 (d, <i>J</i> = 5.0 Hz, 1H) 1.91–1.56 (m, 4 H), 1.21 (d, <i>J</i> = 6.4 Hz, 3 H). HRMS calcd for C<sub>18</sub>H<sub>25</sub>ClN<sub>7</sub>OS (M + H)<sup>+</sup> 422.1530, found 422.1514.</div></div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> Protein Expression and Purification</h3><div class="NLM_p">The gene encoding human SHP2 from residues Met1-L525 was inserted into a pET30 vector. A coding sequence for a 6× histidine tag followed by a TEV protease consensus sequence was added 5′ to the SHP2 gene sequence. The construct was transformed into BL21 Star (DE3) cells and grown at 37 °C in Terrific broth containing 100 μg/mL kanamycin. At an OD<sub>600</sub> of 4.0, SHP2 expression was induced using 1 mM IPTG. Cells were harvested following overnight growth at 18 °C.</div><div class="NLM_p last">Cell pellets were resuspended in lysis buffer containing 50 mM Tris-HCl, pH 8.5, 25 mM imidazole, 500 mM NaCl, 2.5 mM MgCl<sub>2</sub>, 1 mM TCEP, 1 μg/mL DNase1, and complete EDTA-free protease inhibitor and lysed using a microfluidizer, followed by ultracentrifugation. The supernatant was loaded onto a HisTrap HP chelating column in 50 mM Tris-HCl, 25 mM imidazole, 500 mM NaCl, 1 mM TCEP, and protein was eluted with the addition of 250 mM imidazole. The N-terminal histidine tag was removed with an overnight incubation using TEV protease at 4 °C. The protein was subsequently diluted to 50 mM NaCl with 20 mM Tris-HCl, pH 8.5, 1 mM TCEP then applied to a HiTrap Q FastFlow column equilibrated with 20 mM Tris, pH 8.5, 50 mM NaCl, 1 mM TCEP. The protein was eluted with a 10 column volume gradient from 50 to 500 mM NaCl. Fractions containing SHP2 were pooled and concentrated and then loaded onto a HiLoad Superdex200 PG 16/100 column, exchanging the protein into the crystallization buffer, 20 mM Tris-HCl, pH 8.5, 150 mM NaCl, and 3 mM TCEP. The protein was concentrated to 15 mg/mL for use in crystallization. Crystallization, DSF, and high throughput screening assays used the 1-525 construct of SHP2, while biochemical assays used the 2-593 construct.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> Biochemical Assay</h3><div class="NLM_p">SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src homology 2 (SH2) domains. The latter activation step leads to the release of the autoinhibitory interface of SHP2, which in turn renders the SHP2 PTP active and available for substrate recognition and reaction catalysis. The catalytic activity of SHP2 was monitored using the surrogate substrate DiFMUP in a prompt fluorescence assay format. More specifically, the phosphatase reactions were performed at room temperature in a 384-well black polystyrene plate, flat bottom, low flange, nonbinding surface (Corning, catalog no. 3575) using a final reaction volume of 25 μL and the following assay buffer conditions: 60 mM HEPES, pH 7.2, 75 mM NaCl, 75 mM KCl, 1 mM EDTA, 0.05% P-20, 5 mM DTT.</div><div class="NLM_p last">The inhibition of SHP2 from the tested compounds (concentrations varying from 0.003 to 100 μM) was monitored using an assay in which 0.5 nM SHP2 was incubated with 0.5 μM peptide IRS1_pY1172(dPEG8)pY1222 (sequence H<sub>2</sub>N-LN(pY)IDLDLV(dPEG8)LST(pY)ASINFQK-amide). After 30–60 min incubation at 25 °C, the surrogate substrate DiFMUP (Invitrogen, catalog no. D6567, 200 μM) was added to the reaction and incubated at 25 °C for 30 min (200 μM for 2-593, 100 μM for 1-525 construct). The reaction was then quenched by the addition of 5 μL of a 160 μM solution of bpV(Phen) (Enzo Life Sciences catalog no. ALX-270–204). The fluorescence signal was monitored using a microplate reader (Envision, PerkinElmer) using excitation and emission wavelengths of 340 and 450 nm, respectively. The inhibitor dose–response curves were analyzed using normalized IC<sub>50</sub> regression curve fitting with control based normalization. The 1.5 M compound library screening was performed at 40 μM compound concentration in a miniaturized 1536-well plate format with essentially the same assay conditions as described above for the 384-well biochemical assay format.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> Cellular Assay</h3><div class="NLM_p last">For the p-ERK cellular assay using the AlphaScreen SureFire Phospho-ERK 1/2 kit (PerkinElmer), KYSE-520 cells (30 000 cells/well) were grown in 96-well plate culture overnight and treated with SHP2 inhibitors at concentrations of 20, 6.6, 2.2, 0.74, 0.24, 0.08, 0.027 μM for 2 h at 37 °C. Incubations were terminated by addition of 30 μL of lysis buffer (PerkinElmer) supplied with the SureFire phospho-extracellular signal-regulated kinase (p-ERK) assay kit (PerkinElmer). Samples were processed according to the manufacturer’s directions. The fluorescence signal from p-ERK was measured in duplicate using a 2101 multilabel reader (PerkinElmer Envision). The percentage of inhibition was normalized by the total ERK signal and compared with the DMSO vehicle control.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> Cell Proliferation Assay</h3><div class="NLM_p last">Cells (1500 cells/well) were plated onto 96-well plates in 100 μL of medium (RPMI-1640 containing 10% FBS, Lonza). Compounds with various concentrations (1.25, 2.5, 5, 10, 20 μM) were added 24 h after cell plating. At day 5, 50 μL of Celltiter-Glo reagent (Promega) was added, and the luminescent signal was determined according to the supplier’s instruction (Promega).</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> Differential Scanning Fluorimetry</h3><div class="NLM_p last">Differential scanning fluorimetry (DSF) was used as a method to identify compounds that stabilize SHP2 from thermal denaturation. The following assay conditions were used: 100 μg/mL SHP2, 5× SYPRO Orange dye (5000× concentrate in DMSO; Life Technologies), 100 mM Bis-Tris (pH 6.5), 100 mM NaCl, 0.25 mM TCEP, and 5% DMSO. The final compound concentration evaluated was 100 μM. To carry out the experiment, 9.5 μL of DSF assay solution was dispensed into an assay plate (LightCycler; 480 multiwell plate 384 white) containing 500 nL of compound dissolved in DMSO and then mixed. The final assay volume was 10 μL per well in a 384-well format. Plates were then sealed after reagent addition, centrifuged at 1000 rpm for 1 min, and read on a Bio-Rad C1000 thermal cycler with a CFX384 real time system using an excitation of 465 nm and an emission at 580 nm. The temperature was ramped from 25 to 75 °C, and measurements were taken at 0.5 °C increments. The melting temperature (<i>T</i><sub>m</sub>) of the raw fluorescence data was identified as the midpoint of the transitions via a semiparametric fit. The Δ<i>T</i><sub>m</sub> was determined by comparing the individual <i>T</i><sub>m</sub> values for each compound with the mean <i>T</i><sub>m</sub> of the apo SHP2 protein controls (32 per plate) containing DMSO only.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> Crystallization and Structure Determination</h3><div class="NLM_p">Sitting drop vapor diffusion method was used for crystallization, with the crystallization well containing 17% PEG 3350 and 200 mM ammonium phosphate and a drop with a 1:1 volume of SHP2 protein and crystallization solution. Crystals were formed within 5 days and subsequently soaked in the crystallization solution with 2.5 mM <b>1</b>, <b>24</b>. This was followed by cryoprotection using the crystallization solution with the addition of 20% glycerol and 1 mM compound <b>1</b>, <b>24</b> followed by flash freezing directly into liquid nitrogen.</div><div class="NLM_p last">Diffraction data for the SHP2/compound <b>10</b> complex are reported elswhere,<a onclick="showRef(event, 'ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref23 ref24">(23,24)</a> and data for the SHP2/compound <b>1</b>, <b>24</b> complex were collected on a Dectris Pilatus 6M detector at beamline 17ID (IMCA-CAT) at the Advanced Photon Source at Argonne National Laboratories. The data were measured from a single crystal maintained at 100 K at a wavelength of 1 Å, and the reflections were indexed, integrated, and scaled using XDS.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> The space group of the complex was <i>P</i>2<sub>1</sub> with two molecules in the asymmetric unit. The structure was determined with Fourier methods, using the SHP2 apo structure<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> (PDB accession code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2SHP">2SHP</a>) with all waters removed. Structure determination was achieved through iterative rounds of positional and simulated annealing refinement using BUSTER,<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> with model building using COOT.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> Individual <i>B</i>-factors were refined using an overall anisotropic <i>B</i>-factor refinement along with bulk solvent correction. The solvent, phosphate ions, and inhibitor were built into the density in later rounds of the refinement. Data collection and refinement statistics are shown in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> found in the <a href="/doi/suppl/10.1021/acs.jmedchem.0c01170/suppl_file/jm0c01170_si_001.pdf" class="ext-link">Supporting Information</a>.</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> Pharmacokinetics</h3><div class="NLM_p">All animal related procedures were conducted under a Novartis IACUC approved protocol in compliance with Animal Welfare Act regulations and the Guide for the Care and Use of Laboratory Animals. The formulation of <b>1</b> was a suspension in 0.5% Tween 80, 0.5% MC. Following iv and po administration (via tail vein), approximately 50 μL of whole blood was collected and transferred to an Eppendorf microcentrifuge tube containing EDTA. The blood was centrifuged at 5000 rpm, and plasma was transferred to a Matrix 96-well plate, capped and stored frozen (−20 °C) for parent compound analysis. Samples were precipitated and diluted with acetonitrile containing internal standard and prepared for LC/MS/MS. An aliquot (20 μL) of each sample was injected into an API4000 LC/MS/MS system for analysis, and transitions of 352.05 amu (Q1) and 267.10 amu (Q3) were monitored.</div><div class="NLM_p">All pharmacokinetic (PK) parameters were derived from concentration–time data by noncompartmental analyses. All PK parameters were calculated with the computer program WinNonlin (version 6.4) purchased from Certara Company (St. Louis, MO).</div><div class="NLM_p">For the intravenous dose, the concentration of unchanged compound at time 0 was calculated based on a log–linear regression of the first two data points to back-extrapolate <i>C</i>(0). The area under the concentration–time curve (AUC<sub>last</sub>) was calculated using the linear trapezoidal rule.</div><div class="NLM_p last">The bioavailability was estimated using the following equation:<span class="NLM_disp-formula" id="ueq1"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01170/20201120/images/medium/jm0c01170_m001.gif" alt="" id="_i32" /></img></span>Results are expressed as the mean. No further statistical analysis was performed.</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> Tumor Xenograft Experiments</h3><div class="NLM_p last">All animal studies were carried out according to the Novartis Guide for the Care and Use of Laboratory Animals. Mice implanted subcutaneously with KYSE520 esophageal cancer cells were assessed for <i>in vivo</i> PKPD. Once tumors reached approximately 300 mm<sup>3</sup>, a single oral dose of <b>1</b> was administered and plasma and tumor tissue were collected at the dose levels indicated. The formulation of <b>1</b> was a suspension in 0.5% Tween 80, 0.5% MC. The expression level of the downstream PD biomarkers DUSP6 (mRNA) and pERK (protein) were measured by qRT-PCR and MSD, respectively. The dose-dependent tumor PD effect correlates with the free plasma concentration of <b>1</b>. For efficacy, KYSE520 esophageal tumors were established in female NU/NU mice by injection of 1.5 million cells in 50% Matrigel into the subcutaneous space of the right flank of each mouse. When tumors reached an average of 220 mm<sup>3</sup>, mice were randomized according to tumor volume into treatment groups (<i>n</i> = 6). <b>1</b> was administered at the dose levels and schedules indicated. Tumor volumes of treatment groups vs days after randomization were graphed. Body weights were measured twice weekly and the data calculated as a percent change of the initial body weight from the start of dosing.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i34"><a href="/doi/suppl/10.1021/acs.jmedchem.0c01170" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_64352" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_64352" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c01170?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01170</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Selectivity data, histopathology, X-ray data tables, and chemistry experimental details (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01170/suppl_file/jm0c01170_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings and some data (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01170/suppl_file/jm0c01170_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01170/suppl_file/jm0c01170_si_001.pdf">jm0c01170_si_001.pdf (1.65 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01170/suppl_file/jm0c01170_si_002.csv">jm0c01170_si_002.csv (1.7 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">PDB codes are <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7JVM">7JVM</a> for SHP2 in complex with compound <b>1</b> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7JVN">7JVN</a> for SHP2 in complex with compound <b>24</b>. Authors will release the atomic coordinates data upon article publication.</p><div class="testing" data-doi="10.1021/acs.jmedchem.0c01170" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_15574" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_15574" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Matthew J. LaMarche</span> - <span class="hlFld-Affiliation affiliation">Global
Discovery Chemistry, , , , , and , Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-6588-2302" title="Orcid link">http://orcid.org/0000-0002-6588-2302</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#e38e8297978b8694cd8f828e8291808b86a390828d8c858acd808c8e"><span class="__cf_email__" data-cfemail="f19c908585999486df9d909c9083929994b182909f9e9798df929e9c">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael Acker</span> - <span class="hlFld-Affiliation affiliation">Oncology Disease Area, , , , , and , Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andreea Argintaru</span> - <span class="hlFld-Affiliation affiliation">Global
Discovery Chemistry, , , , , and , Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Daniel Bauer</span> - <span class="hlFld-Affiliation affiliation">Preclinical Safety
Novartis Institutes for Biomedical Research, , , , , and , Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Julie Boisclair</span> - <span class="hlFld-Affiliation affiliation">Preclinical Safety
Novartis Institutes for Biomedical Research, , , , , and , Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Homan Chan</span> - <span class="hlFld-Affiliation affiliation">Oncology Disease Area, , , , , and , Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christine Hiu-Tung Chen</span> - <span class="hlFld-Affiliation affiliation">Global
Discovery Chemistry, , , , , and , Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ying-Nan Chen</span> - <span class="hlFld-Affiliation affiliation">Oncology Disease Area, , , , , and , Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhouliang Chen</span> - <span class="hlFld-Affiliation affiliation">Global
Discovery Chemistry, , , , , and , Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhan Deng</span> - <span class="hlFld-Affiliation affiliation">Protein Structure Group, , , , , and , Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael Dore</span> - <span class="hlFld-Affiliation affiliation">Global
Discovery Chemistry, , , , , and , Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David Dunstan</span> - <span class="hlFld-Affiliation affiliation">Global
Discovery Chemistry, , , , , and , Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jianmei Fan</span> - <span class="hlFld-Affiliation affiliation">Global
Discovery Chemistry, , , , , and , Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Peter Fekkes</span> - <span class="hlFld-Affiliation affiliation">Protein Structure Group, , , , , and , Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Brant Firestone</span> - <span class="hlFld-Affiliation affiliation">Oncology Disease Area, , , , , and , Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michelle Fodor</span> - <span class="hlFld-Affiliation affiliation">Protein Structure Group, , , , , and , Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jorge Garcia-Fortanet</span> - <span class="hlFld-Affiliation affiliation">Global
Discovery Chemistry, , , , , and , Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Pascal D. Fortin</span> - <span class="hlFld-Affiliation affiliation">Oncology Disease Area, , , , , and , Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Cary Fridrich</span> - <span class="hlFld-Affiliation affiliation">Global
Discovery Chemistry, , , , , and , Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">John Giraldes</span> - <span class="hlFld-Affiliation affiliation">Global
Discovery Chemistry, , , , , and , Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Meir Glick</span> - <span class="hlFld-Affiliation affiliation">Protein Structure Group, , , , , and , Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Denise Grunenfelder</span> - <span class="hlFld-Affiliation affiliation">Global
Discovery Chemistry, , , , , and , Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Huia-Xiang Hao</span> - <span class="hlFld-Affiliation affiliation">Oncology Disease Area, , , , , and , Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Martin Hentemann</span> - <span class="hlFld-Affiliation affiliation">Oncology Disease Area, , , , , and , Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Samuel Ho</span> - <span class="hlFld-Affiliation affiliation">Protein Structure Group, , , , , and , Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andriana Jouk</span> - <span class="hlFld-Affiliation affiliation">Global
Discovery Chemistry, , , , , and , Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhao B. Kang</span> - <span class="hlFld-Affiliation affiliation">Protein Structure Group, , , , , and , Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rajesh Karki</span> - <span class="hlFld-Affiliation affiliation">Global
Discovery Chemistry, , , , , and , Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mitsunori Kato</span> - <span class="hlFld-Affiliation affiliation">Global
Discovery Chemistry, , , , , and , Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nick Keen</span> - <span class="hlFld-Affiliation affiliation">Oncology Disease Area, , , , , and , Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Robert Koenig</span> - <span class="hlFld-Affiliation affiliation">Global
Discovery Chemistry, , , , , and , Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Laura R. LaBonte</span> - <span class="hlFld-Affiliation affiliation">Metabolism and Pharmacokinetics, , , , , and , Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jay Larrow</span> - <span class="hlFld-Affiliation affiliation">Global
Discovery Chemistry, , , , , and , Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gang Liu</span> - <span class="hlFld-Affiliation affiliation">Global
Discovery Chemistry, , , , , and , Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shumei Liu</span> - <span class="hlFld-Affiliation affiliation">Oncology Disease Area, , , , , and , Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dyuti Majumdar</span> - <span class="hlFld-Affiliation affiliation">Global
Discovery Chemistry, , , , , and , Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Simon Mathieu</span> - <span class="hlFld-Affiliation affiliation">Global
Discovery Chemistry, , , , , and , Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Matthew J. Meyer</span> - <span class="hlFld-Affiliation affiliation">Oncology Disease Area, , , , , and , Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Morvarid Mohseni</span> - <span class="hlFld-Affiliation affiliation">Oncology Disease Area, , , , , and , Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rukundo Ntaganda</span> - <span class="hlFld-Affiliation affiliation">Global
Discovery Chemistry, , , , , and , Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mark Palermo</span> - <span class="hlFld-Affiliation affiliation">Global
Discovery Chemistry, , , , , and , Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lawrence Perez</span> - <span class="hlFld-Affiliation affiliation">Global
Discovery Chemistry, , , , , and , Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Minying Pu</span> - <span class="hlFld-Affiliation affiliation">Oncology Disease Area, , , , , and , Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Timothy Ramsey</span> - <span class="hlFld-Affiliation affiliation">Global
Discovery Chemistry, , , , , and , Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">John Reilly</span> - <span class="hlFld-Affiliation affiliation">Global
Discovery Chemistry, , , , , and , Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Patrick Sarver</span> - <span class="hlFld-Affiliation affiliation">Global
Discovery Chemistry, , , , , and , Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">William R. Sellers</span> - <span class="hlFld-Affiliation affiliation">Oncology Disease Area, , , , , and , Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Martin Sendzik</span> - <span class="hlFld-Affiliation affiliation">Global
Discovery Chemistry, , , , , and , Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael D. Shultz</span> - <span class="hlFld-Affiliation affiliation">Global
Discovery Chemistry, , , , , and , Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-7920-955X" title="Orcid link">http://orcid.org/0000-0001-7920-955X</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Joanna Slisz</span> - <span class="hlFld-Affiliation affiliation">Oncology Disease Area, , , , , and , Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kelly Slocum</span> - <span class="hlFld-Affiliation affiliation">Oncology Disease Area, , , , , and , Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Troy Smith</span> - <span class="hlFld-Affiliation affiliation">Global
Discovery Chemistry, , , , , and , Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stanley Spence</span> - <span class="hlFld-Affiliation affiliation">Preclinical Safety
Novartis Institutes for Biomedical Research, , , , , and , Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Travis Stams</span> - <span class="hlFld-Affiliation affiliation">Protein Structure Group, , , , , and , Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christopher Straub</span> - <span class="hlFld-Affiliation affiliation">Global
Discovery Chemistry, , , , , and , Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Victoriano Tamez</span> - <span class="hlFld-Affiliation affiliation">Global
Discovery Chemistry, , , , , and , Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bakary-Barry Toure</span> - <span class="hlFld-Affiliation affiliation">Global
Discovery Chemistry, , , , , and , Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christopher Towler</span> - <span class="hlFld-Affiliation affiliation">Chemical and Pharmaceutical Profiling, , , , , and , Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ping Wang</span> - <span class="hlFld-Affiliation affiliation">Oncology Disease Area, , , , , and , Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hongyun Wang</span> - <span class="hlFld-Affiliation affiliation">Oncology Disease Area, , , , , and , Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sarah L. Williams</span> - <span class="hlFld-Affiliation affiliation">Global
Discovery Chemistry, , , , , and , Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Fan Yang</span> - <span class="hlFld-Affiliation affiliation">Global
Discovery Chemistry, , , , , and , Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bing Yu</span> - <span class="hlFld-Affiliation affiliation">Global
Discovery Chemistry, , , , , and , Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ji-Hu Zhang</span> - <span class="hlFld-Affiliation affiliation">Protein Structure Group, , , , , and , Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Suzanne Zhu</span> - <span class="hlFld-Affiliation affiliation">Oncology Disease Area, , , , , and , Novartis Pharmaceuticals, Cambridge, Massachusetts 02139, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><p>The authors declare the following competing financial interest(s): The authors declare competing financial interests as Novartis stockholders and employees.<br /></br></p></li></ul></div><div class="ack" id="ACK-d7e3094-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i36">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_81500" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_81500" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Use of the IMCA-CAT beamline 17-ID at the Advanced Photon Source was supported by the companies of the Industrial Macromolecular Crystallography Association through a contract with Hauptman-Woodward Medical Research Institute. Use of the Advanced Photon Source was supported by the U.S. Department of Energy, Office of Science, Office of Basic Energy Sciences, under Contract DE-AC02-06CH11357. The authors thank the entire SHP2 team.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">PTP</td><td class="NLM_def"><p class="first last">protein tyrosine phosphatase</p></td></tr><tr><td class="NLM_term">RAS</td><td class="NLM_def"><p class="first last">rat sarcoma protein</p></td></tr><tr><td class="NLM_term">AKT</td><td class="NLM_def"><p class="first last">protein kinase B</p></td></tr><tr><td class="NLM_term">JAK</td><td class="NLM_def"><p class="first last">Janus kinase</p></td></tr><tr><td class="NLM_term">STAT</td><td class="NLM_def"><p class="first last">signal transducer and activator of transcription proteins</p></td></tr><tr><td class="NLM_term">PKPD</td><td class="NLM_def"><p class="first last">pharmacokinetics pharmacodynamics</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i38">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_80884" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_80884" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 43 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tartaglia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehler, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zampino, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunner, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kremer, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Der
Burgt, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crosby, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ion, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeffery, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalidas, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patton, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kucherlapati, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelb, B. D.</span></span> <span> </span><span class="NLM_article-title">Mutations in PTPN11, Encoding the Protein Tyrosine Phosphatase SHP-2, Cause Noonan Syndrome</span>. <i>Nat. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">465</span>– <span class="NLM_lpage">468</span>, <span class="refDoi"> DOI: 10.1038/ng772</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=10.1038%2Fng772" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=11704759" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADC%252BD3MXovFGjt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2001&pages=465-468&author=M.+Tartagliaauthor=E.+L.+Mehlerauthor=R.+Goldbergauthor=G.+Zampinoauthor=H.+G.+Brunnerauthor=H.+Kremerauthor=I.+Van+Der%0ABurgtauthor=A.+H.+Crosbyauthor=A.+Ionauthor=S.+Jefferyauthor=K.+Kalidasauthor=J.+A.+Pattonauthor=R.+S.+Kucherlapatiauthor=B.+D.+Gelb&title=Mutations+in+PTPN11%2C+Encoding+the+Protein+Tyrosine+Phosphatase+SHP-2%2C+Cause+Noonan+Syndrome&doi=10.1038%2Fng772"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome</span></div><div class="casAuthors">Tartaglia, Marco; Mehler, Ernest L.; Goldberg, Rosalie; Zampino, Giuseppe; Brunner, Han G.; Kremer, Hannie; van der Burgt, Ineke; Crosby, Andrew H.; Ion, Andra; Jeffery, Steve; Kalidas, Kamini; Patton, Michael A.; Kucherlapati, Raju S.; Gelb, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">465-468</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature America Inc.</span>)
        </div><div class="casAbstract">Noonan syndrome (MIM 163950) is an autosomal dominant disorder characterized by dysmorphic facial features, proportionate short stature and heart disease (most commonly pulmonic stenosis and hypertrophic cardiomyopathy).  Webbed neck, chest deformity, cryptorchidism, mental retardation and bleeding diathesis also are frequently assocd. with this disease.  This syndrome is relatively common, with an estd. incidence of 1 in 1000-2500 live births.  It has been mapped to a 5-cM region (N-SH2) on chromosome 12q24.1, and genetic heterogeneity has also been documented.  Here we show that missense mutations in PTPN11 (MIM 176876)-a gene encoding the nonreceptor protein tyrosine phosphatase SHP-2, which contains two Src homol. 2 (SH2) domains-cause Noonan syndrome and account for more than 50% of the cases that we examd.  All PTPN11 missense mutations cluster in interacting portions of the amino N-SH2 domain and the phosphotyrosine phosphatase domains, which are involved in switching the protein between its inactive and active conformations.  An energetics-based structural anal. of two N-SH2 mutants indicates that in these mutants there may be a significant shift of the equil. favoring the active conformation.  This implies that they are gain-of-function changes and that the pathogenesis of Noonan syndrome arises from excessive SHP-2 activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKg7QISHW0bbVg90H21EOLACvtfcHk0ljfxvSpclbZHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXovFGjt7w%253D&md5=c8225c08340f9446cd58c249de42e515</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fng772&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng772%26sid%3Dliteratum%253Aachs%26aulast%3DTartaglia%26aufirst%3DM.%26aulast%3DMehler%26aufirst%3DE.%2BL.%26aulast%3DGoldberg%26aufirst%3DR.%26aulast%3DZampino%26aufirst%3DG.%26aulast%3DBrunner%26aufirst%3DH.%2BG.%26aulast%3DKremer%26aufirst%3DH.%26aulast%3DVan%2BDer%2BBurgt%26aufirst%3DI.%26aulast%3DCrosby%26aufirst%3DA.%2BH.%26aulast%3DIon%26aufirst%3DA.%26aulast%3DJeffery%26aufirst%3DS.%26aulast%3DKalidas%26aufirst%3DK.%26aulast%3DPatton%26aufirst%3DJ.%2BA.%26aulast%3DKucherlapati%26aufirst%3DR.%2BS.%26aulast%3DGelb%26aufirst%3DB.%2BD.%26atitle%3DMutations%2520in%2520PTPN11%252C%2520Encoding%2520the%2520Protein%2520Tyrosine%2520Phosphatase%2520SHP-2%252C%2520Cause%2520Noonan%2520Syndrome%26jtitle%3DNat.%2520Genet.%26date%3D2001%26volume%3D29%26spage%3D465%26epage%3D468%26doi%3D10.1038%2Fng772" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tartaglia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niemeyer, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fragale, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buechner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hählen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasle, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Licht, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelb, B. D.</span></span> <span> </span><span class="NLM_article-title">Somatic Mutations in PTPN11 in Juvenile Myelomonocytic Leukemia, Myelodysplastic Syndromes and Acute Myeloid Leukemia</span>. <i>Nat. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">148</span>– <span class="NLM_lpage">150</span>, <span class="refDoi"> DOI: 10.1038/ng1156</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=10.1038%2Fng1156" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=12717436" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADC%252BD3sXktFSltrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2003&pages=148-150&author=M.+Tartagliaauthor=C.+M.+Niemeyerauthor=A.+Fragaleauthor=X.+Songauthor=J.+Buechnerauthor=A.+Jungauthor=K.+H%C3%A4hlenauthor=H.+Hasleauthor=J.+D.+Lichtauthor=B.+D.+Gelb&title=Somatic+Mutations+in+PTPN11+in+Juvenile+Myelomonocytic+Leukemia%2C+Myelodysplastic+Syndromes+and+Acute+Myeloid+Leukemia&doi=10.1038%2Fng1156"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia</span></div><div class="casAuthors">Tartaglia, Marco; Niemeyer, Charlotte M.; Fragale, Alessandra; Song, Xiaoling; Buechner, Jochen; Jung, Andreas; Haehlen, Karel; Hasle, Henrik; Licht, Jonathan D.; Gelb, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">148-150</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We report here that individuals with Noonan syndrome and juvenile myelomonocytic leukemia (JMML) have germline mutations in PTPN11 and that somatic mutations in PTPN11 account for 34% of non-syndromic JMML.  Furthermore, we found mutations in PTPN11 in a small percentage of individuals with myelodysplastic syndrome (MDS) and de novo acute myeloid leukemia (AML).  Functional analyses documented that the two most common mutations in PTPN11 assocd. with JMML caused a gain of function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCwFhlUQDJQLVg90H21EOLACvtfcHk0ljfxvSpclbZHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXktFSltrY%253D&md5=67d6900b46520ee461330bed95cbc890</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fng1156&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng1156%26sid%3Dliteratum%253Aachs%26aulast%3DTartaglia%26aufirst%3DM.%26aulast%3DNiemeyer%26aufirst%3DC.%2BM.%26aulast%3DFragale%26aufirst%3DA.%26aulast%3DSong%26aufirst%3DX.%26aulast%3DBuechner%26aufirst%3DJ.%26aulast%3DJung%26aufirst%3DA.%26aulast%3DH%25C3%25A4hlen%26aufirst%3DK.%26aulast%3DHasle%26aufirst%3DH.%26aulast%3DLicht%26aufirst%3DJ.%2BD.%26aulast%3DGelb%26aufirst%3DB.%2BD.%26atitle%3DSomatic%2520Mutations%2520in%2520PTPN11%2520in%2520Juvenile%2520Myelomonocytic%2520Leukemia%252C%2520Myelodysplastic%2520Syndromes%2520and%2520Acute%2520Myeloid%2520Leukemia%26jtitle%3DNat.%2520Genet.%26date%3D2003%26volume%3D34%26spage%3D148%26epage%3D150%26doi%3D10.1038%2Fng1156" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalaitzidis, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neel, B. G.</span></span> <span> </span><span class="NLM_article-title">The Tyrosine Phosphatase SHP2 (<i>PTPN11</i>) in Cancer</span>. <i>Cancer Metastasis Rev.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">179</span>– <span class="NLM_lpage">192</span>, <span class="refDoi"> DOI: 10.1007/s10555-008-9126-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=10.1007%2Fs10555-008-9126-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=18286234" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlt1Ckur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2008&pages=179-192&author=G.+Chanauthor=D.+Kalaitzidisauthor=B.+G.+Neel&title=The+Tyrosine+Phosphatase+SHP2+%28PTPN11%29+in+Cancer&doi=10.1007%2Fs10555-008-9126-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3aR"><div class="casContent"><span class="casTitleNuber">3a</span><div class="casTitle"><span class="NLM_cas:atitle">The tyrosine phosphatase Shp2 (PTPN11) in cancer</span></div><div class="casAuthors">Chan, Gordon; Kalaitzidis, Demetrios; Neel, Benjamin G.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer and Metastasis Reviews</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">179-192</span>CODEN:
                <span class="NLM_cas:coden">CMRED4</span>;
        ISSN:<span class="NLM_cas:issn">0167-7659</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Diverse cellular processes are regulated by tyrosyl phosphorylation, which is controlled by protein-tyrosine kinases (PTKs) and protein-tyrosine phosphatases (PTPs).  De-regulated tyrosyl phosphorylation, evoked by gain-of-function mutations and/or over-expression of PTKs, contributes to the pathogenesis of many cancers and other human diseases.  PTPs, because they oppose the action of PTKs, had been considered to be prime suspects for potential tumor suppressor genes.  Surprisingly, few, if any, tumor suppressor PTPs have been identified.  However, the Src homol.-2 domain-contg. phosphatase Shp2 (encoded by PTPN11) is a bona fide proto-oncogene.  Germline mutations in PTPN11 cause Noonan and LEOPARD syndromes, whereas somatic PTPN11 mutations occur in several types of hematol. malignancies, most notably juvenile myelomonocytic leukemia and, more rarely, in solid tumors.  Shp2 also is an essential component in several other oncogene signaling pathways.  Elucidation of the events underlying Shp2-evoked transformation may provide new insights into oncogenic mechanisms and novel targets for anti-cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbJ8OYsBzvg7Vg90H21EOLACvtfcHk0lgdycq_nnx50A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlt1Ckur4%253D&md5=fb514f60b97f8ff0dcc0dbd57cab2c9a</span></div><a href="/servlet/linkout?suffix=cit3a&amp;dbid=16384&amp;doi=10.1007%2Fs10555-008-9126-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10555-008-9126-y%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DG.%26aulast%3DKalaitzidis%26aufirst%3DD.%26aulast%3DNeel%26aufirst%3DB.%2BG.%26atitle%3DThe%2520Tyrosine%2520Phosphatase%2520SHP2%2520%2528PTPN11%2529%2520in%2520Cancer%26jtitle%3DCancer%2520Metastasis%2520Rev.%26date%3D2008%26volume%3D27%26spage%3D179%26epage%3D192%26doi%3D10.1007%2Fs10555-008-9126-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit3b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Miyamoto, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyamoto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yomogita, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higashi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatakeyama, M.</span></span> <span> </span><span class="NLM_article-title">Isolation of a Distinct Class of Gain-of-Function SHP-2 Mutants with Oncogenic RAS-like Transforming Activity from Solid Tumors</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">3508</span>– <span class="NLM_lpage">3515</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1211019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=10.1038%2Fsj.onc.1211019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=18223690" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmslWmurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2008&pages=3508-3515&author=D.+Miyamotoauthor=M.+Miyamotoauthor=A.+Takahashiauthor=Y.+Yomogitaauthor=H.+Higashiauthor=S.+Kondoauthor=M.+Hatakeyama&title=Isolation+of+a+Distinct+Class+of+Gain-of-Function+SHP-2+Mutants+with+Oncogenic+RAS-like+Transforming+Activity+from+Solid+Tumors&doi=10.1038%2Fsj.onc.1211019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3bR"><div class="casContent"><span class="casTitleNuber">3b</span><div class="casTitle"><span class="NLM_cas:atitle">Isolation of a distinct class of gain-of-function SHP-2 mutants with oncogenic RAS-like transforming activity from solid tumors</span></div><div class="casAuthors">Miyamoto, D.; Miyamoto, M.; Takahashi, A.; Yomogita, Y.; Higashi, H.; Kondo, S.; Hatakeyama, M.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">3508-3515</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">SHP-2 protein tyrosine phosphatase plays an important role in activation of the RAS-dependent signaling.  Gain-of-function mutations in the PTPN11 gene, which encodes SHP-2, have been found in the leukemia-prone developmental disorder Noonan syndrome as well as sporadic childhood leukemias, indicating that SHP-2 is a bona fide human oncoprotein.  However, the role of SHP-2 mutations in non-hematol. malignancies remains obscure.  Here, we screened for PTPN11 mutations in primary solid tumors and identified a 1520C>A mutation that causes threonine-507 to lysine (T507K) substitution in the phosphatase domain of SHP-2 in a case of hepatocellular carcinoma.  T507K SHP-2 exhibited altered substrate specificity with slightly elevated basal phosphatase activity.  Upon expression in NIH3T3 cells, T507K SHP-2 induced transformed foci, which was not obsd. with wild type, Noonan-specific or leukemia-specific SHP-2.  Furthermore, NIH3T3 cells transformed by T507K SHP-2 showed anchorage-independent growth and developed tumors in nude mice.  These results indicate that quant. and/or qual. alteration in phosphatase activity dets. the transforming potential as well as target cell/tissue spectrum of individual SHP-2 mutants as oncoproteins.  Although rare in solid tumors, the identified T507K SHP-2 represents a distinct class of SHP-2 mutants with oncogenic RAS-like transforming activity, which could contribute to the development of solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwOMpOPEfD0rVg90H21EOLACvtfcHk0lgdycq_nnx50A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmslWmurY%253D&md5=e0a0e2df71b6998a92b40bbba05ffef8</span></div><a href="/servlet/linkout?suffix=cit3b&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1211019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1211019%26sid%3Dliteratum%253Aachs%26aulast%3DMiyamoto%26aufirst%3DD.%26aulast%3DMiyamoto%26aufirst%3DM.%26aulast%3DTakahashi%26aufirst%3DA.%26aulast%3DYomogita%26aufirst%3DY.%26aulast%3DHigashi%26aufirst%3DH.%26aulast%3DKondo%26aufirst%3DS.%26aulast%3DHatakeyama%26aufirst%3DM.%26atitle%3DIsolation%2520of%2520a%2520Distinct%2520Class%2520of%2520Gain-of-Function%2520SHP-2%2520Mutants%2520with%2520Oncogenic%2520RAS-like%2520Transforming%2520Activity%2520from%2520Solid%2520Tumors%26jtitle%3DOncogene%26date%3D2008%26volume%3D27%26spage%3D3508%26epage%3D3515%26doi%3D10.1038%2Fsj.onc.1211019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Neel, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pao, L.</span></span> <span> </span><span class="NLM_article-title">The ‘Shp’ing News: SH2 Domain-Containing Tyrosine Phosphatases in Cell Signaling</span>. <i>Trends Biochem. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">284</span>– <span class="NLM_lpage">293</span>, <span class="refDoi"> DOI: 10.1016/S0968-0004(03)00091-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=10.1016%2FS0968-0004%2803%2900091-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=12826400" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADC%252BD3sXkvVCnu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2003&pages=284-293&author=B.+G.+Neelauthor=H.+Guauthor=L.+Pao&title=The+%E2%80%98Shp%E2%80%99ing+News%3A+SH2+Domain-Containing+Tyrosine+Phosphatases+in+Cell+Signaling&doi=10.1016%2FS0968-0004%2803%2900091-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4aR"><div class="casContent"><span class="casTitleNuber">4a</span><div class="casTitle"><span class="NLM_cas:atitle">The Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling</span></div><div class="casAuthors">Neel, Benjamin G.; Gu, Haihua; Pao, Lily</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Biochemical Sciences</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">284-293</span>CODEN:
                <span class="NLM_cas:coden">TBSCDB</span>;
        ISSN:<span class="NLM_cas:issn">0968-0004</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Src homol.-2 (SH2) domain-contg. phosphatases (Shps) are a small, highly conserved subfamily of protein tyrosine phosphatases, members of which are present in both vertebrates and invertebrates.  The mechanism of regulation of Shps by ligand binding is now well understood.  Much is also known about the normal signaling pathways regulated by each Shp and the consequences of Shp deficiency.  Recent studies have identified mutations in human Shp2 as the cause of the inherited disorder, Noonan syndrome.  Shp2 mutations might also contribute to the pathogenesis of some leukemias.  In addn., Shp2 might be a key virulence determinant for the important human pathogen, Helicobacter pylori.  Despite these efforts, however, the key targets of each Shp have remained elusive.  Identifying these substrates remains a major challenge for future research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7zIEChntK0rVg90H21EOLACvtfcHk0ljktClhfF5ScA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXkvVCnu7k%253D&md5=bce9fc3db0a41b29ba605251dc46c64f</span></div><a href="/servlet/linkout?suffix=cit4a&amp;dbid=16384&amp;doi=10.1016%2FS0968-0004%2803%2900091-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0968-0004%252803%252900091-4%26sid%3Dliteratum%253Aachs%26aulast%3DNeel%26aufirst%3DB.%2BG.%26aulast%3DGu%26aufirst%3DH.%26aulast%3DPao%26aufirst%3DL.%26atitle%3DThe%2520%25E2%2580%2598Shp%25E2%2580%2599ing%2520News%253A%2520SH2%2520Domain-Containing%2520Tyrosine%2520Phosphatases%2520in%2520Cell%2520Signaling%26jtitle%3DTrends%2520Biochem.%2520Sci.%26date%3D2003%26volume%3D28%26spage%3D284%26epage%3D293%26doi%3D10.1016%2FS0968-0004%2803%2900091-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit4b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, G. S.</span></span> <span> </span><span class="NLM_article-title">PTPN11 is the First Identified Proto-Oncogene That Encodes a Tyrosine Phosphatase</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">862</span>– <span class="NLM_lpage">867</span>, <span class="refDoi"> DOI: 10.1182/blood-2006-07-028829</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=10.1182%2Fblood-2006-07-028829" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=17053061" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjtFersLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2007&pages=862-867&author=R.+J.+Chanauthor=G.+S.+Feng&title=PTPN11+is+the+First+Identified+Proto-Oncogene+That+Encodes+a+Tyrosine+Phosphatase&doi=10.1182%2Fblood-2006-07-028829"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4bR"><div class="casContent"><span class="casTitleNuber">4b</span><div class="casTitle"><span class="NLM_cas:atitle">PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase</span></div><div class="casAuthors">Chan, Rebecca J.; Feng, Gen-Sheng</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">862-867</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">A review.  Elucidation of the mol. mechanisms underlying carcinogenesis has benefited tremendously from the identification and characterization of oncogenes and tumor suppressor genes.  One new advance in this field is the identification of PTPN11 as the first proto-oncogene that encodes a cytoplasmic tyrosine phosphatase with 2 Src-homol. 2 (SH2) domains (Shp2).  This tyrosine phosphatase was previously shown to play an essential role in normal hematopoiesis.  More recently, somatic missense PTPN11 gain-of-function mutations were detected in leukemias and rarely in solid tumors, and were found to induce aberrant hyperactivation of the Ras-Erk pathway.  This progress represents another milestone in the leukemia/cancer research field and provides a fresh view on the mol. mechanisms underlying cell transformation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqsuOora-d37Vg90H21EOLACvtfcHk0ljktClhfF5ScA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjtFersLg%253D&md5=8c5760a6ac385635f9794acbf5b64a03</span></div><a href="/servlet/linkout?suffix=cit4b&amp;dbid=16384&amp;doi=10.1182%2Fblood-2006-07-028829&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2006-07-028829%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DR.%2BJ.%26aulast%3DFeng%26aufirst%3DG.%2BS.%26atitle%3DPTPN11%2520is%2520the%2520First%2520Identified%2520Proto-Oncogene%2520That%2520Encodes%2520a%2520Tyrosine%2520Phosphatase%26jtitle%3DBlood%26date%3D2007%26volume%3D109%26spage%3D862%26epage%3D867%26doi%3D10.1182%2Fblood-2006-07-028829" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit4c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Tiganis, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, A. M.</span></span> <span> </span><span class="NLM_article-title">Protein Tyrosine Phosphatase Function: the Substrated Perspective</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>402</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">15</span>, <span class="refDoi"> DOI: 10.1042/BJ20061548</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=10.1042%2FBJ20061548" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=17238862" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADC%252BD2sXosFOisQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=402&publication_year=2007&pages=1-15&author=T.+Tiganisauthor=A.+M.+Bennett&title=Protein+Tyrosine+Phosphatase+Function%3A+the+Substrated+Perspective&doi=10.1042%2FBJ20061548"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4cR"><div class="casContent"><span class="casTitleNuber">4c</span><div class="casTitle"><span class="NLM_cas:atitle">Protein tyrosine phosphatase function: the substrate perspective</span></div><div class="casAuthors">Tiganis, Tony; Bennett, Anton M.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">402</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-15</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">A review.  It is now well established that the members of the protein tyrosine phosphatase (PTP) superfamily play crit. roles in fundamental biol. processes.  Although there has been much progress in defining the function of PTPs, the task of identifying substrates for these enzymes still presents a challenge.  Many PTPs have yet to have their physiol. substrates identified.  The focus of this review is on the current state of knowledge of PTP substrates and the approaches used to identify them.  The authors propose exptl. criteria that should be satisfied in order to rigorously assign PTP substrates as bona fide.  Finally, the progress that has been made in defining the biol. roles of PTPs through the identification of their substrates is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGod89zW3LtOs7Vg90H21EOLACvtfcHk0ljktClhfF5ScA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXosFOisQ%253D%253D&md5=e0b404da50fc57e25efe140026d6cd53</span></div><a href="/servlet/linkout?suffix=cit4c&amp;dbid=16384&amp;doi=10.1042%2FBJ20061548&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBJ20061548%26sid%3Dliteratum%253Aachs%26aulast%3DTiganis%26aufirst%3DT.%26aulast%3DBennett%26aufirst%3DA.%2BM.%26atitle%3DProtein%2520Tyrosine%2520Phosphatase%2520Function%253A%2520the%2520Substrated%2520Perspective%26jtitle%3DBiochem.%2520J.%26date%3D2007%26volume%3D402%26spage%3D1%26epage%3D15%26doi%3D10.1042%2FBJ20061548" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bunda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrell, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heir, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alamsahebpour, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kano, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raught, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zadeh, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohh, M.</span></span> <span> </span><span class="NLM_article-title">Inhibition of SHP2-Mediated Dephosphorylation of Ras Suppresses Oncogenesis</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">8859</span>, <span class="refDoi"> DOI: 10.1038/ncomms9859</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=10.1038%2Fncomms9859" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=26617336" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFWksLbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=8859&author=S.+Bundaauthor=K.+Burrellauthor=P.+Heirauthor=L.+Zengauthor=A.+Alamsahebpourauthor=Y.+Kanoauthor=B.+Raughtauthor=Z.-Y.+Zhangauthor=G.+Zadehauthor=M.+Ohh&title=Inhibition+of+SHP2-Mediated+Dephosphorylation+of+Ras+Suppresses+Oncogenesis&doi=10.1038%2Fncomms9859"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of SHP2-mediated dephosphorylation of Ras suppresses oncogenesis</span></div><div class="casAuthors">Bunda, Severa; Burrell, Kelly; Heir, Pardeep; Zeng, Lifan; Alamsahebpour, Amir; Kano, Yoshihito; Raught, Brian; Zhang, Zhong-Yin; Zadeh, Gelareh; Ohh, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">8859</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Ras is phosphorylated on a conserved tyrosine at position 32 within the switch I region via Src kinase.  This phosphorylation inhibits the binding of effector Raf while promoting the engagement of GTPase-activating protein (GAP) and GTP hydrolysis.  Here we identify SHP2 as the ubiquitously expressed tyrosine phosphatase that preferentially binds to and dephosphorylates Ras to increase its assocn. with Raf and activate downstream proliferative Ras/ERK/MAPK signalling.  In comparison to normal astrocytes, SHP2 activity is elevated in astrocytes isolated from glioblastoma multiforme (GBM)-prone H-Ras(12V) knock-in mice as well as in glioma cell lines and patient-derived GBM specimens exhibiting hyperactive Ras.  Pharmacol. inhibition of SHP2 activity attenuates cell proliferation, soft-agar colony formation and orthotopic GBM growth in NOD/SCID mice and decelerates the progression of low-grade astrocytoma to GBM in a spontaneous transgenic glioma mouse model.  These results identify SHP2 as a direct activator of Ras and a potential therapeutic target for cancers driven by a previously 'undruggable' oncogenic or hyperactive Ras.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhWi25AJiphrVg90H21EOLACvtfcHk0ljktClhfF5ScA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFWksLbP&md5=8524ad9cc6f2e85abaff6b07c698f464</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fncomms9859&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms9859%26sid%3Dliteratum%253Aachs%26aulast%3DBunda%26aufirst%3DS.%26aulast%3DBurrell%26aufirst%3DK.%26aulast%3DHeir%26aufirst%3DP.%26aulast%3DZeng%26aufirst%3DL.%26aulast%3DAlamsahebpour%26aufirst%3DA.%26aulast%3DKano%26aufirst%3DY.%26aulast%3DRaught%26aufirst%3DB.%26aulast%3DZhang%26aufirst%3DZ.-Y.%26aulast%3DZadeh%26aufirst%3DG.%26aulast%3DOhh%26aufirst%3DM.%26atitle%3DInhibition%2520of%2520SHP2-Mediated%2520Dephosphorylation%2520of%2520Ras%2520Suppresses%2520Oncogenesis%26jtitle%3DNat.%2520Commun.%26date%3D2015%26volume%3D6%26spage%3D8859%26doi%3D10.1038%2Fncomms9859" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kovats, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velazquez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pant, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shirley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleming, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexander, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farsidjani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaMarche, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moody, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silver, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caponigro, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuart, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abrams, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammerman, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldoni, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohseni, M.</span></span> <span> </span><span class="NLM_article-title">Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS Mutant Cancers</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">2368</span>– <span class="NLM_lpage">2380</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-19-0170</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=10.1158%2F1535-7163.MCT-19-0170" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=31439712" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADC%252BB3cXktFOiur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2019&pages=2368-2380&author=H.+Haoauthor=H.+Wangauthor=C.+Liuauthor=S.+Kovatsauthor=R.+Velazquezauthor=H.+Luauthor=B.+Pantauthor=M.+Shirleyauthor=M.+J.+Meyerauthor=M.+Puauthor=J.+Limauthor=M.+Flemingauthor=L.+Alexanderauthor=A.+Farsidjaniauthor=M.+J.+LaMarcheauthor=S.+Moodyauthor=S.+J.+Silverauthor=G.+Caponigroauthor=D.+D.+Stuartauthor=T.+J.+Abramsauthor=P.+S.+Hammermanauthor=J.+Williamsauthor=J.+A.+Engelmanauthor=S.+Goldoniauthor=M.+Mohseni&title=Tumor+Intrinsic+Efficacy+by+SHP2+and+RTK+Inhibitors+in+KRAS+Mutant+Cancers&doi=10.1158%2F1535-7163.MCT-19-0170"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Tumor intrinsic efficacy by SHP2 and RTK inhibitors in KRAS-mutant cancers</span></div><div class="casAuthors">Hao, Huai-Xiang; Wang, Hongyun; Liu, Chen; Kovats, Steven; Velazquez, Roberto; Lu, Hengyu; Pant, Bhavesh; Shirley, Matthew; Meyer, Matthew J.; Pu, Minying; Lim, Joanne; Fleming, Michael; Alexander, Leigh Ann; Farsidjani, Ali; LaMarche, Matthew J.; Moody, Susan; Silver, Serena J.; Caponigro, Giordano; Stuart, Darrin D.; Abrams, Tinya J.; Hammerman, Peter S.; Williams, Juliet; Engelman, Jeffrey A.; Goldoni, Silvia; Mohseni, Morvarid</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2368-2380</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">KRAS, an oncogene mutated in nearly one third of human cancers, remains a pharmacol. challenge for direct inhibition except for recent advances in selective inhibitors targeting the G12C variant.  Here, we report that selective inhibition of the protein tyrosine phosphatase, SHP2, can impair the proliferation of KRAS-mutant cancer cells in vitro and in vivo using cell line xenografts and primary human tumors.  In vitro, sensitivity of KRAS-mutant cells toward the allosteric SHP2 inhibitor, SHP099, is not apparent when cells are grown on plastic in 2D monolayer, but is revealed when cells are grown as 3D multicellular spheroids.  This antitumor activity is also obsd. in vivo in mouse models.  Interrogation of the MAPK pathway in SHP099-treated KRAS-mutant cancer models demonstrated similar modulation of p-ERK and DUSP6 transcripts in 2D, 3D, and in vivo, suggesting a MAPK pathway-dependent mechanism and possible non-MAPK pathway-dependent mechanisms in tumor cells or tumor microenvironment for the in vivo efficacy.  For the KRASG12C MIAPaCa-2 model, we demonstrate that the efficacy is cancer cell intrinsic as there is minimal antiangiogenic activity by SHP099, and the effects of SHP099 is recapitulated by genetic depletion of SHP2 in cancer cells.  Furthermore, we demonstrate that SHP099 efficacy in KRAS-mutant models can be recapitulated with RTK inhibitors, suggesting RTK activity is responsible for the SHP2 activation.  Taken together, these data reveal that many KRAS-mutant cancers depend on upstream signaling from RTK and SHP2, and provide a new therapeutic framework for treating KRAS-mutant cancers with SHP2 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1sXDzXA3V7bVg90H21EOLACvtfcHk0lgMyZI6XgzpQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXktFOiur4%253D&md5=00f008e63ad5edc091cf18a60fe2aed2</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-19-0170&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-19-0170%26sid%3Dliteratum%253Aachs%26aulast%3DHao%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DKovats%26aufirst%3DS.%26aulast%3DVelazquez%26aufirst%3DR.%26aulast%3DLu%26aufirst%3DH.%26aulast%3DPant%26aufirst%3DB.%26aulast%3DShirley%26aufirst%3DM.%26aulast%3DMeyer%26aufirst%3DM.%2BJ.%26aulast%3DPu%26aufirst%3DM.%26aulast%3DLim%26aufirst%3DJ.%26aulast%3DFleming%26aufirst%3DM.%26aulast%3DAlexander%26aufirst%3DL.%26aulast%3DFarsidjani%26aufirst%3DA.%26aulast%3DLaMarche%26aufirst%3DM.%2BJ.%26aulast%3DMoody%26aufirst%3DS.%26aulast%3DSilver%26aufirst%3DS.%2BJ.%26aulast%3DCaponigro%26aufirst%3DG.%26aulast%3DStuart%26aufirst%3DD.%2BD.%26aulast%3DAbrams%26aufirst%3DT.%2BJ.%26aulast%3DHammerman%26aufirst%3DP.%2BS.%26aulast%3DWilliams%26aufirst%3DJ.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DGoldoni%26aufirst%3DS.%26aulast%3DMohseni%26aufirst%3DM.%26atitle%3DTumor%2520Intrinsic%2520Efficacy%2520by%2520SHP2%2520and%2520RTK%2520Inhibitors%2520in%2520KRAS%2520Mutant%2520Cancers%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2019%26volume%3D18%26spage%3D2368%26epage%3D2380%26doi%3D10.1158%2F1535-7163.MCT-19-0170" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bivona, T. G.</span></span> <span> </span><span class="NLM_article-title">Dampening Oncogenic RAS Signaling</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>363</i></span>,  <span class="NLM_fpage">1280</span>– <span class="NLM_lpage">1281</span>, <span class="refDoi"> DOI: 10.1126/science.aav6703</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=10.1126%2Fscience.aav6703" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=30898918" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFCju73E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2019&pages=1280-1281&author=T.+G.+Bivona&title=Dampening+Oncogenic+RAS+Signaling&doi=10.1126%2Fscience.aav6703"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Dampening oncogenic RAS signaling: recent insights into the mechanism of oncogenic RAS prompt new anticancer strategies</span></div><div class="casAuthors">Bivona, Trever G.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">6433</span>),
    <span class="NLM_cas:pages">1280-1281</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">A review.  The conventional model of oncogenic RAS-MAPK pathway signaling in cancer suggests that mutations in the pathway render downstream signaling largely independent of regulation (autonomous).  However, the emerging model of a semiautonomous state through which pathol. RAS signaling remains under some control suggests a potential therapeutic opportunity to target upstream regulators, such as SHP2, SOS, and GRB2.  The recent insights into the mechanism of oncogenic RAS prompt new anticancer strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfVFpPtfDfXbVg90H21EOLACvtfcHk0lgMyZI6XgzpQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFCju73E&md5=c73f3524e9d328397dce7324af0d6c3e</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1126%2Fscience.aav6703&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aav6703%26sid%3Dliteratum%253Aachs%26aulast%3DBivona%26aufirst%3DT.%2BG.%26atitle%3DDampening%2520Oncogenic%2520RAS%2520Signaling%26jtitle%3DScience%26date%3D2019%26volume%3D363%26spage%3D1280%26epage%3D1281%26doi%3D10.1126%2Fscience.aav6703" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mainardi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulero-Sanchez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prahallad, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Germano, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krimpenfort, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lieftink, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinberg, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Wit, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goncalves-Ribeiro, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nadal, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bardelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villanueva, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernards, R.</span></span> <span> </span><span class="NLM_article-title">SHP2 is Required for Growth of KRAS-Mutant Non-Small-Cell Lung Cancer <i>In Vivo</i></span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">961</span>– <span class="NLM_lpage">967</span>, <span class="refDoi"> DOI: 10.1038/s41591-018-0023-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=10.1038%2Fs41591-018-0023-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=29808006" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVelsbvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=961-967&author=S.+Mainardiauthor=A.+Mulero-Sanchezauthor=A.+Prahalladauthor=G.+Germanoauthor=A.+Bosmaauthor=P.+Krimpenfortauthor=C.+Lieftinkauthor=J.+D.+Steinbergauthor=N.+de+Witauthor=S.+Goncalves-Ribeiroauthor=E.+Nadalauthor=A.+Bardelliauthor=A.+Villanuevaauthor=R.+Bernards&title=SHP2+is+Required+for+Growth+of+KRAS-Mutant+Non-Small-Cell+Lung+Cancer+In+Vivo&doi=10.1038%2Fs41591-018-0023-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo</span></div><div class="casAuthors">Mainardi, Sara; Mulero-Sanchez, Antonio; Prahallad, Anirudh; Germano, Giovanni; Bosma, Astrid; Krimpenfort, Paul; Lieftink, Cor; Steinberg, Jeffrey D.; de Wit, Niels; Goncalves-Ribeiro, Samuel; Nadal, Ernest; Bardelli, Alberto; Villanueva, Alberto; Bernards, Rene</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">961-967</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">RAS mutations are frequent in human cancer, esp. in pancreatic, colorectal and non-small-cell lung cancers (NSCLCs).  Inhibition of the RAS oncoproteins has proven difficult, and attempts to target downstream effectors have been hampered by the activation of compensatory resistance mechanisms.  It is also well established that KRAS-mutant tumors are insensitive to inhibition of upstream growth factor receptor signaling.  Thus, epidermal growth factor receptor antibody therapy is only effective in KRAS wild-type colon cancers.  Consistently, inhibition of SHP2 (also known as PTPN11), which links receptor tyrosine kinase signaling to the RAS-RAF-MEK-ERK pathway11,12, was shown to be ineffective in KRAS-mutant or BRAF-mutant cancer cell lines.  Tha data also indicate that SHP2 inhibition in KRAS-mutant NSCLC cells under normal cell culture conditions has little effect.  By contrast, SHP2 inhibition under growth factor-limiting conditions in vitro results in a senescence response.  In vivo, inhibition of SHP2 in KRAS-mutant NSCLC also provokes a senescence response, which is exacerbated by MEK inhibition.  Tha data identify SHP2 inhibition as an unexpected vulnerability of KRAS-mutant NSCLC cells that remains undetected in cell culture and can be exploited therapeutically.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLHUMCtBqtZrVg90H21EOLACvtfcHk0liV24yBIcUNXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVelsbvL&md5=8e1ce1eb5d30d3985aafdec9d07f205d</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fs41591-018-0023-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41591-018-0023-9%26sid%3Dliteratum%253Aachs%26aulast%3DMainardi%26aufirst%3DS.%26aulast%3DMulero-Sanchez%26aufirst%3DA.%26aulast%3DPrahallad%26aufirst%3DA.%26aulast%3DGermano%26aufirst%3DG.%26aulast%3DBosma%26aufirst%3DA.%26aulast%3DKrimpenfort%26aufirst%3DP.%26aulast%3DLieftink%26aufirst%3DC.%26aulast%3DSteinberg%26aufirst%3DJ.%2BD.%26aulast%3Dde%2BWit%26aufirst%3DN.%26aulast%3DGoncalves-Ribeiro%26aufirst%3DS.%26aulast%3DNadal%26aufirst%3DE.%26aulast%3DBardelli%26aufirst%3DA.%26aulast%3DVillanueva%26aufirst%3DA.%26aulast%3DBernards%26aufirst%3DR.%26atitle%3DSHP2%2520is%2520Required%2520for%2520Growth%2520of%2520KRAS-Mutant%2520Non-Small-Cell%2520Lung%2520Cancer%2520In%2520Vivo%26jtitle%3DNat.%2520Med.%26date%3D2018%26volume%3D24%26spage%3D961%26epage%3D967%26doi%3D10.1038%2Fs41591-018-0023-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xue, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aronowitz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mai, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vides, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qeriqi, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Stanchina, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazutis, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Risso, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lito, P.</span></span> <span> </span><span class="NLM_article-title">Rapid Non-Uniform Adaptation to Conformation-Specific KRAS(G12C) Inhibition</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>577</i></span>,  <span class="NLM_fpage">421</span>– <span class="NLM_lpage">425</span>, <span class="refDoi"> DOI: 10.1038/s41586-019-1884-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=10.1038%2Fs41586-019-1884-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=31915379" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADC%252BB3cXlsleisA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=577&publication_year=2020&pages=421-425&author=J.+Y.+Xueauthor=Y.+Zhaoauthor=J.+Aronowitzauthor=T.+T.+Maiauthor=A.+Videsauthor=B.+Qeriqiauthor=D.+Kimauthor=C.+Liauthor=E.+de+Stanchinaauthor=L.+Mazutisauthor=D.+Rissoauthor=P.+Lito&title=Rapid+Non-Uniform+Adaptation+to+Conformation-Specific+KRAS%28G12C%29+Inhibition&doi=10.1038%2Fs41586-019-1884-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition</span></div><div class="casAuthors">Xue, Jenny Y.; Zhao, Yulei; Aronowitz, Jordan; Mai, Trang T.; Vides, Alberto; Qeriqi, Besnik; Kim, Dongsung; Li, Chuanchuan; de Stanchina, Elisa; Mazutis, Linas; Risso, Davide; Lito, Piro</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">577</span>
        (<span class="NLM_cas:issue">7790</span>),
    <span class="NLM_cas:pages">421-425</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">KRAS GTPases are activated in one-third of cancers, and KRAS(G12C) is one of the most common activating alterations in lung adenocarcinoma1,2.  KRAS(G12C) inhibitors3,4 are in phase-I clin. trials and early data show partial responses in nearly half of patients with lung cancer.  How cancer cells bypass inhibition to prevent maximal response to therapy is not understood.  Because KRAS(G12C) cycles between an active and inactive conformation4-6, and the inhibitors bind only to the latter, we tested whether isogenic cell populations respond in a non-uniform manner by studying the effect of treatment at a single-cell resoln.  Here we report that, shortly after treatment, some cancer cells are sequestered in a quiescent state with low KRAS activity, whereas others bypass this effect to resume proliferation.  This rapid divergent response occurs because some quiescent cells produce new KRAS(G12C) in response to suppressed mitogen-activated protein kinase output.  New KRAS(G12C) is maintained in its active, drug-insensitive state by epidermal growth factor receptor and aurora kinase signalling.  Cells without these adaptive changes-or cells in which these changes are pharmacol. inhibited-remain sensitive to drug treatment, because new KRAS(G12C) is either not available or exists in its inactive, drug-sensitive state.  The direct targeting of KRAS oncoproteins has been a longstanding objective in precision oncol.  Our study uncovers a flexible non-uniform fitness mechanism that enables groups of cells within a population to rapidly bypass the effect of treatment.  This adaptive process must be overcome if we are to achieve complete and durable responses in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqs98vxCKonTbVg90H21EOLACvtfcHk0liV24yBIcUNXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXlsleisA%253D%253D&md5=23df9a8dc75959ebb136f3412e40fc36</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fs41586-019-1884-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41586-019-1884-x%26sid%3Dliteratum%253Aachs%26aulast%3DXue%26aufirst%3DJ.%2BY.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DAronowitz%26aufirst%3DJ.%26aulast%3DMai%26aufirst%3DT.%2BT.%26aulast%3DVides%26aufirst%3DA.%26aulast%3DQeriqi%26aufirst%3DB.%26aulast%3DKim%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DC.%26aulast%3Dde%2BStanchina%26aufirst%3DE.%26aulast%3DMazutis%26aufirst%3DL.%26aulast%3DRisso%26aufirst%3DD.%26aulast%3DLito%26aufirst%3DP.%26atitle%3DRapid%2520Non-Uniform%2520Adaptation%2520to%2520Conformation-Specific%2520KRAS%2528G12C%2529%2520Inhibition%26jtitle%3DNature%26date%3D2020%26volume%3D577%26spage%3D421%26epage%3D425%26doi%3D10.1038%2Fs41586-019-1884-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ruess, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heynen, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciecielski, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berninger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kabacaoglu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Görgülü, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dantes, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wörmann, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diakopoulos, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karpathaki, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kowalska, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaya-Aksoy, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeeuw van der Laan, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">López-Alberca, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nazaré, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saur, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erkan, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopt, U. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sainz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birchmeier, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmid, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Algül, H.</span></span> <span> </span><span class="NLM_article-title">Mutant KRAS-Driven Cancers Depend on PTPN11/SHP2 Phosphatase</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">954</span>– <span class="NLM_lpage">960</span>, <span class="refDoi"> DOI: 10.1038/s41591-018-0024-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=10.1038%2Fs41591-018-0024-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=29808009" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVelsbvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=954-960&author=D.+A.+Ruessauthor=G.+J.+Heynenauthor=K.+J.+Ciecielskiauthor=J.+Aiauthor=A.+Berningerauthor=D.+Kabacaogluauthor=K.+G%C3%B6rg%C3%BCl%C3%BCauthor=Z.+Dantesauthor=S.+M.+W%C3%B6rmannauthor=K.+N.+Diakopoulosauthor=A.+F.+Karpathakiauthor=M.+Kowalskaauthor=E.+Kaya-Aksoyauthor=L.+Songauthor=E.+A.+Zeeuw+van+der+Laanauthor=M.+P.+L%C3%B3pez-Albercaauthor=M.+Nazar%C3%A9author=M.+Reichertauthor=D.+Saurauthor=M.+M.+Erkanauthor=U.+T.+Hoptauthor=B.+Sainzauthor=W.+Birchmeierauthor=R.+M.+Schmidauthor=M.+Lesinaauthor=H.+Alg%C3%BCl&title=Mutant+KRAS-Driven+Cancers+Depend+on+PTPN11%2FSHP2+Phosphatase&doi=10.1038%2Fs41591-018-0024-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase</span></div><div class="casAuthors">Ruess, Dietrich A.; Heynen, Guus J.; Ciecielski, Katrin J.; Ai, Jiaoyu; Berninger, Alexandra; Kabacaoglu, Derya; Goerguelue, Kivanc; Dantes, Zahra; Woermann, Sonja M.; Diakopoulos, Kalliope N.; Karpathaki, Angeliki F.; Kowalska, Marlena; Kaya-Aksoy, Ezgi; Song, Liang; van der Laan, Eveline A. Zeeuw; Lopez-Alberca, Maria P.; Nazare, Marc; Reichert, Maximilian; Saur, Dieter; Erkan, Mert M.; Hopt, Ulrich T.; Sainz, Jr, Bruno; Birchmeier, Walter; Schmid, Roland M.; Lesina, Marina; Alguel, Hana</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">954-960</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The ubiquitously expressed non-receptor protein tyrosine phosphatase SHP2, encoded by PTPN11, is involved in signal transduction downstream of multiple growth factor, cytokine and integrin receptors1.  Its requirement for complete RAS-MAPK activation and its role as a neg. regulator of JAK-STAT signaling have established SHP2 as an essential player in oncogenic signaling pathways1-7.  Recently, a novel potent allosteric SHP2 inhibitor was presented as a viable therapeutic option for receptor tyrosine kinase-driven cancers, but was shown to be ineffective in KRAS-mutant tumor cell lines in vitro8.  Here, we report a central and indispensable role for SHP2 in oncogenic KRAS-driven tumors.  Genetic deletion of Ptpn11 profoundly inhibited tumor development in mutant KRAS-driven murine models of pancreatic ductal adenocarcinoma and non-small-cell lung cancer.  We provide evidence for a crit. dependence of mutant KRAS on SHP2 during carcinogenesis.  Deletion or inhibition of SHP2 in established tumors delayed tumor progression but was not sufficient to achieve tumor regression.  However, SHP2 was necessary for resistance mechanisms upon blockade of MEK.  Synergy was obsd. when both SHP2 and MEK were targeted, resulting in sustained tumor growth control in murine and human patient-derived organoids and xenograft models of pancreatic ductal adenocarcinoma and non-small-cell lung cancer.  Our data indicate the clin. utility of dual SHP2/MEK inhibition as a targeted therapy approach for KRAS-mutant cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoepq09hU77abVg90H21EOLACvtfcHk0liV24yBIcUNXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVelsbvF&md5=cc09897c2c4b8e32b035b991e5032f32</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fs41591-018-0024-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41591-018-0024-8%26sid%3Dliteratum%253Aachs%26aulast%3DRuess%26aufirst%3DD.%2BA.%26aulast%3DHeynen%26aufirst%3DG.%2BJ.%26aulast%3DCiecielski%26aufirst%3DK.%2BJ.%26aulast%3DAi%26aufirst%3DJ.%26aulast%3DBerninger%26aufirst%3DA.%26aulast%3DKabacaoglu%26aufirst%3DD.%26aulast%3DG%25C3%25B6rg%25C3%25BCl%25C3%25BC%26aufirst%3DK.%26aulast%3DDantes%26aufirst%3DZ.%26aulast%3DW%25C3%25B6rmann%26aufirst%3DS.%2BM.%26aulast%3DDiakopoulos%26aufirst%3DK.%2BN.%26aulast%3DKarpathaki%26aufirst%3DA.%2BF.%26aulast%3DKowalska%26aufirst%3DM.%26aulast%3DKaya-Aksoy%26aufirst%3DE.%26aulast%3DSong%26aufirst%3DL.%26aulast%3DZeeuw%2Bvan%2Bder%2BLaan%26aufirst%3DE.%2BA.%26aulast%3DL%25C3%25B3pez-Alberca%26aufirst%3DM.%2BP.%26aulast%3DNazar%25C3%25A9%26aufirst%3DM.%26aulast%3DReichert%26aufirst%3DM.%26aulast%3DSaur%26aufirst%3DD.%26aulast%3DErkan%26aufirst%3DM.%2BM.%26aulast%3DHopt%26aufirst%3DU.%2BT.%26aulast%3DSainz%26aufirst%3DB.%26aulast%3DBirchmeier%26aufirst%3DW.%26aulast%3DSchmid%26aufirst%3DR.%2BM.%26aulast%3DLesina%26aufirst%3DM.%26aulast%3DAlg%25C3%25BCl%26aufirst%3DH.%26atitle%3DMutant%2520KRAS-Driven%2520Cancers%2520Depend%2520on%2520PTPN11%252FSHP2%2520Phosphatase%26jtitle%3DNat.%2520Med.%26date%3D2018%26volume%3D24%26spage%3D954%26epage%3D960%26doi%3D10.1038%2Fs41591-018-0024-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nichols, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haderk, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahlhut, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulze, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hemmati, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wildes, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tzitzilonis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mordec, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marquez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olivas, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCoach, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blakely, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiss, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koltun, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gill, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldsmith, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J. A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bivona, T. G.</span></span> <span> </span><span class="NLM_article-title">RAS Nucleotide Cycling Underlies the SHP2 Phosphatase Dependence of Mutant BRAF-, NF1- and RAS-Driven Cancers</span>. <i>Nat. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1064</span>– <span class="NLM_lpage">1073</span>, <span class="refDoi"> DOI: 10.1038/s41556-018-0169-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=10.1038%2Fs41556-018-0169-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=30104724" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsV2isLnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2018&pages=1064-1073&author=R.+J.+Nicholsauthor=F.+Haderkauthor=C.+Stahlhutauthor=C.+J.+Schulzeauthor=G.+Hemmatiauthor=D.+Wildesauthor=C.+Tzitzilonisauthor=K.+Mordecauthor=A.+Marquezauthor=J.+Romeroauthor=T.+Hsiehauthor=A.+Zamanauthor=V.+Olivasauthor=C.+McCoachauthor=C.+M.+Blakelyauthor=Z.+Wangauthor=G.+Kissauthor=E.+S.+Koltunauthor=A.+L.+Gillauthor=M.+Singhauthor=M.+A.+Goldsmithauthor=J.+A.+M.+Smithauthor=T.+G.+Bivona&title=RAS+Nucleotide+Cycling+Underlies+the+SHP2+Phosphatase+Dependence+of+Mutant+BRAF-%2C+NF1-+and+RAS-Driven+Cancers&doi=10.1038%2Fs41556-018-0169-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers</span></div><div class="casAuthors">Nichols, Robert J.; Haderk, Franziska; Stahlhut, Carlos; Schulze, Christopher J.; Hemmati, Golzar; Wildes, David; Tzitzilonis, Christos; Mordec, Kasia; Marquez, Abby; Romero, Jason; Hsieh, Tientien; Zaman, Aubhishek; Olivas, Victor; McCoach, Caroline; Blakely, Collin M.; Wang, Zhengping; Kiss, Gert; Koltun, Elena S.; Gill, Adrian L.; Singh, Mallika; Goldsmith, Mark A.; Smith, Jacqueline A. M.; Bivona, Trever G.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Cell Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1064-1073</span>CODEN:
                <span class="NLM_cas:coden">NCBIFN</span>;
        ISSN:<span class="NLM_cas:issn">1465-7392</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Oncogenic alterations in the RAS/RAF/MEK/ERK pathway drive the growth of a wide spectrum of cancers.  While BRAF and MEK inhibitors are efficacious against BRAFV600E-driven cancers, effective targeted therapies are lacking for most cancers driven by other pathway alterations, including non-V600E oncogenic BRAF, RAS GTPase-activating protein (GAP) NF1 (neurofibromin 1) loss and oncogenic KRAS.  Here, we show that targeting the SHP2 phosphatase (encoded by PTPN11) with RMC-4550, a small-mol. allosteric inhibitor, is effective in human cancer models bearing RAS-GTP-dependent oncogenic BRAF (for example, class 3 BRAF mutants), NF1 loss or nucleotide-cycling oncogenic RAS (for example, KRASG12C).  SHP2 inhibitor treatment decreases oncogenic RAS/RAF/MEK/ERK signalling and cancer growth by disrupting SOS1-mediated RAS-GTP loading.  Our findings illuminate a crit. function for SHP2 in promoting oncogenic RAS/MAPK pathway activation in cancers with RAS-GTP-dependent oncogenic BRAF, NF1 loss and nucleotide-cycling oncogenic KRAS.  SHP2 inhibition is a promising mol. therapeutic strategy for patients with cancers bearing these oncogenic drivers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2gVKE5Juu_LVg90H21EOLACvtfcHk0lj-I5CRO-Vvpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsV2isLnP&md5=05e84e5c0d51d501c229e118f44aa6cd</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fs41556-018-0169-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41556-018-0169-1%26sid%3Dliteratum%253Aachs%26aulast%3DNichols%26aufirst%3DR.%2BJ.%26aulast%3DHaderk%26aufirst%3DF.%26aulast%3DStahlhut%26aufirst%3DC.%26aulast%3DSchulze%26aufirst%3DC.%2BJ.%26aulast%3DHemmati%26aufirst%3DG.%26aulast%3DWildes%26aufirst%3DD.%26aulast%3DTzitzilonis%26aufirst%3DC.%26aulast%3DMordec%26aufirst%3DK.%26aulast%3DMarquez%26aufirst%3DA.%26aulast%3DRomero%26aufirst%3DJ.%26aulast%3DHsieh%26aufirst%3DT.%26aulast%3DZaman%26aufirst%3DA.%26aulast%3DOlivas%26aufirst%3DV.%26aulast%3DMcCoach%26aufirst%3DC.%26aulast%3DBlakely%26aufirst%3DC.%2BM.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DKiss%26aufirst%3DG.%26aulast%3DKoltun%26aufirst%3DE.%2BS.%26aulast%3DGill%26aufirst%3DA.%2BL.%26aulast%3DSingh%26aufirst%3DM.%26aulast%3DGoldsmith%26aufirst%3DM.%2BA.%26aulast%3DSmith%26aufirst%3DJ.%2BA.%2BM.%26aulast%3DBivona%26aufirst%3DT.%2BG.%26atitle%3DRAS%2520Nucleotide%2520Cycling%2520Underlies%2520the%2520SHP2%2520Phosphatase%2520Dependence%2520of%2520Mutant%2520BRAF-%252C%2520NF1-%2520and%2520RAS-Driven%2520Cancers%26jtitle%3DNat.%2520Cell%2520Biol.%26date%3D2018%26volume%3D20%26spage%3D1064%26epage%3D1073%26doi%3D10.1038%2Fs41556-018-0169-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jie, H.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lei, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gildener-Leapman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trivedi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kane, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferris, R. L.</span></span> <span> </span><span class="NLM_article-title">PD-1/SHP-2 Inhibits Tc1/Th1 Phenotypic Responses and the Activation of T Cells in the Tumor Microenvironment</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">508</span>– <span class="NLM_lpage">518</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-14-1215</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=10.1158%2F0008-5472.CAN-14-1215" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=25480946" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVenurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=508-518&author=J.+Liauthor=H.-B.+Jieauthor=Y.+Leiauthor=N.+Gildener-Leapmanauthor=S.+Trivediauthor=T.+Greenauthor=L.+P.+Kaneauthor=R.+L.+Ferris&title=PD-1%2FSHP-2+Inhibits+Tc1%2FTh1+Phenotypic+Responses+and+the+Activation+of+T+Cells+in+the+Tumor+Microenvironment&doi=10.1158%2F0008-5472.CAN-14-1215"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">PD-1/SHP-2 Inhibits Tc1/Th1 Phenotypic Responses and the Activation of T Cells in the Tumor Microenvironment</span></div><div class="casAuthors">Li, Jing; Jie, Hyun-Bae; Lei, Yu; Gildener-Leapman, Neil; Trivedi, Sumita; Green, Tony; Kane, Lawrence P.; Ferris, Robert L.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">508-518</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">This study addresses the mechanisms through which PD-1 antibody therapy restores the ability of the immune system to recognize and attack tumors by skewing intratumoral T cells toward a more potent activation phenotype that is assocd. with enhanced signaling and a reversal of their immunosuppressed phenotype.  Immune rejection of tumors is mediated by IFNγ prodn. and T-cell cytolytic activity.  These processes are impeded by PD-1, a coinhibitory mol. expressed on T cells that is elevated in tumor-infiltrating lymphocytes (TIL).  PD-1 elevation may reflect T-cell exhaustion marked by decreased proliferation, prodn. of type I cytokines, and poor cytolytic activity.  Although anti-PD-1 antibodies enhance IFNγ secretion after stimulation of the T-cell receptor (TCR), the mechanistic link between PD-1 and its effects on T-cell help (Tc1/Th1 skewing) remains unclear.  In prospectively collected cancer tissues, we found that TIL exhibited dampened Tc1/Th1 skewing and activation compared with peripheral blood lymphocytes (PBL).  When PD-1 bound its ligand PD-L1, we obsd. a marked suppression of crit. TCR target genes and Th1 cytokines.  Conversely, PD-1 blockade reversed these suppressive effects of PD-1:PD-L1 ligation.  We also found that the TCR-regulated phosphatase SHP-2 was expressed higher in TIL than in PBL, tightly correlating with PD-1 expression and neg. regulation of TCR target genes.  Overall, these results defined a PD-1/SHP-2/STAT1/T-bet signaling axis mediating the suppressive effects of PD-1 on Th1 immunity at tumor sites.  Our findings argue that PD-1 or SHP-2 blockade will be sufficient to restore robust Th1 immunity and T-cell activation and thereby reverse immunosuppression in the tumor microenvironment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqe6jAWHNatvLVg90H21EOLACvtfcHk0lj-I5CRO-Vvpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVenurY%253D&md5=695007f0715b5eee2b7e47deaf87ae23</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-14-1215&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-14-1215%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DJie%26aufirst%3DH.-B.%26aulast%3DLei%26aufirst%3DY.%26aulast%3DGildener-Leapman%26aufirst%3DN.%26aulast%3DTrivedi%26aufirst%3DS.%26aulast%3DGreen%26aufirst%3DT.%26aulast%3DKane%26aufirst%3DL.%2BP.%26aulast%3DFerris%26aufirst%3DR.%2BL.%26atitle%3DPD-1%252FSHP-2%2520Inhibits%2520Tc1%252FTh1%2520Phenotypic%2520Responses%2520and%2520the%2520Activation%2520of%2520T%2520Cells%2520in%2520the%2520Tumor%2520Microenvironment%26jtitle%3DCancer%2520Res.%26date%3D2015%26volume%3D75%26spage%3D508%26epage%3D518%26doi%3D10.1158%2F0008-5472.CAN-14-1215" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hui, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallweber, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasmal, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mellman, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vale, R. D.</span></span> <span> </span><span class="NLM_article-title">T Cell Costimulatory Receptor CD28 is a Primary Target for PD-1-Mediated Inhibition</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>355</i></span>,  <span class="NLM_fpage">1428</span>– <span class="NLM_lpage">1433</span>, <span class="refDoi"> DOI: 10.1126/science.aaf1292</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=10.1126%2Fscience.aaf1292" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=28280247" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlsVWhu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=355&publication_year=2017&pages=1428-1433&author=E.+Huiauthor=J.+Cheungauthor=J.+Zhuauthor=X.+Suauthor=M.+J.+Taylorauthor=H.+A.+Wallweberauthor=D.+K.+Sasmalauthor=J.+Huangauthor=J.+M.+Kimauthor=I.+Mellmanauthor=R.+D.+Vale&title=T+Cell+Costimulatory+Receptor+CD28+is+a+Primary+Target+for+PD-1-Mediated+Inhibition&doi=10.1126%2Fscience.aaf1292"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition</span></div><div class="casAuthors">Hui, Enfu; Cheung, Jeanne; Zhu, Jing; Su, Xiaolei; Taylor, Marcus J.; Wallweber, Heidi A.; Sasmal, Dibyendu K.; Huang, Jun; Kim, Jeong M.; Mellman, Ira; Vale, Ronald D.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">355</span>
        (<span class="NLM_cas:issue">6332</span>),
    <span class="NLM_cas:pages">1428-1433</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">PD-1-targeted therapies have been a breakthrough for treating certain tumors and can rejuvenate T cells to unleash the anticancer immune response (see the Perspective by Clouthier and Ohashi).  It is widely believed that PD-1 suppresses signaling through the T cell receptor (TCR).  However, Hui et al. find instead that the TCR costimulatory receptor, CD28, is the primary target of PD-1 signaling.  Independently, Kamphorst et al. show that CD28 is required for PD-1 therapies to kill cancer cells efficiently and eliminate chronic viral infections in mice.  Lung cancer patients that responded to PD-1 therapy had more CD28+ T cells, which suggests that CD28 may predict treatment response.  Science, ibid p. 1428, p. 1423; see also p. 1373.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpM_s4cf1lkxrVg90H21EOLACvtfcHk0lj-I5CRO-Vvpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlsVWhu7g%253D&md5=69750b99b68316ee035a0b7eeddfb9fa</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1126%2Fscience.aaf1292&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aaf1292%26sid%3Dliteratum%253Aachs%26aulast%3DHui%26aufirst%3DE.%26aulast%3DCheung%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DSu%26aufirst%3DX.%26aulast%3DTaylor%26aufirst%3DM.%2BJ.%26aulast%3DWallweber%26aufirst%3DH.%2BA.%26aulast%3DSasmal%26aufirst%3DD.%2BK.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DJ.%2BM.%26aulast%3DMellman%26aufirst%3DI.%26aulast%3DVale%26aufirst%3DR.%2BD.%26atitle%3DT%2520Cell%2520Costimulatory%2520Receptor%2520CD28%2520is%2520a%2520Primary%2520Target%2520for%2520PD-1-Mediated%2520Inhibition%26jtitle%3DScience%26date%3D2017%26volume%3D355%26spage%3D1428%26epage%3D1433%26doi%3D10.1126%2Fscience.aaf1292" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Topalian, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodi, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brahmer, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gettinger, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDermott, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powderly, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carvajal, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sosman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atkins, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leming, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spigel, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonia, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horn, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drake, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pardoll, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharfman, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anders, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taube, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMiller, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korman, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jure-Kunkel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agrawal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kollia, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wigginton, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sznol, M.</span></span> <span> </span><span class="NLM_article-title">Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>366</i></span>,  <span class="NLM_fpage">2443</span>– <span class="NLM_lpage">2454</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1200690</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=10.1056%2FNEJMoa1200690" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=22658127" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtV2rs7fN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=366&publication_year=2012&pages=2443-2454&author=S.+L.+Topalianauthor=F.+S.+Hodiauthor=J.+R.+Brahmerauthor=S.+N.+Gettingerauthor=D.+C.+Smithauthor=D.+F.+McDermottauthor=J.+D.+Powderlyauthor=R.+D.+Carvajalauthor=J.+A.+Sosmanauthor=M.+B.+Atkinsauthor=P.+D.+Lemingauthor=D.+R.+Spigelauthor=S.+J.+Antoniaauthor=L.+Hornauthor=C.+G.+Drakeauthor=D.+M.+Pardollauthor=L.+Chenauthor=W.+H.+Sharfmanauthor=R.+A.+Andersauthor=J.+M.+Taubeauthor=T.+L.+McMillerauthor=H.+Xuauthor=A.+J.+Kormanauthor=M.+Jure-Kunkelauthor=S.+Agrawalauthor=D.+McDonaldauthor=G.+D.+Kolliaauthor=A.+Guptaauthor=J.+M.+Wiggintonauthor=M.+Sznol&title=Safety%2C+Activity%2C+and+Immune+Correlates+of+Anti-PD-1+Antibody+in+Cancer&doi=10.1056%2FNEJMoa1200690"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14aR"><div class="casContent"><span class="casTitleNuber">14a</span><div class="casTitle"><span class="NLM_cas:atitle">Safety, activity, and immune correlates of anti-PD-1 antibody in cancer</span></div><div class="casAuthors">Topalian, Suzanne L.; Hodi, F. Stephen; Brahmer, Julie R.; Gettinger, Scott N.; Smith, David C.; McDermott, David F.; Powderly, John D.; Carvajal, Richard D.; Sosman, Jeffrey A.; Atkins, Michael B.; Leming, Philip D.; Spigel, David R.; Antonia, Scott J.; Horn, Leora; Drake, Charles G.; Pardoll, Drew M.; Chen, Lieping; Sharfman, William H.; Anders, Robert A.; Taube, Janis M.; McMiller, Tracee L.; Xu, Haiying; Korman, Alan J.; Jure-Kunkel, Maria; Agrawal, Shruti; McDonald, Daniel; Kollia, Georgia D.; Gupta, Ashok; Wigginton, Jon M.; Sznol, Mario</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">366</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">2443-2454</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Blockade of programmed death 1 (PD-1), an inhibitory receptor expressed by T cells, can overcome immune resistance.  We assessed the antitumor activity and safety of BMS-936558, an antibody that specifically blocks PD-1.  Methods: We enrolled patients with advanced melanoma, non-small-cell lung cancer, castration-resistant prostate cancer, or renal-cell or colorectal cancer to receive anti-PD-1 antibody at a dose of 0.1 to 10.0 mg per kg of body wt. every 2 wk.  Response was assessed after each 8-wk treatment cycle.  Patients received up to 12 cycles until disease progression or a complete response occurred.  Results: A total of 296 patients received treatment through Feb. 24, 2012.  Grade 3 or 4 drug-related adverse events occurred in 14% of patients; there were three deaths from pulmonary toxicity.  No max. tolerated dose was defined.  Adverse events consistent with immune-related causes were obsd.  Among 236 patients in whom response could be evaluated, objective responses (complete or partial responses) were obsd. in those with non-small-cell lung cancer, melanoma, or renal-cell cancer.  Cumulative response rates (all doses) were 18% among patients with non-small-cell lung cancer (14 of 76 patients), 28% among patients with melanoma (26 of 94 patients), and 27% among patients with renal-cell cancer (9 of 33 patients).  Responses were durable; 20 of 31 responses lasted 1 yr or more in patients with 1 yr or more of follow-up.  To assess the role of intratumoral PD-1 ligand (PD-L1) expression in the modulation of the PD-1-PD-L1 pathway, immunohistochem. anal. was performed on pretreatment tumor specimens obtained from 42 patients.  Of 17 patients with PD-L1-neg. tumors, none had an objective response; 9 of 25 patients (36%) with PD-L1-pos. tumors had an objective response (P = 0.006).  Conclusions: Anti-PD-1 antibody produced objective responses in approx. one in four to one in five patients with non-small-cell lung cancer, melanoma, or renal-cell cancer; the adverse-event profile does not appear to preclude its use.  Preliminary data suggest a relationship between PD-L1 expression on tumor cells and objective response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLOPvHybmlvbVg90H21EOLACvtfcHk0liekWFz60HGjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtV2rs7fN&md5=7c13f228ef92b6089982fc878d3a394b</span></div><a href="/servlet/linkout?suffix=cit14a&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1200690&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1200690%26sid%3Dliteratum%253Aachs%26aulast%3DTopalian%26aufirst%3DS.%2BL.%26aulast%3DHodi%26aufirst%3DF.%2BS.%26aulast%3DBrahmer%26aufirst%3DJ.%2BR.%26aulast%3DGettinger%26aufirst%3DS.%2BN.%26aulast%3DSmith%26aufirst%3DD.%2BC.%26aulast%3DMcDermott%26aufirst%3DD.%2BF.%26aulast%3DPowderly%26aufirst%3DJ.%2BD.%26aulast%3DCarvajal%26aufirst%3DR.%2BD.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DAtkins%26aufirst%3DM.%2BB.%26aulast%3DLeming%26aufirst%3DP.%2BD.%26aulast%3DSpigel%26aufirst%3DD.%2BR.%26aulast%3DAntonia%26aufirst%3DS.%2BJ.%26aulast%3DHorn%26aufirst%3DL.%26aulast%3DDrake%26aufirst%3DC.%2BG.%26aulast%3DPardoll%26aufirst%3DD.%2BM.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DSharfman%26aufirst%3DW.%2BH.%26aulast%3DAnders%26aufirst%3DR.%2BA.%26aulast%3DTaube%26aufirst%3DJ.%2BM.%26aulast%3DMcMiller%26aufirst%3DT.%2BL.%26aulast%3DXu%26aufirst%3DH.%26aulast%3DKorman%26aufirst%3DA.%2BJ.%26aulast%3DJure-Kunkel%26aufirst%3DM.%26aulast%3DAgrawal%26aufirst%3DS.%26aulast%3DMcDonald%26aufirst%3DD.%26aulast%3DKollia%26aufirst%3DG.%2BD.%26aulast%3DGupta%26aufirst%3DA.%26aulast%3DWigginton%26aufirst%3DJ.%2BM.%26aulast%3DSznol%26aufirst%3DM.%26atitle%3DSafety%252C%2520Activity%252C%2520and%2520Immune%2520Correlates%2520of%2520Anti-PD-1%2520Antibody%2520in%2520Cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D366%26spage%3D2443%26epage%3D2454%26doi%3D10.1056%2FNEJMoa1200690" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit14b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ohigashi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sho, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsurui, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamada, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikeda, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizuno, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoriki, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kashizuka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yane, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsushima, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otsuki, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yagita, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azuma, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakajima, Y.</span></span> <span> </span><span class="NLM_article-title">Clinical Significance of Programmed Death-1 Ligand-1 and Programmed Death-1 Ligand-2 Expression in Human Esophageal Cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">2947</span>– <span class="NLM_lpage">2953</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-04-1469</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=10.1158%2F1078-0432.CCR-04-1469" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=15837746" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjtlejt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=2947-2953&author=Y.+Ohigashiauthor=M.+Shoauthor=Y.+Yamadaauthor=Y.+Tsuruiauthor=K.+Hamadaauthor=N.+Ikedaauthor=T.+Mizunoauthor=R.+Yorikiauthor=H.+Kashizukaauthor=K.+Yaneauthor=F.+Tsushimaauthor=N.+Otsukiauthor=H.+Yagitaauthor=M.+Azumaauthor=Y.+Nakajima&title=Clinical+Significance+of+Programmed+Death-1+Ligand-1+and+Programmed+Death-1+Ligand-2+Expression+in+Human+Esophageal+Cancer&doi=10.1158%2F1078-0432.CCR-04-1469"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14bR"><div class="casContent"><span class="casTitleNuber">14b</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical Significance of Programmed Death-1 Ligand-1 and Programmed Death-1 Ligand-2 Expression in Human Esophageal Cancer</span></div><div class="casAuthors">Ohigashi, Yuichiro; Sho, Masayuki; Yamada, Yukishige; Tsurui, Yoshikazu; Hamada, Kaoru; Ikeda, Naoya; Mizuno, Takashi; Yoriki, Ryo; Kashizuka, Hisanori; Yane, Katsunari; Tsushima, Fumihiko; Otsuki, Noriko; Yagita, Hideo; Azuma, Miyuki; Nakajima, Yoshiyuki</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2947-2953</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: The neg. regulatory programmed death-1/programmed death-1 ligand (PD-1/PD-L) pathway in T-cell activation has been suggested to play an important role in tumor evasion from host immunity.  In this study, we investigated the expression of PD-L1 and PD-L2 in human esophageal cancer to define their clin. significance in patients' prognosis after surgery.  Exptl. Design: PD-L1 and PD-L2 gene expression was evaluated in 41 esophagectomy patients by real-time quant. PCR.  The protein expression was also evaluated with newly generated monoclonal antibodies that recognize human PD-L1 (MIH1) and PD-L2 (MIH18).  Results: The protein and the mRNA levels of detn. by immunohistochem. and real-time quant. PCR were closely correlated.  PD-L-pos. patients had a significantly poorer prognosis than the neg. patients.  This was more pronounced in the advanced stage of tumor than in the early stage.  Furthermore, multivariate anal. indicated that PD-L status was an independent prognostic factor.  Although there was no significant correlation between PD-L1 expression and tumor-infiltrating T lymphocytes, PD-L2 expression was inversely correlated with tumor-infiltrating CD8+ T cells.  Conclusions: These data suggest that PD-L1 and PD-L2 status may be a new predictor of prognosis for patients with esophageal cancer and provide the rationale for developing novel immunotherapy of targeting PD-1/PD-L pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIMQiC4R0LD7Vg90H21EOLACvtfcHk0liekWFz60HGjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjtlejt7k%253D&md5=1dd37b483171a10070310ccd559c9e35</span></div><a href="/servlet/linkout?suffix=cit14b&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-04-1469&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-04-1469%26sid%3Dliteratum%253Aachs%26aulast%3DOhigashi%26aufirst%3DY.%26aulast%3DSho%26aufirst%3DM.%26aulast%3DYamada%26aufirst%3DY.%26aulast%3DTsurui%26aufirst%3DY.%26aulast%3DHamada%26aufirst%3DK.%26aulast%3DIkeda%26aufirst%3DN.%26aulast%3DMizuno%26aufirst%3DT.%26aulast%3DYoriki%26aufirst%3DR.%26aulast%3DKashizuka%26aufirst%3DH.%26aulast%3DYane%26aufirst%3DK.%26aulast%3DTsushima%26aufirst%3DF.%26aulast%3DOtsuki%26aufirst%3DN.%26aulast%3DYagita%26aufirst%3DH.%26aulast%3DAzuma%26aufirst%3DM.%26aulast%3DNakajima%26aufirst%3DY.%26atitle%3DClinical%2520Significance%2520of%2520Programmed%2520Death-1%2520Ligand-1%2520and%2520Programmed%2520Death-1%2520Ligand-2%2520Expression%2520in%2520Human%2520Esophageal%2520Cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2005%26volume%3D11%26spage%3D2947%26epage%3D2953%26doi%3D10.1158%2F1078-0432.CCR-04-1469" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hof, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pluskey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhe-Paganon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoelson, S. E.</span></span> <span> </span><span class="NLM_article-title">Crystal Structure of the Tyrosine Phosphatase SHP-2</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>92</i></span>,  <span class="NLM_fpage">441</span>– <span class="NLM_lpage">450</span>, <span class="refDoi"> DOI: 10.1016/S0092-8674(00)80938-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=10.1016%2FS0092-8674%2800%2980938-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=9491886" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADyaK1cXhsVKnsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=1998&pages=441-450&author=P.+Hofauthor=S.+Pluskeyauthor=S.+Dhe-Paganonauthor=M.+J.+Eckauthor=S.+E.+Shoelson&title=Crystal+Structure+of+the+Tyrosine+Phosphatase+SHP-2&doi=10.1016%2FS0092-8674%2800%2980938-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15aR"><div class="casContent"><span class="casTitleNuber">15a</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of the tyrosine phosphatase SHP-2</span></div><div class="casAuthors">Hof, Peter; Pluskey, Scott; Dhe-Paganon, Sirano; Eck, Michael J.; Shoelson, Steven E.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, Massachusetts)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">441-450</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The structure of the SHP-2 tyrosine phosphatase, detd. at 2.0 Å resoln., shows how its catalytic activity is regulated by its two SH2 domains.  In the absence of a tyrosine-phosphorylated binding partner, the N-terminal SH2 domain binds the phosphatase domain and directly blocks its active site.  This interaction alters the structure of the N-SH2 domain, disrupting its phosphopeptide-binding cleft.  Conversely, interaction of the N-SH2 domain with phosphopeptide disrupts its phosphatase recognition surface.  Thus, the N-SH2 domain is a conformational switch; it either binds and inhibits the phosphatase, or it binds phosphoproteins and activates the enzyme.  Recognition of bisphosphorylated ligands by the tandem SH2 domains is an integral element of this switch; the C-terminal SH2 domain contributes binding energy and specificity, but it does not have a direct role in activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcAryHYl6D5bVg90H21EOLACvtfcHk0lhnJ5LRh6FAJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXhsVKnsLc%253D&md5=ea99b7adb90b5db07754c0be75a63c66</span></div><a href="/servlet/linkout?suffix=cit15a&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2800%2980938-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252800%252980938-1%26sid%3Dliteratum%253Aachs%26aulast%3DHof%26aufirst%3DP.%26aulast%3DPluskey%26aufirst%3DS.%26aulast%3DDhe-Paganon%26aufirst%3DS.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DShoelson%26aufirst%3DS.%2BE.%26atitle%3DCrystal%2520Structure%2520of%2520the%2520Tyrosine%2520Phosphatase%2520SHP-2%26jtitle%3DCell%26date%3D1998%26volume%3D92%26spage%3D441%26epage%3D450%26doi%3D10.1016%2FS0092-8674%2800%2980938-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit15b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Barford, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neel, B. G.</span></span> <span> </span><span class="NLM_article-title">Revealing Mechanisms for SH2 Domain Mediated Regulation of the Protein Tyrosine Phosphatase SHP-2</span>. <i>Structure</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">249</span>– <span class="NLM_lpage">254</span>, <span class="refDoi"> DOI: 10.1016/S0969-2126(98)00027-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=10.1016%2FS0969-2126%2898%2900027-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=9551546" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADyaK1cXisFSlsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1998&pages=249-254&author=D.+Barfordauthor=B.+G.+Neel&title=Revealing+Mechanisms+for+SH2+Domain+Mediated+Regulation+of+the+Protein+Tyrosine+Phosphatase+SHP-2&doi=10.1016%2FS0969-2126%2898%2900027-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15bR"><div class="casContent"><span class="casTitleNuber">15b</span><div class="casTitle"><span class="NLM_cas:atitle">Revealing mechanisms for SH2 domain mediated regulation of the protein tyrosine phosphatase SHP-2</span></div><div class="casAuthors">Barford, David; Neel, Benjamin G.</div><div class="citationInfo"><span class="NLM_cas:title">Structure (London)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">249-254</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Current Biology Ltd.</span>)
        </div><div class="casAbstract">A review with 33 refs.  The crystal structure of the protein tyrosine phosphatase SHP-2 reveals the mechanism of auto-inhibition of phosphatase activity by its SH2 domains.  Phosphotyrosine peptide stimulation of the phosphatase activity, resulting from peptide binding to the N-terminal SH2 domain, is linked to conformational changes within the protein, including an unprecedented allosteric transition of the N-terminal SH2 domain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9DfZ8YhMKJLVg90H21EOLACvtfcHk0lhnJ5LRh6FAJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXisFSlsrw%253D&md5=d2e136ed9c10302c18d06cb45ed42bf6</span></div><a href="/servlet/linkout?suffix=cit15b&amp;dbid=16384&amp;doi=10.1016%2FS0969-2126%2898%2900027-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0969-2126%252898%252900027-6%26sid%3Dliteratum%253Aachs%26aulast%3DBarford%26aufirst%3DD.%26aulast%3DNeel%26aufirst%3DB.%2BG.%26atitle%3DRevealing%2520Mechanisms%2520for%2520SH2%2520Domain%2520Mediated%2520Regulation%2520of%2520the%2520Protein%2520Tyrosine%2520Phosphatase%2520SHP-2%26jtitle%3DStructure%26date%3D1998%26volume%3D6%26spage%3D249%26epage%3D254%26doi%3D10.1016%2FS0969-2126%2898%2900027-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pluskey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wandless, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walsh, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoelson, S. E.</span></span> <span> </span><span class="NLM_article-title">Potent Stimulation of SH-PTP2 Phosphatase Activity by Simultaneous Occupancy of Both SH2 Domains</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>270</i></span>,  <span class="NLM_fpage">2897</span>– <span class="NLM_lpage">2900</span>, <span class="refDoi"> DOI: 10.1074/jbc.270.7.2897</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=10.1074%2Fjbc.270.7.2897" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=7531695" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADyaK28XltVyltrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=270&publication_year=1995&pages=2897-2900&author=S.+Pluskeyauthor=T.+J.+Wandlessauthor=C.+T.+Walshauthor=S.+E.+Shoelson&title=Potent+Stimulation+of+SH-PTP2+Phosphatase+Activity+by+Simultaneous+Occupancy+of+Both+SH2+Domains&doi=10.1074%2Fjbc.270.7.2897"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Potent stimulation of SH-PTP2 phosphatase activity by simultaneous occupancy of both SH2 domains</span></div><div class="casAuthors">Pluskey, Scott; Wandless, Thomas J.; Walsh, Christopher, T.; Shoelson, Steven E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">270</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2897-2900</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Src homol. 2 (SH2) domains are phosphotyrosine binding modules found within many cytoplasmic proteins.  A major function of SH2 domains is to bring about the phys. assembly of signaling complexes.  Here, it is shown that, that in addn., simultaneous occupancy of both SH2 domains of phosphoprotein tyrosine phosphatase SH-PTP2 (Syp, PTP 1D, PTP-2C) by a tethered peptide with 2 IRS-1-derived phosphorylation sites potently stimulates phosphatase activity.  The concn. required for activation by the tethered peptide was 80-160-fold lower than either corresponding monophosphorylated peptide.  Moreover, the diphosphorylated peptide stimulated catalytic activity 37-fold, compared with 9-16-fold for the monophosphorylated peptides.  Mutational analyses of the SH2 domains of SH-PTP2 confirmed that both SH2 domains participate in this effect.  Binding studies with a tandem construct comprising the N-plus C-terminal SH2 domains showed that the diphosphorylated peptide binds with 60-90-fold higher affinity than either monophosphorylated sequence.  These results demonstrated that SH-PTP2 activity can be potently regulated by interacting via both of its SH2 domains with phosphoproteins having 2 cognate phosphorylation sites.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTlCRxkwiHh7Vg90H21EOLACvtfcHk0lhnJ5LRh6FAJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XltVyltrs%253D&md5=c17c9344fc6b9978f7021263855b776d</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1074%2Fjbc.270.7.2897&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.270.7.2897%26sid%3Dliteratum%253Aachs%26aulast%3DPluskey%26aufirst%3DS.%26aulast%3DWandless%26aufirst%3DT.%2BJ.%26aulast%3DWalsh%26aufirst%3DC.%2BT.%26aulast%3DShoelson%26aufirst%3DS.%2BE.%26atitle%3DPotent%2520Stimulation%2520of%2520SH-PTP2%2520Phosphatase%2520Activity%2520by%2520Simultaneous%2520Occupancy%2520of%2520Both%2520SH2%2520Domains%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1995%26volume%3D270%26spage%3D2897%26epage%3D2900%26doi%3D10.1074%2Fjbc.270.7.2897" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="note"><p class="first last">SHP2 activation has been extensively reviewed:</p></div><div class="NLM_citation" id="cit17a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Barford, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neel, B. G.</span></span> <span> </span><span class="NLM_article-title">Revealing Mechanisms for SH2 Domain Mediated Regulation of the Protein Tyrosine Phosphatase SHP-2</span>. <i>Structure</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">249</span>– <span class="NLM_lpage">254</span>, <span class="refDoi"> DOI: 10.1016/S0969-2126(98)00027-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=10.1016%2FS0969-2126%2898%2900027-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=9551546" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADyaK1cXisFSlsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1998&pages=249-254&author=D.+Barfordauthor=B.+G.+Neel&title=Revealing+Mechanisms+for+SH2+Domain+Mediated+Regulation+of+the+Protein+Tyrosine+Phosphatase+SHP-2&doi=10.1016%2FS0969-2126%2898%2900027-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17aR"><div class="casContent"><span class="casTitleNuber">17a</span><div class="casTitle"><span class="NLM_cas:atitle">Revealing mechanisms for SH2 domain mediated regulation of the protein tyrosine phosphatase SHP-2</span></div><div class="casAuthors">Barford, David; Neel, Benjamin G.</div><div class="citationInfo"><span class="NLM_cas:title">Structure (London)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">249-254</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Current Biology Ltd.</span>)
        </div><div class="casAbstract">A review with 33 refs.  The crystal structure of the protein tyrosine phosphatase SHP-2 reveals the mechanism of auto-inhibition of phosphatase activity by its SH2 domains.  Phosphotyrosine peptide stimulation of the phosphatase activity, resulting from peptide binding to the N-terminal SH2 domain, is linked to conformational changes within the protein, including an unprecedented allosteric transition of the N-terminal SH2 domain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9DfZ8YhMKJLVg90H21EOLACvtfcHk0ljyj4ks2YyNqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXisFSlsrw%253D&md5=d2e136ed9c10302c18d06cb45ed42bf6</span></div><a href="/servlet/linkout?suffix=cit17a&amp;dbid=16384&amp;doi=10.1016%2FS0969-2126%2898%2900027-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0969-2126%252898%252900027-6%26sid%3Dliteratum%253Aachs%26aulast%3DBarford%26aufirst%3DD.%26aulast%3DNeel%26aufirst%3DB.%2BG.%26atitle%3DRevealing%2520Mechanisms%2520for%2520SH2%2520Domain%2520Mediated%2520Regulation%2520of%2520the%2520Protein%2520Tyrosine%2520Phosphatase%2520SHP-2%26jtitle%3DStructure%26date%3D1998%26volume%3D6%26spage%3D249%26epage%3D254%26doi%3D10.1016%2FS0969-2126%2898%2900027-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit17b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalaitzidis</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neel, B. G.</span></span> <span> </span><span class="NLM_article-title">The Tyrosine Phosphatase SHP2 (PTPN11) in Cancer</span>. <i>Cancer Metastasis Rev.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">179</span>– <span class="NLM_lpage">182</span>, <span class="refDoi"> DOI: 10.1007/s10555-008-9126-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=10.1007%2Fs10555-008-9126-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=18286234" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlt1Ckur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2008&pages=179-182&author=G.+Chanauthor=+Kalaitzidisauthor=B.+G.+Neel&title=The+Tyrosine+Phosphatase+SHP2+%28PTPN11%29+in+Cancer&doi=10.1007%2Fs10555-008-9126-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17bR"><div class="casContent"><span class="casTitleNuber">17b</span><div class="casTitle"><span class="NLM_cas:atitle">The tyrosine phosphatase Shp2 (PTPN11) in cancer</span></div><div class="casAuthors">Chan, Gordon; Kalaitzidis, Demetrios; Neel, Benjamin G.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer and Metastasis Reviews</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">179-192</span>CODEN:
                <span class="NLM_cas:coden">CMRED4</span>;
        ISSN:<span class="NLM_cas:issn">0167-7659</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Diverse cellular processes are regulated by tyrosyl phosphorylation, which is controlled by protein-tyrosine kinases (PTKs) and protein-tyrosine phosphatases (PTPs).  De-regulated tyrosyl phosphorylation, evoked by gain-of-function mutations and/or over-expression of PTKs, contributes to the pathogenesis of many cancers and other human diseases.  PTPs, because they oppose the action of PTKs, had been considered to be prime suspects for potential tumor suppressor genes.  Surprisingly, few, if any, tumor suppressor PTPs have been identified.  However, the Src homol.-2 domain-contg. phosphatase Shp2 (encoded by PTPN11) is a bona fide proto-oncogene.  Germline mutations in PTPN11 cause Noonan and LEOPARD syndromes, whereas somatic PTPN11 mutations occur in several types of hematol. malignancies, most notably juvenile myelomonocytic leukemia and, more rarely, in solid tumors.  Shp2 also is an essential component in several other oncogene signaling pathways.  Elucidation of the events underlying Shp2-evoked transformation may provide new insights into oncogenic mechanisms and novel targets for anti-cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbJ8OYsBzvg7Vg90H21EOLACvtfcHk0ljyj4ks2YyNqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlt1Ckur4%253D&md5=fb514f60b97f8ff0dcc0dbd57cab2c9a</span></div><a href="/servlet/linkout?suffix=cit17b&amp;dbid=16384&amp;doi=10.1007%2Fs10555-008-9126-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10555-008-9126-y%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DG.%26aulast%3DKalaitzidis%26aulast%3DNeel%26aufirst%3DB.%2BG.%26atitle%3DThe%2520Tyrosine%2520Phosphatase%2520SHP2%2520%2528PTPN11%2529%2520in%2520Cancer%26jtitle%3DCancer%2520Metastasis%2520Rev.%26date%3D2008%26volume%3D27%26spage%3D179%26epage%3D182%26doi%3D10.1007%2Fs10555-008-9126-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit17c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Poole, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, M. L.</span></span> <span> </span><span class="NLM_article-title">A SHPing Tale: Perspectives on the Regulation of SHP-1 and SHP-2 Tyrosine Phosphatases by the C-terminal Tail</span>. <i>Cell. Signalling</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">1323</span>– <span class="NLM_lpage">1332</span>, <span class="refDoi"> DOI: 10.1016/j.cellsig.2005.05.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=10.1016%2Fj.cellsig.2005.05.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=16084691" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADC%252BD2MXptVWnsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2005&pages=1323-1332&author=A.+W.+Pooleauthor=M.+L.+Jones&title=A+SHPing+Tale%3A+Perspectives+on+the+Regulation+of+SHP-1+and+SHP-2+Tyrosine+Phosphatases+by+the+C-terminal+Tail&doi=10.1016%2Fj.cellsig.2005.05.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17cR"><div class="casContent"><span class="casTitleNuber">17c</span><div class="casTitle"><span class="NLM_cas:atitle">A SHPing tale: Perspectives on the regulation of SHP-1 and SHP-2 tyrosine phosphatases by the C-terminal tail</span></div><div class="casAuthors">Poole, Alastair W.; Jones, Matthew L.</div><div class="citationInfo"><span class="NLM_cas:title">Cellular Signalling</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1323-1332</span>CODEN:
                <span class="NLM_cas:coden">CESIEY</span>;
        ISSN:<span class="NLM_cas:issn">0898-6568</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Protein tyrosine phosphorylation is a ubiquitous signaling mechanism and is regulated by a balance between the action of kinases and phosphatases.  The SH2 domain-contg. phosphatases, SHP-1 and SHP-2, are the best studied of the classical non-receptor tyrosine phosphatases, but it is intriguing that despite their close sequence and structural homol. these 2 phosphatases play quite different cellular roles.  In particular, whereas SHP-1 plays a largely neg. signaling role suppressing cellular activation, SHP-2 plays a largely pos. signaling role.  Major sequence differences between the 2 mols. are apparent in the ∼100 amino acid residues at the extreme C-terminus of the proteins, beyond the phosphatase catalytic domain.  Here, the authors review how the differences in the tails of these proteins may regulate their activities and explain some of their functional differences.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQNdG8bGaIjLVg90H21EOLACvtfcHk0ljyj4ks2YyNqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXptVWnsLY%253D&md5=2980ba96216967f7b89fb347415199c4</span></div><a href="/servlet/linkout?suffix=cit17c&amp;dbid=16384&amp;doi=10.1016%2Fj.cellsig.2005.05.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cellsig.2005.05.016%26sid%3Dliteratum%253Aachs%26aulast%3DPoole%26aufirst%3DA.%2BW.%26aulast%3DJones%26aufirst%3DM.%2BL.%26atitle%3DA%2520SHPing%2520Tale%253A%2520Perspectives%2520on%2520the%2520Regulation%2520of%2520SHP-1%2520and%2520SHP-2%2520Tyrosine%2520Phosphatases%2520by%2520the%2520C-terminal%2520Tail%26jtitle%3DCell.%2520Signalling%26date%3D2005%26volume%3D17%26spage%3D1323%26epage%3D1332%26doi%3D10.1016%2Fj.cellsig.2005.05.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit17d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Butterworth, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overduin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barr, A. J.</span></span> <span> </span><span class="NLM_article-title">Targeting Protein Tyrosine Phosphatase SHP2 for Therapeutic Intervention</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1423</span>– <span class="NLM_lpage">1437</span>, <span class="refDoi"> DOI: 10.4155/fmc.14.88</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=10.4155%2Ffmc.14.88" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=25329198" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslOhu7jO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=1423-1437&author=S.+Butterworthauthor=M.+Overduinauthor=A.+J.+Barr&title=Targeting+Protein+Tyrosine+Phosphatase+SHP2+for+Therapeutic+Intervention&doi=10.4155%2Ffmc.14.88"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17dR"><div class="casContent"><span class="casTitleNuber">17d</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting protein tyrosine phosphatase SHP2 for therapeutic intervention</span></div><div class="casAuthors">Butterworth, Sam; Overduin, Michael; Barr, Alastair J.</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1423-1437</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Protein tyrosine phosphatases have been the focus of considerable research efforts aimed at developing novel therapeutics; however, these targets are often characterized as being 'undruggable' due to the challenge of achieving selectivity, potency and cell permeability.  More recently, there has been renewed interest in developing inhibitors of the tyrosine phosphatase SHP2 (PTPN11) in the light of its broad role in cancer, specifically juvenile myelomonocytic leukemia, and recent studies that implicate SHP2 as a key factor in breast cancer progression.  Recent significant advances in the field of SHP2 inhibitor development raise the question: are we on the verge of a new era of protein tyrosine phosphatase-directed therapeutics This article critically appraises recent developments, assesses ongoing challenges and presents a perspective on possible future directions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEVdQ5GiIy9LVg90H21EOLACvtfcHk0ljyj4ks2YyNqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslOhu7jO&md5=85c071c906c6c047d524460df5e0a9b5</span></div><a href="/servlet/linkout?suffix=cit17d&amp;dbid=16384&amp;doi=10.4155%2Ffmc.14.88&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.14.88%26sid%3Dliteratum%253Aachs%26aulast%3DButterworth%26aufirst%3DS.%26aulast%3DOverduin%26aufirst%3DM.%26aulast%3DBarr%26aufirst%3DA.%2BJ.%26atitle%3DTargeting%2520Protein%2520Tyrosine%2520Phosphatase%2520SHP2%2520for%2520Therapeutic%2520Intervention%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2014%26volume%3D6%26spage%3D1423%26epage%3D1437%26doi%3D10.4155%2Ffmc.14.88" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Prahallad, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heynen, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Germano, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willems, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evers, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vecchione, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gambino, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lieftink, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beijersbergen, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Nicolantonio, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bardelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernards, R.</span></span> <span> </span><span class="NLM_article-title">PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1978</span>– <span class="NLM_lpage">1985</span>, <span class="refDoi"> DOI: 10.1016/j.celrep.2015.08.037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=10.1016%2Fj.celrep.2015.08.037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=26365186" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsV2ls7fN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2015&pages=1978-1985&author=A.+Prahalladauthor=G.+J.+Heynenauthor=G.+Germanoauthor=S.+M.+Willemsauthor=B.+Eversauthor=L.+Vecchioneauthor=V.+Gambinoauthor=C.+Lieftinkauthor=R.+L.+Beijersbergenauthor=F.+Di+Nicolantonioauthor=A.+Bardelliauthor=R.+Bernards&title=PTPN11+Is+a+Central+Node+in+Intrinsic+and+Acquired+Resistance+to+Targeted+Cancer+Drugs&doi=10.1016%2Fj.celrep.2015.08.037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18aR"><div class="casContent"><span class="casTitleNuber">18a</span><div class="casTitle"><span class="NLM_cas:atitle">PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs</span></div><div class="casAuthors">Prahallad, Anirudh; Heynen, Guus J. J. E.; Germano, Giovanni; Willems, Stefan M.; Evers, Bastiaan; Vecchione, Loredana; Gambino, Valentina; Lieftink, Cor; Beijersbergen, Roderick L.; Di Nicolantonio, Federica; Bardelli, Alberto; Bernards, Rene</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1978-1985</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Most BRAF (V600E) mutant melanomas are sensitive to selective BRAF inhibitors, but BRAF mutant colon cancers are intrinsically resistant to these drugs because of feedback activation of EGFR.  We performed an RNA-interference-based genetic screen in BRAF mutant colon cancer cells to search for phosphatases whose knockdown induces sensitivity to BRAF inhibition.  We found that suppression of protein tyrosine phosphatase non-receptor type 11 (PTPN11) confers sensitivity to BRAF inhibitors in colon cancer.  Mechanistically, we found that inhibition of PTPN11 blocks signaling from receptor tyrosine kinases (RTKs) to the RAS-MEK-ERK pathway.  PTPN11 suppression is lethal to cells that are driven by activated RTKs and prevents acquired resistance to targeted cancer drugs that results from RTK activation.  Our findings identify PTPN11 as a drug target to combat both intrinsic and acquired resistance to several targeted cancer drugs.  Moreover, activated PTPN11 can serve as a biomarker of drug resistance resulting from RTK activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrr2cE8g_Ejr7Vg90H21EOLACvtfcHk0lhSJpVNXpklfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsV2ls7fN&md5=521d9847bba4c7c6529ad355da097787</span></div><a href="/servlet/linkout?suffix=cit18a&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2015.08.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2015.08.037%26sid%3Dliteratum%253Aachs%26aulast%3DPrahallad%26aufirst%3DA.%26aulast%3DHeynen%26aufirst%3DG.%2BJ.%26aulast%3DGermano%26aufirst%3DG.%26aulast%3DWillems%26aufirst%3DS.%2BM.%26aulast%3DEvers%26aufirst%3DB.%26aulast%3DVecchione%26aufirst%3DL.%26aulast%3DGambino%26aufirst%3DV.%26aulast%3DLieftink%26aufirst%3DC.%26aulast%3DBeijersbergen%26aufirst%3DR.%2BL.%26aulast%3DDi%2BNicolantonio%26aufirst%3DF.%26aulast%3DBardelli%26aufirst%3DA.%26aulast%3DBernards%26aufirst%3DR.%26atitle%3DPTPN11%2520Is%2520a%2520Central%2520Node%2520in%2520Intrinsic%2520and%2520Acquired%2520Resistance%2520to%2520Targeted%2520Cancer%2520Drugs%26jtitle%3DCell%2520Rep.%26date%3D2015%26volume%3D12%26spage%3D1978%26epage%3D1985%26doi%3D10.1016%2Fj.celrep.2015.08.037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit18b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiang, H.</span></span> <span> </span><span class="NLM_article-title">Src Homology 2 Domain-Containing Tyrosine Phosphatase 2 Promotes Oral Cancer Invasion and Metastasis</span>. <i>BMC Cancer</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">442</span>, <span class="refDoi"> DOI: 10.1186/1471-2407-14-442</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=10.1186%2F1471-2407-14-442" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=24931737" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVymtrfM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2014&pages=442&author=H.+Wangauthor=W.+Chiangauthor=H.+Huangauthor=Y.+Shenauthor=H.+Chiang&title=Src+Homology+2+Domain-Containing+Tyrosine+Phosphatase+2+Promotes+Oral+Cancer+Invasion+and+Metastasis&doi=10.1186%2F1471-2407-14-442"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18bR"><div class="casContent"><span class="casTitleNuber">18b</span><div class="casTitle"><span class="NLM_cas:atitle">Src-homology 2 domain-containing tyrosine phosphatase 2 promotes oral cancer invasion and metastasis</span></div><div class="casAuthors">Wang, Hsueh-Chun; Chiang, Wei-Fan; Huang, Hsin-Hsiu; Shen, Ying-Ying; Chiang, Hung-Che</div><div class="citationInfo"><span class="NLM_cas:title">BMC Cancer</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">442/1-442/13</span>CODEN:
                <span class="NLM_cas:coden">BCMACL</span>;
        ISSN:<span class="NLM_cas:issn">1471-2407</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Tumor invasion and metastasis represent a major unsolved problem in cancer pathogenesis.  Recent studies have indicated the involvement of Src-homol. 2 domain-contg. tyrosine phosphatase 2 (SHP2) in multiple malignancies; however, the role of SHP2 in oral cancer progression has yet to be elucidated.  We propose that SHP2 is involved in the progression of oral cancer toward metastasis.  Methods: SHP2 expression was evaluated in paired oral cancer tissues by using immunohistochem. staining and real-time reverse transcription polymerase chain reaction.  Isogenic highly invasive oral cancer cell lines from their resp. low invasive parental lines were established using a Boyden chamber assay, and changes in the hallmarks of the epithelial-mesenchymal transition (EMT) were assessed to evaluate SHP2 function.  SHP2 activity in oral cancer cells was reduced using si-RNA knockdown or enforced expression of a catalytically deficient mutant to analyze migratory and invasive ability in vitro and metastasis toward the lung in mice in vivo.  Results: We obsd. the significant upregulation of SHP2 in oral cancer tissues and cell lines.  Following SHP2 knockdown, the oral cancer cells markedly attenuated migratory and invasion ability.  We obsd. similar results in phosphatase-dead SHP2 C459S mutant expressing cells.  Enhanced invasiveness was assocd. with significant upregulation of E-cadherin, vimentin, Snail/Twist1, and matrix metalloproteinase-2 in the highly invasive clones.  In addn., we detd. that SHP2 activity is required for the downregulation of phosphorylated ERK1/2, which modulates the downstream effectors, Snail and Twist1 at a transcript level.  In lung tissue sections of mice, we obsd. that HSC3 tumors with SHP2 deletion exhibited significantly reduced metastatic capacity, compared with tumors administered control si-RNA.  Conclusions: Our data suggest that SHP2 promotes the invasion and metastasis of oral cancer cells.  These results provide a rationale for further investigating the effects of small-mol. SHP2 inhibitors on the progression of oral cancer, and indicate a previously unrecognized SHP2-ERK1/2-Snail/Twist1 pathway that is likely to play a crucial role in oral cancer invasion and metastasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4fInuWtOHl7Vg90H21EOLACvtfcHk0lhSJpVNXpklfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVymtrfM&md5=b1dd0157d70ac01327bbdbc473dab8ee</span></div><a href="/servlet/linkout?suffix=cit18b&amp;dbid=16384&amp;doi=10.1186%2F1471-2407-14-442&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1471-2407-14-442%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DH.%26aulast%3DChiang%26aufirst%3DW.%26aulast%3DHuang%26aufirst%3DH.%26aulast%3DShen%26aufirst%3DY.%26aulast%3DChiang%26aufirst%3DH.%26atitle%3DSrc%2520Homology%25202%2520Domain-Containing%2520Tyrosine%2520Phosphatase%25202%2520Promotes%2520Oral%2520Cancer%2520Invasion%2520and%2520Metastasis%26jtitle%3DBMC%2520Cancer%26date%3D2014%26volume%3D14%26spage%3D442%26doi%3D10.1186%2F1471-2407-14-442" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">LaRochelle, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fodor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durzynska, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stams, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaMarche, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chopra, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fortin, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acker, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blacklow, S. C.</span></span> <span> </span><span class="NLM_article-title">Structural and Functional Consequences of Three Cancer-Associated Mutations of the Oncogenic Phosphatase SHP2</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">2269</span>– <span class="NLM_lpage">2277</span>, <span class="refDoi"> DOI: 10.1021/acs.biochem.5b01287</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.biochem.5b01287" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADC%252BC28XltVagtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2016&pages=2269-2277&author=J.+R.+LaRochelleauthor=M.+Fodorauthor=X.+Xuauthor=I.+Durzynskaauthor=L.+Fanauthor=T.+Stamsauthor=H.+M.+Chanauthor=M.+J.+LaMarcheauthor=R.+Chopraauthor=P.+Wangauthor=P.+D.+Fortinauthor=M.+G.+Ackerauthor=S.+C.+Blacklow&title=Structural+and+Functional+Consequences+of+Three+Cancer-Associated+Mutations+of+the+Oncogenic+Phosphatase+SHP2&doi=10.1021%2Facs.biochem.5b01287"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Structural and Functional Consequences of Three Cancer-Associated Mutations of the Oncogenic Phosphatase SHP2</span></div><div class="casAuthors">LaRochelle, Jonathan R.; Fodor, Michelle; Xu, Xiang; Durzynska, Izabela; Fan, Lixin; Stams, Travis; Chan, Ho Man; LaMarche, Matthew J.; Chopra, Rajiv; Wang, Ping; Fortin, Pascal D.; Acker, Michael G.; Blacklow, Stephen C.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">2269-2277</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The proto-oncogene PTPN11 encodes a cytoplasmic protein tyrosine phosphatase, SHP2, which is required for normal development and sustained activation of the Ras-MAPK signaling pathway.  Germline mutations in SHP2 cause developmental disorders, and somatic mutations have been identified in childhood and adult cancers and drive leukemia in mice.  Despite our knowledge of the PTPN11 variations assocd. with pathol., the structural and functional consequences of many disease-assocd. mutants remain poorly understood.  Here, we combine X-ray crystallog., small-angle X-ray scattering, and biochem. to elucidate structural and mechanistic features of three cancer-assocd. SHP2 variants harboring single point mutations within the N-SH2:PTP interdomain autoinhibitory interface.  Our findings directly compare the impact of each mutation on autoinhibition of the phosphatase and advance the development of structure-guided and mutation-specific SHP2 therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdIaFVGm5lArVg90H21EOLACvtfcHk0ljgz1zxL8yTFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XltVagtLw%253D&md5=720b3dd9b18edde2c443d488cfb90dfc</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Facs.biochem.5b01287&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.biochem.5b01287%26sid%3Dliteratum%253Aachs%26aulast%3DLaRochelle%26aufirst%3DJ.%2BR.%26aulast%3DFodor%26aufirst%3DM.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DDurzynska%26aufirst%3DI.%26aulast%3DFan%26aufirst%3DL.%26aulast%3DStams%26aufirst%3DT.%26aulast%3DChan%26aufirst%3DH.%2BM.%26aulast%3DLaMarche%26aufirst%3DM.%2BJ.%26aulast%3DChopra%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DFortin%26aufirst%3DP.%2BD.%26aulast%3DAcker%26aufirst%3DM.%2BG.%26aulast%3DBlacklow%26aufirst%3DS.%2BC.%26atitle%3DStructural%2520and%2520Functional%2520Consequences%2520of%2520Three%2520Cancer-Associated%2520Mutations%2520of%2520the%2520Oncogenic%2520Phosphatase%2520SHP2%26jtitle%3DBiochemistry%26date%3D2016%26volume%3D55%26spage%3D2269%26epage%3D2277%26doi%3D10.1021%2Facs.biochem.5b01287" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gee, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhalgat, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Upson, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klaubert, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Latham, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haugland, R. P.</span></span> <span> </span><span class="NLM_article-title">Fluorogenic Substrates Based on Fluorinated Umbelliferones for Continuous Assays of Phosphatases and Beta-Galactosidases</span>. <i>Anal. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>273</i></span>,  <span class="NLM_fpage">41</span>, <span class="refDoi"> DOI: 10.1006/abio.1999.4202</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=10.1006%2Fabio.1999.4202" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=10452797" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADyaK1MXlt1Wktbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=273&publication_year=1999&pages=41&author=K.+R.+Geeauthor=W.+C.+Sunauthor=M.+K.+Bhalgatauthor=R.+H.+Upsonauthor=D.+H.+Klaubertauthor=K.+A.+Lathamauthor=R.+P.+Haugland&title=Fluorogenic+Substrates+Based+on+Fluorinated+Umbelliferones+for+Continuous+Assays+of+Phosphatases+and+Beta-Galactosidases&doi=10.1006%2Fabio.1999.4202"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Fluorogenic Substrates Based on Fluorinated Umbelliferones for Continuous Assays of Phosphatases and β-Galactosidases</span></div><div class="casAuthors">Gee, Kyle R.; Sun, Wei-Chuan; Bhalgat, Mahesh K.; Upson, Rosalyn H.; Klaubert, Dieter H.; Latham, Katherine A.; Haugland, Richard P.</div><div class="citationInfo"><span class="NLM_cas:title">Analytical Biochemistry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">273</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-48</span>CODEN:
                <span class="NLM_cas:coden">ANBCA2</span>;
        ISSN:<span class="NLM_cas:issn">0003-2697</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">Fluorogenic substrates based on 4-methylumbelliferone (4-MU) have been widely used for the detection of phosphatase and glycosidase activities.  One disadvantage of these substrates, however, is that max. fluorescence of the reaction product requires an alk. pH, since 4-MU has a pKa ≈ 8.  In an initial screening of five phosphatase substrates based on fluorinated derivs. of 4-MU, all with pKa values lower than that of 4-MU, we found that one substrate, 6,8-difluoro-4-methylumbelliferyl phosphate (DiFMUP), was much improved for the detection of acid phosphatase activity.  When measured at the preferred acid phosphatase reaction pH (5.0), DiFMUP yielded fluorescence signals that were more than 10-fold higher than those of 4-methylumbelliferyl phosphate (MUP).  DiFMUP was also superior to MUP for the detection of protein phosphatase 1 activity at pH 7 and was just as sensitive as MUP for the detection of alk. phosphatase activity at pH 10.  A β-galactosidase substrate was also prepd. based on 6,8-difluoro-4-methylumbelliferone.  This substrate, 6,8-difluoro-4-methylumbelliferyl β-D-galactopyranoside (DiFMUG), was found to be considerably more sensitive than the commonly used substrate 4-methylumbelliferyl β-D-galactopyranoside (MUG), for the detection of β-galactosidase activity at pH 7.  DiFMUP and DiFMUG should have great utility for the continuous assay of phosphatase and β-galactosidase activity, resp., at neutral and acid pH.  (c) 1999 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZOR_jnhxiLrVg90H21EOLACvtfcHk0ljgz1zxL8yTFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXlt1Wktbs%253D&md5=879424dc5f8830990218385ccb9d8fe0</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1006%2Fabio.1999.4202&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fabio.1999.4202%26sid%3Dliteratum%253Aachs%26aulast%3DGee%26aufirst%3DK.%2BR.%26aulast%3DSun%26aufirst%3DW.%2BC.%26aulast%3DBhalgat%26aufirst%3DM.%2BK.%26aulast%3DUpson%26aufirst%3DR.%2BH.%26aulast%3DKlaubert%26aufirst%3DD.%2BH.%26aulast%3DLatham%26aufirst%3DK.%2BA.%26aulast%3DHaugland%26aufirst%3DR.%2BP.%26atitle%3DFluorogenic%2520Substrates%2520Based%2520on%2520Fluorinated%2520Umbelliferones%2520for%2520Continuous%2520Assays%2520of%2520Phosphatases%2520and%2520Beta-Galactosidases%26jtitle%3DAnal.%2520Biochem.%26date%3D1999%26volume%3D273%26spage%3D41%26doi%3D10.1006%2Fabio.1999.4202" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Z. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nabinger, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunawan, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z. Y.</span></span> <span> </span><span class="NLM_article-title">Salicylic Acid Based Small Molecule Inhibitor for the Oncogenic Src Homology-2 Domain Containing Protein Tyrsosine Phosphatase-2 (SHP2)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">2482</span>– <span class="NLM_lpage">2493</span>, <span class="refDoi"> DOI: 10.1021/jm901645u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901645u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADC%252BC3cXitFyhs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2482-2493&author=X.+Zhangauthor=Y.+Heauthor=S.+Liuauthor=Z.+Yuauthor=Z.+X.+Jiangauthor=Z.+Yangauthor=Y.+Dongauthor=S.+C.+Nabingerauthor=L.+Wuauthor=A.+M.+Gunawanauthor=L.+Wangauthor=R.+J.+Chanauthor=Z.+Y.+Zhang&title=Salicylic+Acid+Based+Small+Molecule+Inhibitor+for+the+Oncogenic+Src+Homology-2+Domain+Containing+Protein+Tyrsosine+Phosphatase-2+%28SHP2%29&doi=10.1021%2Fjm901645u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21aR"><div class="casContent"><span class="casTitleNuber">21a</span><div class="casTitle"><span class="NLM_cas:atitle">Salicylic Acid Based Small Molecule Inhibitor for the Oncogenic Src Homology-2 Domain Containing Protein Tyrosine Phosphatase-2 (SHP2)</span></div><div class="casAuthors">Zhang, Xian; He, Yantao; Liu, Sijiu; Yu, Zhihong; Jiang, Zhong-Xing; Yang, Zhenyun; Dong, Yuanshu; Nabinger, Sarah C.; Wu, Li; Gunawan, Andrea M.; Wang, Lina; Chan, Rebecca J.; Zhang, Zhong-Yin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2482-2493</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The Src homol.-2 domain contg. protein tyrosine phosphatase-2 (SHP2) plays a pivotal role in growth factor and cytokine signaling.  Gain-of-function SHP2 mutations are assocd. with Noonan syndrome, various kinds of leukemias, and solid tumors.  Thus, there is considerable interest in SHP2 as a potential target for anticancer and antileukemia therapy.  We report a salicylic acid based combinatorial library approach aimed at binding both active site and unique nearby subpockets for enhanced affinity and selectivity.  Screening of the library led to the identification of a SHP2 inhibitor II-B08 (compd. 9) with highly efficacious cellular activity.  Compd. 9 blocks growth factor stimulated ERK1/2 activation and hematopoietic progenitor proliferation, providing supporting evidence that chem. inhibition of SHP2 may be therapeutically useful for anticancer and antileukemia treatment.  X-ray crystallog. anal. of the structure of SHP2 in complex with 9 reveals mol. determinants that can be exploited for the acquisition of more potent and selective SHP2 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrC82T5JpCRArVg90H21EOLACvtfcHk0ljgz1zxL8yTFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXitFyhs7k%253D&md5=6f87897eda38ea485dc08e189f1b5ca8</span></div><a href="/servlet/linkout?suffix=cit21a&amp;dbid=16384&amp;doi=10.1021%2Fjm901645u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901645u%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DHe%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DYu%26aufirst%3DZ.%26aulast%3DJiang%26aufirst%3DZ.%2BX.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DDong%26aufirst%3DY.%26aulast%3DNabinger%26aufirst%3DS.%2BC.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DGunawan%26aufirst%3DA.%2BM.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DChan%26aufirst%3DR.%2BJ.%26aulast%3DZhang%26aufirst%3DZ.%2BY.%26atitle%3DSalicylic%2520Acid%2520Based%2520Small%2520Molecule%2520Inhibitor%2520for%2520the%2520Oncogenic%2520Src%2520Homology-2%2520Domain%2520Containing%2520Protein%2520Tyrsosine%2520Phosphatase-2%2520%2528SHP2%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2482%26epage%3D2493%26doi%3D10.1021%2Fjm901645u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit21b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Z. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunawan, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mali, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapur, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z. Y.</span></span> <span> </span><span class="NLM_article-title">Therapeutic Potential of Targeting the Oncogenic SHP2 Phosphatase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">6594</span>– <span class="NLM_lpage">6609</span>, <span class="refDoi"> DOI: 10.1021/jm5006176</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5006176" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFajtrvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=6594-6609&author=L.+F.+Zengauthor=R.+Y.+Zhangauthor=Z.+H.+Yuauthor=S.+Liauthor=L.+Wuauthor=A.+M.+Gunawanauthor=B.+S.+Laneauthor=R.+S.+Maliauthor=X.+Liauthor=R.+J.+Chanauthor=R.+Kapurauthor=C.+D.+Wellsauthor=Z.+Y.+Zhang&title=Therapeutic+Potential+of+Targeting+the+Oncogenic+SHP2+Phosphatase&doi=10.1021%2Fjm5006176"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21bR"><div class="casContent"><span class="casTitleNuber">21b</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic Potential of Targeting the Oncogenic SHP2 Phosphatase</span></div><div class="casAuthors">Zeng, Li-Fan; Zhang, Ruo-Yu; Yu, Zhi-Hong; Li, Sijiu; Wu, Li; Gunawan, Andrea M.; Lane, Brandon S.; Mali, Raghuveer S.; Li, Xingjun; Chan, Rebecca J.; Kapur, Reuben; Wells, Clark D.; Zhang, Zhong-Yin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6594-6609</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The Src homol. 2 domain contg. protein tyrosine phosphatase-2 (SHP2) is an oncogenic phosphatase assocd. with various kinds of leukemia and solid tumors.  Thus, there is substantial interest in developing SHP2 inhibitors as potential anticancer and antileukemia agents.  Using a structure-guided and fragment-based library approach, we identified a novel hydroxyindole carboxylic acid-based SHP2 inhibitor (I), with an IC50 value of 200 nM and greater than 5-fold selectivity against 20 mammalian PTPs.  Structural and modeling studies reveal that the hydroxyindole carboxylic acid anchors the inhibitor to the SHP2 active site, while interactions of the oxalamide linker and the phenylthiophene tail with residues in the β5-β6 loop contribute to I's binding potency and selectivity.  Evidence suggests that I specifically attenuates the SHP2-dependent signaling inside the cell.  Moreover, I blocks growth factor mediated Erk1/2 and Akt activation and exhibits excellent antiproliferative activity in lung cancer and breast cancer as well as leukemia cell lines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3ko-q4-PSXbVg90H21EOLACvtfcHk0lhEA8OmoHvqRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFajtrvO&md5=ac8e5359387e614782c95c02f32fd97d</span></div><a href="/servlet/linkout?suffix=cit21b&amp;dbid=16384&amp;doi=10.1021%2Fjm5006176&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5006176%26sid%3Dliteratum%253Aachs%26aulast%3DZeng%26aufirst%3DL.%2BF.%26aulast%3DZhang%26aufirst%3DR.%2BY.%26aulast%3DYu%26aufirst%3DZ.%2BH.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DGunawan%26aufirst%3DA.%2BM.%26aulast%3DLane%26aufirst%3DB.%2BS.%26aulast%3DMali%26aufirst%3DR.%2BS.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DChan%26aufirst%3DR.%2BJ.%26aulast%3DKapur%26aufirst%3DR.%26aulast%3DWells%26aufirst%3DC.%2BD.%26aulast%3DZhang%26aufirst%3DZ.%2BY.%26atitle%3DTherapeutic%2520Potential%2520of%2520Targeting%2520the%2520Oncogenic%2520SHP2%2520Phosphatase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D6594%26epage%3D6609%26doi%3D10.1021%2Fjm5006176" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit21c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Bunda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrell, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heir, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alamsahebpour, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kano, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raught, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zadeh, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohh, M.</span></span> <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">8859</span>, <span class="refDoi"> DOI: 10.1038/ncomms9859</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=10.1038%2Fncomms9859" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=26617336" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFWksLbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Bunda%2C+S.%3B+Burrell%2C+K.%3B+Heir%2C+P.%3B+Zeng%2C+L.%3B+Alamsahebpour%2C+A.%3B+Kano%2C+Y.%3B+Raught%2C+B.%3B+Zhang%2C+Z.+Y.%3B+Zadeh%2C+G.%3B+Ohh%2C+M.+Nat.+Commun.+2015%2C+6%2C+8859%2C+10.1038%2Fncomms9859"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21cR"><div class="casContent"><span class="casTitleNuber">21c</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of SHP2-mediated dephosphorylation of Ras suppresses oncogenesis</span></div><div class="casAuthors">Bunda, Severa; Burrell, Kelly; Heir, Pardeep; Zeng, Lifan; Alamsahebpour, Amir; Kano, Yoshihito; Raught, Brian; Zhang, Zhong-Yin; Zadeh, Gelareh; Ohh, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">8859</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Ras is phosphorylated on a conserved tyrosine at position 32 within the switch I region via Src kinase.  This phosphorylation inhibits the binding of effector Raf while promoting the engagement of GTPase-activating protein (GAP) and GTP hydrolysis.  Here we identify SHP2 as the ubiquitously expressed tyrosine phosphatase that preferentially binds to and dephosphorylates Ras to increase its assocn. with Raf and activate downstream proliferative Ras/ERK/MAPK signalling.  In comparison to normal astrocytes, SHP2 activity is elevated in astrocytes isolated from glioblastoma multiforme (GBM)-prone H-Ras(12V) knock-in mice as well as in glioma cell lines and patient-derived GBM specimens exhibiting hyperactive Ras.  Pharmacol. inhibition of SHP2 activity attenuates cell proliferation, soft-agar colony formation and orthotopic GBM growth in NOD/SCID mice and decelerates the progression of low-grade astrocytoma to GBM in a spontaneous transgenic glioma mouse model.  These results identify SHP2 as a direct activator of Ras and a potential therapeutic target for cancers driven by a previously 'undruggable' oncogenic or hyperactive Ras.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhWi25AJiphrVg90H21EOLACvtfcHk0lhEA8OmoHvqRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFWksLbP&md5=8524ad9cc6f2e85abaff6b07c698f464</span></div><a href="/servlet/linkout?suffix=cit21c&amp;dbid=16384&amp;doi=10.1038%2Fncomms9859&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms9859%26sid%3Dliteratum%253Aachs%26aulast%3DBunda%26aufirst%3DS.%26aulast%3DBurrell%26aufirst%3DK.%26aulast%3DHeir%26aufirst%3DP.%26aulast%3DZeng%26aufirst%3DL.%26aulast%3DAlamsahebpour%26aufirst%3DA.%26aulast%3DKano%26aufirst%3DY.%26aulast%3DRaught%26aufirst%3DB.%26aulast%3DZhang%26aufirst%3DZ.%2BY.%26aulast%3DZadeh%26aufirst%3DG.%26aulast%3DOhh%26aufirst%3DM.%26jtitle%3DNat.%2520Commun.%26date%3D2015%26volume%3D6%26spage%3D8859%26doi%3D10.1038%2Fncomms9859" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scott, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sebti, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span> <span> </span><span class="NLM_article-title">Targeting Protein Tyrosine Phosphatases for Anticancer Drug Discovery</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1843</span>– <span class="NLM_lpage">1862</span>, <span class="refDoi"> DOI: 10.2174/138161210791209027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=10.2174%2F138161210791209027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=20337577" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADC%252BC3cXot1ClsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=1843-1862&author=L.+M.+Scottauthor=H.+R.+Lawrenceauthor=S.+M.+Sebtiauthor=N.+J.+Lawrenceauthor=J.+Wu&title=Targeting+Protein+Tyrosine+Phosphatases+for+Anticancer+Drug+Discovery&doi=10.2174%2F138161210791209027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting protein tyrosine phosphatases for anticancer drug discovery</span></div><div class="casAuthors">Scott, Latanya M.; Lawrence, Harshani R.; Sebti, Said M.; Lawrence, Nicholas J.; Wu, Jie</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1843-1862</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Protein tyrosine phosphatases (PTPs) are a diverse family of enzymes encoded by 107 genes in the human genome.  Together with protein tyrosine kinases (PTKs), PTPs regulate various cellular activities essential for the initiation and maintenance of malignant phenotypes.  While PTK inhibitors are now used routinely for cancer treatment, the PTP inhibitor development field is still in the discovery phase.  In this article, the suitability of targeting PTPs for novel anticancer drug discovery is discussed.  Examples are presented for PTPs that have been targeted for anticancer drug discovery as well as potential new PTP targets for novel anticancer drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHuBrNeSP0n7Vg90H21EOLACvtfcHk0lhEA8OmoHvqRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXot1ClsLY%253D&md5=17813d1fba0225fd5e54692b1159bc4a</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.2174%2F138161210791209027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161210791209027%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DL.%2BM.%26aulast%3DLawrence%26aufirst%3DH.%2BR.%26aulast%3DSebti%26aufirst%3DS.%2BM.%26aulast%3DLawrence%26aufirst%3DN.%2BJ.%26aulast%3DWu%26aufirst%3DJ.%26atitle%3DTargeting%2520Protein%2520Tyrosine%2520Phosphatases%2520for%2520Anticancer%2520Drug%2520Discovery%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2010%26volume%3D16%26spage%3D1843%26epage%3D1862%26doi%3D10.2174%2F138161210791209027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Gilmartin, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faitg, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richter, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seefeld, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darcy, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Federowicz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minthorn, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaworski, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaber, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martens, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNulty, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinnamon, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkpatrick, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nevins, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pietrak, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diaz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heerding, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, R.</span></span> <span> </span><span class="NLM_article-title">Allosteric WIP1 Phosphatase Inhibition Through Flap-Subdomain Interaction</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">181</span>– <span class="NLM_lpage">187</span>, <span class="refDoi"> DOI: 10.1038/nchembio.1427</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=10.1038%2Fnchembio.1427" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=24390428" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADC%252BC2cXis1egsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=181-187&author=A.+G.+Gilmartinauthor=T.+H.+Faitgauthor=M.+Richterauthor=A.+Groyauthor=M.+A.+Seefeldauthor=M.+G.+Darcyauthor=X.+Pengauthor=K.+Federowiczauthor=J.+Yangauthor=S.+Y.+Zhangauthor=E.+Minthornauthor=J.+P.+Jaworskiauthor=M.+Schaberauthor=S.+Martensauthor=D.+E.+McNultyauthor=R.+H.+Sinnamonauthor=H.+Zhangauthor=R.+B.+Kirkpatrickauthor=N.+Nevinsauthor=G.+Cuiauthor=B.+Pietrakauthor=E.+Diazauthor=A.+Jonesauthor=M.+Brandtauthor=B.+Schwartzauthor=D.+A.+Heerdingauthor=R.+Kumar&title=Allosteric+WIP1+Phosphatase+Inhibition+Through+Flap-Subdomain+Interaction&doi=10.1038%2Fnchembio.1427"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23aR"><div class="casContent"><span class="casTitleNuber">23a</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric Wip1 phosphatase inhibition through flap-subdomain interaction</span></div><div class="casAuthors">Gilmartin, Aidan G.; Faitg, Thomas H.; Richter, Mark; Groy, Arthur; Seefeld, Mark A.; Darcy, Michael G.; Peng, Xin; Federowicz, Kelly; Yang, Jingsong; Zhang, Shu-Yun; Minthorn, Elisabeth; Jaworski, Jon-Paul; Schaber, Michael; Martens, Stan; McNulty, Dean E.; Sinnamon, Robert H.; Zhang, Hong; Kirkpatrick, Robert B.; Nevins, Neysa; Cui, Guanglei; Pietrak, Beth; Diaz, Elsie; Jones, Amber; Brandt, Martin; Schwartz, Benjamin; Heerding, Dirk A.; Kumar, Rakesh</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">181-187</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Although therapeutic interventions of signal-transduction cascades with targeted kinase inhibitors are a well-established strategy, drug-discovery efforts to identify targeted phosphatase inhibitors have proven challenging.  Herein we report a series of allosteric, small-mol. inhibitors of wild-type p53-induced phosphatase (Wip1), an oncogenic phosphatase common to multiple cancers.  Compd. binding to Wip1 is dependent on a 'flap' subdomain located near the Wip1 catalytic site that renders Wip1 structurally divergent from other members of the protein phosphatase 2C (PP2C) family and that thereby confers selectivity for Wip1 over other phosphatases.  Treatment of tumor cells with the inhibitor GSK2830371 increases phosphorylation of Wip1 substrates and causes growth inhibition in both hematopoietic tumor cell lines and Wip1-amplified breast tumor cells harboring wild-type TP53.  Oral administration of Wip1 inhibitors in mice results in expected pharmacodynamic effects and causes inhibition of lymphoma xenograft growth.  To our knowledge, GSK2830371 is the first orally active, allosteric inhibitor of Wip1 phosphatase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-jXZXKTKTL7Vg90H21EOLACvtfcHk0ljAPR_VCyYTEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXis1egsA%253D%253D&md5=47524caa70df233fb152a2d683417e7d</span></div><a href="/servlet/linkout?suffix=cit23a&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1427&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1427%26sid%3Dliteratum%253Aachs%26aulast%3DGilmartin%26aufirst%3DA.%2BG.%26aulast%3DFaitg%26aufirst%3DT.%2BH.%26aulast%3DRichter%26aufirst%3DM.%26aulast%3DGroy%26aufirst%3DA.%26aulast%3DSeefeld%26aufirst%3DM.%2BA.%26aulast%3DDarcy%26aufirst%3DM.%2BG.%26aulast%3DPeng%26aufirst%3DX.%26aulast%3DFederowicz%26aufirst%3DK.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DS.%2BY.%26aulast%3DMinthorn%26aufirst%3DE.%26aulast%3DJaworski%26aufirst%3DJ.%2BP.%26aulast%3DSchaber%26aufirst%3DM.%26aulast%3DMartens%26aufirst%3DS.%26aulast%3DMcNulty%26aufirst%3DD.%2BE.%26aulast%3DSinnamon%26aufirst%3DR.%2BH.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DKirkpatrick%26aufirst%3DR.%2BB.%26aulast%3DNevins%26aufirst%3DN.%26aulast%3DCui%26aufirst%3DG.%26aulast%3DPietrak%26aufirst%3DB.%26aulast%3DDiaz%26aufirst%3DE.%26aulast%3DJones%26aufirst%3DA.%26aulast%3DBrandt%26aufirst%3DM.%26aulast%3DSchwartz%26aufirst%3DB.%26aulast%3DHeerding%26aufirst%3DD.%2BA.%26aulast%3DKumar%26aufirst%3DR.%26atitle%3DAllosteric%2520WIP1%2520Phosphatase%2520Inhibition%2520Through%2520Flap-Subdomain%2520Interaction%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2014%26volume%3D10%26spage%3D181%26epage%3D187%26doi%3D10.1038%2Fnchembio.1427" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit23b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Chio, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bishop, A. C.</span></span> <span> </span><span class="NLM_article-title">Rational Design of Allosteric-Inhibition Sites in Classical Protein Tyrosine Phosphatases</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">2828</span>– <span class="NLM_lpage">2838</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2015.03.027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=10.1016%2Fj.bmc.2015.03.027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=25828055" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADC%252BC2MXkvVWhs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=2828-2838&author=C.+M.+Chioauthor=X.+Yuauthor=A.+C.+Bishop&title=Rational+Design+of+Allosteric-Inhibition+Sites+in+Classical+Protein+Tyrosine+Phosphatases&doi=10.1016%2Fj.bmc.2015.03.027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23bR"><div class="casContent"><span class="casTitleNuber">23b</span><div class="casTitle"><span class="NLM_cas:atitle">Rational design of allosteric-inhibition sites in classical protein tyrosine phosphatases</span></div><div class="casAuthors">Chio, Cynthia M.; Yu, Xiaoling; Bishop, Anthony C.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2828-2838</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Protein tyrosine phosphatases (PTPs), which catalyze the dephosphorylation of phosphotyrosine in protein substrates, are crit. regulators of metazoan cell signaling and have emerged as potential drug targets for a range of human diseases.  Strategies for chem. targeting the function of individual PTPs selectively could serve to elucidate the signaling roles of these enzymes and would potentially expedite validation of the therapeutic promise of PTP inhibitors.  Here we report a novel strategy for the design of non-natural allosteric-inhibition sites in PTPs; these sites, which can be introduced into target PTPs through protein engineering, serve to sensitize target PTPs to potent and selective inhibition by a biarsenical small mol.  Building on the recent discovery of a naturally occurring cryptic allosteric site in wild-type Src-homol.-2 domain contg. PTP (Shp2) that can be targeted by biarsenical compds., we hypothesized that Shp2's unusual sensitivity to biarsenicals could be strengthened through rational design and that the Shp2-specific site could serve as a blueprint for the introduction of non-natural inhibitor sensitivity in other PTPs.  Indeed, we show here that the strategic introduction of a cysteine residue at a position removed from the Shp2 active site can serve to increase the potency and selectivity of the interaction between Shp2's allosteric site and the biarsenical inhibitor.  Moreover, we find that 'Shp2-like' allosteric sites can be installed de novo in PTP enzymes that do not possess naturally occurring sensitivity to biarsenical compds.  Using primary-sequence alignments to guide our enzyme engineering, we have successfully introduced allosteric-inhibition sites in four classical PTPs-PTP1B, PTPH-1, FAP-1, and HePTP-from four different PTP subfamilies, suggesting that our sensitization approach can likely be applied widely across the classical PTP family to generate biarsenical-responsive PTPs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwDXbkv2RdC7Vg90H21EOLACvtfcHk0ljAPR_VCyYTEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXkvVWhs7s%253D&md5=14a48e70c722a586a2e3ccb3fa9006ae</span></div><a href="/servlet/linkout?suffix=cit23b&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2015.03.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2015.03.027%26sid%3Dliteratum%253Aachs%26aulast%3DChio%26aufirst%3DC.%2BM.%26aulast%3DYu%26aufirst%3DX.%26aulast%3DBishop%26aufirst%3DA.%2BC.%26atitle%3DRational%2520Design%2520of%2520Allosteric-Inhibition%2520Sites%2520in%2520Classical%2520Protein%2520Tyrosine%2520Phosphatases%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2015%26volume%3D23%26spage%3D2828%26epage%3D2838%26doi%3D10.1016%2Fj.bmc.2015.03.027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit23c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beumer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simard, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grutter, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rauh, D.</span></span> <span> </span><span class="NLM_article-title">Selective Detection of Allosteric Phosphatase Inhibitors</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>135</i></span>,  <span class="NLM_fpage">6838</span>– <span class="NLM_lpage">6841</span>, <span class="refDoi"> DOI: 10.1021/ja4030484</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja4030484" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmtlWhtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=135&publication_year=2013&pages=6838-6841&author=R.+Schneiderauthor=C.+Beumerauthor=J.+R.+Simardauthor=C.+Grutterauthor=D.+Rauh&title=Selective+Detection+of+Allosteric+Phosphatase+Inhibitors&doi=10.1021%2Fja4030484"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23cR"><div class="casContent"><span class="casTitleNuber">23c</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Detection of Allosteric Phosphatase Inhibitors</span></div><div class="casAuthors">Schneider, Ralf; Beumer, Claudia; Simard, Jeffrey R.; Gruetter, Christian; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">135</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6838-6841</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Normal cellular function, such as signal transduction, is largely controlled by the reversible phosphorylation of cellular proteins catalyzed by two major classes of enzymes, kinases and phosphatases.  A misbalance in this complex and dynamic interplay leads to a variety of severe diseases, such as cancer, inflammation, or autoimmune diseases.  This makes kinases as well as phosphatases equally attractive targets for therapeutic manipulation by small mols.  While the development of kinase inhibitors has resulted in several blockbuster drugs, such as imatinib, with remarkable success in the clinic and sales of many billions of U.S. dollars per yr, not a single phosphatase inhibitor has yet been approved for clin. use.  Similar to the kinase world, substrate-competitive phosphatase inhibitors have been developed but were not suitable for further development into clin. candidates due to their charge and limited selectivity.  Research efforts, therefore, have shifted to the exploitation of allosteric sites that can regulate phosphatase activity and may enable the discovery of novel modulators of phosphatase activity with much improved pharmacol. properties.  However, assay systems, which enable the straightforward discovery of these inhibitor types, are missing.  Here, we present a novel binding assay capable of detecting ligands of an allosteric pocket of the protein tyrosine phosphatase 1B.  This assay is suitable for high-throughput screening and selectively detects ligands which bind to this unique site with a clear discrimination from substrate-competitive ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMMpcm8RfGWrVg90H21EOLACvtfcHk0li0ys-dFgtpgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmtlWhtbk%253D&md5=49a980ad7f749718803f1afe1d8d1a04</span></div><a href="/servlet/linkout?suffix=cit23c&amp;dbid=16384&amp;doi=10.1021%2Fja4030484&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja4030484%26sid%3Dliteratum%253Aachs%26aulast%3DSchneider%26aufirst%3DR.%26aulast%3DBeumer%26aufirst%3DC.%26aulast%3DSimard%26aufirst%3DJ.%2BR.%26aulast%3DGrutter%26aufirst%3DC.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DSelective%2520Detection%2520of%2520Allosteric%2520Phosphatase%2520Inhibitors%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2013%26volume%3D135%26spage%3D6838%26epage%3D6841%26doi%3D10.1021%2Fja4030484" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.-N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaMarche, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fekkes, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Fortanet, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acker, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonakos, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. H.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooke, V. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobson, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fei, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Firestone, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fodor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fridrich, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grunenfelder, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, H.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacob, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsiao, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, Z. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karki, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larrow, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La Bonte, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenoir, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majumdar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palermo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quinn, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shakya, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shultz, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slisz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkatesan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warmuth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramsey, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keen, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellers, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stams, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fortin, P. D.</span></span> <span> </span><span class="NLM_article-title">Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinase</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>535</i></span>,  <span class="NLM_fpage">148</span>– <span class="NLM_lpage">152</span>, <span class="refDoi"> DOI: 10.1038/nature18621</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=10.1038%2Fnature18621" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=27362227" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVOns7bI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=535&publication_year=2016&pages=148-152&author=Y.-N.+P.+Chenauthor=M.+J.+LaMarcheauthor=H.+M.+Chanauthor=P.+Fekkesauthor=J.+Garcia-Fortanetauthor=M.+G.+Ackerauthor=B.+Antonakosauthor=C.+H.-T.+Chenauthor=Z.+Chenauthor=V.+G.+Cookeauthor=J.+R.+Dobsonauthor=Z.+Dengauthor=F.+Feiauthor=B.+Firestoneauthor=M.+Fodorauthor=C.+Fridrichauthor=H.+Gaoauthor=D.+Grunenfelderauthor=H.-X.+Haoauthor=J.+Jacobauthor=S.+Hoauthor=K.+Hsiaoauthor=Z.+B.+Kangauthor=R.+Karkiauthor=M.+Katoauthor=J.+Larrowauthor=L.+R.+La+Bonteauthor=F.+Lenoirauthor=G.+Liuauthor=S.+Liuauthor=D.+Majumdarauthor=M.+J.+Meyerauthor=M.+Palermoauthor=L.+Perezauthor=M.+Puauthor=E.+Priceauthor=C.+Quinnauthor=S.+Shakyaauthor=M.+D.+Shultzauthor=J.+Sliszauthor=K.+Venkatesanauthor=P.+Wangauthor=M.+Warmuthauthor=S.+Williamsauthor=G.+Yangauthor=J.+Yuanauthor=J.-H.+Zhangauthor=P.+Zhuauthor=T.+Ramseyauthor=N.+J.+Keenauthor=W.+R.+Sellersauthor=T.+Stamsauthor=P.+D.+Fortin&title=Allosteric+inhibition+of+SHP2+phosphatase+inhibits+cancers+driven+by+receptor+tyrosine+kinase&doi=10.1038%2Fnature18621"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases</span></div><div class="casAuthors">Chen, Ying-Nan P.; LaMarche, Matthew J.; Chan, Ho Man; Fekkes, Peter; Garcia-Fortanet, Jorge; Acker, Michael G.; Antonakos, Brandon; Chen, Christine Hiu-Tung; Chen, Zhouliang; Cooke, Vesselina G.; Dobson, Jason R.; Deng, Zhan; Fei, Feng; Firestone, Brant; Fodor, Michelle; Fridrich, Cary; Gao, Hui; Grunenfelder, Denise; Hao, Huai-Xiang; Jacob, Jaison; Ho, Samuel; Hsiao, Kathy; Kang, Zhao B.; Karki, Rajesh; Kato, Mitsunori; Larrow, Jay; La Bonte, Laura R.; Lenoir, Francois; Liu, Gang; Liu, Shumei; Majumdar, Dyuti; Meyer, Matthew J.; Palermo, Mark; Perez, Lawrence; Pu, Minying; Price, Edmund; Quinn, Christopher; Shakya, Subarna; Shultz, Michael D.; Slisz, Joanna; Venkatesan, Kavitha; Wang, Ping; Warmuth, Markus; Williams, Sarah; Yang, Guizhi; Yuan, Jing; Zhang, Ji-Hu; Zhu, Ping; Ramsey, Timothy; Keen, Nicholas J.; Sellers, William R.; Stams, Travis; Fortin, Pascal D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">535</span>
        (<span class="NLM_cas:issue">7610</span>),
    <span class="NLM_cas:pages">148-152</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The non-receptor protein tyrosine phosphatase SHP2, encoded by PTPN11, has an important role in signal transduction downstream of growth factor receptor signalling and was the first reported oncogenic tyrosine phosphatase.  Activating mutations of SHP2 have been assocd. with developmental pathologies such as Noonan syndrome and are found in multiple cancer types, including leukemia, lung and breast cancer and neuroblastoma.  SHP2 is ubiquitously expressed and regulates cell survival and proliferation primarily through activation of the RAS-ERK signalling pathway2,3.  It is also a key mediator of the programmed cell death 1 (PD-1) and B- and T-lymphocyte attenuator (BTLA) immune checkpoint pathways.  Redn. of SHP2 activity suppresses tumor cell growth and is a potential target of cancer therapy.  Here we report the discovery of a highly potent (IC50 = 0.071 μM), selective and orally bioavailable small-mol. SHP2 inhibitor, SHP099, that stabilizes SHP2 in an auto-inhibited conformation.  SHP099 concurrently binds to the interface of the N-terminal SH2, C-terminal SH2, and protein tyrosine phosphatase domains, thus inhibiting SHP2 activity through an allosteric mechanism.  SHP099 suppresses RAS-ERK signalling to inhibit the proliferation of receptor-tyrosine-kinase-driven human cancer cells in vitro and is efficacious in mouse tumor xenograft models.  Together, these data demonstrate that pharmacol. inhibition of SHP2 is a valid therapeutic approach for the treatment of cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBs_e02S0Sp7Vg90H21EOLACvtfcHk0li0ys-dFgtpgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVOns7bI&md5=ec8a4b612d5008a2519bd846d45ce019</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1038%2Fnature18621&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature18621%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DY.-N.%2BP.%26aulast%3DLaMarche%26aufirst%3DM.%2BJ.%26aulast%3DChan%26aufirst%3DH.%2BM.%26aulast%3DFekkes%26aufirst%3DP.%26aulast%3DGarcia-Fortanet%26aufirst%3DJ.%26aulast%3DAcker%26aufirst%3DM.%2BG.%26aulast%3DAntonakos%26aufirst%3DB.%26aulast%3DChen%26aufirst%3DC.%2BH.-T.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DCooke%26aufirst%3DV.%2BG.%26aulast%3DDobson%26aufirst%3DJ.%2BR.%26aulast%3DDeng%26aufirst%3DZ.%26aulast%3DFei%26aufirst%3DF.%26aulast%3DFirestone%26aufirst%3DB.%26aulast%3DFodor%26aufirst%3DM.%26aulast%3DFridrich%26aufirst%3DC.%26aulast%3DGao%26aufirst%3DH.%26aulast%3DGrunenfelder%26aufirst%3DD.%26aulast%3DHao%26aufirst%3DH.-X.%26aulast%3DJacob%26aufirst%3DJ.%26aulast%3DHo%26aufirst%3DS.%26aulast%3DHsiao%26aufirst%3DK.%26aulast%3DKang%26aufirst%3DZ.%2BB.%26aulast%3DKarki%26aufirst%3DR.%26aulast%3DKato%26aufirst%3DM.%26aulast%3DLarrow%26aufirst%3DJ.%26aulast%3DLa%2BBonte%26aufirst%3DL.%2BR.%26aulast%3DLenoir%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DMajumdar%26aufirst%3DD.%26aulast%3DMeyer%26aufirst%3DM.%2BJ.%26aulast%3DPalermo%26aufirst%3DM.%26aulast%3DPerez%26aufirst%3DL.%26aulast%3DPu%26aufirst%3DM.%26aulast%3DPrice%26aufirst%3DE.%26aulast%3DQuinn%26aufirst%3DC.%26aulast%3DShakya%26aufirst%3DS.%26aulast%3DShultz%26aufirst%3DM.%2BD.%26aulast%3DSlisz%26aufirst%3DJ.%26aulast%3DVenkatesan%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DWarmuth%26aufirst%3DM.%26aulast%3DWilliams%26aufirst%3DS.%26aulast%3DYang%26aufirst%3DG.%26aulast%3DYuan%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DJ.-H.%26aulast%3DZhu%26aufirst%3DP.%26aulast%3DRamsey%26aufirst%3DT.%26aulast%3DKeen%26aufirst%3DN.%2BJ.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DStams%26aufirst%3DT.%26aulast%3DFortin%26aufirst%3DP.%2BD.%26atitle%3DAllosteric%2520inhibition%2520of%2520SHP2%2520phosphatase%2520inhibits%2520cancers%2520driven%2520by%2520receptor%2520tyrosine%2520kinase%26jtitle%3DNature%26date%3D2016%26volume%3D535%26spage%3D148%26epage%3D152%26doi%3D10.1038%2Fnature18621" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garcia
Fortanet, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. H.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.-N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Firestone, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fekkes, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fodor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fortin, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fridrich, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grunenfelder, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, Z. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karki, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaBonte, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larrow, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenoir, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majumdar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palermo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramsey, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellers, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shultz, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stams, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Towler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaMarche, M. J.</span></span> <span> </span><span class="NLM_article-title">Allosteric Inhibition of SHP2: Identification of a Potent, Selective, and Orally Efficacious Phosphatase Inhibitor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">7773</span>– <span class="NLM_lpage">7782</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00680</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00680" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVKju7fP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=7773-7782&author=J.+Garcia%0AFortanetauthor=C.+H.-T.+Chenauthor=Y.-N.+P.+Chenauthor=Z.+Chenauthor=Z.+Dengauthor=B.+Firestoneauthor=P.+Fekkesauthor=M.+Fodorauthor=P.+D.+Fortinauthor=C.+Fridrichauthor=D.+Grunenfelderauthor=S.+Hoauthor=Z.+B.+Kangauthor=R.+Karkiauthor=M.+Katoauthor=N.+Keenauthor=L.+R.+LaBonteauthor=J.+Larrowauthor=F.+Lenoirauthor=G.+Liuauthor=S.+Liuauthor=F.+Lombardoauthor=D.+Majumdarauthor=M.+J.+Meyerauthor=M.+Palermoauthor=L.+Perezauthor=M.+Puauthor=T.+Ramseyauthor=W.+R.+Sellersauthor=M.+D.+Shultzauthor=T.+Stamsauthor=C.+Towlerauthor=P.+Wangauthor=S.+L.+Williamsauthor=J.-H.+Zhangauthor=M.+J.+LaMarche&title=Allosteric+Inhibition+of+SHP2%3A+Identification+of+a+Potent%2C+Selective%2C+and+Orally+Efficacious+Phosphatase+Inhibitor&doi=10.1021%2Facs.jmedchem.6b00680"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric Inhibition of SHP2: Identification of a Potent, Selective, and Orally Efficacious Phosphatase Inhibitor</span></div><div class="casAuthors">Garcia Fortanet, Jorge; Chen, Christine Hiu-Tung; Chen, Ying-Nan P.; Chen, Zhouliang; Deng, Zhan; Firestone, Brant; Fekkes, Peter; Fodor, Michelle; Fortin, Pascal D.; Fridrich, Cary; Grunenfelder, Denise; Ho, Samuel; Kang, Zhao B.; Karki, Rajesh; Kato, Mitsunori; Keen, Nick; LaBonte, Laura R.; Larrow, Jay; Lenoir, Francois; Liu, Gang; Liu, Shumei; Lombardo, Franco; Majumdar, Dyuti; Meyer, Matthew J.; Palermo, Mark; Perez, Lawrence; Pu, Minying; Ramsey, Timothy; Sellers, William R.; Shultz, Michael D.; Stams, Travis; Towler, Christopher; Wang, Ping; Williams, Sarah L.; Zhang, Ji-Hu; LaMarche, Matthew J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7773-7782</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">SHP2 is a nonreceptor protein tyrosine phosphatase (PTP) encoded by the PTPN11 gene involved in cell growth and differentiation via the MAPK signaling pathway.  SHP2 also purportedly plays an important role in the programmed cell death pathway (PD-1/PD-L1).  Because it is an oncoprotein assocd. with multiple cancer-related diseases, as well as a potential immunomodulator, controlling SHP2 activity is of significant therapeutic interest.  Recently in our labs., a small mol. inhibitor of SHP2 was identified as an allosteric modulator that stabilizes the autoinhibited conformation of SHP2.  A high throughput screen was performed to identify progressable chem. matter, and X-ray crystallog. revealed the location of binding in a previously undisclosed allosteric binding pocket.  Structure-based drug design was employed to optimize for SHP2 inhibition, and several new protein-ligand interactions were characterized.  These studies culminated in the discovery of 6-(4-amino-4-methylpiperidin-1-yl)-3-(2,3-dichlorophenyl)pyrazin-2-amine (SHP099, 1), a potent, selective, orally bioavailable, and efficacious SHP2 inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6RT7zfZnvfLVg90H21EOLACvtfcHk0lhhuYQix8ii1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVKju7fP&md5=dfe43b5253e172576386f86797087f7b</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00680&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00680%26sid%3Dliteratum%253Aachs%26aulast%3DGarcia%2BFortanet%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DC.%2BH.-T.%26aulast%3DChen%26aufirst%3DY.-N.%2BP.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DDeng%26aufirst%3DZ.%26aulast%3DFirestone%26aufirst%3DB.%26aulast%3DFekkes%26aufirst%3DP.%26aulast%3DFodor%26aufirst%3DM.%26aulast%3DFortin%26aufirst%3DP.%2BD.%26aulast%3DFridrich%26aufirst%3DC.%26aulast%3DGrunenfelder%26aufirst%3DD.%26aulast%3DHo%26aufirst%3DS.%26aulast%3DKang%26aufirst%3DZ.%2BB.%26aulast%3DKarki%26aufirst%3DR.%26aulast%3DKato%26aufirst%3DM.%26aulast%3DKeen%26aufirst%3DN.%26aulast%3DLaBonte%26aufirst%3DL.%2BR.%26aulast%3DLarrow%26aufirst%3DJ.%26aulast%3DLenoir%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DLombardo%26aufirst%3DF.%26aulast%3DMajumdar%26aufirst%3DD.%26aulast%3DMeyer%26aufirst%3DM.%2BJ.%26aulast%3DPalermo%26aufirst%3DM.%26aulast%3DPerez%26aufirst%3DL.%26aulast%3DPu%26aufirst%3DM.%26aulast%3DRamsey%26aufirst%3DT.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DShultz%26aufirst%3DM.%2BD.%26aulast%3DStams%26aufirst%3DT.%26aulast%3DTowler%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DWilliams%26aufirst%3DS.%2BL.%26aulast%3DZhang%26aufirst%3DJ.-H.%26aulast%3DLaMarche%26aufirst%3DM.%2BJ.%26atitle%3DAllosteric%2520Inhibition%2520of%2520SHP2%253A%2520Identification%2520of%2520a%2520Potent%252C%2520Selective%252C%2520and%2520Orally%2520Efficacious%2520Phosphatase%2520Inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D7773%26epage%3D7782%26doi%3D10.1021%2Facs.jmedchem.6b00680" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span> <span> </span><span class="NLM_article-title">SHP2 Inhibition Triggers Anti-tumor Immunity and Synergizes with PD-1 Blockade</span>. <i>Acta Pharm. Sin. B</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">304</span>– <span class="NLM_lpage">315</span>, <span class="refDoi"> DOI: 10.1016/j.apsb.2018.08.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=10.1016%2Fj.apsb.2018.08.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=30972278" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A280%3ADC%252BB3M%252FktFKktw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=304-315&author=M.+Zhaoauthor=W.+Guoauthor=Y.+Wuauthor=C.+Yangauthor=L.+Zhongauthor=G.+Dengauthor=Y.+Zhuauthor=W.+Liuauthor=Y.+Guauthor=Y.+Luauthor=L.+Kongauthor=X.+Mengauthor=Q.+Xuauthor=Y.+Sun&title=SHP2+Inhibition+Triggers+Anti-tumor+Immunity+and+Synergizes+with+PD-1+Blockade&doi=10.1016%2Fj.apsb.2018.08.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">SHP2 inhibition triggers anti-tumor immunity and synergizes with PD-1 blockade</span></div><div class="casAuthors">Zhao Mingxia; Guo Wenjie; Yang Chenxi; Deng Guoliang; Zhu Yuyu; Liu Wen; Kong Lingdong; Meng Xiangbao; Xu Qiang; Sun Yang; Wu Yuanyuan; Lu Yin; Zhong Liang; Meng Xiangbao; Gu Yanhong</div><div class="citationInfo"><span class="NLM_cas:title">Acta pharmaceutica Sinica. B</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">304-315</span>
        ISSN:<span class="NLM_cas:issn">2211-3835</span>.
    </div><div class="casAbstract">Tyrosine phosphatase SHP2 is a promising drug target in cancer immunotherapy due to its bidirectional role in both tumor growth promotion and T-cell inactivation.  Its allosteric inhibitor SHP099 is known to inhibit cancer cell growth both in vitro and in vivo.  However, whether SHP099-mediated SHP2 inhibition retards tumor growth in vivo via anti-tumor immunity remains elusive.  To address this, a CT-26 colon cancer xenograft model was established in mice since this cell line is insensitive to SHP099.  Consequently, SHP099 minimally affected CT-26 tumor growth in immuno-deficient nude mice, but significantly decreased the tumor burden in CT-26 tumor-bearing mice with intact immune system.  SHP099 augmented anti-tumor immunity, as shown by the elevated proportion of CD8(+)IFN-γ(+) T cells and the upregulation of cytotoxic T-cell related genes including Granzyme B andPerforin, which decreased the tumor load.  In addition, tumor growth in mice with SHP2-deficient T-cells was markedly slowed down because of enhanced anti-tumor responses.  Finally, the combination of SHP099 and anti-PD-1 antibody showed a higher therapeutic efficacy than either monotherapy in controlling tumor growth in two colon cancer xenograft models, indicating that these agents complement each other.  Our study suggests that SHP2 inhibitor SHP099 is a promising candidate drug for cancer immunotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSB60VxKgx5l_h3YQQtAhNufW6udTcc2eafcKk4q_uWgrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M%252FktFKktw%253D%253D&md5=759babe45705b88551f6ac62cb3cee2e</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.apsb.2018.08.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.apsb.2018.08.009%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DM.%26aulast%3DGuo%26aufirst%3DW.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DC.%26aulast%3DZhong%26aufirst%3DL.%26aulast%3DDeng%26aufirst%3DG.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DGu%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DKong%26aufirst%3DL.%26aulast%3DMeng%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DSun%26aufirst%3DY.%26atitle%3DSHP2%2520Inhibition%2520Triggers%2520Anti-tumor%2520Immunity%2520and%2520Synergizes%2520with%2520PD-1%2520Blockade%26jtitle%3DActa%2520Pharm.%2520Sin.%2520B%26date%3D2019%26volume%3D9%26spage%3D304%26epage%3D315%26doi%3D10.1016%2Fj.apsb.2018.08.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27a"><span><span class="NLM_label">(a) </span> OECD guidelines, <i>In Vitro</i> 3T3 NRU
Phototoxicity
Test. <a href="https://ntp.niehs.nih.gov/iccvam/suppdocs/feddocs/oecd/oecdtg432-508.pdf" class="extLink">https://ntp.niehs.nih.gov/iccvam/suppdocs/feddocs/oecd/oecdtg432-508.pdf</a> (accessed Aug 19, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+OECD+guidelines%2C+In+Vitro+3T3+NRU%0APhototoxicity%0ATest.+https%3A%2F%2Fntp.niehs.nih.gov%2Ficcvam%2Fsuppdocs%2Ffeddocs%2Foecd%2Foecdtg432-508.pdf+%28accessed+Aug+19%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit27b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Schumann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boudon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulrich, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loll, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaffner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Streich, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kittel, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, D.</span></span> <span> </span><span class="NLM_article-title">Integrated Preclinical Photosafety Testing Strategy for Systemically Applied Pharmaceuticals</span>. <i>Toxicol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>139</i></span>,  <span class="NLM_fpage">245</span>– <span class="NLM_lpage">256</span>, <span class="refDoi"> DOI: 10.1093/toxsci/kfu026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=10.1093%2Ftoxsci%2Fkfu026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=24519524" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A280%3ADC%252BC2cvjvF2huw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=139&publication_year=2014&pages=245-256&author=J.+Schumannauthor=S.+Boudonauthor=P.+Ulrichauthor=N.+Lollauthor=D.+Garciaauthor=R.+Schaffnerauthor=J.+Streichauthor=B.+Kittelauthor=D.+Bauer&title=Integrated+Preclinical+Photosafety+Testing+Strategy+for+Systemically+Applied+Pharmaceuticals&doi=10.1093%2Ftoxsci%2Fkfu026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27bR"><div class="casContent"><span class="casTitleNuber">27b</span><div class="casTitle"><span class="NLM_cas:atitle">Integrated preclinical photosafety testing strategy for systemically applied pharmaceuticals</span></div><div class="casAuthors">Schumann Jens; Boudon Stephanie; Ulrich Peter; Loll Nathalie; Garcia Deborah; Schaffner Rene; Streich Jeannine; Kittel Birgit; Bauer Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological sciences : an official journal of the Society of Toxicology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">139</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">245-56</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Phototoxic properties of systemically applied pharmaceuticals may be the cause of serious adverse drug reactions.  Therefore, a reliable preclinical photosafety assessment strategy, combining in vitro and in vivo approaches in a quantitative manner, is important and has not been described so far.  Here, we report the establishment of an optimized modified murine local lymph node assay (LLNA), adapted for phototoxicity assessment of systemically applied compounds, as well as the test results for 34 drug candidates in this in vivo photo-LLNA.  The drug candidates were selected based on their ability to absorb ultraviolet/visible light and the photo irritation factors (PIFs) determined in the well-established in vitro 3T3 neutral red uptake phototoxicity test.  An in vivo phototoxic potential was identified for 13 of these drug candidates.  The use of multiple dose levels in the described murine in vivo phototoxicity studies enabled the establishment of no- and/or lowest-observed-adverse-effect levels (NOAELs/LOAELs), also supporting human photosafety assessment.  An in vitro-in vivo correlation demonstrated that a drug candidate classified as "phototoxic" in vitro is not necessarily phototoxic in vivo.  However, the probability for a drug candidate to cause phototoxicity in vivo clearly correlated with the magnitude of the phototoxicity identified in vitro.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTPHAsrez4GpyXXDYhVZBdlfW6udTcc2eafcKk4q_uWgrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cvjvF2huw%253D%253D&md5=9d638c7064af0765e7f1ab93165f42c6</span></div><a href="/servlet/linkout?suffix=cit27b&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2Fkfu026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252Fkfu026%26sid%3Dliteratum%253Aachs%26aulast%3DSchumann%26aufirst%3DJ.%26aulast%3DBoudon%26aufirst%3DS.%26aulast%3DUlrich%26aufirst%3DP.%26aulast%3DLoll%26aufirst%3DN.%26aulast%3DGarcia%26aufirst%3DD.%26aulast%3DSchaffner%26aufirst%3DR.%26aulast%3DStreich%26aufirst%3DJ.%26aulast%3DKittel%26aufirst%3DB.%26aulast%3DBauer%26aufirst%3DD.%26atitle%3DIntegrated%2520Preclinical%2520Photosafety%2520Testing%2520Strategy%2520for%2520Systemically%2520Applied%2520Pharmaceuticals%26jtitle%3DToxicol.%2520Sci.%26date%3D2014%26volume%3D139%26spage%3D245%26epage%3D256%26doi%3D10.1093%2Ftoxsci%2Fkfu026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Canon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rex, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saiki, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohr, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooke, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagal, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaida, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holt, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knutson, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koppada, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanman, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rapaport, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">San Miguel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortiz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osgood, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarter, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volak, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houk, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fakih, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Neil, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falchook, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Govindan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouyang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henary, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arvedson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cee, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipford, J.R.</span></span> <span> </span><span class="NLM_article-title">The Clinical KRAS(G12C) Inhibitor AMG510 Drives Anti-Tumour Immunity</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>575</i></span>,  <span class="NLM_fpage">217</span>– <span class="NLM_lpage">223</span>, <span class="refDoi"> DOI: 10.1038/s41586-019-1694-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=10.1038%2Fs41586-019-1694-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=31666701" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitV2hsb7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=575&publication_year=2019&pages=217-223&author=J.+Canonauthor=K.+Rexauthor=A.+Y.+Saikiauthor=C.+Mohrauthor=K.+Cookeauthor=D.+Bagalauthor=K.+Gaidaauthor=T.+Holtauthor=C.+G.+Knutsonauthor=N.+Koppadaauthor=B.+A.+Lanmanauthor=J.+Wernerauthor=A.+S.+Rapaportauthor=T.+San+Miguelauthor=R.+Ortizauthor=T.+Osgoodauthor=J.+R.+Sunauthor=X.+Zhuauthor=J.+D.+McCarterauthor=L.+P.+Volakauthor=B.+E.+Houkauthor=M.+G.+Fakihauthor=B.+H.+O%E2%80%99Neilauthor=T.+J.+Priceauthor=G.+S.+Falchookauthor=J.+Desaiauthor=J.+Kuoauthor=R.+Govindanauthor=D.+S.+Hongauthor=W.+Ouyangauthor=H.+Henaryauthor=T.+Arvedsonauthor=V.+J.+Ceeauthor=J.R.+Lipford&title=The+Clinical+KRAS%28G12C%29+Inhibitor+AMG510+Drives+Anti-Tumour+Immunity&doi=10.1038%2Fs41586-019-1694-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28aR"><div class="casContent"><span class="casTitleNuber">28a</span><div class="casTitle"><span class="NLM_cas:atitle">The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity</span></div><div class="casAuthors">Canon, Jude; Rex, Karen; Saiki, Anne Y.; Mohr, Christopher; Cooke, Keegan; Bagal, Dhanashri; Gaida, Kevin; Holt, Tyler; Knutson, Charles G.; Koppada, Neelima; Lanman, Brian A.; Werner, Jonathan; Rapaport, Aaron S.; San Miguel, Tisha; Ortiz, Roberto; Osgood, Tao; Sun, Ji-Rong; Zhu, Xiaochun; McCarter, John D.; Volak, Laurie P.; Houk, Brett E.; Fakih, Marwan G.; O'Neil, Bert H.; Price, Timothy J.; Falchook, Gerald S.; Desai, Jayesh; Kuo, James; Govindan, Ramaswamy; Hong, David S.; Ouyang, Wenjun; Henary, Haby; Arvedson, Tara; Cee, Victor J.; Lipford, J. Russell</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">575</span>
        (<span class="NLM_cas:issue">7781</span>),
    <span class="NLM_cas:pages">217-223</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">KRAS is the most frequently mutated oncogene in cancer and encodes a key signalling protein in tumors1,2.  The KRAS(G12C) mutant has a cysteine residue that has been exploited to design covalent inhibitors that have promising preclin. activity3-5.  Here we optimized a series of inhibitors, using novel binding interactions to markedly enhance their potency and selectivity.  Our efforts have led to the discovery of AMG 510, which is, to our knowledge, the first KRAS(G12C) inhibitor in clin. development.  In preclin. analyses, treatment with AMG 510 led to the regression of KRASG12C tumors and improved the anti-tumor efficacy of chemotherapy and targeted agents.  In immune-competent mice, treatment with AMG 510 resulted in a pro-inflammatory tumor microenvironment and produced durable cures alone as well as in combination with immune-checkpoint inhibitors.  Cured mice rejected the growth of isogenic KRASG12D tumors, which suggests adaptive immunity against shared antigens.  Furthermore, in clin. trials, AMG 510 demonstrated anti-tumor activity in the first dosing cohorts and represents a potentially transformative therapy for patients for whom effective treatments are lacking.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTHdBftQfnhbVg90H21EOLACvtfcHk0liQlTsnqdS6Hw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitV2hsb7F&md5=3819175980905976ba87ff545b9506e1</span></div><a href="/servlet/linkout?suffix=cit28a&amp;dbid=16384&amp;doi=10.1038%2Fs41586-019-1694-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41586-019-1694-1%26sid%3Dliteratum%253Aachs%26aulast%3DCanon%26aufirst%3DJ.%26aulast%3DRex%26aufirst%3DK.%26aulast%3DSaiki%26aufirst%3DA.%2BY.%26aulast%3DMohr%26aufirst%3DC.%26aulast%3DCooke%26aufirst%3DK.%26aulast%3DBagal%26aufirst%3DD.%26aulast%3DGaida%26aufirst%3DK.%26aulast%3DHolt%26aufirst%3DT.%26aulast%3DKnutson%26aufirst%3DC.%2BG.%26aulast%3DKoppada%26aufirst%3DN.%26aulast%3DLanman%26aufirst%3DB.%2BA.%26aulast%3DWerner%26aufirst%3DJ.%26aulast%3DRapaport%26aufirst%3DA.%2BS.%26aulast%3DSan%2BMiguel%26aufirst%3DT.%26aulast%3DOrtiz%26aufirst%3DR.%26aulast%3DOsgood%26aufirst%3DT.%26aulast%3DSun%26aufirst%3DJ.%2BR.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DMcCarter%26aufirst%3DJ.%2BD.%26aulast%3DVolak%26aufirst%3DL.%2BP.%26aulast%3DHouk%26aufirst%3DB.%2BE.%26aulast%3DFakih%26aufirst%3DM.%2BG.%26aulast%3DO%25E2%2580%2599Neil%26aufirst%3DB.%2BH.%26aulast%3DPrice%26aufirst%3DT.%2BJ.%26aulast%3DFalchook%26aufirst%3DG.%2BS.%26aulast%3DDesai%26aufirst%3DJ.%26aulast%3DKuo%26aufirst%3DJ.%26aulast%3DGovindan%26aufirst%3DR.%26aulast%3DHong%26aufirst%3DD.%2BS.%26aulast%3DOuyang%26aufirst%3DW.%26aulast%3DHenary%26aufirst%3DH.%26aulast%3DArvedson%26aufirst%3DT.%26aulast%3DCee%26aufirst%3DV.%2BJ.%26aulast%3DLipford%26aufirst%3DJ.R.%26atitle%3DThe%2520Clinical%2520KRAS%2528G12C%2529%2520Inhibitor%2520AMG510%2520Drives%2520Anti-Tumour%2520Immunity%26jtitle%3DNature%26date%3D2019%26volume%3D575%26spage%3D217%26epage%3D223%26doi%3D10.1038%2Fs41586-019-1694-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit28b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hallin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engstrom, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hargis, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calinisan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aranda, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Briere, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sudhakar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowcut, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baer, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burkard, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fell, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vigers, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gatto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez-Banet, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavlicek, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velastagui, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierobon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baldelli, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patricoin, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cassidy, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marx, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rybkin, I. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, S.-H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lito, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papadopoulos, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, J. G.</span></span> <span> </span><span class="NLM_article-title">The KRASG12C Inhibitor, MRTX849, Provides Insight Toward Therapeutic Susceptibility of KRAS Mutant Cancers in Mouse Models and Patients</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">54</span>– <span class="NLM_lpage">71</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-19-1167</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=10.1158%2F2159-8290.CD-19-1167" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=31658955" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtleitbfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2020&pages=54-71&author=J.+Hallinauthor=L.+D.+Engstromauthor=L.+Hargisauthor=A.+Calinisanauthor=R.+Arandaauthor=D.+M.+Briereauthor=N.+Sudhakarauthor=V.+Bowcutauthor=B.+R.+Baerauthor=J.+A.+Ballardauthor=M.+R.+Burkardauthor=J.+B.+Fellauthor=J.+P.+Fischerauthor=G.+P.+Vigersauthor=Y.+Xueauthor=S.+Gattoauthor=J.+Fernandez-Banetauthor=A.+Pavlicekauthor=K.+Velastaguiauthor=R.+C.+Chaoauthor=J.+Bartonauthor=M.+Pierobonauthor=E.+Baldelliauthor=E.+F.+Patricoinauthor=D.+P.+Cassidyauthor=M.+A.+Marxauthor=I.+I.+Rybkinauthor=M.+L.+Johnsonauthor=S.-H.+I.+Ouauthor=P.+Litoauthor=K.+P.+Papadopoulosauthor=P.+A.+J%C3%A4nneauthor=P.+Olsonauthor=J.+G.+Christensen&title=The+KRASG12C+Inhibitor%2C+MRTX849%2C+Provides+Insight+Toward+Therapeutic+Susceptibility+of+KRAS+Mutant+Cancers+in+Mouse+Models+and+Patients&doi=10.1158%2F2159-8290.CD-19-1167"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28bR"><div class="casContent"><span class="casTitleNuber">28b</span><div class="casTitle"><span class="NLM_cas:atitle">The KRASG12C inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients</span></div><div class="casAuthors">Hallin, Jill; Engstrom, Lars D.; Hargis, Lauren; Calinisan, Andrew; Aranda, Ruth; Briere, David M.; Sudhakar, Niranjan; Bowcut, Vickie; Baer, Brian R.; Ballard, Joshua A.; Burkard, Michael R.; Fell, Jay B.; Fischer, John P.; Vigers, Guy P.; Xue, Yaohua; Gatto, Sole; Fernandez-Banet, Julio; Pavlicek, Adam; Velastagui, Karen; Chao, Richard C.; Barton, Jeremy; Pierobon, Mariaelena; Baldelli, Elisa; Patricoin, Emanuel F., III; Cassidy, Douglas P.; Marx, Matthew A.; Rybkin, Igor I.; Johnson, Melissa L.; Ou, Sai-Hong Ignatius; Lito, Piro; Papadopoulos, Kyriakos P.; Janne, Pasi A.; Olson, Peter; Christensen, James G.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">54-71</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Despite decades of research, efforts to directly target KRAS have been challenging.  MRTX849 was identified as a potent, selective, and covalent KRASG12C inhibitor that exhibits favorable drug-like properties, selectively modifies mutant cysteine 12 in GDP-bound KRASG12C, and inhibits KRAS-dependent signaling.  MRTX849 demonstrated pronounced tumor regression in 17 of 26 (65%) KRASG12C-pos. cell line- and patient-derived xenograft models from multiple tumor types, and objective responses have been obsd. in patients with KRASG12C-pos. lung and colon adenocarcinomas.  Comprehensive pharmacodynamic and pharmacogenomic profiling in sensitive and partially resistant nonclin. models identified mechanisms implicated in limiting antitumor activity including KRAS nucleotide cycling and pathways that induce feedback reactivation and/or bypass KRAS dependence.  These factors included activation of receptor tyrosine kinases (RTK), bypass of KRAS dependence, and genetic dysregulation of cell cycle.  Combinations of MRTX849 with agents that target RTKs, mTOR, or cell cycle demonstrated enhanced response and marked tumor regression in several tumor models, including MRTX849-refractory models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxAUhi3n75ULVg90H21EOLACvtfcHk0liQlTsnqdS6Hw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtleitbfL&md5=48f4c34e757385eed89b47f19cbb10db</span></div><a href="/servlet/linkout?suffix=cit28b&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-19-1167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-19-1167%26sid%3Dliteratum%253Aachs%26aulast%3DHallin%26aufirst%3DJ.%26aulast%3DEngstrom%26aufirst%3DL.%2BD.%26aulast%3DHargis%26aufirst%3DL.%26aulast%3DCalinisan%26aufirst%3DA.%26aulast%3DAranda%26aufirst%3DR.%26aulast%3DBriere%26aufirst%3DD.%2BM.%26aulast%3DSudhakar%26aufirst%3DN.%26aulast%3DBowcut%26aufirst%3DV.%26aulast%3DBaer%26aufirst%3DB.%2BR.%26aulast%3DBallard%26aufirst%3DJ.%2BA.%26aulast%3DBurkard%26aufirst%3DM.%2BR.%26aulast%3DFell%26aufirst%3DJ.%2BB.%26aulast%3DFischer%26aufirst%3DJ.%2BP.%26aulast%3DVigers%26aufirst%3DG.%2BP.%26aulast%3DXue%26aufirst%3DY.%26aulast%3DGatto%26aufirst%3DS.%26aulast%3DFernandez-Banet%26aufirst%3DJ.%26aulast%3DPavlicek%26aufirst%3DA.%26aulast%3DVelastagui%26aufirst%3DK.%26aulast%3DChao%26aufirst%3DR.%2BC.%26aulast%3DBarton%26aufirst%3DJ.%26aulast%3DPierobon%26aufirst%3DM.%26aulast%3DBaldelli%26aufirst%3DE.%26aulast%3DPatricoin%26aufirst%3DE.%2BF.%26aulast%3DCassidy%26aufirst%3DD.%2BP.%26aulast%3DMarx%26aufirst%3DM.%2BA.%26aulast%3DRybkin%26aufirst%3DI.%2BI.%26aulast%3DJohnson%26aufirst%3DM.%2BL.%26aulast%3DOu%26aufirst%3DS.-H.%2BI.%26aulast%3DLito%26aufirst%3DP.%26aulast%3DPapadopoulos%26aufirst%3DK.%2BP.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DOlson%26aufirst%3DP.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26atitle%3DThe%2520KRASG12C%2520Inhibitor%252C%2520MRTX849%252C%2520Provides%2520Insight%2520Toward%2520Therapeutic%2520Susceptibility%2520of%2520KRAS%2520Mutant%2520Cancers%2520in%2520Mouse%2520Models%2520and%2520Patients%26jtitle%3DCancer%2520Discovery%26date%3D2020%26volume%3D10%26spage%3D54%26epage%3D71%26doi%3D10.1158%2F2159-8290.CD-19-1167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Altman, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shafir, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lichtor, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchwald, S. A.</span></span> <span> </span><span class="NLM_article-title">An Improved Cu-Based Catalyst System for the Reactions of Alcohols with Aryl Halides</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">284</span>– <span class="NLM_lpage">286</span>, <span class="refDoi"> DOI: 10.1021/jo702024p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo702024p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlOgsrjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2008&pages=284-286&author=R.+A.+Altmanauthor=A.+Shafirauthor=A.+Choiauthor=P.+A.+Lichtorauthor=S.+A.+Buchwald&title=An+Improved+Cu-Based+Catalyst+System+for+the+Reactions+of+Alcohols+with+Aryl+Halides&doi=10.1021%2Fjo702024p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">An Improved Cu-Based Catalyst System for the Reactions of Alcohols with Aryl Halides</span></div><div class="casAuthors">Altman, Ryan A.; Shafir, Alexandr; Choi, Alice; Lichtor, Phillip A.; Buchwald, Stephen L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">284-286</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The use of 3,4,7,8-tetramethyl-1,10-phenanthroline (Me4Phen) as a ligand improves the Cu-catalyzed cross-coupling reactions of aryl iodides and bromides with primary and secondary aliph., benzylic, allylic, and propargylic alcs to give products, e.g., I, in good yields.  Most importantly, by employing this catalyst system, the need to use an excessive quantity of the alc. coupling partner is alleviated.  The relatively mild conditions, short reaction times, and moderately low catalyst loading allow for a wide array of functional groups to be tolerated on both the electrophilic and nucleophilic coupling partners.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpy2UxAcp1pOrVg90H21EOLACvtfcHk0ljQJtf8zyIBMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlOgsrjF&md5=a99d7184c0f34e2ca688ba0796c95b70</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fjo702024p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo702024p%26sid%3Dliteratum%253Aachs%26aulast%3DAltman%26aufirst%3DR.%2BA.%26aulast%3DShafir%26aufirst%3DA.%26aulast%3DChoi%26aufirst%3DA.%26aulast%3DLichtor%26aufirst%3DP.%2BA.%26aulast%3DBuchwald%26aufirst%3DS.%2BA.%26atitle%3DAn%2520Improved%2520Cu-Based%2520Catalyst%2520System%2520for%2520the%2520Reactions%2520of%2520Alcohols%2520with%2520Aryl%2520Halides%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2008%26volume%3D73%26spage%3D284%26epage%3D286%26doi%3D10.1021%2Fjo702024p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mispelaere-Canivet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spindler, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrio, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beslin, P.</span></span> <span> </span><span class="NLM_article-title">Pd<sub>2</sub>(dba)<sub>3</sub>/Xantphos-Catalyzed Cross-Coupling of Thiols and Aryl Bromides/Triflates</span>. <i>Tetrahedron</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">5253</span>– <span class="NLM_lpage">5259</span>, <span class="refDoi"> DOI: 10.1016/j.tet.2005.03.078</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=10.1016%2Fj.tet.2005.03.078" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADC%252BD2MXktFWgs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2005&pages=5253-5259&author=C.+Mispelaere-Canivetauthor=J.+F.+Spindlerauthor=S.+Perrioauthor=P.+Beslin&title=Pd2%28dba%293%2FXantphos-Catalyzed+Cross-Coupling+of+Thiols+and+Aryl+Bromides%2FTriflates&doi=10.1016%2Fj.tet.2005.03.078"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Pd2(dba)3/Xantphos-catalyzed cross-coupling of thiols and aryl bromides/triflates</span></div><div class="casAuthors">Mispelaere-Canivet, Clotilde; Spindler, Jean-Francis; Perrio, Stephane; Beslin, Pierre</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">5253-5259</span>CODEN:
                <span class="NLM_cas:coden">TETRAB</span>;
        ISSN:<span class="NLM_cas:issn">0040-4020</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The cross-coupling of aliph. and arom. thiols and aryl halides or triflates mediated by a Pd2(dba)3/Xantphos catalytic system in refluxing xylene afforded the corresponding aryl thioethers in good to excellent yields.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfbcJkhwf7l7Vg90H21EOLACvtfcHk0ljQJtf8zyIBMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXktFWgs7k%253D&md5=54027b2333f6deb1df375bd85b36ea71</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.tet.2005.03.078&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tet.2005.03.078%26sid%3Dliteratum%253Aachs%26aulast%3DMispelaere-Canivet%26aufirst%3DC.%26aulast%3DSpindler%26aufirst%3DJ.%2BF.%26aulast%3DPerrio%26aufirst%3DS.%26aulast%3DBeslin%26aufirst%3DP.%26atitle%3DPd2%2528dba%25293%252FXantphos-Catalyzed%2520Cross-Coupling%2520of%2520Thiols%2520and%2520Aryl%2520Bromides%252FTriflates%26jtitle%3DTetrahedron%26date%3D2005%26volume%3D61%26spage%3D5253%26epage%3D5259%26doi%3D10.1016%2Fj.tet.2005.03.078" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Becht, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mioskowski, C.</span></span> <span> </span><span class="NLM_article-title">Facile Introduction of SH Group on Aromatic Substrates via Electrophilic Substitution Reactions</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">5758</span>– <span class="NLM_lpage">5761</span>, <span class="refDoi"> DOI: 10.1021/jo034013h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo034013h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADC%252BD3sXktlGqsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2003&pages=5758-5761&author=J.+M.+Bechtauthor=A.+Wagnerauthor=C.+Mioskowski&title=Facile+Introduction+of+SH+Group+on+Aromatic+Substrates+via+Electrophilic+Substitution+Reactions&doi=10.1021%2Fjo034013h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Facile Introduction of SH Group on Aromatic Substrates via Electrophilic Substitution Reactions</span></div><div class="casAuthors">Becht, Jean-Michel; Wagner, Alain; Mioskowski, Charles</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5758-5761</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A mild and efficient two-step procedure to introduce a thiol group on arom. substrates was developed.  First, reaction of arenes RH [R = Ph, 4-MeOC6H4, 4-Me2NC6H4, 2,4,6-Me3C6H2, etc.] with activated sulfoxide (MeO2CCH2CH2)2SO resulted in the corresponding arylsulfonium salt intermediates, which on treatment in situ with Et3N underwent dealkylation to give aryl sulfides RSCH2CH2CO2Me (I) in 53-95% yields.  The second β-elimination-based dealkylation reaction of I afforded the desired arylthiols RSH in good to excellent yields (71-97%).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosTB3voA8x-7Vg90H21EOLACvtfcHk0ljQJtf8zyIBMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXktlGqsLo%253D&md5=6a377e8ecf56d2392b18f989c507f6d9</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fjo034013h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo034013h%26sid%3Dliteratum%253Aachs%26aulast%3DBecht%26aufirst%3DJ.%2BM.%26aulast%3DWagner%26aufirst%3DA.%26aulast%3DMioskowski%26aufirst%3DC.%26atitle%3DFacile%2520Introduction%2520of%2520SH%2520Group%2520on%2520Aromatic%2520Substrates%2520via%2520Electrophilic%2520Substitution%2520Reactions%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2003%26volume%3D68%26spage%3D5758%26epage%3D5761%26doi%3D10.1021%2Fjo034013h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dess, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, J. C.</span></span> <span> </span><span class="NLM_article-title">Readily Accessible 12-I-5 Oxidant for the Conversion of Primary and Secondary Alcohols to Aldehydes and Ketones</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1983</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">4155</span>– <span class="NLM_lpage">4156</span>, <span class="refDoi"> DOI: 10.1021/jo00170a070</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo00170a070" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADyaL3sXlslCqsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=1983&pages=4155-4156&author=D.+B.+Dessauthor=J.+C.+Martin&title=Readily+Accessible+12-I-5+Oxidant+for+the+Conversion+of+Primary+and+Secondary+Alcohols+to+Aldehydes+and+Ketones&doi=10.1021%2Fjo00170a070"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Readily accessible 12-I-5 oxidant for the conversion of primary and secondary alcohols to aldehydes and ketones</span></div><div class="casAuthors">Dess, D. B.; Martin, J. C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">1983</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">4155-6</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    </div><div class="casAbstract">Oxidn. of 2-IC6H4CO2H with KBrO3 in aq. H2SO4, followed by treatment of the oxidn. product with Ac2O gave 87% periodinane I, a 10-I-5 species (i.e., 10 valence electrons are formally involved in binding 5 ligands to the central iodine atom).  I reacted rapidly with primary or secondary alcs. at room temp. to give the corresponding aldehydes or ketones in high yield.  Excess I does not further oxidize the aldehyde or ketone under the reaction conditions.  The reaction is strongly catalyzed by excess alc. or strong acid, but is unaffected by pyridine.  I oxidizes benzylic alcs. selectively in the presence of satd. alcs.  Procedures for sepg. the carbonyl product from the reaction mixt. are mild and simple.  Cryst. I is stable at room temp. in the absence of moisture.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAtQbosBW467Vg90H21EOLACvtfcHk0ljQJtf8zyIBMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3sXlslCqsro%253D&md5=31b4835cd94c04773221d921e76231d1</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fjo00170a070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo00170a070%26sid%3Dliteratum%253Aachs%26aulast%3DDess%26aufirst%3DD.%2BB.%26aulast%3DMartin%26aufirst%3DJ.%2BC.%26atitle%3DReadily%2520Accessible%252012-I-5%2520Oxidant%2520for%2520the%2520Conversion%2520of%2520Primary%2520and%2520Secondary%2520Alcohols%2520to%2520Aldehydes%2520and%2520Ketones%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1983%26volume%3D48%26spage%3D4155%26epage%3D4156%26doi%3D10.1021%2Fjo00170a070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ellman, J. A.</span></span> <span> </span><span class="NLM_article-title">Applications of <i>Tert</i>-Butanesulfinamide in the Asymmetric Synthesis of Amines</span>. <i>Pure Appl. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>75</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">39</span>– <span class="NLM_lpage">46</span>, <span class="refDoi"> DOI: 10.1351/pac200375010039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=10.1351%2Fpac200375010039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADC%252BD3sXit1Sisr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2003&pages=39-46&issue=1&author=J.+A.+Ellman&title=Applications+of+Tert-Butanesulfinamide+in+the+Asymmetric+Synthesis+of+Amines&doi=10.1351%2Fpac200375010039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Applications of tert-butanesulfinamide in the asymmetric synthesis of amines</span></div><div class="casAuthors">Ellman, Jonathan A.</div><div class="citationInfo"><span class="NLM_cas:title">Pure and Applied Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">39-46</span>CODEN:
                <span class="NLM_cas:coden">PACHAS</span>;
        ISSN:<span class="NLM_cas:issn">0033-4545</span>.
    
            (<span class="NLM_cas:orgname">International Union of Pure and Applied Chemistry</span>)
        </div><div class="casAbstract">A review.  Tert-Butanesulfinamide (2-methyl-2-propanesulfinamide) is prepd. using catalytic enantioselective methods in two steps from the extremely inexpensive oil waste byproduct, tert-Bu disulfide.  Direct condensation of tert-butanesulfinamide with aldehydes and ketones provides tert-butanesulfinyl imines in uniformly high yields.  The tert-butanesulfinyl group activates the imines for the addn. of many different classes of nucleophiles, serves as a powerful chiral directing group, and after nucleophilic addn. is readily cleaved by treatment with acid.  A wide range of highly enantioenriched amines, including a-branched and α,α-dibranched amines, α- and β-amino acids, 1,2- and 1,3-amino alcs. and α-trifluoromethyl amines are efficiently synthesized using this methodol.  A review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreXHI36VE2U7Vg90H21EOLACvtfcHk0lgiMknFUaVRKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXit1Sisr8%253D&md5=d4f9b92b02e94084e0ca0285ecb30af3</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1351%2Fpac200375010039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1351%252Fpac200375010039%26sid%3Dliteratum%253Aachs%26aulast%3DEllman%26aufirst%3DJ.%2BA.%26atitle%3DApplications%2520of%2520Tert-Butanesulfinamide%2520in%2520the%2520Asymmetric%2520Synthesis%2520of%2520Amines%26jtitle%3DPure%2520Appl.%2520Chem.%26date%3D2003%26volume%3D75%26issue%3D1%26spage%3D39%26epage%3D46%26doi%3D10.1351%2Fpac200375010039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Bagdanoff, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dore, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Firestone, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fodor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fortanet, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hentemann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koenig, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaBonte, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohseni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ntaganda, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarver, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sendzik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stams, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spence, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Towler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaMarche, M. J.</span></span> <span> </span><span class="NLM_article-title">Optimization of Fused Bicyclic Allosteric SHP2 Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">1781</span>– <span class="NLM_lpage">1792</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01725</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01725" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFKjtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=1781-1792&author=J.+T.+Bagdanoffauthor=Z.+Chenauthor=M.+Ackerauthor=Y.+Chenauthor=H.+Chanauthor=M.+Doreauthor=B.+Firestoneauthor=M.+Fodorauthor=J.+Fortanetauthor=M.+Hentemannauthor=M.+Katoauthor=R.+Koenigauthor=L.+R.+LaBonteauthor=S.+Liuauthor=M.+Mohseniauthor=R.+Ntagandaauthor=P.+Sarverauthor=T.+Smithauthor=M.+Sendzikauthor=T.+Stamsauthor=S.+Spenceauthor=C.+Towlerauthor=H.+Wangauthor=P.+Wangauthor=S.+L.+Williamsauthor=M.+J.+LaMarche&title=Optimization+of+Fused+Bicyclic+Allosteric+SHP2+Inhibitors&doi=10.1021%2Facs.jmedchem.8b01725"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34aR"><div class="casContent"><span class="casTitleNuber">34a</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of Fused Bicyclic Allosteric SHP2 Inhibitors</span></div><div class="casAuthors">Bagdanoff, Jeffrey T.; Chen, Zhouliang; Acker, Michael; Chen, Ying-Nan; Chan, Homan; Dore, Michael; Firestone, Brant; Fodor, Michelle; Fortanet, Jorge; Hentemann, Murphy; Kato, Mitsunori; Koenig, Robert; La Bonte, Laura R.; Liu, Shumei; Mohseni, Movarid; Ntaganda, Rukundo; Sarver, Patrick; Smith, Troy; Sendzik, Martin; Stams, Travis; Spence, Stan; Towler, Christopher; Wang, Hongyun; Wang, Ping; Williams, Sarah L.; La Marche, Matthew J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1781-1792</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">SHP2 is a nonreceptor protein tyrosine phosphatase within the mitogen-activated protein kinase (MAPK) pathway controlling cell growth, differentiation, and oncogenic transformation.  SHP2 also participates in the programed cell death pathway (PD-1/PD-L1) governing immune surveillance.  Small-mol. inhibition of SHP2 has been widely investigated, including in our previous reports describing SHP099 (2), which binds to a tunnel-like allosteric binding site.  To broaden our approach to allosteric inhibition of SHP2, we conducted addnl. hit finding, evaluation, and structure-based scaffold morphing.  These studies, reported here in the first of two papers, led to the identification of multiple 5,6-fused bicyclic scaffolds that bind to the same allosteric tunnel as 2.  We demonstrate the structural diversity permitted by the tunnel pharmacophore and culminated in the identification of pyrazolopyrimidinones (e.g., SHP389, 1) that modulate MAPK signaling in vivo.  These studies also served as the basis for further scaffold morphing and optimization, detailed in the following manuscript.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGra2OF_vrNnP7Vg90H21EOLACvtfcHk0lgiMknFUaVRKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFKjtbo%253D&md5=e810a8a6bd1d1fb7bfadc5bc1448ff22</span></div><a href="/servlet/linkout?suffix=cit34a&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01725&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01725%26sid%3Dliteratum%253Aachs%26aulast%3DBagdanoff%26aufirst%3DJ.%2BT.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DAcker%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DChan%26aufirst%3DH.%26aulast%3DDore%26aufirst%3DM.%26aulast%3DFirestone%26aufirst%3DB.%26aulast%3DFodor%26aufirst%3DM.%26aulast%3DFortanet%26aufirst%3DJ.%26aulast%3DHentemann%26aufirst%3DM.%26aulast%3DKato%26aufirst%3DM.%26aulast%3DKoenig%26aufirst%3DR.%26aulast%3DLaBonte%26aufirst%3DL.%2BR.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DMohseni%26aufirst%3DM.%26aulast%3DNtaganda%26aufirst%3DR.%26aulast%3DSarver%26aufirst%3DP.%26aulast%3DSmith%26aufirst%3DT.%26aulast%3DSendzik%26aufirst%3DM.%26aulast%3DStams%26aufirst%3DT.%26aulast%3DSpence%26aufirst%3DS.%26aulast%3DTowler%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DWilliams%26aufirst%3DS.%2BL.%26aulast%3DLaMarche%26aufirst%3DM.%2BJ.%26atitle%3DOptimization%2520of%2520Fused%2520Bicyclic%2520Allosteric%2520SHP2%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D1781%26epage%3D1792%26doi%3D10.1021%2Facs.jmedchem.8b01725" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit34b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Sarver, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagdanoff, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Firestone, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fodor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fortanet, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hentemann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koenig, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaBonte, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNeill, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohseni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sendzik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stams, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spence, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamez, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tichkule, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Towler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaMarche, M. J.</span></span> <span> </span><span class="NLM_article-title">6-Amino-3-methylpyrimidinones as Potent, Selective, and Orally Efficacious SHP2 Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">1793</span>– <span class="NLM_lpage">1802</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01726</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01726" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFKisLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=1793-1802&author=P.+Sarverauthor=M.+Ackerauthor=J.+T.+Bagdanoffauthor=Z.+Chenauthor=Y.+Chenauthor=H.+Chanauthor=B.+Firestoneauthor=M.+Fodorauthor=J.+Fortanetauthor=H.+Haoauthor=M.+Hentemannauthor=M.+Katoauthor=R.+Koenigauthor=L.+R.+LaBonteauthor=G.+Liuauthor=S.+Liuauthor=C.+Liuauthor=E.+McNeillauthor=M.+Mohseniauthor=M.+Sendzikauthor=T.+Stamsauthor=S.+Spenceauthor=V.+Tamezauthor=R.+Tichkuleauthor=C.+Towlerauthor=H.+Wangauthor=P.+Wangauthor=S.+L.+Williamsauthor=B.+Yuauthor=M.+J.+LaMarche&title=6-Amino-3-methylpyrimidinones+as+Potent%2C+Selective%2C+and+Orally+Efficacious+SHP2+Inhibitors&doi=10.1021%2Facs.jmedchem.8b01726"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34bR"><div class="casContent"><span class="casTitleNuber">34b</span><div class="casTitle"><span class="NLM_cas:atitle">6-Amino-3-methylpyrimidinones as Potent, Selective, and Orally Efficacious SHP2 Inhibitors</span></div><div class="casAuthors">Sarver, Patrick; Acker, Michael; Bagdanoff, Jeffrey T.; Chen, Zhouliang; Chen, Ying-Nan; Chan, Homan; Firestone, Brant; Fodor, Michelle; Fortanet, Jorge; Hao, Huaixiang; Hentemann, Murphy; Koenig, Robert; Kato, Mitsunori; LaBonte, Laura R.; Liu, Gang; Liu, Shumei; Liu, Chen; McNeill, Eric; Mohseni, Morvarid; Sendzik, Martin; Stams, Travis; Spence, Stan; Tamez, Victoriano; Tichkule, Ritesh; Towler, Christopher; Wang, Hongyun; Wang, Ping; Williams, Sarah L.; Yu, Bing; LaMarche, Matthew J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1793-1802</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Protein tyrosine phosphatase SHP2 is an oncoprotein assocd. with cancer as well as a potential immune modulator because of its role in the programmed cell death PD-L1/PD-1 pathway.  In the preceding manuscript, we described the optimization of a fused, bicyclic screening hit for potency, selectivity, and physicochem. properties in order to further expand the chem. diversity of allosteric SHP2 inhibitors.  In this manuscript, we describe the further expansion of our approach, morphing the fused, bicyclic system into a novel monocyclic pyrimidinone scaffold through our understanding of SAR and use of structure-based design.  These studies led to the identification of SHP394 (1), an orally efficacious inhibitor of SHP2, with high lipophilic efficiency, improved potency, and enhanced pharmacokinetic properties.  We also report other pyrimidinone analogs with favorable pharmacokinetic and potency profiles.  Overall, this work improves upon our previously described allosteric inhibitors and exemplifies and extends the range of permissible chem. templates that inhibit SHP2 via the allosteric mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaRey6_uE0ULVg90H21EOLACvtfcHk0lgJmQrST6Pfig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFKisLs%253D&md5=29c357236b7ff51596385e3e256320a5</span></div><a href="/servlet/linkout?suffix=cit34b&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01726&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01726%26sid%3Dliteratum%253Aachs%26aulast%3DSarver%26aufirst%3DP.%26aulast%3DAcker%26aufirst%3DM.%26aulast%3DBagdanoff%26aufirst%3DJ.%2BT.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DChan%26aufirst%3DH.%26aulast%3DFirestone%26aufirst%3DB.%26aulast%3DFodor%26aufirst%3DM.%26aulast%3DFortanet%26aufirst%3DJ.%26aulast%3DHao%26aufirst%3DH.%26aulast%3DHentemann%26aufirst%3DM.%26aulast%3DKato%26aufirst%3DM.%26aulast%3DKoenig%26aufirst%3DR.%26aulast%3DLaBonte%26aufirst%3DL.%2BR.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DMcNeill%26aufirst%3DE.%26aulast%3DMohseni%26aufirst%3DM.%26aulast%3DSendzik%26aufirst%3DM.%26aulast%3DStams%26aufirst%3DT.%26aulast%3DSpence%26aufirst%3DS.%26aulast%3DTamez%26aufirst%3DV.%26aulast%3DTichkule%26aufirst%3DR.%26aulast%3DTowler%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DWilliams%26aufirst%3DS.%2BL.%26aulast%3DYu%26aufirst%3DB.%26aulast%3DLaMarche%26aufirst%3DM.%2BJ.%26atitle%3D6-Amino-3-methylpyrimidinones%2520as%2520Potent%252C%2520Selective%252C%2520and%2520Orally%2520Efficacious%2520SHP2%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D1793%26epage%3D1802%26doi%3D10.1021%2Facs.jmedchem.8b01726" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="note"><p class="first last">Novartis SHP2 patents:</p></div><div class="NLM_citation" id="cit35a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span>; <span class="NLM_string-name">Fortanet, J. G.</span>; <span class="NLM_string-name">Grunenfelder, D.</span>; <span class="NLM_string-name">Karki, R.</span>; <span class="NLM_string-name">Kato, M.</span>; <span class="NLM_string-name">LaMarche, M. J.</span>; <span class="NLM_string-name">Perez, L. B.</span>; <span class="NLM_string-name">Stams, T. M.</span>; <span class="NLM_string-name">Williams, S.</span></span> <span> </span><span class="NLM_article-title">1-Pyridazine-/triazine-3-yl-piper(-azine)idine/pyrolidine Derivatives and Compositions Thereof for Inhibiting the Activity of SHP2</span>. Patent <span class="NLM_patent">WO2015107493</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=Z.+Chen&author=J.+G.+Fortanet&author=D.+Grunenfelder&author=R.+Karki&author=M.+Kato&author=M.+J.+LaMarche&author=L.+B.+Perez&author=T.+M.+Stams&author=S.+Williams&title=1-Pyridazine-%2Ftriazine-3-yl-piper%28-azine%29idine%2Fpyrolidine+Derivatives+and+Compositions+Thereof+for+Inhibiting+the+Activity+of+SHP2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DZ.%26atitle%3D1-Pyridazine-%252Ftriazine-3-yl-piper%2528-azine%2529idine%252Fpyrolidine%2520Derivatives%2520and%2520Compositions%2520Thereof%2520for%2520Inhibiting%2520the%2520Activity%2520of%2520SHP2%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit35b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span>; <span class="NLM_string-name">Dore, M.</span>; <span class="NLM_string-name">Fortanet, J. G.</span>; <span class="NLM_string-name">Karki, R.</span>; <span class="NLM_string-name">Kato, M.</span>; <span class="NLM_string-name">LaMarche, M. J.</span>; <span class="NLM_string-name">Perez, L. B.</span>; <span class="NLM_string-name">Williams, S.</span>; <span class="NLM_string-name">Sendzik, M.</span></span> <span> </span><span class="NLM_article-title">1-(Triazin-3-yl/pyridazine-3-yl)-piper(-azine)idine Derivatives and Compositions Thereof for Inhibiting the Activity of SHP2</span>. Patent <span class="NLM_patent">WO2015107494</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=Z.+Chen&author=M.+Dore&author=J.+G.+Fortanet&author=R.+Karki&author=M.+Kato&author=M.+J.+LaMarche&author=L.+B.+Perez&author=S.+Williams&author=M.+Sendzik&title=1-%28Triazin-3-yl%2Fpyridazine-3-yl%29-piper%28-azine%29idine+Derivatives+and+Compositions+Thereof+for+Inhibiting+the+Activity+of+SHP2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DZ.%26atitle%3D1-%2528Triazin-3-yl%252Fpyridazine-3-yl%2529-piper%2528-azine%2529idine%2520Derivatives%2520and%2520Compositions%2520Thereof%2520for%2520Inhibiting%2520the%2520Activity%2520of%2520SHP2%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit35c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. H.</span>; <span class="NLM_string-name">Chen, Z.</span>; <span class="NLM_string-name">Dore, M.</span>; <span class="NLM_string-name">Fortanet, J. G.</span>; <span class="NLM_string-name">Karki, R.</span>; <span class="NLM_string-name">Kato, M.</span>; <span class="NLM_string-name">LaMarche, M. J.</span>; <span class="NLM_string-name">Perez, L. B.</span>; <span class="NLM_string-name">Smith, T.</span>; <span class="NLM_string-name">Williams, S.</span>; <span class="NLM_string-name">Toure, B. B.</span>; <span class="NLM_string-name">Sendzik, M.</span></span> <span> </span><span class="NLM_article-title"><i>N</i>-azaspirocycloalkane Substituted <i>N</i>-heteroaryl Compounds and Compositions for Inhibiting the Activity of SHP2</span>. Patent <span class="NLM_patent">WO2015107495</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=C.+H.+Chen&author=Z.+Chen&author=M.+Dore&author=J.+G.+Fortanet&author=R.+Karki&author=M.+Kato&author=M.+J.+LaMarche&author=L.+B.+Perez&author=T.+Smith&author=S.+Williams&author=B.+B.+Toure&author=M.+Sendzik&title=N-azaspirocycloalkane+Substituted+N-heteroaryl+Compounds+and+Compositions+for+Inhibiting+the+Activity+of+SHP2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DC.%2BH.%26atitle%3DN-azaspirocycloalkane%2520Substituted%2520N-heteroaryl%2520Compounds%2520and%2520Compositions%2520for%2520Inhibiting%2520the%2520Activity%2520of%2520SHP2%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit35d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Bagdanoff, J. T.</span>; <span class="NLM_string-name">Chen, Z.</span>; <span class="NLM_string-name">Dore, M.</span>; <span class="NLM_string-name">Fortanet, J. G.</span>; <span class="NLM_string-name">Kato, M.</span>; <span class="NLM_string-name">LaMarche, M. J.</span>; <span class="NLM_string-name">Sarver, P. J.</span>; <span class="NLM_string-name">Shultz, M.</span>; <span class="NLM_string-name">Smith, T. D.</span>; <span class="NLM_string-name">Williams, S.</span></span> <span> </span><span class="NLM_article-title">Compounds and Compositions for Inhibiting the Activity of SHP2</span>. Patent <span class="NLM_patent">WO2016203404</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=J.+T.+Bagdanoff&author=Z.+Chen&author=M.+Dore&author=J.+G.+Fortanet&author=M.+Kato&author=M.+J.+LaMarche&author=P.+J.+Sarver&author=M.+Shultz&author=T.+D.+Smith&author=S.+Williams&title=Compounds+and+Compositions+for+Inhibiting+the+Activity+of+SHP2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBagdanoff%26aufirst%3DJ.%2BT.%26atitle%3DCompounds%2520and%2520Compositions%2520for%2520Inhibiting%2520the%2520Activity%2520of%2520SHP2%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit35e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span>; <span class="NLM_string-name">Fortanet, J. G.</span>; <span class="NLM_string-name">LaMarche, M. J.</span>; <span class="NLM_string-name">Sendzik, M.</span>; <span class="NLM_string-name">Tamez, V.</span>; <span class="NLM_string-name">Yu, B.</span></span> <span> </span><span class="NLM_article-title">Compounds and Compositions for Inhibiting the Activity of SHP2</span>. Patent <span class="NLM_patent">WO2016203405</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=Z.+Chen&author=J.+G.+Fortanet&author=M.+J.+LaMarche&author=M.+Sendzik&author=V.+Tamez&author=B.+Yu&title=Compounds+and+Compositions+for+Inhibiting+the+Activity+of+SHP2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35e&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DZ.%26atitle%3DCompounds%2520and%2520Compositions%2520for%2520Inhibiting%2520the%2520Activity%2520of%2520SHP2%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit35f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span>; <span class="NLM_string-name">Fortanet, J. G.</span>; <span class="NLM_string-name">Jouk, A.</span>; <span class="NLM_string-name">Karki, R.</span>; <span class="NLM_string-name">LaMarche, M. J.</span>; <span class="NLM_string-name">Liu, G.</span>; <span class="NLM_string-name">Palermo, M.</span>; <span class="NLM_string-name">Perez, L. B.</span>; <span class="NLM_string-name">Sarver, P. J.</span>; <span class="NLM_string-name">Shultz, M. D.</span>; <span class="NLM_string-name">Sendzik, M.</span>; <span class="NLM_string-name">Toure, B. B.</span>; <span class="NLM_string-name">Yu, B.</span></span> <span> </span><span class="NLM_article-title">Compounds and Compositions for Inhibiting the Activity of SHP2</span>. Patent <span class="NLM_patent">WO2016203406</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=Z.+Chen&author=J.+G.+Fortanet&author=A.+Jouk&author=R.+Karki&author=M.+J.+LaMarche&author=G.+Liu&author=M.+Palermo&author=L.+B.+Perez&author=P.+J.+Sarver&author=M.+D.+Shultz&author=M.+Sendzik&author=B.+B.+Toure&author=B.+Yu&title=Compounds+and+Compositions+for+Inhibiting+the+Activity+of+SHP2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35f&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DZ.%26atitle%3DCompounds%2520and%2520Compositions%2520for%2520Inhibiting%2520the%2520Activity%2520of%2520SHP2%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit35g"><span><span class="NLM_label">(g) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span>; <span class="NLM_string-name">Fortanet, J. G.</span>; <span class="NLM_string-name">Karki, R.</span>; <span class="NLM_string-name">LaMarche, M. J.</span>; <span class="NLM_string-name">Majumdar, D.</span>; <span class="NLM_string-name">Perez, L. B.</span>; <span class="NLM_string-name">Sendzik, M.</span>; <span class="NLM_string-name">Smith, T. D.</span>; <span class="NLM_string-name">Yang, F.</span>; <span class="NLM_string-name">Yu, B.</span></span> <span> </span><span class="NLM_article-title">Compounds and Compositions for Inhibiting the Activity of SHP2</span>. Patent <span class="NLM_patent">WO2017216706</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=Z.+Chen&author=J.+G.+Fortanet&author=R.+Karki&author=M.+J.+LaMarche&author=D.+Majumdar&author=L.+B.+Perez&author=M.+Sendzik&author=T.+D.+Smith&author=F.+Yang&author=B.+Yu&title=Compounds+and+Compositions+for+Inhibiting+the+Activity+of+SHP2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35g&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DZ.%26atitle%3DCompounds%2520and%2520Compositions%2520for%2520Inhibiting%2520the%2520Activity%2520of%2520SHP2%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Czako, B.</span>; <span class="NLM_string-name">Jones, P.</span>; <span class="NLM_string-name">Cross, P.</span>; <span class="NLM_string-name">Leonard, P.</span></span> <span> </span><span class="NLM_article-title">Heterocyclic Inhibitors of PTPN11</span>. Patent <span class="NLM_patent">WO2017156397</span>, <span class="NLM_year">2017</span> (University of Texas).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=B.+Czako&author=P.+Jones&author=P.+Cross&author=P.+Leonard&title=Heterocyclic+Inhibitors+of+PTPN11"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCzako%26aufirst%3DB.%26atitle%3DHeterocyclic%2520Inhibitors%2520of%2520PTPN11%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit36b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span>; <span class="NLM_string-name">Gu, S.</span>; <span class="NLM_string-name">Si, X.</span>; <span class="NLM_string-name">Xie, J.</span>; <span class="NLM_string-name">Shen, J.</span></span> <span> </span><span class="NLM_article-title"><i>N</i>-heterocyclic Ring Compound, and Intermediate, Preparation Method, Medicine Composition and Application Thereof</span>. Patent <span class="NLM_patent">CN107286150</span>, <span class="NLM_year">2017</span> (Shanghai Organic Institute).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=J.+Zhu&author=S.+Gu&author=X.+Si&author=J.+Xie&author=J.+Shen&title=N-heterocyclic+Ring+Compound%2C+and+Intermediate%2C+Preparation+Method%2C+Medicine+Composition+and+Application+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DJ.%26atitle%3DN-heterocyclic%2520Ring%2520Compound%252C%2520and%2520Intermediate%252C%2520Preparation%2520Method%252C%2520Medicine%2520Composition%2520and%2520Application%2520Thereof%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit36c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Jones, P.</span>; <span class="NLM_string-name">Czako, B.</span>; <span class="NLM_string-name">Cross, P.</span>; <span class="NLM_string-name">Leonard, P.</span>; <span class="NLM_string-name">Mseeh, F.</span></span> <span> </span><span class="NLM_article-title">Heterocyclic Inhibitors of PTPN11</span>. <span class="NLM_patent">WO2017210134</span>, <span class="NLM_year">2017</span> (University of Texas).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=P.+Jones&author=B.+Czako&author=P.+Cross&author=P.+Leonard&author=F.+Mseeh&title=Heterocyclic+Inhibitors+of+PTPN11"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DP.%26atitle%3DHeterocyclic%2520Inhibitors%2520of%2520PTPN11%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit36d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Jones, P.</span>; <span class="NLM_string-name">Cross, P.</span>; <span class="NLM_string-name">Burke, J.</span>; <span class="NLM_string-name">Mcafoos, T.</span>; <span class="NLM_string-name">Kang, Z.</span></span> <span> </span><span class="NLM_article-title">Substituted Heterocyclic Inhibitors of PTPN11</span>. Patent <span class="NLM_patent">WO2019213318</span>, <span class="NLM_year">2019</span> (University of Texas).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=P.+Jones&author=P.+Cross&author=J.+Burke&author=T.+Mcafoos&author=Z.+Kang&title=Substituted+Heterocyclic+Inhibitors+of+PTPN11"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DP.%26atitle%3DSubstituted%2520Heterocyclic%2520Inhibitors%2520of%2520PTPN11%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit36e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Jones, P.</span>; <span class="NLM_string-name">Czako, B.</span>; <span class="NLM_string-name">Carroll, C.</span>; <span class="NLM_string-name">Mandal, P.</span>; <span class="NLM_string-name">Cross, P.</span></span> <span> </span><span class="NLM_article-title">6-(4-Amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(2,3-dichlorophenyl)-2-methylpyrimidine-4(3H)-one Derivatives and Related Compounds as PTPN11 (SHP2) Inhibitors for Treating Cancer</span>. Patent <span class="NLM_patent">WO2020033828</span>, <span class="NLM_year">2019</span> (University of Texas).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=P.+Jones&author=B.+Czako&author=C.+Carroll&author=P.+Mandal&author=P.+Cross&title=6-%284-Amino-3-methyl-2-oxa-8-azaspiro%5B4.5%5Ddecan-8-yl%29-3-%282%2C3-dichlorophenyl%29-2-methylpyrimidine-4%283H%29-one+Derivatives+and+Related+Compounds+as+PTPN11+%28SHP2%29+Inhibitors+for+Treating+Cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36e&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DP.%26atitle%3D6-%25284-Amino-3-methyl-2-oxa-8-azaspiro%255B4.5%255Ddecan-8-yl%2529-3-%25282%252C3-dichlorophenyl%2529-2-methylpyrimidine-4%25283H%2529-one%2520Derivatives%2520and%2520Related%2520Compounds%2520as%2520PTPN11%2520%2528SHP2%2529%2520Inhibitors%2520for%2520Treating%2520Cancer%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, C.</span>; <span class="NLM_string-name">Gao, P.</span>; <span class="NLM_string-name">Chu, J.</span>; <span class="NLM_string-name">Wu, X.</span>; <span class="NLM_string-name">Wen, C.</span>; <span class="NLM_string-name">Kang, D.</span>; <span class="NLM_string-name">Bai, J.</span>; <span class="NLM_string-name">Pei, X.</span></span> <span> </span><span class="NLM_article-title">Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors</span>. Patent <span class="NLM_patent">WO2017211303</span>, <span class="NLM_year">2017</span> (Jacobio).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=C.+Ma&author=P.+Gao&author=J.+Chu&author=X.+Wu&author=C.+Wen&author=D.+Kang&author=J.+Bai&author=X.+Pei&title=Novel+Heterocyclic+Derivatives+Useful+as+SHP2+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DC.%26atitle%3DNovel%2520Heterocyclic%2520Derivatives%2520Useful%2520as%2520SHP2%2520Inhibitors%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit37b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, C.</span>; <span class="NLM_string-name">Gao, P.</span>; <span class="NLM_string-name">Hu, S.</span>; <span class="NLM_string-name">Xu, Z.</span>; <span class="NLM_string-name">Han, H.</span>; <span class="NLM_string-name">Wu, X.</span>; <span class="NLM_string-name">Kang, D.</span>; <span class="NLM_string-name">Long, W.</span></span> <span> </span><span class="NLM_article-title">Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors</span>. Patent <span class="NLM_patent">WO2018172984</span>, <span class="NLM_year">2018</span> (Jacobio).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=C.+Ma&author=P.+Gao&author=S.+Hu&author=Z.+Xu&author=H.+Han&author=X.+Wu&author=D.+Kang&author=W.+Long&title=Novel+Heterocyclic+Derivatives+Useful+as+SHP2+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DC.%26atitle%3DNovel%2520Heterocyclic%2520Derivatives%2520Useful%2520as%2520SHP2%2520Inhibitors%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit37c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Han, H.</span>; <span class="NLM_string-name">Gao, P.</span>; <span class="NLM_string-name">Ma, C.</span>; <span class="NLM_string-name">Kang, D.</span></span> <span> </span><span class="NLM_article-title">Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors</span>. Patent <span class="NLM_patent">WO2020063760</span>, <span class="NLM_year">2019</span> (Jacobio).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=H.+Han&author=P.+Gao&author=C.+Ma&author=D.+Kang&title=Novel+Heterocyclic+Derivatives+Useful+as+SHP2+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DH.%26atitle%3DNovel%2520Heterocyclic%2520Derivatives%2520Useful%2520as%2520SHP2%2520Inhibitors%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit37d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Jogalekar, A.</span>; <span class="NLM_string-name">Won, W.</span>; <span class="NLM_string-name">Koltun, E. S.</span>; <span class="NLM_string-name">Gill, A.</span>; <span class="NLM_string-name">Mellem, K.</span>; <span class="NLM_string-name">Aay, N.</span>; <span class="NLM_string-name">Buckl, A.</span>; <span class="NLM_string-name">Semko, C.</span>; <span class="NLM_string-name">Kiss, G.</span></span> <span> </span><span class="NLM_article-title">2,5-Disubstituted 3-Methyl Pyrazines and 2,5,6-Trisubstituted 3-Methyl Pyrazines as Allosteric SHP2 Inhibitors</span>. Patent <span class="NLM_patent">WO2018013597</span>, <span class="NLM_year">2017</span> (Revolution Medicines).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=A.+Jogalekar&author=W.+Won&author=E.+S.+Koltun&author=A.+Gill&author=K.+Mellem&author=N.+Aay&author=A.+Buckl&author=C.+Semko&author=G.+Kiss&title=2%2C5-Disubstituted+3-Methyl+Pyrazines+and+2%2C5%2C6-Trisubstituted+3-Methyl+Pyrazines+as+Allosteric+SHP2+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DJogalekar%26aufirst%3DA.%26atitle%3D2%252C5-Disubstituted%25203-Methyl%2520Pyrazines%2520and%25202%252C5%252C6-Trisubstituted%25203-Methyl%2520Pyrazines%2520as%2520Allosteric%2520SHP2%2520Inhibitors%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit37e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Gill, A.</span>; <span class="NLM_string-name">Aay, N.</span>; <span class="NLM_string-name">Mellem, K.</span>; <span class="NLM_string-name">Buckyl, A.</span>; <span class="NLM_string-name">Koltun, E. S.</span>; <span class="NLM_string-name">Semko, C.</span>; <span class="NLM_string-name">Kiss, G.</span></span> <span> </span><span class="NLM_article-title">Pyridine Compounds as Allosteric SHP2 Inhibitors</span>. Patent <span class="NLM_patent">WO2018136264</span>, <span class="NLM_year">2018</span> (Revolution Medicines).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=A.+Gill&author=N.+Aay&author=K.+Mellem&author=A.+Buckyl&author=E.+S.+Koltun&author=C.+Semko&author=G.+Kiss&title=Pyridine+Compounds+as+Allosteric+SHP2+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37e&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGill%26aufirst%3DA.%26atitle%3DPyridine%2520Compounds%2520as%2520Allosteric%2520SHP2%2520Inhibitors%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit37f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Blank, B. R.</span>; <span class="NLM_string-name">Pitzen, J.</span>; <span class="NLM_string-name">Wang, G.</span>; <span class="NLM_string-name">Won, W. S.</span>; <span class="NLM_string-name">Tzitzilonis, C.</span>; <span class="NLM_string-name">Li, J. J.</span>; <span class="NLM_string-name">Koltun, E. S.</span>; <span class="NLM_string-name">Aay, N.</span>; <span class="NLM_string-name">Buckyl, A.</span>; <span class="NLM_string-name">Mellem, K.</span>; <span class="NLM_string-name">Semko, C.</span>; <span class="NLM_string-name">Jogalekar, A.</span>; <span class="NLM_string-name">Kiss, G.</span>; <span class="NLM_string-name">Gill, A.</span></span> <span> </span><span class="NLM_article-title">Bicyclic Compounds as Allosteric SHP2 Inhibitors</span>. Patent <span class="NLM_patent">WO2018136265</span>, <span class="NLM_year">2018</span> (Revolution Medicines).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=B.+R.+Blank&author=J.+Pitzen&author=G.+Wang&author=W.+S.+Won&author=C.+Tzitzilonis&author=J.+J.+Li&author=E.+S.+Koltun&author=N.+Aay&author=A.+Buckyl&author=K.+Mellem&author=C.+Semko&author=A.+Jogalekar&author=G.+Kiss&author=A.+Gill&title=Bicyclic+Compounds+as+Allosteric+SHP2+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37f&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBlank%26aufirst%3DB.%2BR.%26atitle%3DBicyclic%2520Compounds%2520as%2520Allosteric%2520SHP2%2520Inhibitors%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit37g"><span><span class="NLM_label">(g) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Albrecht, B. K.</span>; <span class="NLM_string-name">Giordanetto, F.</span>; <span class="NLM_string-name">Greisman, J. B.</span>; <span class="NLM_string-name">Maragakis, P.</span>; <span class="NLM_string-name">Taylor, A. M.</span>; <span class="NLM_string-name">Walters, W. P.</span></span> <span> </span><span class="NLM_article-title">SHP2 Phosphatase Inhibitors and Methods of Use Thereof</span>. Patent <span class="NLM_patent">WO2018057884</span>, <span class="NLM_year">2017</span> (Relay Therapeutics).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=B.+K.+Albrecht&author=F.+Giordanetto&author=J.+B.+Greisman&author=P.+Maragakis&author=A.+M.+Taylor&author=W.+P.+Walters&title=SHP2+Phosphatase+Inhibitors+and+Methods+of+Use+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37g&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAlbrecht%26aufirst%3DB.%2BK.%26atitle%3DSHP2%2520Phosphatase%2520Inhibitors%2520and%2520Methods%2520of%2520Use%2520Thereof%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit37h"><span><span class="NLM_label">(h) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Giordanetto, F.</span>; <span class="NLM_string-name">Greisman, J. B.</span>; <span class="NLM_string-name">Maragakis, P.</span>; <span class="NLM_string-name">Taylor, A. M.</span>; <span class="NLM_string-name">Dipietro, L. V.</span>; <span class="NLM_string-name">Kelley, E. H.</span>; <span class="NLM_string-name">Lescarbeau, A.</span>; <span class="NLM_string-name">Murcko, M. A.</span>; <span class="NLM_string-name">Pierce, L. C. T.</span>; <span class="NLM_string-name">Shortsleeves, K. C.</span>; <span class="NLM_string-name">Walters, W. P.</span>; <span class="NLM_string-name">Bhat, S.</span>; <span class="NLM_string-name">Therrien, E.</span>; <span class="NLM_string-name">Dahlgren, M. K.</span></span> <span> </span><span class="NLM_article-title">Pyrazolo[3,4-b]pyrazine Derivatives as SHP2 Phosphatase Inhibitors</span>. Patent <span class="NLM_patent">WO2018081091</span>, <span class="NLM_year">2017</span> (Relay Therapeutics).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=F.+Giordanetto&author=J.+B.+Greisman&author=P.+Maragakis&author=A.+M.+Taylor&author=L.+V.+Dipietro&author=E.+H.+Kelley&author=A.+Lescarbeau&author=M.+A.+Murcko&author=L.+C.+T.+Pierce&author=K.+C.+Shortsleeves&author=W.+P.+Walters&author=S.+Bhat&author=E.+Therrien&author=M.+K.+Dahlgren&title=Pyrazolo%5B3%2C4-b%5Dpyrazine+Derivatives+as+SHP2+Phosphatase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37h&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGiordanetto%26aufirst%3DF.%26atitle%3DPyrazolo%255B3%252C4-b%255Dpyrazine%2520Derivatives%2520as%2520SHP2%2520Phosphatase%2520Inhibitors%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit37i"><span><span class="NLM_label">(i) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, A. M.</span>; <span class="NLM_string-name">Lescarbeau, A.</span>; <span class="NLM_string-name">Kelley, E. H.</span>; <span class="NLM_string-name">Shortsleeves, K. C.</span>; <span class="NLM_string-name">Dipietro, L. V.</span>; <span class="NLM_string-name">Walters, W. P.</span>; <span class="NLM_string-name">Murcko, M. A.</span>; <span class="NLM_string-name">Pierce, L. C.</span>; <span class="NLM_string-name">Tang, Y.</span>; <span class="NLM_string-name">Giordanetto, F.</span>; <span class="NLM_string-name">Greisman, J. B.</span>; <span class="NLM_string-name">Maragakis, P.</span>; <span class="NLM_string-name">Bhat, S.</span>; <span class="NLM_string-name">Dahlgeren, M. K.</span>; <span class="NLM_string-name">Therrien, E.</span></span> <span> </span><span class="NLM_article-title">Pyrazolo[3,4-b]pyrazine Derivatives as SHP2 Phosphatase Inhibitors</span>. Patent <span class="NLM_patent">WO2018218133</span>, <span class="NLM_year">2018</span> (Relay Therapeutics).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=A.+M.+Taylor&author=A.+Lescarbeau&author=E.+H.+Kelley&author=K.+C.+Shortsleeves&author=L.+V.+Dipietro&author=W.+P.+Walters&author=M.+A.+Murcko&author=L.+C.+Pierce&author=Y.+Tang&author=F.+Giordanetto&author=J.+B.+Greisman&author=P.+Maragakis&author=S.+Bhat&author=M.+K.+Dahlgeren&author=E.+Therrien&title=Pyrazolo%5B3%2C4-b%5Dpyrazine+Derivatives+as+SHP2+Phosphatase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37i&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DTaylor%26aufirst%3DA.%2BM.%26atitle%3DPyrazolo%255B3%252C4-b%255Dpyrazine%2520Derivatives%2520as%2520SHP2%2520Phosphatase%2520Inhibitors%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit37j"><span><span class="NLM_label">(j) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Nichols, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haderk, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahlhut, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulze, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hemmati, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wildes, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tzitzilonis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mordec, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marquez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olivas, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCoach, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blakely, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiss, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koltun, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gill, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldsmith, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J. A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bivona, T. G.</span></span> <span> </span><span class="NLM_article-title">RAS Nucleotide Cycling Underlies the SHP2 Phosphatase Dependence of Mutant BRAF-, NF1- and RAS-Driven Cancers</span>. <i>Nat. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1064</span>, <span class="refDoi"> DOI: 10.1038/s41556-018-0169-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37j&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=10.1038%2Fs41556-018-0169-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37j&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=30104724" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37j&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsV2isLnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2018&pages=1064&author=R.+J.+Nicholsauthor=F.+Haderkauthor=C.+Stahlhutauthor=C.+J.+Schulzeauthor=G.+Hemmatiauthor=D.+Wildesauthor=C.+Tzitzilonisauthor=K.+Mordecauthor=A.+Marquezauthor=J.+Romeroauthor=T.+Hsiehauthor=A.+Zamanauthor=V.+Olivasauthor=C.+McCoachauthor=C.+M.+Blakelyauthor=Z.+Wangauthor=G.+Kissauthor=E.+S.+Koltunauthor=A.+L.+Gillauthor=M.+Singhauthor=M.+A.+Goldsmithauthor=J.+A.+M.+Smithauthor=T.+G.+Bivona&title=RAS+Nucleotide+Cycling+Underlies+the+SHP2+Phosphatase+Dependence+of+Mutant+BRAF-%2C+NF1-+and+RAS-Driven+Cancers&doi=10.1038%2Fs41556-018-0169-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37jR"><div class="casContent"><span class="casTitleNuber">37j</span><div class="casTitle"><span class="NLM_cas:atitle">RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers</span></div><div class="casAuthors">Nichols, Robert J.; Haderk, Franziska; Stahlhut, Carlos; Schulze, Christopher J.; Hemmati, Golzar; Wildes, David; Tzitzilonis, Christos; Mordec, Kasia; Marquez, Abby; Romero, Jason; Hsieh, Tientien; Zaman, Aubhishek; Olivas, Victor; McCoach, Caroline; Blakely, Collin M.; Wang, Zhengping; Kiss, Gert; Koltun, Elena S.; Gill, Adrian L.; Singh, Mallika; Goldsmith, Mark A.; Smith, Jacqueline A. M.; Bivona, Trever G.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Cell Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1064-1073</span>CODEN:
                <span class="NLM_cas:coden">NCBIFN</span>;
        ISSN:<span class="NLM_cas:issn">1465-7392</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Oncogenic alterations in the RAS/RAF/MEK/ERK pathway drive the growth of a wide spectrum of cancers.  While BRAF and MEK inhibitors are efficacious against BRAFV600E-driven cancers, effective targeted therapies are lacking for most cancers driven by other pathway alterations, including non-V600E oncogenic BRAF, RAS GTPase-activating protein (GAP) NF1 (neurofibromin 1) loss and oncogenic KRAS.  Here, we show that targeting the SHP2 phosphatase (encoded by PTPN11) with RMC-4550, a small-mol. allosteric inhibitor, is effective in human cancer models bearing RAS-GTP-dependent oncogenic BRAF (for example, class 3 BRAF mutants), NF1 loss or nucleotide-cycling oncogenic RAS (for example, KRASG12C).  SHP2 inhibitor treatment decreases oncogenic RAS/RAF/MEK/ERK signalling and cancer growth by disrupting SOS1-mediated RAS-GTP loading.  Our findings illuminate a crit. function for SHP2 in promoting oncogenic RAS/MAPK pathway activation in cancers with RAS-GTP-dependent oncogenic BRAF, NF1 loss and nucleotide-cycling oncogenic KRAS.  SHP2 inhibition is a promising mol. therapeutic strategy for patients with cancers bearing these oncogenic drivers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2gVKE5Juu_LVg90H21EOLACvtfcHk0lj-L4IB1ZfJ6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsV2isLnP&md5=05e84e5c0d51d501c229e118f44aa6cd</span></div><a href="/servlet/linkout?suffix=cit37j&amp;dbid=16384&amp;doi=10.1038%2Fs41556-018-0169-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41556-018-0169-1%26sid%3Dliteratum%253Aachs%26aulast%3DNichols%26aufirst%3DR.%2BJ.%26aulast%3DHaderk%26aufirst%3DF.%26aulast%3DStahlhut%26aufirst%3DC.%26aulast%3DSchulze%26aufirst%3DC.%2BJ.%26aulast%3DHemmati%26aufirst%3DG.%26aulast%3DWildes%26aufirst%3DD.%26aulast%3DTzitzilonis%26aufirst%3DC.%26aulast%3DMordec%26aufirst%3DK.%26aulast%3DMarquez%26aufirst%3DA.%26aulast%3DRomero%26aufirst%3DJ.%26aulast%3DHsieh%26aufirst%3DT.%26aulast%3DZaman%26aufirst%3DA.%26aulast%3DOlivas%26aufirst%3DV.%26aulast%3DMcCoach%26aufirst%3DC.%26aulast%3DBlakely%26aufirst%3DC.%2BM.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DKiss%26aufirst%3DG.%26aulast%3DKoltun%26aufirst%3DE.%2BS.%26aulast%3DGill%26aufirst%3DA.%2BL.%26aulast%3DSingh%26aufirst%3DM.%26aulast%3DGoldsmith%26aufirst%3DM.%2BA.%26aulast%3DSmith%26aufirst%3DJ.%2BA.%2BM.%26aulast%3DBivona%26aufirst%3DT.%2BG.%26atitle%3DRAS%2520Nucleotide%2520Cycling%2520Underlies%2520the%2520SHP2%2520Phosphatase%2520Dependence%2520of%2520Mutant%2520BRAF-%252C%2520NF1-%2520and%2520RAS-Driven%2520Cancers%26jtitle%3DNat.%2520Cell%2520Biol.%26date%3D2018%26volume%3D20%26spage%3D1064%26doi%3D10.1038%2Fs41556-018-0169-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit37k"><span><span class="NLM_label">(k) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Zou, H.</span>; <span class="NLM_string-name">Li, Z.</span>; <span class="NLM_string-name">Wang, Y.</span>; <span class="NLM_string-name">Yu, J.</span>; <span class="NLM_string-name">Zhu, W.</span></span> <span> </span><span class="NLM_article-title">Pyrimidine and Five-membered Nitrogen Heterocycle Derivative, Preparation Method Therefor, and Medical Uses Thereof</span>. Patent <span class="NLM_patent">WO2020108590</span>, <span class="NLM_year">2020</span> (Tuojie Biotech Co., Ltd.).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=H.+Zou&author=Z.+Li&author=Y.+Wang&author=J.+Yu&author=W.+Zhu&title=Pyrimidine+and+Five-membered+Nitrogen+Heterocycle+Derivative%2C+Preparation+Method+Therefor%2C+and+Medical+Uses+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37k&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DZou%26aufirst%3DH.%26atitle%3DPyrimidine%2520and%2520Five-membered%2520Nitrogen%2520Heterocycle%2520Derivative%252C%2520Preparation%2520Method%2520Therefor%252C%2520and%2520Medical%2520Uses%2520Thereof%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit37l"><span><span class="NLM_label">(l) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J.</span>; <span class="NLM_string-name">Babiss, L. E.</span></span> <span> </span><span class="NLM_article-title">SHP2 Inhibitors and Uses Thereof</span>. Patent <span class="NLM_patent">WO2019182960</span>, <span class="NLM_year">2019</span> (Synblia Therapeutics, Inc.).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=J.+Xie&author=L.+E.+Babiss&title=SHP2+Inhibitors+and+Uses+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37l&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DXie%26aufirst%3DJ.%26atitle%3DSHP2%2520Inhibitors%2520and%2520Uses%2520Thereof%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit37m"><span><span class="NLM_label">(m) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Zou, B.</span>; <span class="NLM_string-name">Fu, X.</span>; <span class="NLM_string-name">Zhang, R.</span>; <span class="NLM_string-name">Ma, S.</span>; <span class="NLM_string-name">Xu, S.</span>; <span class="NLM_string-name">Fu, W.</span>; <span class="NLM_string-name">Liu, L.</span></span> <span> </span><span class="NLM_article-title">Pyrimidine-fused Cyclic Compound, Preparation Method Therefor, and Application Thereof</span>. Patent <span class="NLM_patent">WO2019158019</span>, <span class="NLM_year">2019</span> (Shanghai Blueray BioPharma Co. Ltd.).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=B.+Zou&author=X.+Fu&author=R.+Zhang&author=S.+Ma&author=S.+Xu&author=W.+Fu&author=L.+Liu&title=Pyrimidine-fused+Cyclic+Compound%2C+Preparation+Method+Therefor%2C+and+Application+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37m&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DZou%26aufirst%3DB.%26atitle%3DPyrimidine-fused%2520Cyclic%2520Compound%252C%2520Preparation%2520Method%2520Therefor%252C%2520and%2520Application%2520Thereof%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit37n"><span><span class="NLM_label">(n) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, C. N.</span>; <span class="NLM_string-name">Buck, I. M.</span>; <span class="NLM_string-name">Chessari, G.</span>; <span class="NLM_string-name">Day, J. E. H.</span>; <span class="NLM_string-name">Fujiwara, H.</span>; <span class="NLM_string-name">Hamlett, C. C. F.</span>; <span class="NLM_string-name">Hiscock, S. D.</span>; <span class="NLM_string-name">Holvey, R. S.</span>; <span class="NLM_string-name">Howard, S.</span>; <span class="NLM_string-name">Liebeschuetz, J. W.</span>; <span class="NLM_string-name">Palmer, N. J.</span>; <span class="NLM_string-name">St Denis, J. D.</span>; <span class="NLM_string-name">Twigg, D. G.</span>; <span class="NLM_string-name">Woodehead, A. J.</span></span> <span> </span><span class="NLM_article-title">Pharmaceutical Compounds</span>. Patent <span class="NLM_patent">WO2019167000</span>, <span class="NLM_year">2019</span> (Otsuka Pharmaceutical Co. Ltd., Taiho Pharmaceutical Co. Ltd.).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=C.+N.+Johnson&author=I.+M.+Buck&author=G.+Chessari&author=J.+E.+H.+Day&author=H.+Fujiwara&author=C.+C.+F.+Hamlett&author=S.+D.+Hiscock&author=R.+S.+Holvey&author=S.+Howard&author=J.+W.+Liebeschuetz&author=N.+J.+Palmer&author=J.+D.+St+Denis&author=D.+G.+Twigg&author=A.+J.+Woodehead&title=Pharmaceutical+Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37n&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DC.%2BN.%26atitle%3DPharmaceutical%2520Compounds%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit37o"><span><span class="NLM_label">(o) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Shimamura, T.</span>; <span class="NLM_string-name">Kato, R.</span>; <span class="NLM_string-name">Miura, R.</span>; <span class="NLM_string-name">Mita, T.</span>; <span class="NLM_string-name">Ogawa, T.</span>; <span class="NLM_string-name">Sagara, Y.</span>; <span class="NLM_string-name">Johnson, C. N.</span>; <span class="NLM_string-name">Howard, S.</span>; <span class="NLM_string-name">Day, J. E. H.</span>; <span class="NLM_string-name">St Denis, J. D.</span>; <span class="NLM_string-name">Liebeschuetz, J. W.</span></span> <span> </span><span class="NLM_article-title">Heterocyclic Compounds for Inhibiting the Activity of SHP2</span>. Patent <span class="NLM_patent">WO2020022323</span>, <span class="NLM_year">2019</span> (Otsuka Pharmaceutical Co. Ltd., Taiho Pharmaceutical Co. Ltd.).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=T.+Shimamura&author=R.+Kato&author=R.+Miura&author=T.+Mita&author=T.+Ogawa&author=Y.+Sagara&author=C.+N.+Johnson&author=S.+Howard&author=J.+E.+H.+Day&author=J.+D.+St+Denis&author=J.+W.+Liebeschuetz&title=Heterocyclic+Compounds+for+Inhibiting+the+Activity+of+SHP2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37o&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DShimamura%26aufirst%3DT.%26atitle%3DHeterocyclic%2520Compounds%2520for%2520Inhibiting%2520the%2520Activity%2520of%2520SHP2%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit37p"><span><span class="NLM_label">(p) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Fu, J.</span>; <span class="NLM_string-name">Lou, Y.</span>; <span class="NLM_string-name">He, Y.</span></span> <span> </span><span class="NLM_article-title">Fused Tricyclic Ring Derivatives as SRC Homology-2 Phosphatase Inhibitors</span>. Patent <span class="NLM_patent">WO2020061103</span>, <span class="NLM_year">2019</span> (Nikang Therapeutics, Inc.).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=J.+Fu&author=Y.+Lou&author=Y.+He&title=Fused+Tricyclic+Ring+Derivatives+as+SRC+Homology-2+Phosphatase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37p&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFu%26aufirst%3DJ.%26atitle%3DFused%2520Tricyclic%2520Ring%2520Derivatives%2520as%2520SRC%2520Homology-2%2520Phosphatase%2520Inhibitors%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit37q"><span><span class="NLM_label">(q) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Volkmann, R.</span>; <span class="NLM_string-name">Marfat, A.</span>; <span class="NLM_string-name">Nelson, F.</span>; <span class="NLM_string-name">Zagouras, P.</span></span> <span> </span><span class="NLM_article-title">Octahydrocyclopenta[c]pyrrole Allosteric Inhibitors of SHP2</span>. Patent <span class="NLM_patent">WO2019051469</span>, <span class="NLM_year">2018</span> (Krouzon Pharmaceuticals, Inc.).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=R.+Volkmann&author=A.+Marfat&author=F.+Nelson&author=P.+Zagouras&title=Octahydrocyclopenta%5Bc%5Dpyrrole+Allosteric+Inhibitors+of+SHP2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37q&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DVolkmann%26aufirst%3DR.%26atitle%3DOctahydrocyclopenta%255Bc%255Dpyrrole%2520Allosteric%2520Inhibitors%2520of%2520SHP2%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">LaMarche, M. J.</span>; <span class="NLM_string-name">Chen, J.</span></span> Unpublished results.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=LaMarche%2C+M.+J.%3B+Chen%2C+J.+Unpublished+results."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dunpublished%26sid%3Dliteratum%253Aachs%26aulast%3DLaMarche%26aufirst%3DM.%2BJ." title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fodor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Argintaru, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glick, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koenig, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaRochelle, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNeill, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majumdar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishiguchi, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paris, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quinn, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramsey, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sendzik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shultz, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stams, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blacklow, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acker, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaMarche, M. J.</span></span> <span> </span><span class="NLM_article-title">Dual Allosteric Inhibition of SHP2 Phosphatase</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">647</span>– <span class="NLM_lpage">656</span>, <span class="refDoi"> DOI: 10.1021/acschembio.7b00980</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.7b00980" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjslOgtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=647-656&author=M.+Fodorauthor=E.+Priceauthor=P.+Wangauthor=H.+Luauthor=A.+Argintaruauthor=Z.+Chenauthor=M.+Glickauthor=H.+Haoauthor=M.+Katoauthor=R.+Koenigauthor=J.+R.+LaRochelleauthor=G.+Liuauthor=E.+McNeillauthor=D.+Majumdarauthor=G.+A.+Nishiguchiauthor=L.+B.+Perezauthor=G.+Parisauthor=C.+M.+Quinnauthor=T.+Ramseyauthor=M.+Sendzikauthor=M.+D.+Shultzauthor=S.+L.+Williamsauthor=T.+Stamsauthor=S.+C.+Blacklowauthor=M.+G.+Ackerauthor=M.+J.+LaMarche&title=Dual+Allosteric+Inhibition+of+SHP2+Phosphatase&doi=10.1021%2Facschembio.7b00980"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Dual allosteric inhibition of SHP2 phosphatase</span></div><div class="casAuthors">Fodor, Michelle; Price, Edmund; Wang, Ping; Lu, Hengyu; Argintaru, Andreea; Chen, Zhouliang; Glick, Meir; Hao, Huai-Xiang; Kato, Mitsunori; Koenig, Robert; La Rochelle, Jonathan R.; Liu, Gang; McNeill, Eric; Majumdar, Dyuti; Nishiguchi, Gisele A.; Perez, Lawrence B.; Paris, Gregory; Quinn, Christopher M.; Ramsey, Timothy; Sendzik, Martin; Shultz, Michael David; Williams, Sarah L.; Stams, Travis; Blacklow, Stephen C.; Acker, Michael G.; LaMarche, Matthew J.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">647-656</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">SHP2 is a cytoplasmic protein tyrosine phosphatase encoded by the PTPN11 gene and is involved in cell proliferation, differentiation, and survival.  Recently, we reported an allosteric mechanism of inhibition that stabilizes the auto-inhibited conformation of SHP2.  SHP099 (1) was identified and characterized as a moderately potent, orally bioavailable, allosteric small mol. inhibitor, which binds to a tunnel-like pocket formed by the confluence of three domains of SHP2.  In this report, we describe further screening strategies that enabled the identification of a second, distinct small mol. allosteric site.  SHP244 (2) was identified as a weak inhibitor of SHP2 with modest thermal stabilization of the enzyme.  X-ray crystallog. revealed that 2 binds and stabilizes the inactive, closed conformation of SHP2, at a distinct, previously unexplored binding site-a cleft formed at the interface of the N-terminal SH2 and PTP domains.  Derivatization of 2 using structure-based design resulted in an increase in SHP2 thermal stabilization, biochem. inhibition, and subsequent MAPK pathway modulation.  Downregulation of DUSP6 mRNA, a downstream MAPK pathway marker, was obsd. in KYSE-520 cancer cells.  Remarkably, simultaneous occupation of both allosteric sites by 1 and 2 was possible, as characterized by cooperative biochem. inhibition expts. and X-ray crystallog.  Combining an allosteric site 1 inhibitor with an allosteric site 2 inhibitor led to enhanced pharmacol. pathway inhibition in cells.  This work illustrates a rare example of dual allosteric targeted protein inhibition, demonstrates screening methodol. and tactics to identify allosteric inhibitors, and enables further interrogation of SHP2 in cancer and related pathologies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWdw7pTS6sOLVg90H21EOLACvtfcHk0liZVDreH5TTbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjslOgtg%253D%253D&md5=8e4de4c353b9fc196c81e1cb51e367df</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Facschembio.7b00980&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.7b00980%26sid%3Dliteratum%253Aachs%26aulast%3DFodor%26aufirst%3DM.%26aulast%3DPrice%26aufirst%3DE.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DLu%26aufirst%3DH.%26aulast%3DArgintaru%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DGlick%26aufirst%3DM.%26aulast%3DHao%26aufirst%3DH.%26aulast%3DKato%26aufirst%3DM.%26aulast%3DKoenig%26aufirst%3DR.%26aulast%3DLaRochelle%26aufirst%3DJ.%2BR.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DMcNeill%26aufirst%3DE.%26aulast%3DMajumdar%26aufirst%3DD.%26aulast%3DNishiguchi%26aufirst%3DG.%2BA.%26aulast%3DPerez%26aufirst%3DL.%2BB.%26aulast%3DParis%26aufirst%3DG.%26aulast%3DQuinn%26aufirst%3DC.%2BM.%26aulast%3DRamsey%26aufirst%3DT.%26aulast%3DSendzik%26aufirst%3DM.%26aulast%3DShultz%26aufirst%3DM.%2BD.%26aulast%3DWilliams%26aufirst%3DS.%2BL.%26aulast%3DStams%26aufirst%3DT.%26aulast%3DBlacklow%26aufirst%3DS.%2BC.%26aulast%3DAcker%26aufirst%3DM.%2BG.%26aulast%3DLaMarche%26aufirst%3DM.%2BJ.%26atitle%3DDual%2520Allosteric%2520Inhibition%2520of%2520SHP2%2520Phosphatase%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2018%26volume%3D13%26spage%3D647%26epage%3D656%26doi%3D10.1021%2Facschembio.7b00980" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><a href="https://Clinicaltrials.gov" class="extLink">https://Clinicaltrials.gov</a> (accessed Aug 19, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2FClinicaltrials.gov+%28accessed+Aug+19%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kabsch, W.</span></span> <span> </span><span class="NLM_article-title">XDS</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>D66</i></span>,  <span class="NLM_fpage">125</span>– <span class="NLM_lpage">132</span>, <span class="refDoi"> DOI: 10.1107/S0907444909047337</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=10.1107%2FS0907444909047337" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1SisLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=D66&publication_year=2010&pages=125-132&author=W.+Kabsch&title=XDS&doi=10.1107%2FS0907444909047337"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Software XDS for image rotation, recognition and crystal symmetry assignment</span></div><div class="casAuthors">Kabsch, Wolfgang</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">125-132</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">The usage and control of recent modifications of the program package XDS for the processing of rotation images are described in the context of previous versions.  New features include automatic detn. of spot size and reflecting range and recognition and assignment of crystal symmetry.  Moreover, the limitations of earlier package versions on the no. of correction/scaling factors and the representation of pixel contents have been removed.  Large program parts have been restructured for parallel processing so that the quality and completeness of collected data can be assessed soon after measurement.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpv5AyUw00DYbVg90H21EOLACvtfcHk0lg-1jJX0cckOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1SisLc%253D&md5=1aa9a38aeb3ce95af4ffb7d8b8a142bd</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1107%2FS0907444909047337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444909047337%26sid%3Dliteratum%253Aachs%26aulast%3DKabsch%26aufirst%3DW.%26atitle%3DXDS%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2010%26volume%3DD66%26spage%3D125%26epage%3D132%26doi%3D10.1107%2FS0907444909047337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bricogne, G.</span>; <span class="NLM_string-name">Blanc, E.</span>; <span class="NLM_string-name">Brandl, M.</span>; <span class="NLM_string-name">Flensburg, C.</span>; <span class="NLM_string-name">Keller, P.</span>; <span class="NLM_string-name">Paciorek, W.</span>; <span class="NLM_string-name">Roversi, P.</span>; <span class="NLM_string-name">Smart, O. S.</span>; <span class="NLM_string-name">Vonrhein, C.</span>; <span class="NLM_string-name">Womack, T. O.</span></span> <i>BUSTER</i>, version <span class="NLM_edition">2.8.0</span>; <span class="NLM_publisher-name">Global Phasing Ltd.</span>, <span class="NLM_publisher-loc">Cambridge, U.K.</span>, <span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=G.+Bricogne&author=E.+Blanc&author=M.+Brandl&author=C.+Flensburg&author=P.+Keller&author=W.+Paciorek&author=P.+Roversi&author=O.+S.+Smart&author=C.+Vonrhein&author=T.+O.+Womack&title=BUSTER"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26aulast%3DBricogne%26aufirst%3DG.%26jtitle%3DBUSTER%26pub%3DGlobal%2520Phasing%2520Ltd%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Emsley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lohkamp, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowtan, K.</span></span> <span> </span><span class="NLM_article-title">Features and Development of Coot</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>D66</i></span>,  <span class="NLM_fpage">486</span>– <span class="NLM_lpage">501</span>, <span class="refDoi"> DOI: 10.1107/S0907444910007493</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=10.1107%2FS0907444910007493" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADC%252BC3cXksFKisb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=D66&publication_year=2010&pages=486-501&author=P.+Emsleyauthor=B.+Lohkampauthor=W.+G.+Scottauthor=K.+Cowtan&title=Features+and+Development+of+Coot&doi=10.1107%2FS0907444910007493"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Features and development of Coot</span></div><div class="casAuthors">Emsley, P.; Lohkamp, B.; Scott, W. G.; Cowtan, K.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">486-501</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Coot is a mol.-graphics application for model building and validation of biol. macromols.  The program displays electron-d. maps and at. models and allows model manipulations such as idealization, real-space refinement, manual rotation/translation, rigid-body fitting, ligand search, solvation, mutations, rotamers and Ramachandran idealization.  Furthermore, tools are provided for model validation as well as interfaces to external programs for refinement, validation and graphics.  The software is designed to be easy to learn for novice users, which is achieved by ensuring that tools for common tasks are 'discoverable' through familiar user-interface elements (menus and toolbars) or by intuitive behavior (mouse controls).  Recent developments have focused on providing tools for expert users, with customisable key bindings, extensions and an extensive scripting interface.  The software is under rapid development, but has already achieved very widespread use within the crystallog. community.  The current state of the software is presented, with a description of the facilities available and of some of the underlying methods employed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAKBKszbqb_7Vg90H21EOLACvtfcHk0lg-1jJX0cckOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXksFKisb8%253D&md5=67262cbfc60004de5ef962d5c043c910</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1107%2FS0907444910007493&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444910007493%26sid%3Dliteratum%253Aachs%26aulast%3DEmsley%26aufirst%3DP.%26aulast%3DLohkamp%26aufirst%3DB.%26aulast%3DScott%26aufirst%3DW.%2BG.%26aulast%3DCowtan%26aufirst%3DK.%26atitle%3DFeatures%2520and%2520Development%2520of%2520Coot%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2010%26volume%3DD66%26spage%3D486%26epage%3D501%26doi%3D10.1107%2FS0907444910007493" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3a','cit3b'],'ref4':['cit4a','cit4b','cit4c'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14a','cit14b'],'ref15':['cit15a','cit15b'],'ref16':['cit16'],'ref17':['cit17a','cit17b','cit17c','cit17d'],'ref18':['cit18a','cit18b'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21a','cit21b','cit21c'],'ref22':['cit22'],'ref23':['cit23a','cit23b','cit23c'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27a','cit27b'],'ref28':['cit28a','cit28b'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34a','cit34b'],'ref35':['cit35a','cit35b','cit35c','cit35d','cit35e','cit35f','cit35g'],'ref36':['cit36a','cit36b','cit36c','cit36d','cit36e'],'ref37':['cit37a','cit37b','cit37c','cit37d','cit37e','cit37f','cit37g','cit37h','cit37i','cit37j','cit37k','cit37l','cit37m','cit37n','cit37o','cit37p','cit37q'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 11 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiangbo  Yang</span>, <span class="hlFld-ContribAuthor ">Zhijia  Wang</span>, <span class="hlFld-ContribAuthor ">Yuan  Pei</span>, <span class="hlFld-ContribAuthor ">Ning  Song</span>, <span class="hlFld-ContribAuthor ">Lei  Xu</span>, <span class="hlFld-ContribAuthor ">Bo  Feng</span>, <span class="hlFld-ContribAuthor ">Hanlin  Wang</span>, <span class="hlFld-ContribAuthor ">Xiaomin  Luo</span>, <span class="hlFld-ContribAuthor ">Xiaobei  Hu</span>, <span class="hlFld-ContribAuthor ">Xiaohui  Qiu</span>, <span class="hlFld-ContribAuthor ">Huijin  Feng</span>, <span class="hlFld-ContribAuthor ">Yaxi  Yang</span>, <span class="hlFld-ContribAuthor ">Yubo  Zhou</span>, <span class="hlFld-ContribAuthor ">Jia  Li</span>, <span class="hlFld-ContribAuthor ">Bing  Zhou</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of thalidomide-based PROTAC small molecules as the highly efficient SHP2 degraders. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>218 </em>, 113341. <a href="https://doi.org/10.1016/j.ejmech.2021.113341" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113341</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113341&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113341%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bthalidomide-based%252BPROTAC%252Bsmall%252Bmolecules%252Bas%252Bthe%252Bhighly%252Befficient%252BSHP2%252Bdegraders%26aulast%3DYang%26aufirst%3DXiangbo%26date%3D2021%26volume%3D218%26spage%3D113341" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Suresh  Velnati</span>, <span class="hlFld-ContribAuthor ">Sara  Centonze</span>, <span class="hlFld-ContribAuthor ">Federico  Girivetto</span>, <span class="hlFld-ContribAuthor ">Gianluca  Baldanzi</span>. </span><span class="cited-content_cbyCitation_article-title">Diacylglycerol Kinase alpha in X Linked Lymphoproliferative Disease Type 1. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2021,</strong> <em>22 </em>
                                    (11)
                                     , 5816. <a href="https://doi.org/10.3390/ijms22115816" title="DOI URL">https://doi.org/10.3390/ijms22115816</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms22115816&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms22115816%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DDiacylglycerol%252BKinase%252Balpha%252Bin%252BX%252BLinked%252BLymphoproliferative%252BDisease%252BType%252B1%26aulast%3DVelnati%26aufirst%3DSuresh%26date%3D2021%26date%3D2021%26volume%3D22%26issue%3D11%26spage%3D5816" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">D. Lucas  Kerr</span>, <span class="hlFld-ContribAuthor ">Franziska  Haderk</span>, <span class="hlFld-ContribAuthor ">Trever G.  Bivona</span>. </span><span class="cited-content_cbyCitation_article-title">Allosteric SHP2 inhibitors in cancer: Targeting the intersection of RAS, resistance, and the immune microenvironment. </span><span class="cited-content_cbyCitation_journal-name">Current Opinion in Chemical Biology</span><span> <strong>2021,</strong> <em>62 </em>, 1-12. <a href="https://doi.org/10.1016/j.cbpa.2020.11.007" title="DOI URL">https://doi.org/10.1016/j.cbpa.2020.11.007</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.cbpa.2020.11.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.cbpa.2020.11.007%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Opinion%2520in%2520Chemical%2520Biology%26atitle%3DAllosteric%252BSHP2%252Binhibitors%252Bin%252Bcancer%25253A%252BTargeting%252Bthe%252Bintersection%252Bof%252BRAS%25252C%252Bresistance%25252C%252Band%252Bthe%252Bimmune%252Bmicroenvironment%26aulast%3DKerr%26aufirst%3DD.%2BLucas%26date%3D2021%26volume%3D62%26spage%3D1%26epage%3D12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qing  Nian</span>, <span class="hlFld-ContribAuthor ">Jinhao  Zeng</span>, <span class="hlFld-ContribAuthor ">Li  He</span>, <span class="hlFld-ContribAuthor ">Yu  Chen</span>, <span class="hlFld-ContribAuthor ">Zhiqiang  Zhang</span>, <span class="hlFld-ContribAuthor ">Fernando  Rodrigues-Lima</span>, <span class="hlFld-ContribAuthor ">Liyun  Zhao</span>, <span class="hlFld-ContribAuthor ">Xuanlin  Feng</span>, <span class="hlFld-ContribAuthor ">Jianyou  Shi</span>. </span><span class="cited-content_cbyCitation_article-title">A small molecule inhibitor targeting SHP2 mutations for the lung carcinoma. </span><span class="cited-content_cbyCitation_journal-name">Chinese Chemical Letters</span><span> <strong>2021,</strong> <em>32 </em>
                                    (5)
                                     , 1645-1652. <a href="https://doi.org/10.1016/j.cclet.2021.01.002" title="DOI URL">https://doi.org/10.1016/j.cclet.2021.01.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.cclet.2021.01.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.cclet.2021.01.002%26sid%3Dliteratum%253Aachs%26jtitle%3DChinese%2520Chemical%2520Letters%26atitle%3DA%252Bsmall%252Bmolecule%252Binhibitor%252Btargeting%252BSHP2%252Bmutations%252Bfor%252Bthe%252Blung%252Bcarcinoma%26aulast%3DNian%26aufirst%3DQing%26date%3D2021%26volume%3D32%26issue%3D5%26spage%3D1645%26epage%3D1652" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Takamasa  Koga</span>, <span class="hlFld-ContribAuthor ">Kenichi  Suda</span>, <span class="hlFld-ContribAuthor ">Toshio  Fujino</span>, <span class="hlFld-ContribAuthor ">Shuta  Ohara</span>, <span class="hlFld-ContribAuthor ">Akira  Hamada</span>, <span class="hlFld-ContribAuthor ">Masaya  Nishino</span>, <span class="hlFld-ContribAuthor ">Masato  Chiba</span>, <span class="hlFld-ContribAuthor ">Masaki  Shimoji</span>, <span class="hlFld-ContribAuthor ">Toshiki  Takemoto</span>, <span class="hlFld-ContribAuthor ">Takeo  Arita</span>, <span class="hlFld-ContribAuthor ">Michael  Gmachl</span>, <span class="hlFld-ContribAuthor ">Marco H.  Hofmann</span>, <span class="hlFld-ContribAuthor ">Junichi  Soh</span>, <span class="hlFld-ContribAuthor ">Tetsuya  Mitsudomi</span>. </span><span class="cited-content_cbyCitation_article-title">KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From the In Vitro Experiments. </span><span class="cited-content_cbyCitation_journal-name">Journal of Thoracic Oncology</span><span> <strong>2021,</strong> <em>304 </em><a href="https://doi.org/10.1016/j.jtho.2021.04.015" title="DOI URL">https://doi.org/10.1016/j.jtho.2021.04.015</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jtho.2021.04.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jtho.2021.04.015%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Thoracic%2520Oncology%26atitle%3DKRAS%252BSecondary%252BMutations%252BThat%252BConfer%252BAcquired%252BResistance%252Bto%252BKRAS%252BG12C%252BInhibitors%25252C%252BSotorasib%252Band%252BAdagrasib%25252C%252Band%252BOvercoming%252BStrategies%25253A%252BInsights%252BFrom%252Bthe%252BIn%2525C2%2525A0Vitro%252BExperiments%26aulast%3DKoga%26aufirst%3DTakamasa%26date%3D2021%26volume%3D304" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rajwanth  Veluswamy</span>, <span class="hlFld-ContribAuthor ">Philip C.  Mack</span>, <span class="hlFld-ContribAuthor ">Jane  Houldsworth</span>, <span class="hlFld-ContribAuthor ">Ehab  Elkhouly</span>, <span class="hlFld-ContribAuthor ">Fred R.  Hirsch</span>. </span><span class="cited-content_cbyCitation_article-title">KRAS G12C–Mutant Non–Small Cell Lung Cancer. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Molecular Diagnostics</span><span> <strong>2021,</strong> <em>23 </em>
                                    (5)
                                     , 507-520. <a href="https://doi.org/10.1016/j.jmoldx.2021.02.002" title="DOI URL">https://doi.org/10.1016/j.jmoldx.2021.02.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jmoldx.2021.02.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jmoldx.2021.02.002%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Molecular%2520Diagnostics%26atitle%3DKRAS%252BG12C%2525E2%252580%252593Mutant%252BNon%2525E2%252580%252593Small%252BCell%252BLung%252BCancer%26aulast%3DVeluswamy%26aufirst%3DRajwanth%26date%3D2021%26volume%3D23%26issue%3D5%26spage%3D507%26epage%3D520" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ziqiao  Zhang</span>, <span class="hlFld-ContribAuthor ">Jihong  Guan</span>, <span class="hlFld-ContribAuthor ">Shuigeng  Zhou</span>, . </span><span class="cited-content_cbyCitation_article-title">FraGAT: a fragment-oriented multi-scale graph attention model for molecular property prediction. </span><span class="cited-content_cbyCitation_journal-name">Bioinformatics</span><span> <strong>2021,</strong> <em>57 </em><a href="https://doi.org/10.1093/bioinformatics/btab195" title="DOI URL">https://doi.org/10.1093/bioinformatics/btab195</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1093/bioinformatics/btab195&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1093%2Fbioinformatics%2Fbtab195%26sid%3Dliteratum%253Aachs%26jtitle%3DBioinformatics%26atitle%3DFraGAT%25253A%252Ba%252Bfragment-oriented%252Bmulti-scale%252Bgraph%252Battention%252Bmodel%252Bfor%252Bmolecular%252Bproperty%252Bprediction%26aulast%3DZhang%26aufirst%3DZiqiao%26date%3D2021%26date%3D2021%26volume%3D57" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Vidyasiri  Vemulapalli</span>, <span class="hlFld-ContribAuthor ">Lily A  Chylek</span>, <span class="hlFld-ContribAuthor ">Alison  Erickson</span>, <span class="hlFld-ContribAuthor ">Anamarija  Pfeiffer</span>, <span class="hlFld-ContribAuthor ">Khal-Hentz  Gabriel</span>, <span class="hlFld-ContribAuthor ">Jonathan  LaRochelle</span>, <span class="hlFld-ContribAuthor ">Kartik  Subramanian</span>, <span class="hlFld-ContribAuthor ">Ruili  Cao</span>, <span class="hlFld-ContribAuthor ">Kimberley  Stegmaier</span>, <span class="hlFld-ContribAuthor ">Morvarid  Mohseni</span>, <span class="hlFld-ContribAuthor ">Matthew J  LaMarche</span>, <span class="hlFld-ContribAuthor ">Michael G  Acker</span>, <span class="hlFld-ContribAuthor ">Peter K  Sorger</span>, <span class="hlFld-ContribAuthor ">Steven P  Gygi</span>, <span class="hlFld-ContribAuthor ">Stephen C  Blacklow</span>. </span><span class="cited-content_cbyCitation_article-title">Time resolved phosphoproteomics reveals scaffolding and catalysis-responsive patterns of SHP2-dependent signaling. </span><span class="cited-content_cbyCitation_journal-name">eLife</span><span> <strong>2021,</strong> <em>10 </em><a href="https://doi.org/10.7554/eLife.64251" title="DOI URL">https://doi.org/10.7554/eLife.64251</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.7554/eLife.64251&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.7554%2FeLife.64251%26sid%3Dliteratum%253Aachs%26jtitle%3DeLife%26atitle%3DTime%252Bresolved%252Bphosphoproteomics%252Breveals%252Bscaffolding%252Band%252Bcatalysis-responsive%252Bpatterns%252Bof%252BSHP2-dependent%252Bsignaling%26aulast%3DVemulapalli%26aufirst%3DVidyasiri%26date%3D2021%26date%3D2021%26volume%3D10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jennifer E.  Klomp</span>, <span class="hlFld-ContribAuthor ">Jeff A.  Klomp</span>, <span class="hlFld-ContribAuthor ">Channing J.  Der</span>. </span><span class="cited-content_cbyCitation_article-title">The ERK mitogen-activated protein kinase signaling network: the final frontier in RAS signal transduction. </span><span class="cited-content_cbyCitation_journal-name">Biochemical Society Transactions</span><span> <strong>2021,</strong> <em>49 </em>
                                    (1)
                                     , 253-267. <a href="https://doi.org/10.1042/BST20200507" title="DOI URL">https://doi.org/10.1042/BST20200507</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1042/BST20200507&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1042%2FBST20200507%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemical%2520Society%2520Transactions%26atitle%3DThe%252BERK%252Bmitogen-activated%252Bprotein%252Bkinase%252Bsignaling%252Bnetwork%25253A%252Bthe%252Bfinal%252Bfrontier%252Bin%252BRAS%252Bsignal%252Btransduction%26aulast%3DKlomp%26aufirst%3DJennifer%2BE.%26date%3D2021%26date%3D2021%26volume%3D49%26issue%3D1%26spage%3D253%26epage%3D267" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">. </span><span class="cited-content_cbyCitation_article-title">Synthesis of TNO155. </span><span class="cited-content_cbyCitation_journal-name">Synfacts</span><span> <strong>2021,</strong>,, 0128. <a href="https://doi.org/10.1055/s-0040-1719325" title="DOI URL">https://doi.org/10.1055/s-0040-1719325</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1055/s-0040-1719325&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1055%2Fs-0040-1719325%26sid%3Dliteratum%253Aachs%26jtitle%3DSynfacts%26atitle%3DSynthesis%252Bof%252BTNO155%26date%3D2021%26date%3D2021%26volume%3D17%26issue%3D02%26spage%3D0128" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Elisa  Pardella</span>, <span class="hlFld-ContribAuthor ">Erica  Pranzini</span>, <span class="hlFld-ContribAuthor ">Angela  Leo</span>, <span class="hlFld-ContribAuthor ">Maria Letizia  Taddei</span>, <span class="hlFld-ContribAuthor ">Paolo  Paoli</span>, <span class="hlFld-ContribAuthor ">Giovanni  Raugei</span>. </span><span class="cited-content_cbyCitation_article-title">Oncogenic Tyrosine Phosphatases: Novel Therapeutic Targets for Melanoma Treatment. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2020,</strong> <em>12 </em>
                                    (10)
                                     , 2799. <a href="https://doi.org/10.3390/cancers12102799" title="DOI URL">https://doi.org/10.3390/cancers12102799</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers12102799&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers12102799%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DOncogenic%252BTyrosine%252BPhosphatases%25253A%252BNovel%252BTherapeutic%252BTargets%252Bfor%252BMelanoma%252BTreatment%26aulast%3DPardella%26aufirst%3DElisa%26date%3D2020%26date%3D2020%26volume%3D12%26issue%3D10%26spage%3D2799" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01170/20201120/images/medium/jm0c01170_0020.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01170/20201120/images/large/jm0c01170_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01170&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01170/20201120/images/medium/jm0c01170_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01170/20201120/images/large/jm0c01170_0001.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. (A) Equilibrium of SHP2 in closed (blocked active site) and open (free active site) states via a diphosphotyrosyl peptide, where the N-terminal SH2 domain is shown in green, the C-terminal SH2 domain is shown in blue, and the PTP domain is shown in beige. (B) DIFMUP assay measuring phosphatase activity. Figure adapted with permission from   <cite><i>J. Med. Chem.</i></cite> <span class="NLM_year">2016</span>, <em>59</em>, 7773–7782.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01170/20201120/images/large/jm0c01170_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01170&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01170/20201120/images/medium/jm0c01170_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01170/20201120/images/large/jm0c01170_0002.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) Pyrimidine HTS hit, <b>2</b>. (B) Cocrystal structure of <b>2</b> with SHP2 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EHP">5EHP</a>), 1.85 Å, in the closed, inactive conformation, where the <i>N</i>-terminal SH2 domain is shown in green, the <i>C</i>-terminal SH2 domain is shown in blue, and the PTP domain is shown in beige. Inset: allosteric binding pocket at the junction of three domains. (C) Allosteric tunnel binding site of <b>2</b> with key residues noted. Figure adapted with permission from   <cite><i>J. Med.
Chem.</i></cite> <span class="NLM_year">2016</span>, <em>59</em>, 7773–7782.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01170/20201120/images/large/jm0c01170_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01170&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01170/20201120/images/medium/jm0c01170_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01170/20201120/images/large/jm0c01170_0003.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Select small molecule inhibitors of the RTK-RAS-MAPK pathway.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01170/20201120/images/large/jm0c01170_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01170&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01170/20201120/images/medium/jm0c01170_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01170/20201120/images/large/jm0c01170_0004.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (A) Aminopyrazine <b>10</b> and azabenzimidazole HTS hit <b>18</b>. (B) Cocrystal structure of <b>18</b> with SHP2, 2.05 Å, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6MDD">6MDD</a>, where R111 is shown in orange. (C) Binding conformation of <b>18</b> (blue) overlaid with binding conformation of <b>10</b> (gray), showing central ring deviation and western arene movement.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01170/20201120/images/large/jm0c01170_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01170&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01170/20201120/images/medium/jm0c01170_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01170/20201120/images/large/jm0c01170_0008.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Thioether-aminopyrazinyl-amines<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01170/20201120/images/large/jm0c01170_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01170&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) CuI, K<sub>3</sub>PO<sub>4</sub>, 1,10-phenathroline, dioxane, 85 °C; (b) DIPEA, 90 °C; (c) Xantphos, Pd(OAc)<sub>2</sub>, DIPEA, dioxane, 95 °C, 90%; (d) NaOEt, RT, THF, 100%; (e) Xantphos, Pd<sub>2</sub>(dba)<sub>3</sub>, DIPEA, dioxane, 105 °C, 91%.</p></p></figure><figure data-id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01170/20201120/images/medium/jm0c01170_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01170/20201120/images/large/jm0c01170_0005.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (A) Cocrystal structure of <b>24</b> with SHP2, 1.92 Å, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7JVN">7JVN</a>, showing H-bonds from the aminopyrazine ring with R111 and E250. (B) Amine region of <b>24</b> making interactions with E249, F113, and water.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01170/20201120/images/large/jm0c01170_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01170&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01170/20201120/images/medium/jm0c01170_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01170/20201120/images/large/jm0c01170_0006.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. (A) Cocrystal of <b>1</b> bound to SHP2, 2.15 Å, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7JVM">7JVM</a>. (B) Amine region interactions with S109, E110, F113, and H114.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01170/20201120/images/large/jm0c01170_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01170&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch2" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01170/20201120/images/medium/jm0c01170_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01170/20201120/images/large/jm0c01170_0009.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of TNO155 (<b>1</b>)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01170/20201120/images/large/jm0c01170_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01170&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) diisopropylamine, <i>n</i>-BuLi, THF, 0 °C; (b) LiBH<sub>4</sub>, 0 °C, THF; (c) TBAF, THF, 65%, 3 steps; (d)TsCl, NaH, THF; (e) DMP, DCM, 0 °C, 45%, 2 steps; (f) Ti(OEt)<sub>4</sub>, <i>R</i>-2-methylpropane-2-sulfinamide, THF, LiBH<sub>4</sub>, 90 °C, 65%; (g) HCl, dioxane, 0 °C, 90%; (h) DIPEA, DMSO, 100 °C, 65%.</p></p></figure><figure data-id="fig7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01170/20201120/images/medium/jm0c01170_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01170/20201120/images/large/jm0c01170_0007.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. (A) Dose-dependent exposure, p-ERK and DUSP-6 mRNA modulation of <b>1</b> after oral administration in KYSE-520 tumor bearing nude mouse at 2.5, 10, and 10 mg/kg. (B) Dose-dependent efficacy of <b>1</b> after oral administration in KYSE-520 tumor bearing nude mouse at 2.5, 10, and 20 mg/kg BID and effect on body weight.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01170/20201120/images/large/jm0c01170_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01170&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i38">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_77206" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_77206" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 43 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tartaglia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehler, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zampino, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunner, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kremer, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Der
Burgt, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crosby, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ion, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeffery, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalidas, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patton, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kucherlapati, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelb, B. D.</span></span> <span> </span><span class="NLM_article-title">Mutations in PTPN11, Encoding the Protein Tyrosine Phosphatase SHP-2, Cause Noonan Syndrome</span>. <i>Nat. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">465</span>– <span class="NLM_lpage">468</span>, <span class="refDoi"> DOI: 10.1038/ng772</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=10.1038%2Fng772" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=11704759" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADC%252BD3MXovFGjt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2001&pages=465-468&author=M.+Tartagliaauthor=E.+L.+Mehlerauthor=R.+Goldbergauthor=G.+Zampinoauthor=H.+G.+Brunnerauthor=H.+Kremerauthor=I.+Van+Der%0ABurgtauthor=A.+H.+Crosbyauthor=A.+Ionauthor=S.+Jefferyauthor=K.+Kalidasauthor=J.+A.+Pattonauthor=R.+S.+Kucherlapatiauthor=B.+D.+Gelb&title=Mutations+in+PTPN11%2C+Encoding+the+Protein+Tyrosine+Phosphatase+SHP-2%2C+Cause+Noonan+Syndrome&doi=10.1038%2Fng772"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome</span></div><div class="casAuthors">Tartaglia, Marco; Mehler, Ernest L.; Goldberg, Rosalie; Zampino, Giuseppe; Brunner, Han G.; Kremer, Hannie; van der Burgt, Ineke; Crosby, Andrew H.; Ion, Andra; Jeffery, Steve; Kalidas, Kamini; Patton, Michael A.; Kucherlapati, Raju S.; Gelb, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">465-468</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature America Inc.</span>)
        </div><div class="casAbstract">Noonan syndrome (MIM 163950) is an autosomal dominant disorder characterized by dysmorphic facial features, proportionate short stature and heart disease (most commonly pulmonic stenosis and hypertrophic cardiomyopathy).  Webbed neck, chest deformity, cryptorchidism, mental retardation and bleeding diathesis also are frequently assocd. with this disease.  This syndrome is relatively common, with an estd. incidence of 1 in 1000-2500 live births.  It has been mapped to a 5-cM region (N-SH2) on chromosome 12q24.1, and genetic heterogeneity has also been documented.  Here we show that missense mutations in PTPN11 (MIM 176876)-a gene encoding the nonreceptor protein tyrosine phosphatase SHP-2, which contains two Src homol. 2 (SH2) domains-cause Noonan syndrome and account for more than 50% of the cases that we examd.  All PTPN11 missense mutations cluster in interacting portions of the amino N-SH2 domain and the phosphotyrosine phosphatase domains, which are involved in switching the protein between its inactive and active conformations.  An energetics-based structural anal. of two N-SH2 mutants indicates that in these mutants there may be a significant shift of the equil. favoring the active conformation.  This implies that they are gain-of-function changes and that the pathogenesis of Noonan syndrome arises from excessive SHP-2 activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKg7QISHW0bbVg90H21EOLACvtfcHk0lgqBxdrkiZoCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXovFGjt7w%253D&md5=c8225c08340f9446cd58c249de42e515</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fng772&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng772%26sid%3Dliteratum%253Aachs%26aulast%3DTartaglia%26aufirst%3DM.%26aulast%3DMehler%26aufirst%3DE.%2BL.%26aulast%3DGoldberg%26aufirst%3DR.%26aulast%3DZampino%26aufirst%3DG.%26aulast%3DBrunner%26aufirst%3DH.%2BG.%26aulast%3DKremer%26aufirst%3DH.%26aulast%3DVan%2BDer%2BBurgt%26aufirst%3DI.%26aulast%3DCrosby%26aufirst%3DA.%2BH.%26aulast%3DIon%26aufirst%3DA.%26aulast%3DJeffery%26aufirst%3DS.%26aulast%3DKalidas%26aufirst%3DK.%26aulast%3DPatton%26aufirst%3DJ.%2BA.%26aulast%3DKucherlapati%26aufirst%3DR.%2BS.%26aulast%3DGelb%26aufirst%3DB.%2BD.%26atitle%3DMutations%2520in%2520PTPN11%252C%2520Encoding%2520the%2520Protein%2520Tyrosine%2520Phosphatase%2520SHP-2%252C%2520Cause%2520Noonan%2520Syndrome%26jtitle%3DNat.%2520Genet.%26date%3D2001%26volume%3D29%26spage%3D465%26epage%3D468%26doi%3D10.1038%2Fng772" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tartaglia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niemeyer, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fragale, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buechner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hählen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasle, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Licht, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelb, B. D.</span></span> <span> </span><span class="NLM_article-title">Somatic Mutations in PTPN11 in Juvenile Myelomonocytic Leukemia, Myelodysplastic Syndromes and Acute Myeloid Leukemia</span>. <i>Nat. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">148</span>– <span class="NLM_lpage">150</span>, <span class="refDoi"> DOI: 10.1038/ng1156</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=10.1038%2Fng1156" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=12717436" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADC%252BD3sXktFSltrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2003&pages=148-150&author=M.+Tartagliaauthor=C.+M.+Niemeyerauthor=A.+Fragaleauthor=X.+Songauthor=J.+Buechnerauthor=A.+Jungauthor=K.+H%C3%A4hlenauthor=H.+Hasleauthor=J.+D.+Lichtauthor=B.+D.+Gelb&title=Somatic+Mutations+in+PTPN11+in+Juvenile+Myelomonocytic+Leukemia%2C+Myelodysplastic+Syndromes+and+Acute+Myeloid+Leukemia&doi=10.1038%2Fng1156"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia</span></div><div class="casAuthors">Tartaglia, Marco; Niemeyer, Charlotte M.; Fragale, Alessandra; Song, Xiaoling; Buechner, Jochen; Jung, Andreas; Haehlen, Karel; Hasle, Henrik; Licht, Jonathan D.; Gelb, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">148-150</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We report here that individuals with Noonan syndrome and juvenile myelomonocytic leukemia (JMML) have germline mutations in PTPN11 and that somatic mutations in PTPN11 account for 34% of non-syndromic JMML.  Furthermore, we found mutations in PTPN11 in a small percentage of individuals with myelodysplastic syndrome (MDS) and de novo acute myeloid leukemia (AML).  Functional analyses documented that the two most common mutations in PTPN11 assocd. with JMML caused a gain of function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCwFhlUQDJQLVg90H21EOLACvtfcHk0lirVTWfplEk0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXktFSltrY%253D&md5=67d6900b46520ee461330bed95cbc890</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fng1156&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng1156%26sid%3Dliteratum%253Aachs%26aulast%3DTartaglia%26aufirst%3DM.%26aulast%3DNiemeyer%26aufirst%3DC.%2BM.%26aulast%3DFragale%26aufirst%3DA.%26aulast%3DSong%26aufirst%3DX.%26aulast%3DBuechner%26aufirst%3DJ.%26aulast%3DJung%26aufirst%3DA.%26aulast%3DH%25C3%25A4hlen%26aufirst%3DK.%26aulast%3DHasle%26aufirst%3DH.%26aulast%3DLicht%26aufirst%3DJ.%2BD.%26aulast%3DGelb%26aufirst%3DB.%2BD.%26atitle%3DSomatic%2520Mutations%2520in%2520PTPN11%2520in%2520Juvenile%2520Myelomonocytic%2520Leukemia%252C%2520Myelodysplastic%2520Syndromes%2520and%2520Acute%2520Myeloid%2520Leukemia%26jtitle%3DNat.%2520Genet.%26date%3D2003%26volume%3D34%26spage%3D148%26epage%3D150%26doi%3D10.1038%2Fng1156" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalaitzidis, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neel, B. G.</span></span> <span> </span><span class="NLM_article-title">The Tyrosine Phosphatase SHP2 (<i>PTPN11</i>) in Cancer</span>. <i>Cancer Metastasis Rev.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">179</span>– <span class="NLM_lpage">192</span>, <span class="refDoi"> DOI: 10.1007/s10555-008-9126-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=10.1007%2Fs10555-008-9126-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=18286234" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlt1Ckur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2008&pages=179-192&author=G.+Chanauthor=D.+Kalaitzidisauthor=B.+G.+Neel&title=The+Tyrosine+Phosphatase+SHP2+%28PTPN11%29+in+Cancer&doi=10.1007%2Fs10555-008-9126-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3aR"><div class="casContent"><span class="casTitleNuber">3a</span><div class="casTitle"><span class="NLM_cas:atitle">The tyrosine phosphatase Shp2 (PTPN11) in cancer</span></div><div class="casAuthors">Chan, Gordon; Kalaitzidis, Demetrios; Neel, Benjamin G.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer and Metastasis Reviews</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">179-192</span>CODEN:
                <span class="NLM_cas:coden">CMRED4</span>;
        ISSN:<span class="NLM_cas:issn">0167-7659</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Diverse cellular processes are regulated by tyrosyl phosphorylation, which is controlled by protein-tyrosine kinases (PTKs) and protein-tyrosine phosphatases (PTPs).  De-regulated tyrosyl phosphorylation, evoked by gain-of-function mutations and/or over-expression of PTKs, contributes to the pathogenesis of many cancers and other human diseases.  PTPs, because they oppose the action of PTKs, had been considered to be prime suspects for potential tumor suppressor genes.  Surprisingly, few, if any, tumor suppressor PTPs have been identified.  However, the Src homol.-2 domain-contg. phosphatase Shp2 (encoded by PTPN11) is a bona fide proto-oncogene.  Germline mutations in PTPN11 cause Noonan and LEOPARD syndromes, whereas somatic PTPN11 mutations occur in several types of hematol. malignancies, most notably juvenile myelomonocytic leukemia and, more rarely, in solid tumors.  Shp2 also is an essential component in several other oncogene signaling pathways.  Elucidation of the events underlying Shp2-evoked transformation may provide new insights into oncogenic mechanisms and novel targets for anti-cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbJ8OYsBzvg7Vg90H21EOLACvtfcHk0lirVTWfplEk0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlt1Ckur4%253D&md5=fb514f60b97f8ff0dcc0dbd57cab2c9a</span></div><a href="/servlet/linkout?suffix=cit3a&amp;dbid=16384&amp;doi=10.1007%2Fs10555-008-9126-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10555-008-9126-y%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DG.%26aulast%3DKalaitzidis%26aufirst%3DD.%26aulast%3DNeel%26aufirst%3DB.%2BG.%26atitle%3DThe%2520Tyrosine%2520Phosphatase%2520SHP2%2520%2528PTPN11%2529%2520in%2520Cancer%26jtitle%3DCancer%2520Metastasis%2520Rev.%26date%3D2008%26volume%3D27%26spage%3D179%26epage%3D192%26doi%3D10.1007%2Fs10555-008-9126-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit3b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Miyamoto, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyamoto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yomogita, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higashi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatakeyama, M.</span></span> <span> </span><span class="NLM_article-title">Isolation of a Distinct Class of Gain-of-Function SHP-2 Mutants with Oncogenic RAS-like Transforming Activity from Solid Tumors</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">3508</span>– <span class="NLM_lpage">3515</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1211019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=10.1038%2Fsj.onc.1211019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=18223690" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmslWmurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2008&pages=3508-3515&author=D.+Miyamotoauthor=M.+Miyamotoauthor=A.+Takahashiauthor=Y.+Yomogitaauthor=H.+Higashiauthor=S.+Kondoauthor=M.+Hatakeyama&title=Isolation+of+a+Distinct+Class+of+Gain-of-Function+SHP-2+Mutants+with+Oncogenic+RAS-like+Transforming+Activity+from+Solid+Tumors&doi=10.1038%2Fsj.onc.1211019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3bR"><div class="casContent"><span class="casTitleNuber">3b</span><div class="casTitle"><span class="NLM_cas:atitle">Isolation of a distinct class of gain-of-function SHP-2 mutants with oncogenic RAS-like transforming activity from solid tumors</span></div><div class="casAuthors">Miyamoto, D.; Miyamoto, M.; Takahashi, A.; Yomogita, Y.; Higashi, H.; Kondo, S.; Hatakeyama, M.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">3508-3515</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">SHP-2 protein tyrosine phosphatase plays an important role in activation of the RAS-dependent signaling.  Gain-of-function mutations in the PTPN11 gene, which encodes SHP-2, have been found in the leukemia-prone developmental disorder Noonan syndrome as well as sporadic childhood leukemias, indicating that SHP-2 is a bona fide human oncoprotein.  However, the role of SHP-2 mutations in non-hematol. malignancies remains obscure.  Here, we screened for PTPN11 mutations in primary solid tumors and identified a 1520C>A mutation that causes threonine-507 to lysine (T507K) substitution in the phosphatase domain of SHP-2 in a case of hepatocellular carcinoma.  T507K SHP-2 exhibited altered substrate specificity with slightly elevated basal phosphatase activity.  Upon expression in NIH3T3 cells, T507K SHP-2 induced transformed foci, which was not obsd. with wild type, Noonan-specific or leukemia-specific SHP-2.  Furthermore, NIH3T3 cells transformed by T507K SHP-2 showed anchorage-independent growth and developed tumors in nude mice.  These results indicate that quant. and/or qual. alteration in phosphatase activity dets. the transforming potential as well as target cell/tissue spectrum of individual SHP-2 mutants as oncoproteins.  Although rare in solid tumors, the identified T507K SHP-2 represents a distinct class of SHP-2 mutants with oncogenic RAS-like transforming activity, which could contribute to the development of solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwOMpOPEfD0rVg90H21EOLACvtfcHk0lirVTWfplEk0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmslWmurY%253D&md5=e0a0e2df71b6998a92b40bbba05ffef8</span></div><a href="/servlet/linkout?suffix=cit3b&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1211019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1211019%26sid%3Dliteratum%253Aachs%26aulast%3DMiyamoto%26aufirst%3DD.%26aulast%3DMiyamoto%26aufirst%3DM.%26aulast%3DTakahashi%26aufirst%3DA.%26aulast%3DYomogita%26aufirst%3DY.%26aulast%3DHigashi%26aufirst%3DH.%26aulast%3DKondo%26aufirst%3DS.%26aulast%3DHatakeyama%26aufirst%3DM.%26atitle%3DIsolation%2520of%2520a%2520Distinct%2520Class%2520of%2520Gain-of-Function%2520SHP-2%2520Mutants%2520with%2520Oncogenic%2520RAS-like%2520Transforming%2520Activity%2520from%2520Solid%2520Tumors%26jtitle%3DOncogene%26date%3D2008%26volume%3D27%26spage%3D3508%26epage%3D3515%26doi%3D10.1038%2Fsj.onc.1211019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Neel, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pao, L.</span></span> <span> </span><span class="NLM_article-title">The ‘Shp’ing News: SH2 Domain-Containing Tyrosine Phosphatases in Cell Signaling</span>. <i>Trends Biochem. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">284</span>– <span class="NLM_lpage">293</span>, <span class="refDoi"> DOI: 10.1016/S0968-0004(03)00091-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=10.1016%2FS0968-0004%2803%2900091-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=12826400" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADC%252BD3sXkvVCnu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2003&pages=284-293&author=B.+G.+Neelauthor=H.+Guauthor=L.+Pao&title=The+%E2%80%98Shp%E2%80%99ing+News%3A+SH2+Domain-Containing+Tyrosine+Phosphatases+in+Cell+Signaling&doi=10.1016%2FS0968-0004%2803%2900091-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4aR"><div class="casContent"><span class="casTitleNuber">4a</span><div class="casTitle"><span class="NLM_cas:atitle">The Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling</span></div><div class="casAuthors">Neel, Benjamin G.; Gu, Haihua; Pao, Lily</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Biochemical Sciences</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">284-293</span>CODEN:
                <span class="NLM_cas:coden">TBSCDB</span>;
        ISSN:<span class="NLM_cas:issn">0968-0004</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Src homol.-2 (SH2) domain-contg. phosphatases (Shps) are a small, highly conserved subfamily of protein tyrosine phosphatases, members of which are present in both vertebrates and invertebrates.  The mechanism of regulation of Shps by ligand binding is now well understood.  Much is also known about the normal signaling pathways regulated by each Shp and the consequences of Shp deficiency.  Recent studies have identified mutations in human Shp2 as the cause of the inherited disorder, Noonan syndrome.  Shp2 mutations might also contribute to the pathogenesis of some leukemias.  In addn., Shp2 might be a key virulence determinant for the important human pathogen, Helicobacter pylori.  Despite these efforts, however, the key targets of each Shp have remained elusive.  Identifying these substrates remains a major challenge for future research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7zIEChntK0rVg90H21EOLACvtfcHk0liPoC65SgNTHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXkvVCnu7k%253D&md5=bce9fc3db0a41b29ba605251dc46c64f</span></div><a href="/servlet/linkout?suffix=cit4a&amp;dbid=16384&amp;doi=10.1016%2FS0968-0004%2803%2900091-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0968-0004%252803%252900091-4%26sid%3Dliteratum%253Aachs%26aulast%3DNeel%26aufirst%3DB.%2BG.%26aulast%3DGu%26aufirst%3DH.%26aulast%3DPao%26aufirst%3DL.%26atitle%3DThe%2520%25E2%2580%2598Shp%25E2%2580%2599ing%2520News%253A%2520SH2%2520Domain-Containing%2520Tyrosine%2520Phosphatases%2520in%2520Cell%2520Signaling%26jtitle%3DTrends%2520Biochem.%2520Sci.%26date%3D2003%26volume%3D28%26spage%3D284%26epage%3D293%26doi%3D10.1016%2FS0968-0004%2803%2900091-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit4b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, G. S.</span></span> <span> </span><span class="NLM_article-title">PTPN11 is the First Identified Proto-Oncogene That Encodes a Tyrosine Phosphatase</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">862</span>– <span class="NLM_lpage">867</span>, <span class="refDoi"> DOI: 10.1182/blood-2006-07-028829</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=10.1182%2Fblood-2006-07-028829" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=17053061" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjtFersLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2007&pages=862-867&author=R.+J.+Chanauthor=G.+S.+Feng&title=PTPN11+is+the+First+Identified+Proto-Oncogene+That+Encodes+a+Tyrosine+Phosphatase&doi=10.1182%2Fblood-2006-07-028829"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4bR"><div class="casContent"><span class="casTitleNuber">4b</span><div class="casTitle"><span class="NLM_cas:atitle">PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase</span></div><div class="casAuthors">Chan, Rebecca J.; Feng, Gen-Sheng</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">862-867</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">A review.  Elucidation of the mol. mechanisms underlying carcinogenesis has benefited tremendously from the identification and characterization of oncogenes and tumor suppressor genes.  One new advance in this field is the identification of PTPN11 as the first proto-oncogene that encodes a cytoplasmic tyrosine phosphatase with 2 Src-homol. 2 (SH2) domains (Shp2).  This tyrosine phosphatase was previously shown to play an essential role in normal hematopoiesis.  More recently, somatic missense PTPN11 gain-of-function mutations were detected in leukemias and rarely in solid tumors, and were found to induce aberrant hyperactivation of the Ras-Erk pathway.  This progress represents another milestone in the leukemia/cancer research field and provides a fresh view on the mol. mechanisms underlying cell transformation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqsuOora-d37Vg90H21EOLACvtfcHk0liPoC65SgNTHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjtFersLg%253D&md5=8c5760a6ac385635f9794acbf5b64a03</span></div><a href="/servlet/linkout?suffix=cit4b&amp;dbid=16384&amp;doi=10.1182%2Fblood-2006-07-028829&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2006-07-028829%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DR.%2BJ.%26aulast%3DFeng%26aufirst%3DG.%2BS.%26atitle%3DPTPN11%2520is%2520the%2520First%2520Identified%2520Proto-Oncogene%2520That%2520Encodes%2520a%2520Tyrosine%2520Phosphatase%26jtitle%3DBlood%26date%3D2007%26volume%3D109%26spage%3D862%26epage%3D867%26doi%3D10.1182%2Fblood-2006-07-028829" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit4c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Tiganis, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, A. M.</span></span> <span> </span><span class="NLM_article-title">Protein Tyrosine Phosphatase Function: the Substrated Perspective</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>402</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">15</span>, <span class="refDoi"> DOI: 10.1042/BJ20061548</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=10.1042%2FBJ20061548" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=17238862" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADC%252BD2sXosFOisQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=402&publication_year=2007&pages=1-15&author=T.+Tiganisauthor=A.+M.+Bennett&title=Protein+Tyrosine+Phosphatase+Function%3A+the+Substrated+Perspective&doi=10.1042%2FBJ20061548"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4cR"><div class="casContent"><span class="casTitleNuber">4c</span><div class="casTitle"><span class="NLM_cas:atitle">Protein tyrosine phosphatase function: the substrate perspective</span></div><div class="casAuthors">Tiganis, Tony; Bennett, Anton M.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">402</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-15</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">A review.  It is now well established that the members of the protein tyrosine phosphatase (PTP) superfamily play crit. roles in fundamental biol. processes.  Although there has been much progress in defining the function of PTPs, the task of identifying substrates for these enzymes still presents a challenge.  Many PTPs have yet to have their physiol. substrates identified.  The focus of this review is on the current state of knowledge of PTP substrates and the approaches used to identify them.  The authors propose exptl. criteria that should be satisfied in order to rigorously assign PTP substrates as bona fide.  Finally, the progress that has been made in defining the biol. roles of PTPs through the identification of their substrates is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGod89zW3LtOs7Vg90H21EOLACvtfcHk0liPoC65SgNTHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXosFOisQ%253D%253D&md5=e0b404da50fc57e25efe140026d6cd53</span></div><a href="/servlet/linkout?suffix=cit4c&amp;dbid=16384&amp;doi=10.1042%2FBJ20061548&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBJ20061548%26sid%3Dliteratum%253Aachs%26aulast%3DTiganis%26aufirst%3DT.%26aulast%3DBennett%26aufirst%3DA.%2BM.%26atitle%3DProtein%2520Tyrosine%2520Phosphatase%2520Function%253A%2520the%2520Substrated%2520Perspective%26jtitle%3DBiochem.%2520J.%26date%3D2007%26volume%3D402%26spage%3D1%26epage%3D15%26doi%3D10.1042%2FBJ20061548" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bunda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrell, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heir, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alamsahebpour, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kano, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raught, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zadeh, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohh, M.</span></span> <span> </span><span class="NLM_article-title">Inhibition of SHP2-Mediated Dephosphorylation of Ras Suppresses Oncogenesis</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">8859</span>, <span class="refDoi"> DOI: 10.1038/ncomms9859</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=10.1038%2Fncomms9859" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=26617336" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFWksLbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=8859&author=S.+Bundaauthor=K.+Burrellauthor=P.+Heirauthor=L.+Zengauthor=A.+Alamsahebpourauthor=Y.+Kanoauthor=B.+Raughtauthor=Z.-Y.+Zhangauthor=G.+Zadehauthor=M.+Ohh&title=Inhibition+of+SHP2-Mediated+Dephosphorylation+of+Ras+Suppresses+Oncogenesis&doi=10.1038%2Fncomms9859"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of SHP2-mediated dephosphorylation of Ras suppresses oncogenesis</span></div><div class="casAuthors">Bunda, Severa; Burrell, Kelly; Heir, Pardeep; Zeng, Lifan; Alamsahebpour, Amir; Kano, Yoshihito; Raught, Brian; Zhang, Zhong-Yin; Zadeh, Gelareh; Ohh, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">8859</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Ras is phosphorylated on a conserved tyrosine at position 32 within the switch I region via Src kinase.  This phosphorylation inhibits the binding of effector Raf while promoting the engagement of GTPase-activating protein (GAP) and GTP hydrolysis.  Here we identify SHP2 as the ubiquitously expressed tyrosine phosphatase that preferentially binds to and dephosphorylates Ras to increase its assocn. with Raf and activate downstream proliferative Ras/ERK/MAPK signalling.  In comparison to normal astrocytes, SHP2 activity is elevated in astrocytes isolated from glioblastoma multiforme (GBM)-prone H-Ras(12V) knock-in mice as well as in glioma cell lines and patient-derived GBM specimens exhibiting hyperactive Ras.  Pharmacol. inhibition of SHP2 activity attenuates cell proliferation, soft-agar colony formation and orthotopic GBM growth in NOD/SCID mice and decelerates the progression of low-grade astrocytoma to GBM in a spontaneous transgenic glioma mouse model.  These results identify SHP2 as a direct activator of Ras and a potential therapeutic target for cancers driven by a previously 'undruggable' oncogenic or hyperactive Ras.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhWi25AJiphrVg90H21EOLACvtfcHk0liPoC65SgNTHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFWksLbP&md5=8524ad9cc6f2e85abaff6b07c698f464</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fncomms9859&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms9859%26sid%3Dliteratum%253Aachs%26aulast%3DBunda%26aufirst%3DS.%26aulast%3DBurrell%26aufirst%3DK.%26aulast%3DHeir%26aufirst%3DP.%26aulast%3DZeng%26aufirst%3DL.%26aulast%3DAlamsahebpour%26aufirst%3DA.%26aulast%3DKano%26aufirst%3DY.%26aulast%3DRaught%26aufirst%3DB.%26aulast%3DZhang%26aufirst%3DZ.-Y.%26aulast%3DZadeh%26aufirst%3DG.%26aulast%3DOhh%26aufirst%3DM.%26atitle%3DInhibition%2520of%2520SHP2-Mediated%2520Dephosphorylation%2520of%2520Ras%2520Suppresses%2520Oncogenesis%26jtitle%3DNat.%2520Commun.%26date%3D2015%26volume%3D6%26spage%3D8859%26doi%3D10.1038%2Fncomms9859" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kovats, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velazquez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pant, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shirley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleming, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexander, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farsidjani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaMarche, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moody, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silver, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caponigro, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuart, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abrams, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammerman, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldoni, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohseni, M.</span></span> <span> </span><span class="NLM_article-title">Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS Mutant Cancers</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">2368</span>– <span class="NLM_lpage">2380</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-19-0170</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=10.1158%2F1535-7163.MCT-19-0170" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=31439712" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADC%252BB3cXktFOiur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2019&pages=2368-2380&author=H.+Haoauthor=H.+Wangauthor=C.+Liuauthor=S.+Kovatsauthor=R.+Velazquezauthor=H.+Luauthor=B.+Pantauthor=M.+Shirleyauthor=M.+J.+Meyerauthor=M.+Puauthor=J.+Limauthor=M.+Flemingauthor=L.+Alexanderauthor=A.+Farsidjaniauthor=M.+J.+LaMarcheauthor=S.+Moodyauthor=S.+J.+Silverauthor=G.+Caponigroauthor=D.+D.+Stuartauthor=T.+J.+Abramsauthor=P.+S.+Hammermanauthor=J.+Williamsauthor=J.+A.+Engelmanauthor=S.+Goldoniauthor=M.+Mohseni&title=Tumor+Intrinsic+Efficacy+by+SHP2+and+RTK+Inhibitors+in+KRAS+Mutant+Cancers&doi=10.1158%2F1535-7163.MCT-19-0170"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Tumor intrinsic efficacy by SHP2 and RTK inhibitors in KRAS-mutant cancers</span></div><div class="casAuthors">Hao, Huai-Xiang; Wang, Hongyun; Liu, Chen; Kovats, Steven; Velazquez, Roberto; Lu, Hengyu; Pant, Bhavesh; Shirley, Matthew; Meyer, Matthew J.; Pu, Minying; Lim, Joanne; Fleming, Michael; Alexander, Leigh Ann; Farsidjani, Ali; LaMarche, Matthew J.; Moody, Susan; Silver, Serena J.; Caponigro, Giordano; Stuart, Darrin D.; Abrams, Tinya J.; Hammerman, Peter S.; Williams, Juliet; Engelman, Jeffrey A.; Goldoni, Silvia; Mohseni, Morvarid</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2368-2380</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">KRAS, an oncogene mutated in nearly one third of human cancers, remains a pharmacol. challenge for direct inhibition except for recent advances in selective inhibitors targeting the G12C variant.  Here, we report that selective inhibition of the protein tyrosine phosphatase, SHP2, can impair the proliferation of KRAS-mutant cancer cells in vitro and in vivo using cell line xenografts and primary human tumors.  In vitro, sensitivity of KRAS-mutant cells toward the allosteric SHP2 inhibitor, SHP099, is not apparent when cells are grown on plastic in 2D monolayer, but is revealed when cells are grown as 3D multicellular spheroids.  This antitumor activity is also obsd. in vivo in mouse models.  Interrogation of the MAPK pathway in SHP099-treated KRAS-mutant cancer models demonstrated similar modulation of p-ERK and DUSP6 transcripts in 2D, 3D, and in vivo, suggesting a MAPK pathway-dependent mechanism and possible non-MAPK pathway-dependent mechanisms in tumor cells or tumor microenvironment for the in vivo efficacy.  For the KRASG12C MIAPaCa-2 model, we demonstrate that the efficacy is cancer cell intrinsic as there is minimal antiangiogenic activity by SHP099, and the effects of SHP099 is recapitulated by genetic depletion of SHP2 in cancer cells.  Furthermore, we demonstrate that SHP099 efficacy in KRAS-mutant models can be recapitulated with RTK inhibitors, suggesting RTK activity is responsible for the SHP2 activation.  Taken together, these data reveal that many KRAS-mutant cancers depend on upstream signaling from RTK and SHP2, and provide a new therapeutic framework for treating KRAS-mutant cancers with SHP2 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1sXDzXA3V7bVg90H21EOLACvtfcHk0lgijv7A9PXLFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXktFOiur4%253D&md5=00f008e63ad5edc091cf18a60fe2aed2</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-19-0170&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-19-0170%26sid%3Dliteratum%253Aachs%26aulast%3DHao%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DKovats%26aufirst%3DS.%26aulast%3DVelazquez%26aufirst%3DR.%26aulast%3DLu%26aufirst%3DH.%26aulast%3DPant%26aufirst%3DB.%26aulast%3DShirley%26aufirst%3DM.%26aulast%3DMeyer%26aufirst%3DM.%2BJ.%26aulast%3DPu%26aufirst%3DM.%26aulast%3DLim%26aufirst%3DJ.%26aulast%3DFleming%26aufirst%3DM.%26aulast%3DAlexander%26aufirst%3DL.%26aulast%3DFarsidjani%26aufirst%3DA.%26aulast%3DLaMarche%26aufirst%3DM.%2BJ.%26aulast%3DMoody%26aufirst%3DS.%26aulast%3DSilver%26aufirst%3DS.%2BJ.%26aulast%3DCaponigro%26aufirst%3DG.%26aulast%3DStuart%26aufirst%3DD.%2BD.%26aulast%3DAbrams%26aufirst%3DT.%2BJ.%26aulast%3DHammerman%26aufirst%3DP.%2BS.%26aulast%3DWilliams%26aufirst%3DJ.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DGoldoni%26aufirst%3DS.%26aulast%3DMohseni%26aufirst%3DM.%26atitle%3DTumor%2520Intrinsic%2520Efficacy%2520by%2520SHP2%2520and%2520RTK%2520Inhibitors%2520in%2520KRAS%2520Mutant%2520Cancers%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2019%26volume%3D18%26spage%3D2368%26epage%3D2380%26doi%3D10.1158%2F1535-7163.MCT-19-0170" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bivona, T. G.</span></span> <span> </span><span class="NLM_article-title">Dampening Oncogenic RAS Signaling</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>363</i></span>,  <span class="NLM_fpage">1280</span>– <span class="NLM_lpage">1281</span>, <span class="refDoi"> DOI: 10.1126/science.aav6703</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=10.1126%2Fscience.aav6703" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=30898918" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFCju73E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2019&pages=1280-1281&author=T.+G.+Bivona&title=Dampening+Oncogenic+RAS+Signaling&doi=10.1126%2Fscience.aav6703"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Dampening oncogenic RAS signaling: recent insights into the mechanism of oncogenic RAS prompt new anticancer strategies</span></div><div class="casAuthors">Bivona, Trever G.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">6433</span>),
    <span class="NLM_cas:pages">1280-1281</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">A review.  The conventional model of oncogenic RAS-MAPK pathway signaling in cancer suggests that mutations in the pathway render downstream signaling largely independent of regulation (autonomous).  However, the emerging model of a semiautonomous state through which pathol. RAS signaling remains under some control suggests a potential therapeutic opportunity to target upstream regulators, such as SHP2, SOS, and GRB2.  The recent insights into the mechanism of oncogenic RAS prompt new anticancer strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfVFpPtfDfXbVg90H21EOLACvtfcHk0liBiE9CAsUy1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFCju73E&md5=c73f3524e9d328397dce7324af0d6c3e</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1126%2Fscience.aav6703&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aav6703%26sid%3Dliteratum%253Aachs%26aulast%3DBivona%26aufirst%3DT.%2BG.%26atitle%3DDampening%2520Oncogenic%2520RAS%2520Signaling%26jtitle%3DScience%26date%3D2019%26volume%3D363%26spage%3D1280%26epage%3D1281%26doi%3D10.1126%2Fscience.aav6703" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mainardi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulero-Sanchez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prahallad, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Germano, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krimpenfort, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lieftink, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinberg, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Wit, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goncalves-Ribeiro, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nadal, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bardelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villanueva, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernards, R.</span></span> <span> </span><span class="NLM_article-title">SHP2 is Required for Growth of KRAS-Mutant Non-Small-Cell Lung Cancer <i>In Vivo</i></span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">961</span>– <span class="NLM_lpage">967</span>, <span class="refDoi"> DOI: 10.1038/s41591-018-0023-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=10.1038%2Fs41591-018-0023-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=29808006" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVelsbvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=961-967&author=S.+Mainardiauthor=A.+Mulero-Sanchezauthor=A.+Prahalladauthor=G.+Germanoauthor=A.+Bosmaauthor=P.+Krimpenfortauthor=C.+Lieftinkauthor=J.+D.+Steinbergauthor=N.+de+Witauthor=S.+Goncalves-Ribeiroauthor=E.+Nadalauthor=A.+Bardelliauthor=A.+Villanuevaauthor=R.+Bernards&title=SHP2+is+Required+for+Growth+of+KRAS-Mutant+Non-Small-Cell+Lung+Cancer+In+Vivo&doi=10.1038%2Fs41591-018-0023-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo</span></div><div class="casAuthors">Mainardi, Sara; Mulero-Sanchez, Antonio; Prahallad, Anirudh; Germano, Giovanni; Bosma, Astrid; Krimpenfort, Paul; Lieftink, Cor; Steinberg, Jeffrey D.; de Wit, Niels; Goncalves-Ribeiro, Samuel; Nadal, Ernest; Bardelli, Alberto; Villanueva, Alberto; Bernards, Rene</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">961-967</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">RAS mutations are frequent in human cancer, esp. in pancreatic, colorectal and non-small-cell lung cancers (NSCLCs).  Inhibition of the RAS oncoproteins has proven difficult, and attempts to target downstream effectors have been hampered by the activation of compensatory resistance mechanisms.  It is also well established that KRAS-mutant tumors are insensitive to inhibition of upstream growth factor receptor signaling.  Thus, epidermal growth factor receptor antibody therapy is only effective in KRAS wild-type colon cancers.  Consistently, inhibition of SHP2 (also known as PTPN11), which links receptor tyrosine kinase signaling to the RAS-RAF-MEK-ERK pathway11,12, was shown to be ineffective in KRAS-mutant or BRAF-mutant cancer cell lines.  Tha data also indicate that SHP2 inhibition in KRAS-mutant NSCLC cells under normal cell culture conditions has little effect.  By contrast, SHP2 inhibition under growth factor-limiting conditions in vitro results in a senescence response.  In vivo, inhibition of SHP2 in KRAS-mutant NSCLC also provokes a senescence response, which is exacerbated by MEK inhibition.  Tha data identify SHP2 inhibition as an unexpected vulnerability of KRAS-mutant NSCLC cells that remains undetected in cell culture and can be exploited therapeutically.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLHUMCtBqtZrVg90H21EOLACvtfcHk0liBiE9CAsUy1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVelsbvL&md5=8e1ce1eb5d30d3985aafdec9d07f205d</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fs41591-018-0023-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41591-018-0023-9%26sid%3Dliteratum%253Aachs%26aulast%3DMainardi%26aufirst%3DS.%26aulast%3DMulero-Sanchez%26aufirst%3DA.%26aulast%3DPrahallad%26aufirst%3DA.%26aulast%3DGermano%26aufirst%3DG.%26aulast%3DBosma%26aufirst%3DA.%26aulast%3DKrimpenfort%26aufirst%3DP.%26aulast%3DLieftink%26aufirst%3DC.%26aulast%3DSteinberg%26aufirst%3DJ.%2BD.%26aulast%3Dde%2BWit%26aufirst%3DN.%26aulast%3DGoncalves-Ribeiro%26aufirst%3DS.%26aulast%3DNadal%26aufirst%3DE.%26aulast%3DBardelli%26aufirst%3DA.%26aulast%3DVillanueva%26aufirst%3DA.%26aulast%3DBernards%26aufirst%3DR.%26atitle%3DSHP2%2520is%2520Required%2520for%2520Growth%2520of%2520KRAS-Mutant%2520Non-Small-Cell%2520Lung%2520Cancer%2520In%2520Vivo%26jtitle%3DNat.%2520Med.%26date%3D2018%26volume%3D24%26spage%3D961%26epage%3D967%26doi%3D10.1038%2Fs41591-018-0023-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xue, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aronowitz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mai, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vides, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qeriqi, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Stanchina, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazutis, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Risso, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lito, P.</span></span> <span> </span><span class="NLM_article-title">Rapid Non-Uniform Adaptation to Conformation-Specific KRAS(G12C) Inhibition</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>577</i></span>,  <span class="NLM_fpage">421</span>– <span class="NLM_lpage">425</span>, <span class="refDoi"> DOI: 10.1038/s41586-019-1884-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=10.1038%2Fs41586-019-1884-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=31915379" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADC%252BB3cXlsleisA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=577&publication_year=2020&pages=421-425&author=J.+Y.+Xueauthor=Y.+Zhaoauthor=J.+Aronowitzauthor=T.+T.+Maiauthor=A.+Videsauthor=B.+Qeriqiauthor=D.+Kimauthor=C.+Liauthor=E.+de+Stanchinaauthor=L.+Mazutisauthor=D.+Rissoauthor=P.+Lito&title=Rapid+Non-Uniform+Adaptation+to+Conformation-Specific+KRAS%28G12C%29+Inhibition&doi=10.1038%2Fs41586-019-1884-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition</span></div><div class="casAuthors">Xue, Jenny Y.; Zhao, Yulei; Aronowitz, Jordan; Mai, Trang T.; Vides, Alberto; Qeriqi, Besnik; Kim, Dongsung; Li, Chuanchuan; de Stanchina, Elisa; Mazutis, Linas; Risso, Davide; Lito, Piro</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">577</span>
        (<span class="NLM_cas:issue">7790</span>),
    <span class="NLM_cas:pages">421-425</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">KRAS GTPases are activated in one-third of cancers, and KRAS(G12C) is one of the most common activating alterations in lung adenocarcinoma1,2.  KRAS(G12C) inhibitors3,4 are in phase-I clin. trials and early data show partial responses in nearly half of patients with lung cancer.  How cancer cells bypass inhibition to prevent maximal response to therapy is not understood.  Because KRAS(G12C) cycles between an active and inactive conformation4-6, and the inhibitors bind only to the latter, we tested whether isogenic cell populations respond in a non-uniform manner by studying the effect of treatment at a single-cell resoln.  Here we report that, shortly after treatment, some cancer cells are sequestered in a quiescent state with low KRAS activity, whereas others bypass this effect to resume proliferation.  This rapid divergent response occurs because some quiescent cells produce new KRAS(G12C) in response to suppressed mitogen-activated protein kinase output.  New KRAS(G12C) is maintained in its active, drug-insensitive state by epidermal growth factor receptor and aurora kinase signalling.  Cells without these adaptive changes-or cells in which these changes are pharmacol. inhibited-remain sensitive to drug treatment, because new KRAS(G12C) is either not available or exists in its inactive, drug-sensitive state.  The direct targeting of KRAS oncoproteins has been a longstanding objective in precision oncol.  Our study uncovers a flexible non-uniform fitness mechanism that enables groups of cells within a population to rapidly bypass the effect of treatment.  This adaptive process must be overcome if we are to achieve complete and durable responses in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqs98vxCKonTbVg90H21EOLACvtfcHk0liBiE9CAsUy1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXlsleisA%253D%253D&md5=23df9a8dc75959ebb136f3412e40fc36</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fs41586-019-1884-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41586-019-1884-x%26sid%3Dliteratum%253Aachs%26aulast%3DXue%26aufirst%3DJ.%2BY.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DAronowitz%26aufirst%3DJ.%26aulast%3DMai%26aufirst%3DT.%2BT.%26aulast%3DVides%26aufirst%3DA.%26aulast%3DQeriqi%26aufirst%3DB.%26aulast%3DKim%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DC.%26aulast%3Dde%2BStanchina%26aufirst%3DE.%26aulast%3DMazutis%26aufirst%3DL.%26aulast%3DRisso%26aufirst%3DD.%26aulast%3DLito%26aufirst%3DP.%26atitle%3DRapid%2520Non-Uniform%2520Adaptation%2520to%2520Conformation-Specific%2520KRAS%2528G12C%2529%2520Inhibition%26jtitle%3DNature%26date%3D2020%26volume%3D577%26spage%3D421%26epage%3D425%26doi%3D10.1038%2Fs41586-019-1884-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ruess, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heynen, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciecielski, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berninger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kabacaoglu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Görgülü, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dantes, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wörmann, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diakopoulos, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karpathaki, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kowalska, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaya-Aksoy, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeeuw van der Laan, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">López-Alberca, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nazaré, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saur, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erkan, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopt, U. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sainz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birchmeier, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmid, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Algül, H.</span></span> <span> </span><span class="NLM_article-title">Mutant KRAS-Driven Cancers Depend on PTPN11/SHP2 Phosphatase</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">954</span>– <span class="NLM_lpage">960</span>, <span class="refDoi"> DOI: 10.1038/s41591-018-0024-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=10.1038%2Fs41591-018-0024-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=29808009" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVelsbvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=954-960&author=D.+A.+Ruessauthor=G.+J.+Heynenauthor=K.+J.+Ciecielskiauthor=J.+Aiauthor=A.+Berningerauthor=D.+Kabacaogluauthor=K.+G%C3%B6rg%C3%BCl%C3%BCauthor=Z.+Dantesauthor=S.+M.+W%C3%B6rmannauthor=K.+N.+Diakopoulosauthor=A.+F.+Karpathakiauthor=M.+Kowalskaauthor=E.+Kaya-Aksoyauthor=L.+Songauthor=E.+A.+Zeeuw+van+der+Laanauthor=M.+P.+L%C3%B3pez-Albercaauthor=M.+Nazar%C3%A9author=M.+Reichertauthor=D.+Saurauthor=M.+M.+Erkanauthor=U.+T.+Hoptauthor=B.+Sainzauthor=W.+Birchmeierauthor=R.+M.+Schmidauthor=M.+Lesinaauthor=H.+Alg%C3%BCl&title=Mutant+KRAS-Driven+Cancers+Depend+on+PTPN11%2FSHP2+Phosphatase&doi=10.1038%2Fs41591-018-0024-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase</span></div><div class="casAuthors">Ruess, Dietrich A.; Heynen, Guus J.; Ciecielski, Katrin J.; Ai, Jiaoyu; Berninger, Alexandra; Kabacaoglu, Derya; Goerguelue, Kivanc; Dantes, Zahra; Woermann, Sonja M.; Diakopoulos, Kalliope N.; Karpathaki, Angeliki F.; Kowalska, Marlena; Kaya-Aksoy, Ezgi; Song, Liang; van der Laan, Eveline A. Zeeuw; Lopez-Alberca, Maria P.; Nazare, Marc; Reichert, Maximilian; Saur, Dieter; Erkan, Mert M.; Hopt, Ulrich T.; Sainz, Jr, Bruno; Birchmeier, Walter; Schmid, Roland M.; Lesina, Marina; Alguel, Hana</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">954-960</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The ubiquitously expressed non-receptor protein tyrosine phosphatase SHP2, encoded by PTPN11, is involved in signal transduction downstream of multiple growth factor, cytokine and integrin receptors1.  Its requirement for complete RAS-MAPK activation and its role as a neg. regulator of JAK-STAT signaling have established SHP2 as an essential player in oncogenic signaling pathways1-7.  Recently, a novel potent allosteric SHP2 inhibitor was presented as a viable therapeutic option for receptor tyrosine kinase-driven cancers, but was shown to be ineffective in KRAS-mutant tumor cell lines in vitro8.  Here, we report a central and indispensable role for SHP2 in oncogenic KRAS-driven tumors.  Genetic deletion of Ptpn11 profoundly inhibited tumor development in mutant KRAS-driven murine models of pancreatic ductal adenocarcinoma and non-small-cell lung cancer.  We provide evidence for a crit. dependence of mutant KRAS on SHP2 during carcinogenesis.  Deletion or inhibition of SHP2 in established tumors delayed tumor progression but was not sufficient to achieve tumor regression.  However, SHP2 was necessary for resistance mechanisms upon blockade of MEK.  Synergy was obsd. when both SHP2 and MEK were targeted, resulting in sustained tumor growth control in murine and human patient-derived organoids and xenograft models of pancreatic ductal adenocarcinoma and non-small-cell lung cancer.  Our data indicate the clin. utility of dual SHP2/MEK inhibition as a targeted therapy approach for KRAS-mutant cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoepq09hU77abVg90H21EOLACvtfcHk0limH6dKdv51fA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVelsbvF&md5=cc09897c2c4b8e32b035b991e5032f32</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fs41591-018-0024-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41591-018-0024-8%26sid%3Dliteratum%253Aachs%26aulast%3DRuess%26aufirst%3DD.%2BA.%26aulast%3DHeynen%26aufirst%3DG.%2BJ.%26aulast%3DCiecielski%26aufirst%3DK.%2BJ.%26aulast%3DAi%26aufirst%3DJ.%26aulast%3DBerninger%26aufirst%3DA.%26aulast%3DKabacaoglu%26aufirst%3DD.%26aulast%3DG%25C3%25B6rg%25C3%25BCl%25C3%25BC%26aufirst%3DK.%26aulast%3DDantes%26aufirst%3DZ.%26aulast%3DW%25C3%25B6rmann%26aufirst%3DS.%2BM.%26aulast%3DDiakopoulos%26aufirst%3DK.%2BN.%26aulast%3DKarpathaki%26aufirst%3DA.%2BF.%26aulast%3DKowalska%26aufirst%3DM.%26aulast%3DKaya-Aksoy%26aufirst%3DE.%26aulast%3DSong%26aufirst%3DL.%26aulast%3DZeeuw%2Bvan%2Bder%2BLaan%26aufirst%3DE.%2BA.%26aulast%3DL%25C3%25B3pez-Alberca%26aufirst%3DM.%2BP.%26aulast%3DNazar%25C3%25A9%26aufirst%3DM.%26aulast%3DReichert%26aufirst%3DM.%26aulast%3DSaur%26aufirst%3DD.%26aulast%3DErkan%26aufirst%3DM.%2BM.%26aulast%3DHopt%26aufirst%3DU.%2BT.%26aulast%3DSainz%26aufirst%3DB.%26aulast%3DBirchmeier%26aufirst%3DW.%26aulast%3DSchmid%26aufirst%3DR.%2BM.%26aulast%3DLesina%26aufirst%3DM.%26aulast%3DAlg%25C3%25BCl%26aufirst%3DH.%26atitle%3DMutant%2520KRAS-Driven%2520Cancers%2520Depend%2520on%2520PTPN11%252FSHP2%2520Phosphatase%26jtitle%3DNat.%2520Med.%26date%3D2018%26volume%3D24%26spage%3D954%26epage%3D960%26doi%3D10.1038%2Fs41591-018-0024-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nichols, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haderk, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahlhut, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulze, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hemmati, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wildes, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tzitzilonis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mordec, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marquez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olivas, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCoach, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blakely, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiss, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koltun, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gill, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldsmith, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J. A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bivona, T. G.</span></span> <span> </span><span class="NLM_article-title">RAS Nucleotide Cycling Underlies the SHP2 Phosphatase Dependence of Mutant BRAF-, NF1- and RAS-Driven Cancers</span>. <i>Nat. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1064</span>– <span class="NLM_lpage">1073</span>, <span class="refDoi"> DOI: 10.1038/s41556-018-0169-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=10.1038%2Fs41556-018-0169-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=30104724" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsV2isLnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2018&pages=1064-1073&author=R.+J.+Nicholsauthor=F.+Haderkauthor=C.+Stahlhutauthor=C.+J.+Schulzeauthor=G.+Hemmatiauthor=D.+Wildesauthor=C.+Tzitzilonisauthor=K.+Mordecauthor=A.+Marquezauthor=J.+Romeroauthor=T.+Hsiehauthor=A.+Zamanauthor=V.+Olivasauthor=C.+McCoachauthor=C.+M.+Blakelyauthor=Z.+Wangauthor=G.+Kissauthor=E.+S.+Koltunauthor=A.+L.+Gillauthor=M.+Singhauthor=M.+A.+Goldsmithauthor=J.+A.+M.+Smithauthor=T.+G.+Bivona&title=RAS+Nucleotide+Cycling+Underlies+the+SHP2+Phosphatase+Dependence+of+Mutant+BRAF-%2C+NF1-+and+RAS-Driven+Cancers&doi=10.1038%2Fs41556-018-0169-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers</span></div><div class="casAuthors">Nichols, Robert J.; Haderk, Franziska; Stahlhut, Carlos; Schulze, Christopher J.; Hemmati, Golzar; Wildes, David; Tzitzilonis, Christos; Mordec, Kasia; Marquez, Abby; Romero, Jason; Hsieh, Tientien; Zaman, Aubhishek; Olivas, Victor; McCoach, Caroline; Blakely, Collin M.; Wang, Zhengping; Kiss, Gert; Koltun, Elena S.; Gill, Adrian L.; Singh, Mallika; Goldsmith, Mark A.; Smith, Jacqueline A. M.; Bivona, Trever G.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Cell Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1064-1073</span>CODEN:
                <span class="NLM_cas:coden">NCBIFN</span>;
        ISSN:<span class="NLM_cas:issn">1465-7392</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Oncogenic alterations in the RAS/RAF/MEK/ERK pathway drive the growth of a wide spectrum of cancers.  While BRAF and MEK inhibitors are efficacious against BRAFV600E-driven cancers, effective targeted therapies are lacking for most cancers driven by other pathway alterations, including non-V600E oncogenic BRAF, RAS GTPase-activating protein (GAP) NF1 (neurofibromin 1) loss and oncogenic KRAS.  Here, we show that targeting the SHP2 phosphatase (encoded by PTPN11) with RMC-4550, a small-mol. allosteric inhibitor, is effective in human cancer models bearing RAS-GTP-dependent oncogenic BRAF (for example, class 3 BRAF mutants), NF1 loss or nucleotide-cycling oncogenic RAS (for example, KRASG12C).  SHP2 inhibitor treatment decreases oncogenic RAS/RAF/MEK/ERK signalling and cancer growth by disrupting SOS1-mediated RAS-GTP loading.  Our findings illuminate a crit. function for SHP2 in promoting oncogenic RAS/MAPK pathway activation in cancers with RAS-GTP-dependent oncogenic BRAF, NF1 loss and nucleotide-cycling oncogenic KRAS.  SHP2 inhibition is a promising mol. therapeutic strategy for patients with cancers bearing these oncogenic drivers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2gVKE5Juu_LVg90H21EOLACvtfcHk0limH6dKdv51fA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsV2isLnP&md5=05e84e5c0d51d501c229e118f44aa6cd</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fs41556-018-0169-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41556-018-0169-1%26sid%3Dliteratum%253Aachs%26aulast%3DNichols%26aufirst%3DR.%2BJ.%26aulast%3DHaderk%26aufirst%3DF.%26aulast%3DStahlhut%26aufirst%3DC.%26aulast%3DSchulze%26aufirst%3DC.%2BJ.%26aulast%3DHemmati%26aufirst%3DG.%26aulast%3DWildes%26aufirst%3DD.%26aulast%3DTzitzilonis%26aufirst%3DC.%26aulast%3DMordec%26aufirst%3DK.%26aulast%3DMarquez%26aufirst%3DA.%26aulast%3DRomero%26aufirst%3DJ.%26aulast%3DHsieh%26aufirst%3DT.%26aulast%3DZaman%26aufirst%3DA.%26aulast%3DOlivas%26aufirst%3DV.%26aulast%3DMcCoach%26aufirst%3DC.%26aulast%3DBlakely%26aufirst%3DC.%2BM.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DKiss%26aufirst%3DG.%26aulast%3DKoltun%26aufirst%3DE.%2BS.%26aulast%3DGill%26aufirst%3DA.%2BL.%26aulast%3DSingh%26aufirst%3DM.%26aulast%3DGoldsmith%26aufirst%3DM.%2BA.%26aulast%3DSmith%26aufirst%3DJ.%2BA.%2BM.%26aulast%3DBivona%26aufirst%3DT.%2BG.%26atitle%3DRAS%2520Nucleotide%2520Cycling%2520Underlies%2520the%2520SHP2%2520Phosphatase%2520Dependence%2520of%2520Mutant%2520BRAF-%252C%2520NF1-%2520and%2520RAS-Driven%2520Cancers%26jtitle%3DNat.%2520Cell%2520Biol.%26date%3D2018%26volume%3D20%26spage%3D1064%26epage%3D1073%26doi%3D10.1038%2Fs41556-018-0169-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jie, H.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lei, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gildener-Leapman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trivedi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kane, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferris, R. L.</span></span> <span> </span><span class="NLM_article-title">PD-1/SHP-2 Inhibits Tc1/Th1 Phenotypic Responses and the Activation of T Cells in the Tumor Microenvironment</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">508</span>– <span class="NLM_lpage">518</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-14-1215</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=10.1158%2F0008-5472.CAN-14-1215" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=25480946" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVenurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=508-518&author=J.+Liauthor=H.-B.+Jieauthor=Y.+Leiauthor=N.+Gildener-Leapmanauthor=S.+Trivediauthor=T.+Greenauthor=L.+P.+Kaneauthor=R.+L.+Ferris&title=PD-1%2FSHP-2+Inhibits+Tc1%2FTh1+Phenotypic+Responses+and+the+Activation+of+T+Cells+in+the+Tumor+Microenvironment&doi=10.1158%2F0008-5472.CAN-14-1215"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">PD-1/SHP-2 Inhibits Tc1/Th1 Phenotypic Responses and the Activation of T Cells in the Tumor Microenvironment</span></div><div class="casAuthors">Li, Jing; Jie, Hyun-Bae; Lei, Yu; Gildener-Leapman, Neil; Trivedi, Sumita; Green, Tony; Kane, Lawrence P.; Ferris, Robert L.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">508-518</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">This study addresses the mechanisms through which PD-1 antibody therapy restores the ability of the immune system to recognize and attack tumors by skewing intratumoral T cells toward a more potent activation phenotype that is assocd. with enhanced signaling and a reversal of their immunosuppressed phenotype.  Immune rejection of tumors is mediated by IFNγ prodn. and T-cell cytolytic activity.  These processes are impeded by PD-1, a coinhibitory mol. expressed on T cells that is elevated in tumor-infiltrating lymphocytes (TIL).  PD-1 elevation may reflect T-cell exhaustion marked by decreased proliferation, prodn. of type I cytokines, and poor cytolytic activity.  Although anti-PD-1 antibodies enhance IFNγ secretion after stimulation of the T-cell receptor (TCR), the mechanistic link between PD-1 and its effects on T-cell help (Tc1/Th1 skewing) remains unclear.  In prospectively collected cancer tissues, we found that TIL exhibited dampened Tc1/Th1 skewing and activation compared with peripheral blood lymphocytes (PBL).  When PD-1 bound its ligand PD-L1, we obsd. a marked suppression of crit. TCR target genes and Th1 cytokines.  Conversely, PD-1 blockade reversed these suppressive effects of PD-1:PD-L1 ligation.  We also found that the TCR-regulated phosphatase SHP-2 was expressed higher in TIL than in PBL, tightly correlating with PD-1 expression and neg. regulation of TCR target genes.  Overall, these results defined a PD-1/SHP-2/STAT1/T-bet signaling axis mediating the suppressive effects of PD-1 on Th1 immunity at tumor sites.  Our findings argue that PD-1 or SHP-2 blockade will be sufficient to restore robust Th1 immunity and T-cell activation and thereby reverse immunosuppression in the tumor microenvironment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqe6jAWHNatvLVg90H21EOLACvtfcHk0limH6dKdv51fA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVenurY%253D&md5=695007f0715b5eee2b7e47deaf87ae23</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-14-1215&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-14-1215%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DJie%26aufirst%3DH.-B.%26aulast%3DLei%26aufirst%3DY.%26aulast%3DGildener-Leapman%26aufirst%3DN.%26aulast%3DTrivedi%26aufirst%3DS.%26aulast%3DGreen%26aufirst%3DT.%26aulast%3DKane%26aufirst%3DL.%2BP.%26aulast%3DFerris%26aufirst%3DR.%2BL.%26atitle%3DPD-1%252FSHP-2%2520Inhibits%2520Tc1%252FTh1%2520Phenotypic%2520Responses%2520and%2520the%2520Activation%2520of%2520T%2520Cells%2520in%2520the%2520Tumor%2520Microenvironment%26jtitle%3DCancer%2520Res.%26date%3D2015%26volume%3D75%26spage%3D508%26epage%3D518%26doi%3D10.1158%2F0008-5472.CAN-14-1215" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hui, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallweber, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasmal, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mellman, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vale, R. D.</span></span> <span> </span><span class="NLM_article-title">T Cell Costimulatory Receptor CD28 is a Primary Target for PD-1-Mediated Inhibition</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>355</i></span>,  <span class="NLM_fpage">1428</span>– <span class="NLM_lpage">1433</span>, <span class="refDoi"> DOI: 10.1126/science.aaf1292</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=10.1126%2Fscience.aaf1292" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=28280247" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlsVWhu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=355&publication_year=2017&pages=1428-1433&author=E.+Huiauthor=J.+Cheungauthor=J.+Zhuauthor=X.+Suauthor=M.+J.+Taylorauthor=H.+A.+Wallweberauthor=D.+K.+Sasmalauthor=J.+Huangauthor=J.+M.+Kimauthor=I.+Mellmanauthor=R.+D.+Vale&title=T+Cell+Costimulatory+Receptor+CD28+is+a+Primary+Target+for+PD-1-Mediated+Inhibition&doi=10.1126%2Fscience.aaf1292"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition</span></div><div class="casAuthors">Hui, Enfu; Cheung, Jeanne; Zhu, Jing; Su, Xiaolei; Taylor, Marcus J.; Wallweber, Heidi A.; Sasmal, Dibyendu K.; Huang, Jun; Kim, Jeong M.; Mellman, Ira; Vale, Ronald D.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">355</span>
        (<span class="NLM_cas:issue">6332</span>),
    <span class="NLM_cas:pages">1428-1433</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">PD-1-targeted therapies have been a breakthrough for treating certain tumors and can rejuvenate T cells to unleash the anticancer immune response (see the Perspective by Clouthier and Ohashi).  It is widely believed that PD-1 suppresses signaling through the T cell receptor (TCR).  However, Hui et al. find instead that the TCR costimulatory receptor, CD28, is the primary target of PD-1 signaling.  Independently, Kamphorst et al. show that CD28 is required for PD-1 therapies to kill cancer cells efficiently and eliminate chronic viral infections in mice.  Lung cancer patients that responded to PD-1 therapy had more CD28+ T cells, which suggests that CD28 may predict treatment response.  Science, ibid p. 1428, p. 1423; see also p. 1373.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpM_s4cf1lkxrVg90H21EOLACvtfcHk0lj7ZY3vPbeBFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlsVWhu7g%253D&md5=69750b99b68316ee035a0b7eeddfb9fa</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1126%2Fscience.aaf1292&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aaf1292%26sid%3Dliteratum%253Aachs%26aulast%3DHui%26aufirst%3DE.%26aulast%3DCheung%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DSu%26aufirst%3DX.%26aulast%3DTaylor%26aufirst%3DM.%2BJ.%26aulast%3DWallweber%26aufirst%3DH.%2BA.%26aulast%3DSasmal%26aufirst%3DD.%2BK.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DJ.%2BM.%26aulast%3DMellman%26aufirst%3DI.%26aulast%3DVale%26aufirst%3DR.%2BD.%26atitle%3DT%2520Cell%2520Costimulatory%2520Receptor%2520CD28%2520is%2520a%2520Primary%2520Target%2520for%2520PD-1-Mediated%2520Inhibition%26jtitle%3DScience%26date%3D2017%26volume%3D355%26spage%3D1428%26epage%3D1433%26doi%3D10.1126%2Fscience.aaf1292" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Topalian, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodi, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brahmer, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gettinger, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDermott, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powderly, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carvajal, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sosman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atkins, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leming, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spigel, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonia, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horn, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drake, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pardoll, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharfman, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anders, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taube, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMiller, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korman, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jure-Kunkel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agrawal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kollia, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wigginton, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sznol, M.</span></span> <span> </span><span class="NLM_article-title">Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>366</i></span>,  <span class="NLM_fpage">2443</span>– <span class="NLM_lpage">2454</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1200690</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=10.1056%2FNEJMoa1200690" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=22658127" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtV2rs7fN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=366&publication_year=2012&pages=2443-2454&author=S.+L.+Topalianauthor=F.+S.+Hodiauthor=J.+R.+Brahmerauthor=S.+N.+Gettingerauthor=D.+C.+Smithauthor=D.+F.+McDermottauthor=J.+D.+Powderlyauthor=R.+D.+Carvajalauthor=J.+A.+Sosmanauthor=M.+B.+Atkinsauthor=P.+D.+Lemingauthor=D.+R.+Spigelauthor=S.+J.+Antoniaauthor=L.+Hornauthor=C.+G.+Drakeauthor=D.+M.+Pardollauthor=L.+Chenauthor=W.+H.+Sharfmanauthor=R.+A.+Andersauthor=J.+M.+Taubeauthor=T.+L.+McMillerauthor=H.+Xuauthor=A.+J.+Kormanauthor=M.+Jure-Kunkelauthor=S.+Agrawalauthor=D.+McDonaldauthor=G.+D.+Kolliaauthor=A.+Guptaauthor=J.+M.+Wiggintonauthor=M.+Sznol&title=Safety%2C+Activity%2C+and+Immune+Correlates+of+Anti-PD-1+Antibody+in+Cancer&doi=10.1056%2FNEJMoa1200690"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14aR"><div class="casContent"><span class="casTitleNuber">14a</span><div class="casTitle"><span class="NLM_cas:atitle">Safety, activity, and immune correlates of anti-PD-1 antibody in cancer</span></div><div class="casAuthors">Topalian, Suzanne L.; Hodi, F. Stephen; Brahmer, Julie R.; Gettinger, Scott N.; Smith, David C.; McDermott, David F.; Powderly, John D.; Carvajal, Richard D.; Sosman, Jeffrey A.; Atkins, Michael B.; Leming, Philip D.; Spigel, David R.; Antonia, Scott J.; Horn, Leora; Drake, Charles G.; Pardoll, Drew M.; Chen, Lieping; Sharfman, William H.; Anders, Robert A.; Taube, Janis M.; McMiller, Tracee L.; Xu, Haiying; Korman, Alan J.; Jure-Kunkel, Maria; Agrawal, Shruti; McDonald, Daniel; Kollia, Georgia D.; Gupta, Ashok; Wigginton, Jon M.; Sznol, Mario</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">366</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">2443-2454</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Blockade of programmed death 1 (PD-1), an inhibitory receptor expressed by T cells, can overcome immune resistance.  We assessed the antitumor activity and safety of BMS-936558, an antibody that specifically blocks PD-1.  Methods: We enrolled patients with advanced melanoma, non-small-cell lung cancer, castration-resistant prostate cancer, or renal-cell or colorectal cancer to receive anti-PD-1 antibody at a dose of 0.1 to 10.0 mg per kg of body wt. every 2 wk.  Response was assessed after each 8-wk treatment cycle.  Patients received up to 12 cycles until disease progression or a complete response occurred.  Results: A total of 296 patients received treatment through Feb. 24, 2012.  Grade 3 or 4 drug-related adverse events occurred in 14% of patients; there were three deaths from pulmonary toxicity.  No max. tolerated dose was defined.  Adverse events consistent with immune-related causes were obsd.  Among 236 patients in whom response could be evaluated, objective responses (complete or partial responses) were obsd. in those with non-small-cell lung cancer, melanoma, or renal-cell cancer.  Cumulative response rates (all doses) were 18% among patients with non-small-cell lung cancer (14 of 76 patients), 28% among patients with melanoma (26 of 94 patients), and 27% among patients with renal-cell cancer (9 of 33 patients).  Responses were durable; 20 of 31 responses lasted 1 yr or more in patients with 1 yr or more of follow-up.  To assess the role of intratumoral PD-1 ligand (PD-L1) expression in the modulation of the PD-1-PD-L1 pathway, immunohistochem. anal. was performed on pretreatment tumor specimens obtained from 42 patients.  Of 17 patients with PD-L1-neg. tumors, none had an objective response; 9 of 25 patients (36%) with PD-L1-pos. tumors had an objective response (P = 0.006).  Conclusions: Anti-PD-1 antibody produced objective responses in approx. one in four to one in five patients with non-small-cell lung cancer, melanoma, or renal-cell cancer; the adverse-event profile does not appear to preclude its use.  Preliminary data suggest a relationship between PD-L1 expression on tumor cells and objective response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLOPvHybmlvbVg90H21EOLACvtfcHk0lj7ZY3vPbeBFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtV2rs7fN&md5=7c13f228ef92b6089982fc878d3a394b</span></div><a href="/servlet/linkout?suffix=cit14a&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1200690&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1200690%26sid%3Dliteratum%253Aachs%26aulast%3DTopalian%26aufirst%3DS.%2BL.%26aulast%3DHodi%26aufirst%3DF.%2BS.%26aulast%3DBrahmer%26aufirst%3DJ.%2BR.%26aulast%3DGettinger%26aufirst%3DS.%2BN.%26aulast%3DSmith%26aufirst%3DD.%2BC.%26aulast%3DMcDermott%26aufirst%3DD.%2BF.%26aulast%3DPowderly%26aufirst%3DJ.%2BD.%26aulast%3DCarvajal%26aufirst%3DR.%2BD.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DAtkins%26aufirst%3DM.%2BB.%26aulast%3DLeming%26aufirst%3DP.%2BD.%26aulast%3DSpigel%26aufirst%3DD.%2BR.%26aulast%3DAntonia%26aufirst%3DS.%2BJ.%26aulast%3DHorn%26aufirst%3DL.%26aulast%3DDrake%26aufirst%3DC.%2BG.%26aulast%3DPardoll%26aufirst%3DD.%2BM.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DSharfman%26aufirst%3DW.%2BH.%26aulast%3DAnders%26aufirst%3DR.%2BA.%26aulast%3DTaube%26aufirst%3DJ.%2BM.%26aulast%3DMcMiller%26aufirst%3DT.%2BL.%26aulast%3DXu%26aufirst%3DH.%26aulast%3DKorman%26aufirst%3DA.%2BJ.%26aulast%3DJure-Kunkel%26aufirst%3DM.%26aulast%3DAgrawal%26aufirst%3DS.%26aulast%3DMcDonald%26aufirst%3DD.%26aulast%3DKollia%26aufirst%3DG.%2BD.%26aulast%3DGupta%26aufirst%3DA.%26aulast%3DWigginton%26aufirst%3DJ.%2BM.%26aulast%3DSznol%26aufirst%3DM.%26atitle%3DSafety%252C%2520Activity%252C%2520and%2520Immune%2520Correlates%2520of%2520Anti-PD-1%2520Antibody%2520in%2520Cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D366%26spage%3D2443%26epage%3D2454%26doi%3D10.1056%2FNEJMoa1200690" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit14b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ohigashi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sho, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsurui, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamada, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikeda, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizuno, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoriki, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kashizuka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yane, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsushima, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otsuki, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yagita, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azuma, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakajima, Y.</span></span> <span> </span><span class="NLM_article-title">Clinical Significance of Programmed Death-1 Ligand-1 and Programmed Death-1 Ligand-2 Expression in Human Esophageal Cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">2947</span>– <span class="NLM_lpage">2953</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-04-1469</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=10.1158%2F1078-0432.CCR-04-1469" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=15837746" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjtlejt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=2947-2953&author=Y.+Ohigashiauthor=M.+Shoauthor=Y.+Yamadaauthor=Y.+Tsuruiauthor=K.+Hamadaauthor=N.+Ikedaauthor=T.+Mizunoauthor=R.+Yorikiauthor=H.+Kashizukaauthor=K.+Yaneauthor=F.+Tsushimaauthor=N.+Otsukiauthor=H.+Yagitaauthor=M.+Azumaauthor=Y.+Nakajima&title=Clinical+Significance+of+Programmed+Death-1+Ligand-1+and+Programmed+Death-1+Ligand-2+Expression+in+Human+Esophageal+Cancer&doi=10.1158%2F1078-0432.CCR-04-1469"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14bR"><div class="casContent"><span class="casTitleNuber">14b</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical Significance of Programmed Death-1 Ligand-1 and Programmed Death-1 Ligand-2 Expression in Human Esophageal Cancer</span></div><div class="casAuthors">Ohigashi, Yuichiro; Sho, Masayuki; Yamada, Yukishige; Tsurui, Yoshikazu; Hamada, Kaoru; Ikeda, Naoya; Mizuno, Takashi; Yoriki, Ryo; Kashizuka, Hisanori; Yane, Katsunari; Tsushima, Fumihiko; Otsuki, Noriko; Yagita, Hideo; Azuma, Miyuki; Nakajima, Yoshiyuki</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2947-2953</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: The neg. regulatory programmed death-1/programmed death-1 ligand (PD-1/PD-L) pathway in T-cell activation has been suggested to play an important role in tumor evasion from host immunity.  In this study, we investigated the expression of PD-L1 and PD-L2 in human esophageal cancer to define their clin. significance in patients' prognosis after surgery.  Exptl. Design: PD-L1 and PD-L2 gene expression was evaluated in 41 esophagectomy patients by real-time quant. PCR.  The protein expression was also evaluated with newly generated monoclonal antibodies that recognize human PD-L1 (MIH1) and PD-L2 (MIH18).  Results: The protein and the mRNA levels of detn. by immunohistochem. and real-time quant. PCR were closely correlated.  PD-L-pos. patients had a significantly poorer prognosis than the neg. patients.  This was more pronounced in the advanced stage of tumor than in the early stage.  Furthermore, multivariate anal. indicated that PD-L status was an independent prognostic factor.  Although there was no significant correlation between PD-L1 expression and tumor-infiltrating T lymphocytes, PD-L2 expression was inversely correlated with tumor-infiltrating CD8+ T cells.  Conclusions: These data suggest that PD-L1 and PD-L2 status may be a new predictor of prognosis for patients with esophageal cancer and provide the rationale for developing novel immunotherapy of targeting PD-1/PD-L pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIMQiC4R0LD7Vg90H21EOLACvtfcHk0lj7ZY3vPbeBFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjtlejt7k%253D&md5=1dd37b483171a10070310ccd559c9e35</span></div><a href="/servlet/linkout?suffix=cit14b&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-04-1469&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-04-1469%26sid%3Dliteratum%253Aachs%26aulast%3DOhigashi%26aufirst%3DY.%26aulast%3DSho%26aufirst%3DM.%26aulast%3DYamada%26aufirst%3DY.%26aulast%3DTsurui%26aufirst%3DY.%26aulast%3DHamada%26aufirst%3DK.%26aulast%3DIkeda%26aufirst%3DN.%26aulast%3DMizuno%26aufirst%3DT.%26aulast%3DYoriki%26aufirst%3DR.%26aulast%3DKashizuka%26aufirst%3DH.%26aulast%3DYane%26aufirst%3DK.%26aulast%3DTsushima%26aufirst%3DF.%26aulast%3DOtsuki%26aufirst%3DN.%26aulast%3DYagita%26aufirst%3DH.%26aulast%3DAzuma%26aufirst%3DM.%26aulast%3DNakajima%26aufirst%3DY.%26atitle%3DClinical%2520Significance%2520of%2520Programmed%2520Death-1%2520Ligand-1%2520and%2520Programmed%2520Death-1%2520Ligand-2%2520Expression%2520in%2520Human%2520Esophageal%2520Cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2005%26volume%3D11%26spage%3D2947%26epage%3D2953%26doi%3D10.1158%2F1078-0432.CCR-04-1469" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hof, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pluskey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhe-Paganon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoelson, S. E.</span></span> <span> </span><span class="NLM_article-title">Crystal Structure of the Tyrosine Phosphatase SHP-2</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>92</i></span>,  <span class="NLM_fpage">441</span>– <span class="NLM_lpage">450</span>, <span class="refDoi"> DOI: 10.1016/S0092-8674(00)80938-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=10.1016%2FS0092-8674%2800%2980938-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=9491886" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADyaK1cXhsVKnsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=1998&pages=441-450&author=P.+Hofauthor=S.+Pluskeyauthor=S.+Dhe-Paganonauthor=M.+J.+Eckauthor=S.+E.+Shoelson&title=Crystal+Structure+of+the+Tyrosine+Phosphatase+SHP-2&doi=10.1016%2FS0092-8674%2800%2980938-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15aR"><div class="casContent"><span class="casTitleNuber">15a</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of the tyrosine phosphatase SHP-2</span></div><div class="casAuthors">Hof, Peter; Pluskey, Scott; Dhe-Paganon, Sirano; Eck, Michael J.; Shoelson, Steven E.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, Massachusetts)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">441-450</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The structure of the SHP-2 tyrosine phosphatase, detd. at 2.0 Å resoln., shows how its catalytic activity is regulated by its two SH2 domains.  In the absence of a tyrosine-phosphorylated binding partner, the N-terminal SH2 domain binds the phosphatase domain and directly blocks its active site.  This interaction alters the structure of the N-SH2 domain, disrupting its phosphopeptide-binding cleft.  Conversely, interaction of the N-SH2 domain with phosphopeptide disrupts its phosphatase recognition surface.  Thus, the N-SH2 domain is a conformational switch; it either binds and inhibits the phosphatase, or it binds phosphoproteins and activates the enzyme.  Recognition of bisphosphorylated ligands by the tandem SH2 domains is an integral element of this switch; the C-terminal SH2 domain contributes binding energy and specificity, but it does not have a direct role in activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcAryHYl6D5bVg90H21EOLACvtfcHk0ljTsV-4lXjAUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXhsVKnsLc%253D&md5=ea99b7adb90b5db07754c0be75a63c66</span></div><a href="/servlet/linkout?suffix=cit15a&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2800%2980938-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252800%252980938-1%26sid%3Dliteratum%253Aachs%26aulast%3DHof%26aufirst%3DP.%26aulast%3DPluskey%26aufirst%3DS.%26aulast%3DDhe-Paganon%26aufirst%3DS.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DShoelson%26aufirst%3DS.%2BE.%26atitle%3DCrystal%2520Structure%2520of%2520the%2520Tyrosine%2520Phosphatase%2520SHP-2%26jtitle%3DCell%26date%3D1998%26volume%3D92%26spage%3D441%26epage%3D450%26doi%3D10.1016%2FS0092-8674%2800%2980938-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit15b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Barford, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neel, B. G.</span></span> <span> </span><span class="NLM_article-title">Revealing Mechanisms for SH2 Domain Mediated Regulation of the Protein Tyrosine Phosphatase SHP-2</span>. <i>Structure</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">249</span>– <span class="NLM_lpage">254</span>, <span class="refDoi"> DOI: 10.1016/S0969-2126(98)00027-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=10.1016%2FS0969-2126%2898%2900027-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=9551546" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADyaK1cXisFSlsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1998&pages=249-254&author=D.+Barfordauthor=B.+G.+Neel&title=Revealing+Mechanisms+for+SH2+Domain+Mediated+Regulation+of+the+Protein+Tyrosine+Phosphatase+SHP-2&doi=10.1016%2FS0969-2126%2898%2900027-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15bR"><div class="casContent"><span class="casTitleNuber">15b</span><div class="casTitle"><span class="NLM_cas:atitle">Revealing mechanisms for SH2 domain mediated regulation of the protein tyrosine phosphatase SHP-2</span></div><div class="casAuthors">Barford, David; Neel, Benjamin G.</div><div class="citationInfo"><span class="NLM_cas:title">Structure (London)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">249-254</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Current Biology Ltd.</span>)
        </div><div class="casAbstract">A review with 33 refs.  The crystal structure of the protein tyrosine phosphatase SHP-2 reveals the mechanism of auto-inhibition of phosphatase activity by its SH2 domains.  Phosphotyrosine peptide stimulation of the phosphatase activity, resulting from peptide binding to the N-terminal SH2 domain, is linked to conformational changes within the protein, including an unprecedented allosteric transition of the N-terminal SH2 domain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9DfZ8YhMKJLVg90H21EOLACvtfcHk0ljTsV-4lXjAUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXisFSlsrw%253D&md5=d2e136ed9c10302c18d06cb45ed42bf6</span></div><a href="/servlet/linkout?suffix=cit15b&amp;dbid=16384&amp;doi=10.1016%2FS0969-2126%2898%2900027-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0969-2126%252898%252900027-6%26sid%3Dliteratum%253Aachs%26aulast%3DBarford%26aufirst%3DD.%26aulast%3DNeel%26aufirst%3DB.%2BG.%26atitle%3DRevealing%2520Mechanisms%2520for%2520SH2%2520Domain%2520Mediated%2520Regulation%2520of%2520the%2520Protein%2520Tyrosine%2520Phosphatase%2520SHP-2%26jtitle%3DStructure%26date%3D1998%26volume%3D6%26spage%3D249%26epage%3D254%26doi%3D10.1016%2FS0969-2126%2898%2900027-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pluskey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wandless, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walsh, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoelson, S. E.</span></span> <span> </span><span class="NLM_article-title">Potent Stimulation of SH-PTP2 Phosphatase Activity by Simultaneous Occupancy of Both SH2 Domains</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>270</i></span>,  <span class="NLM_fpage">2897</span>– <span class="NLM_lpage">2900</span>, <span class="refDoi"> DOI: 10.1074/jbc.270.7.2897</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=10.1074%2Fjbc.270.7.2897" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=7531695" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADyaK28XltVyltrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=270&publication_year=1995&pages=2897-2900&author=S.+Pluskeyauthor=T.+J.+Wandlessauthor=C.+T.+Walshauthor=S.+E.+Shoelson&title=Potent+Stimulation+of+SH-PTP2+Phosphatase+Activity+by+Simultaneous+Occupancy+of+Both+SH2+Domains&doi=10.1074%2Fjbc.270.7.2897"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Potent stimulation of SH-PTP2 phosphatase activity by simultaneous occupancy of both SH2 domains</span></div><div class="casAuthors">Pluskey, Scott; Wandless, Thomas J.; Walsh, Christopher, T.; Shoelson, Steven E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">270</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2897-2900</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Src homol. 2 (SH2) domains are phosphotyrosine binding modules found within many cytoplasmic proteins.  A major function of SH2 domains is to bring about the phys. assembly of signaling complexes.  Here, it is shown that, that in addn., simultaneous occupancy of both SH2 domains of phosphoprotein tyrosine phosphatase SH-PTP2 (Syp, PTP 1D, PTP-2C) by a tethered peptide with 2 IRS-1-derived phosphorylation sites potently stimulates phosphatase activity.  The concn. required for activation by the tethered peptide was 80-160-fold lower than either corresponding monophosphorylated peptide.  Moreover, the diphosphorylated peptide stimulated catalytic activity 37-fold, compared with 9-16-fold for the monophosphorylated peptides.  Mutational analyses of the SH2 domains of SH-PTP2 confirmed that both SH2 domains participate in this effect.  Binding studies with a tandem construct comprising the N-plus C-terminal SH2 domains showed that the diphosphorylated peptide binds with 60-90-fold higher affinity than either monophosphorylated sequence.  These results demonstrated that SH-PTP2 activity can be potently regulated by interacting via both of its SH2 domains with phosphoproteins having 2 cognate phosphorylation sites.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTlCRxkwiHh7Vg90H21EOLACvtfcHk0ljTsV-4lXjAUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XltVyltrs%253D&md5=c17c9344fc6b9978f7021263855b776d</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1074%2Fjbc.270.7.2897&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.270.7.2897%26sid%3Dliteratum%253Aachs%26aulast%3DPluskey%26aufirst%3DS.%26aulast%3DWandless%26aufirst%3DT.%2BJ.%26aulast%3DWalsh%26aufirst%3DC.%2BT.%26aulast%3DShoelson%26aufirst%3DS.%2BE.%26atitle%3DPotent%2520Stimulation%2520of%2520SH-PTP2%2520Phosphatase%2520Activity%2520by%2520Simultaneous%2520Occupancy%2520of%2520Both%2520SH2%2520Domains%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1995%26volume%3D270%26spage%3D2897%26epage%3D2900%26doi%3D10.1074%2Fjbc.270.7.2897" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="note"><p class="first last">SHP2 activation has been extensively reviewed:</p></div><div class="NLM_citation" id="rightTab-cit17a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Barford, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neel, B. G.</span></span> <span> </span><span class="NLM_article-title">Revealing Mechanisms for SH2 Domain Mediated Regulation of the Protein Tyrosine Phosphatase SHP-2</span>. <i>Structure</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">249</span>– <span class="NLM_lpage">254</span>, <span class="refDoi"> DOI: 10.1016/S0969-2126(98)00027-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=10.1016%2FS0969-2126%2898%2900027-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=9551546" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADyaK1cXisFSlsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1998&pages=249-254&author=D.+Barfordauthor=B.+G.+Neel&title=Revealing+Mechanisms+for+SH2+Domain+Mediated+Regulation+of+the+Protein+Tyrosine+Phosphatase+SHP-2&doi=10.1016%2FS0969-2126%2898%2900027-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17aR"><div class="casContent"><span class="casTitleNuber">17a</span><div class="casTitle"><span class="NLM_cas:atitle">Revealing mechanisms for SH2 domain mediated regulation of the protein tyrosine phosphatase SHP-2</span></div><div class="casAuthors">Barford, David; Neel, Benjamin G.</div><div class="citationInfo"><span class="NLM_cas:title">Structure (London)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">249-254</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Current Biology Ltd.</span>)
        </div><div class="casAbstract">A review with 33 refs.  The crystal structure of the protein tyrosine phosphatase SHP-2 reveals the mechanism of auto-inhibition of phosphatase activity by its SH2 domains.  Phosphotyrosine peptide stimulation of the phosphatase activity, resulting from peptide binding to the N-terminal SH2 domain, is linked to conformational changes within the protein, including an unprecedented allosteric transition of the N-terminal SH2 domain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9DfZ8YhMKJLVg90H21EOLACvtfcHk0lgbNDersq66lQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXisFSlsrw%253D&md5=d2e136ed9c10302c18d06cb45ed42bf6</span></div><a href="/servlet/linkout?suffix=cit17a&amp;dbid=16384&amp;doi=10.1016%2FS0969-2126%2898%2900027-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0969-2126%252898%252900027-6%26sid%3Dliteratum%253Aachs%26aulast%3DBarford%26aufirst%3DD.%26aulast%3DNeel%26aufirst%3DB.%2BG.%26atitle%3DRevealing%2520Mechanisms%2520for%2520SH2%2520Domain%2520Mediated%2520Regulation%2520of%2520the%2520Protein%2520Tyrosine%2520Phosphatase%2520SHP-2%26jtitle%3DStructure%26date%3D1998%26volume%3D6%26spage%3D249%26epage%3D254%26doi%3D10.1016%2FS0969-2126%2898%2900027-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit17b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalaitzidis</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neel, B. G.</span></span> <span> </span><span class="NLM_article-title">The Tyrosine Phosphatase SHP2 (PTPN11) in Cancer</span>. <i>Cancer Metastasis Rev.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">179</span>– <span class="NLM_lpage">182</span>, <span class="refDoi"> DOI: 10.1007/s10555-008-9126-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=10.1007%2Fs10555-008-9126-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=18286234" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlt1Ckur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2008&pages=179-182&author=G.+Chanauthor=+Kalaitzidisauthor=B.+G.+Neel&title=The+Tyrosine+Phosphatase+SHP2+%28PTPN11%29+in+Cancer&doi=10.1007%2Fs10555-008-9126-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17bR"><div class="casContent"><span class="casTitleNuber">17b</span><div class="casTitle"><span class="NLM_cas:atitle">The tyrosine phosphatase Shp2 (PTPN11) in cancer</span></div><div class="casAuthors">Chan, Gordon; Kalaitzidis, Demetrios; Neel, Benjamin G.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer and Metastasis Reviews</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">179-192</span>CODEN:
                <span class="NLM_cas:coden">CMRED4</span>;
        ISSN:<span class="NLM_cas:issn">0167-7659</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Diverse cellular processes are regulated by tyrosyl phosphorylation, which is controlled by protein-tyrosine kinases (PTKs) and protein-tyrosine phosphatases (PTPs).  De-regulated tyrosyl phosphorylation, evoked by gain-of-function mutations and/or over-expression of PTKs, contributes to the pathogenesis of many cancers and other human diseases.  PTPs, because they oppose the action of PTKs, had been considered to be prime suspects for potential tumor suppressor genes.  Surprisingly, few, if any, tumor suppressor PTPs have been identified.  However, the Src homol.-2 domain-contg. phosphatase Shp2 (encoded by PTPN11) is a bona fide proto-oncogene.  Germline mutations in PTPN11 cause Noonan and LEOPARD syndromes, whereas somatic PTPN11 mutations occur in several types of hematol. malignancies, most notably juvenile myelomonocytic leukemia and, more rarely, in solid tumors.  Shp2 also is an essential component in several other oncogene signaling pathways.  Elucidation of the events underlying Shp2-evoked transformation may provide new insights into oncogenic mechanisms and novel targets for anti-cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbJ8OYsBzvg7Vg90H21EOLACvtfcHk0lgbNDersq66lQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlt1Ckur4%253D&md5=fb514f60b97f8ff0dcc0dbd57cab2c9a</span></div><a href="/servlet/linkout?suffix=cit17b&amp;dbid=16384&amp;doi=10.1007%2Fs10555-008-9126-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10555-008-9126-y%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DG.%26aulast%3DKalaitzidis%26aulast%3DNeel%26aufirst%3DB.%2BG.%26atitle%3DThe%2520Tyrosine%2520Phosphatase%2520SHP2%2520%2528PTPN11%2529%2520in%2520Cancer%26jtitle%3DCancer%2520Metastasis%2520Rev.%26date%3D2008%26volume%3D27%26spage%3D179%26epage%3D182%26doi%3D10.1007%2Fs10555-008-9126-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit17c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Poole, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, M. L.</span></span> <span> </span><span class="NLM_article-title">A SHPing Tale: Perspectives on the Regulation of SHP-1 and SHP-2 Tyrosine Phosphatases by the C-terminal Tail</span>. <i>Cell. Signalling</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">1323</span>– <span class="NLM_lpage">1332</span>, <span class="refDoi"> DOI: 10.1016/j.cellsig.2005.05.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=10.1016%2Fj.cellsig.2005.05.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=16084691" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADC%252BD2MXptVWnsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2005&pages=1323-1332&author=A.+W.+Pooleauthor=M.+L.+Jones&title=A+SHPing+Tale%3A+Perspectives+on+the+Regulation+of+SHP-1+and+SHP-2+Tyrosine+Phosphatases+by+the+C-terminal+Tail&doi=10.1016%2Fj.cellsig.2005.05.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17cR"><div class="casContent"><span class="casTitleNuber">17c</span><div class="casTitle"><span class="NLM_cas:atitle">A SHPing tale: Perspectives on the regulation of SHP-1 and SHP-2 tyrosine phosphatases by the C-terminal tail</span></div><div class="casAuthors">Poole, Alastair W.; Jones, Matthew L.</div><div class="citationInfo"><span class="NLM_cas:title">Cellular Signalling</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1323-1332</span>CODEN:
                <span class="NLM_cas:coden">CESIEY</span>;
        ISSN:<span class="NLM_cas:issn">0898-6568</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Protein tyrosine phosphorylation is a ubiquitous signaling mechanism and is regulated by a balance between the action of kinases and phosphatases.  The SH2 domain-contg. phosphatases, SHP-1 and SHP-2, are the best studied of the classical non-receptor tyrosine phosphatases, but it is intriguing that despite their close sequence and structural homol. these 2 phosphatases play quite different cellular roles.  In particular, whereas SHP-1 plays a largely neg. signaling role suppressing cellular activation, SHP-2 plays a largely pos. signaling role.  Major sequence differences between the 2 mols. are apparent in the ∼100 amino acid residues at the extreme C-terminus of the proteins, beyond the phosphatase catalytic domain.  Here, the authors review how the differences in the tails of these proteins may regulate their activities and explain some of their functional differences.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQNdG8bGaIjLVg90H21EOLACvtfcHk0lgbNDersq66lQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXptVWnsLY%253D&md5=2980ba96216967f7b89fb347415199c4</span></div><a href="/servlet/linkout?suffix=cit17c&amp;dbid=16384&amp;doi=10.1016%2Fj.cellsig.2005.05.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cellsig.2005.05.016%26sid%3Dliteratum%253Aachs%26aulast%3DPoole%26aufirst%3DA.%2BW.%26aulast%3DJones%26aufirst%3DM.%2BL.%26atitle%3DA%2520SHPing%2520Tale%253A%2520Perspectives%2520on%2520the%2520Regulation%2520of%2520SHP-1%2520and%2520SHP-2%2520Tyrosine%2520Phosphatases%2520by%2520the%2520C-terminal%2520Tail%26jtitle%3DCell.%2520Signalling%26date%3D2005%26volume%3D17%26spage%3D1323%26epage%3D1332%26doi%3D10.1016%2Fj.cellsig.2005.05.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit17d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Butterworth, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overduin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barr, A. J.</span></span> <span> </span><span class="NLM_article-title">Targeting Protein Tyrosine Phosphatase SHP2 for Therapeutic Intervention</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1423</span>– <span class="NLM_lpage">1437</span>, <span class="refDoi"> DOI: 10.4155/fmc.14.88</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=10.4155%2Ffmc.14.88" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=25329198" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslOhu7jO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=1423-1437&author=S.+Butterworthauthor=M.+Overduinauthor=A.+J.+Barr&title=Targeting+Protein+Tyrosine+Phosphatase+SHP2+for+Therapeutic+Intervention&doi=10.4155%2Ffmc.14.88"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17dR"><div class="casContent"><span class="casTitleNuber">17d</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting protein tyrosine phosphatase SHP2 for therapeutic intervention</span></div><div class="casAuthors">Butterworth, Sam; Overduin, Michael; Barr, Alastair J.</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1423-1437</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Protein tyrosine phosphatases have been the focus of considerable research efforts aimed at developing novel therapeutics; however, these targets are often characterized as being 'undruggable' due to the challenge of achieving selectivity, potency and cell permeability.  More recently, there has been renewed interest in developing inhibitors of the tyrosine phosphatase SHP2 (PTPN11) in the light of its broad role in cancer, specifically juvenile myelomonocytic leukemia, and recent studies that implicate SHP2 as a key factor in breast cancer progression.  Recent significant advances in the field of SHP2 inhibitor development raise the question: are we on the verge of a new era of protein tyrosine phosphatase-directed therapeutics This article critically appraises recent developments, assesses ongoing challenges and presents a perspective on possible future directions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEVdQ5GiIy9LVg90H21EOLACvtfcHk0lgbNDersq66lQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslOhu7jO&md5=85c071c906c6c047d524460df5e0a9b5</span></div><a href="/servlet/linkout?suffix=cit17d&amp;dbid=16384&amp;doi=10.4155%2Ffmc.14.88&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.14.88%26sid%3Dliteratum%253Aachs%26aulast%3DButterworth%26aufirst%3DS.%26aulast%3DOverduin%26aufirst%3DM.%26aulast%3DBarr%26aufirst%3DA.%2BJ.%26atitle%3DTargeting%2520Protein%2520Tyrosine%2520Phosphatase%2520SHP2%2520for%2520Therapeutic%2520Intervention%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2014%26volume%3D6%26spage%3D1423%26epage%3D1437%26doi%3D10.4155%2Ffmc.14.88" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Prahallad, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heynen, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Germano, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willems, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evers, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vecchione, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gambino, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lieftink, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beijersbergen, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Nicolantonio, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bardelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernards, R.</span></span> <span> </span><span class="NLM_article-title">PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1978</span>– <span class="NLM_lpage">1985</span>, <span class="refDoi"> DOI: 10.1016/j.celrep.2015.08.037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=10.1016%2Fj.celrep.2015.08.037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=26365186" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsV2ls7fN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2015&pages=1978-1985&author=A.+Prahalladauthor=G.+J.+Heynenauthor=G.+Germanoauthor=S.+M.+Willemsauthor=B.+Eversauthor=L.+Vecchioneauthor=V.+Gambinoauthor=C.+Lieftinkauthor=R.+L.+Beijersbergenauthor=F.+Di+Nicolantonioauthor=A.+Bardelliauthor=R.+Bernards&title=PTPN11+Is+a+Central+Node+in+Intrinsic+and+Acquired+Resistance+to+Targeted+Cancer+Drugs&doi=10.1016%2Fj.celrep.2015.08.037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18aR"><div class="casContent"><span class="casTitleNuber">18a</span><div class="casTitle"><span class="NLM_cas:atitle">PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs</span></div><div class="casAuthors">Prahallad, Anirudh; Heynen, Guus J. J. E.; Germano, Giovanni; Willems, Stefan M.; Evers, Bastiaan; Vecchione, Loredana; Gambino, Valentina; Lieftink, Cor; Beijersbergen, Roderick L.; Di Nicolantonio, Federica; Bardelli, Alberto; Bernards, Rene</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1978-1985</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Most BRAF (V600E) mutant melanomas are sensitive to selective BRAF inhibitors, but BRAF mutant colon cancers are intrinsically resistant to these drugs because of feedback activation of EGFR.  We performed an RNA-interference-based genetic screen in BRAF mutant colon cancer cells to search for phosphatases whose knockdown induces sensitivity to BRAF inhibition.  We found that suppression of protein tyrosine phosphatase non-receptor type 11 (PTPN11) confers sensitivity to BRAF inhibitors in colon cancer.  Mechanistically, we found that inhibition of PTPN11 blocks signaling from receptor tyrosine kinases (RTKs) to the RAS-MEK-ERK pathway.  PTPN11 suppression is lethal to cells that are driven by activated RTKs and prevents acquired resistance to targeted cancer drugs that results from RTK activation.  Our findings identify PTPN11 as a drug target to combat both intrinsic and acquired resistance to several targeted cancer drugs.  Moreover, activated PTPN11 can serve as a biomarker of drug resistance resulting from RTK activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrr2cE8g_Ejr7Vg90H21EOLACvtfcHk0lhRqCIsqYtJ3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsV2ls7fN&md5=521d9847bba4c7c6529ad355da097787</span></div><a href="/servlet/linkout?suffix=cit18a&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2015.08.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2015.08.037%26sid%3Dliteratum%253Aachs%26aulast%3DPrahallad%26aufirst%3DA.%26aulast%3DHeynen%26aufirst%3DG.%2BJ.%26aulast%3DGermano%26aufirst%3DG.%26aulast%3DWillems%26aufirst%3DS.%2BM.%26aulast%3DEvers%26aufirst%3DB.%26aulast%3DVecchione%26aufirst%3DL.%26aulast%3DGambino%26aufirst%3DV.%26aulast%3DLieftink%26aufirst%3DC.%26aulast%3DBeijersbergen%26aufirst%3DR.%2BL.%26aulast%3DDi%2BNicolantonio%26aufirst%3DF.%26aulast%3DBardelli%26aufirst%3DA.%26aulast%3DBernards%26aufirst%3DR.%26atitle%3DPTPN11%2520Is%2520a%2520Central%2520Node%2520in%2520Intrinsic%2520and%2520Acquired%2520Resistance%2520to%2520Targeted%2520Cancer%2520Drugs%26jtitle%3DCell%2520Rep.%26date%3D2015%26volume%3D12%26spage%3D1978%26epage%3D1985%26doi%3D10.1016%2Fj.celrep.2015.08.037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit18b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiang, H.</span></span> <span> </span><span class="NLM_article-title">Src Homology 2 Domain-Containing Tyrosine Phosphatase 2 Promotes Oral Cancer Invasion and Metastasis</span>. <i>BMC Cancer</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">442</span>, <span class="refDoi"> DOI: 10.1186/1471-2407-14-442</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=10.1186%2F1471-2407-14-442" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=24931737" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVymtrfM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2014&pages=442&author=H.+Wangauthor=W.+Chiangauthor=H.+Huangauthor=Y.+Shenauthor=H.+Chiang&title=Src+Homology+2+Domain-Containing+Tyrosine+Phosphatase+2+Promotes+Oral+Cancer+Invasion+and+Metastasis&doi=10.1186%2F1471-2407-14-442"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18bR"><div class="casContent"><span class="casTitleNuber">18b</span><div class="casTitle"><span class="NLM_cas:atitle">Src-homology 2 domain-containing tyrosine phosphatase 2 promotes oral cancer invasion and metastasis</span></div><div class="casAuthors">Wang, Hsueh-Chun; Chiang, Wei-Fan; Huang, Hsin-Hsiu; Shen, Ying-Ying; Chiang, Hung-Che</div><div class="citationInfo"><span class="NLM_cas:title">BMC Cancer</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">442/1-442/13</span>CODEN:
                <span class="NLM_cas:coden">BCMACL</span>;
        ISSN:<span class="NLM_cas:issn">1471-2407</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Tumor invasion and metastasis represent a major unsolved problem in cancer pathogenesis.  Recent studies have indicated the involvement of Src-homol. 2 domain-contg. tyrosine phosphatase 2 (SHP2) in multiple malignancies; however, the role of SHP2 in oral cancer progression has yet to be elucidated.  We propose that SHP2 is involved in the progression of oral cancer toward metastasis.  Methods: SHP2 expression was evaluated in paired oral cancer tissues by using immunohistochem. staining and real-time reverse transcription polymerase chain reaction.  Isogenic highly invasive oral cancer cell lines from their resp. low invasive parental lines were established using a Boyden chamber assay, and changes in the hallmarks of the epithelial-mesenchymal transition (EMT) were assessed to evaluate SHP2 function.  SHP2 activity in oral cancer cells was reduced using si-RNA knockdown or enforced expression of a catalytically deficient mutant to analyze migratory and invasive ability in vitro and metastasis toward the lung in mice in vivo.  Results: We obsd. the significant upregulation of SHP2 in oral cancer tissues and cell lines.  Following SHP2 knockdown, the oral cancer cells markedly attenuated migratory and invasion ability.  We obsd. similar results in phosphatase-dead SHP2 C459S mutant expressing cells.  Enhanced invasiveness was assocd. with significant upregulation of E-cadherin, vimentin, Snail/Twist1, and matrix metalloproteinase-2 in the highly invasive clones.  In addn., we detd. that SHP2 activity is required for the downregulation of phosphorylated ERK1/2, which modulates the downstream effectors, Snail and Twist1 at a transcript level.  In lung tissue sections of mice, we obsd. that HSC3 tumors with SHP2 deletion exhibited significantly reduced metastatic capacity, compared with tumors administered control si-RNA.  Conclusions: Our data suggest that SHP2 promotes the invasion and metastasis of oral cancer cells.  These results provide a rationale for further investigating the effects of small-mol. SHP2 inhibitors on the progression of oral cancer, and indicate a previously unrecognized SHP2-ERK1/2-Snail/Twist1 pathway that is likely to play a crucial role in oral cancer invasion and metastasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4fInuWtOHl7Vg90H21EOLACvtfcHk0lhRqCIsqYtJ3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVymtrfM&md5=b1dd0157d70ac01327bbdbc473dab8ee</span></div><a href="/servlet/linkout?suffix=cit18b&amp;dbid=16384&amp;doi=10.1186%2F1471-2407-14-442&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1471-2407-14-442%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DH.%26aulast%3DChiang%26aufirst%3DW.%26aulast%3DHuang%26aufirst%3DH.%26aulast%3DShen%26aufirst%3DY.%26aulast%3DChiang%26aufirst%3DH.%26atitle%3DSrc%2520Homology%25202%2520Domain-Containing%2520Tyrosine%2520Phosphatase%25202%2520Promotes%2520Oral%2520Cancer%2520Invasion%2520and%2520Metastasis%26jtitle%3DBMC%2520Cancer%26date%3D2014%26volume%3D14%26spage%3D442%26doi%3D10.1186%2F1471-2407-14-442" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">LaRochelle, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fodor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durzynska, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stams, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaMarche, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chopra, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fortin, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acker, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blacklow, S. C.</span></span> <span> </span><span class="NLM_article-title">Structural and Functional Consequences of Three Cancer-Associated Mutations of the Oncogenic Phosphatase SHP2</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">2269</span>– <span class="NLM_lpage">2277</span>, <span class="refDoi"> DOI: 10.1021/acs.biochem.5b01287</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.biochem.5b01287" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADC%252BC28XltVagtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2016&pages=2269-2277&author=J.+R.+LaRochelleauthor=M.+Fodorauthor=X.+Xuauthor=I.+Durzynskaauthor=L.+Fanauthor=T.+Stamsauthor=H.+M.+Chanauthor=M.+J.+LaMarcheauthor=R.+Chopraauthor=P.+Wangauthor=P.+D.+Fortinauthor=M.+G.+Ackerauthor=S.+C.+Blacklow&title=Structural+and+Functional+Consequences+of+Three+Cancer-Associated+Mutations+of+the+Oncogenic+Phosphatase+SHP2&doi=10.1021%2Facs.biochem.5b01287"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Structural and Functional Consequences of Three Cancer-Associated Mutations of the Oncogenic Phosphatase SHP2</span></div><div class="casAuthors">LaRochelle, Jonathan R.; Fodor, Michelle; Xu, Xiang; Durzynska, Izabela; Fan, Lixin; Stams, Travis; Chan, Ho Man; LaMarche, Matthew J.; Chopra, Rajiv; Wang, Ping; Fortin, Pascal D.; Acker, Michael G.; Blacklow, Stephen C.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">2269-2277</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The proto-oncogene PTPN11 encodes a cytoplasmic protein tyrosine phosphatase, SHP2, which is required for normal development and sustained activation of the Ras-MAPK signaling pathway.  Germline mutations in SHP2 cause developmental disorders, and somatic mutations have been identified in childhood and adult cancers and drive leukemia in mice.  Despite our knowledge of the PTPN11 variations assocd. with pathol., the structural and functional consequences of many disease-assocd. mutants remain poorly understood.  Here, we combine X-ray crystallog., small-angle X-ray scattering, and biochem. to elucidate structural and mechanistic features of three cancer-assocd. SHP2 variants harboring single point mutations within the N-SH2:PTP interdomain autoinhibitory interface.  Our findings directly compare the impact of each mutation on autoinhibition of the phosphatase and advance the development of structure-guided and mutation-specific SHP2 therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdIaFVGm5lArVg90H21EOLACvtfcHk0lhRqCIsqYtJ3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XltVagtLw%253D&md5=720b3dd9b18edde2c443d488cfb90dfc</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Facs.biochem.5b01287&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.biochem.5b01287%26sid%3Dliteratum%253Aachs%26aulast%3DLaRochelle%26aufirst%3DJ.%2BR.%26aulast%3DFodor%26aufirst%3DM.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DDurzynska%26aufirst%3DI.%26aulast%3DFan%26aufirst%3DL.%26aulast%3DStams%26aufirst%3DT.%26aulast%3DChan%26aufirst%3DH.%2BM.%26aulast%3DLaMarche%26aufirst%3DM.%2BJ.%26aulast%3DChopra%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DFortin%26aufirst%3DP.%2BD.%26aulast%3DAcker%26aufirst%3DM.%2BG.%26aulast%3DBlacklow%26aufirst%3DS.%2BC.%26atitle%3DStructural%2520and%2520Functional%2520Consequences%2520of%2520Three%2520Cancer-Associated%2520Mutations%2520of%2520the%2520Oncogenic%2520Phosphatase%2520SHP2%26jtitle%3DBiochemistry%26date%3D2016%26volume%3D55%26spage%3D2269%26epage%3D2277%26doi%3D10.1021%2Facs.biochem.5b01287" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gee, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhalgat, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Upson, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klaubert, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Latham, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haugland, R. P.</span></span> <span> </span><span class="NLM_article-title">Fluorogenic Substrates Based on Fluorinated Umbelliferones for Continuous Assays of Phosphatases and Beta-Galactosidases</span>. <i>Anal. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>273</i></span>,  <span class="NLM_fpage">41</span>, <span class="refDoi"> DOI: 10.1006/abio.1999.4202</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=10.1006%2Fabio.1999.4202" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=10452797" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADyaK1MXlt1Wktbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=273&publication_year=1999&pages=41&author=K.+R.+Geeauthor=W.+C.+Sunauthor=M.+K.+Bhalgatauthor=R.+H.+Upsonauthor=D.+H.+Klaubertauthor=K.+A.+Lathamauthor=R.+P.+Haugland&title=Fluorogenic+Substrates+Based+on+Fluorinated+Umbelliferones+for+Continuous+Assays+of+Phosphatases+and+Beta-Galactosidases&doi=10.1006%2Fabio.1999.4202"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Fluorogenic Substrates Based on Fluorinated Umbelliferones for Continuous Assays of Phosphatases and β-Galactosidases</span></div><div class="casAuthors">Gee, Kyle R.; Sun, Wei-Chuan; Bhalgat, Mahesh K.; Upson, Rosalyn H.; Klaubert, Dieter H.; Latham, Katherine A.; Haugland, Richard P.</div><div class="citationInfo"><span class="NLM_cas:title">Analytical Biochemistry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">273</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-48</span>CODEN:
                <span class="NLM_cas:coden">ANBCA2</span>;
        ISSN:<span class="NLM_cas:issn">0003-2697</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">Fluorogenic substrates based on 4-methylumbelliferone (4-MU) have been widely used for the detection of phosphatase and glycosidase activities.  One disadvantage of these substrates, however, is that max. fluorescence of the reaction product requires an alk. pH, since 4-MU has a pKa ≈ 8.  In an initial screening of five phosphatase substrates based on fluorinated derivs. of 4-MU, all with pKa values lower than that of 4-MU, we found that one substrate, 6,8-difluoro-4-methylumbelliferyl phosphate (DiFMUP), was much improved for the detection of acid phosphatase activity.  When measured at the preferred acid phosphatase reaction pH (5.0), DiFMUP yielded fluorescence signals that were more than 10-fold higher than those of 4-methylumbelliferyl phosphate (MUP).  DiFMUP was also superior to MUP for the detection of protein phosphatase 1 activity at pH 7 and was just as sensitive as MUP for the detection of alk. phosphatase activity at pH 10.  A β-galactosidase substrate was also prepd. based on 6,8-difluoro-4-methylumbelliferone.  This substrate, 6,8-difluoro-4-methylumbelliferyl β-D-galactopyranoside (DiFMUG), was found to be considerably more sensitive than the commonly used substrate 4-methylumbelliferyl β-D-galactopyranoside (MUG), for the detection of β-galactosidase activity at pH 7.  DiFMUP and DiFMUG should have great utility for the continuous assay of phosphatase and β-galactosidase activity, resp., at neutral and acid pH.  (c) 1999 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZOR_jnhxiLrVg90H21EOLACvtfcHk0ljF44iI7L6diQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXlt1Wktbs%253D&md5=879424dc5f8830990218385ccb9d8fe0</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1006%2Fabio.1999.4202&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fabio.1999.4202%26sid%3Dliteratum%253Aachs%26aulast%3DGee%26aufirst%3DK.%2BR.%26aulast%3DSun%26aufirst%3DW.%2BC.%26aulast%3DBhalgat%26aufirst%3DM.%2BK.%26aulast%3DUpson%26aufirst%3DR.%2BH.%26aulast%3DKlaubert%26aufirst%3DD.%2BH.%26aulast%3DLatham%26aufirst%3DK.%2BA.%26aulast%3DHaugland%26aufirst%3DR.%2BP.%26atitle%3DFluorogenic%2520Substrates%2520Based%2520on%2520Fluorinated%2520Umbelliferones%2520for%2520Continuous%2520Assays%2520of%2520Phosphatases%2520and%2520Beta-Galactosidases%26jtitle%3DAnal.%2520Biochem.%26date%3D1999%26volume%3D273%26spage%3D41%26doi%3D10.1006%2Fabio.1999.4202" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Z. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nabinger, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunawan, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z. Y.</span></span> <span> </span><span class="NLM_article-title">Salicylic Acid Based Small Molecule Inhibitor for the Oncogenic Src Homology-2 Domain Containing Protein Tyrsosine Phosphatase-2 (SHP2)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">2482</span>– <span class="NLM_lpage">2493</span>, <span class="refDoi"> DOI: 10.1021/jm901645u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901645u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADC%252BC3cXitFyhs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2482-2493&author=X.+Zhangauthor=Y.+Heauthor=S.+Liuauthor=Z.+Yuauthor=Z.+X.+Jiangauthor=Z.+Yangauthor=Y.+Dongauthor=S.+C.+Nabingerauthor=L.+Wuauthor=A.+M.+Gunawanauthor=L.+Wangauthor=R.+J.+Chanauthor=Z.+Y.+Zhang&title=Salicylic+Acid+Based+Small+Molecule+Inhibitor+for+the+Oncogenic+Src+Homology-2+Domain+Containing+Protein+Tyrsosine+Phosphatase-2+%28SHP2%29&doi=10.1021%2Fjm901645u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21aR"><div class="casContent"><span class="casTitleNuber">21a</span><div class="casTitle"><span class="NLM_cas:atitle">Salicylic Acid Based Small Molecule Inhibitor for the Oncogenic Src Homology-2 Domain Containing Protein Tyrosine Phosphatase-2 (SHP2)</span></div><div class="casAuthors">Zhang, Xian; He, Yantao; Liu, Sijiu; Yu, Zhihong; Jiang, Zhong-Xing; Yang, Zhenyun; Dong, Yuanshu; Nabinger, Sarah C.; Wu, Li; Gunawan, Andrea M.; Wang, Lina; Chan, Rebecca J.; Zhang, Zhong-Yin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2482-2493</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The Src homol.-2 domain contg. protein tyrosine phosphatase-2 (SHP2) plays a pivotal role in growth factor and cytokine signaling.  Gain-of-function SHP2 mutations are assocd. with Noonan syndrome, various kinds of leukemias, and solid tumors.  Thus, there is considerable interest in SHP2 as a potential target for anticancer and antileukemia therapy.  We report a salicylic acid based combinatorial library approach aimed at binding both active site and unique nearby subpockets for enhanced affinity and selectivity.  Screening of the library led to the identification of a SHP2 inhibitor II-B08 (compd. 9) with highly efficacious cellular activity.  Compd. 9 blocks growth factor stimulated ERK1/2 activation and hematopoietic progenitor proliferation, providing supporting evidence that chem. inhibition of SHP2 may be therapeutically useful for anticancer and antileukemia treatment.  X-ray crystallog. anal. of the structure of SHP2 in complex with 9 reveals mol. determinants that can be exploited for the acquisition of more potent and selective SHP2 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrC82T5JpCRArVg90H21EOLACvtfcHk0ljF44iI7L6diQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXitFyhs7k%253D&md5=6f87897eda38ea485dc08e189f1b5ca8</span></div><a href="/servlet/linkout?suffix=cit21a&amp;dbid=16384&amp;doi=10.1021%2Fjm901645u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901645u%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DHe%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DYu%26aufirst%3DZ.%26aulast%3DJiang%26aufirst%3DZ.%2BX.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DDong%26aufirst%3DY.%26aulast%3DNabinger%26aufirst%3DS.%2BC.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DGunawan%26aufirst%3DA.%2BM.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DChan%26aufirst%3DR.%2BJ.%26aulast%3DZhang%26aufirst%3DZ.%2BY.%26atitle%3DSalicylic%2520Acid%2520Based%2520Small%2520Molecule%2520Inhibitor%2520for%2520the%2520Oncogenic%2520Src%2520Homology-2%2520Domain%2520Containing%2520Protein%2520Tyrsosine%2520Phosphatase-2%2520%2528SHP2%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2482%26epage%3D2493%26doi%3D10.1021%2Fjm901645u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit21b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Z. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunawan, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mali, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapur, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z. Y.</span></span> <span> </span><span class="NLM_article-title">Therapeutic Potential of Targeting the Oncogenic SHP2 Phosphatase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">6594</span>– <span class="NLM_lpage">6609</span>, <span class="refDoi"> DOI: 10.1021/jm5006176</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5006176" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFajtrvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=6594-6609&author=L.+F.+Zengauthor=R.+Y.+Zhangauthor=Z.+H.+Yuauthor=S.+Liauthor=L.+Wuauthor=A.+M.+Gunawanauthor=B.+S.+Laneauthor=R.+S.+Maliauthor=X.+Liauthor=R.+J.+Chanauthor=R.+Kapurauthor=C.+D.+Wellsauthor=Z.+Y.+Zhang&title=Therapeutic+Potential+of+Targeting+the+Oncogenic+SHP2+Phosphatase&doi=10.1021%2Fjm5006176"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21bR"><div class="casContent"><span class="casTitleNuber">21b</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic Potential of Targeting the Oncogenic SHP2 Phosphatase</span></div><div class="casAuthors">Zeng, Li-Fan; Zhang, Ruo-Yu; Yu, Zhi-Hong; Li, Sijiu; Wu, Li; Gunawan, Andrea M.; Lane, Brandon S.; Mali, Raghuveer S.; Li, Xingjun; Chan, Rebecca J.; Kapur, Reuben; Wells, Clark D.; Zhang, Zhong-Yin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6594-6609</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The Src homol. 2 domain contg. protein tyrosine phosphatase-2 (SHP2) is an oncogenic phosphatase assocd. with various kinds of leukemia and solid tumors.  Thus, there is substantial interest in developing SHP2 inhibitors as potential anticancer and antileukemia agents.  Using a structure-guided and fragment-based library approach, we identified a novel hydroxyindole carboxylic acid-based SHP2 inhibitor (I), with an IC50 value of 200 nM and greater than 5-fold selectivity against 20 mammalian PTPs.  Structural and modeling studies reveal that the hydroxyindole carboxylic acid anchors the inhibitor to the SHP2 active site, while interactions of the oxalamide linker and the phenylthiophene tail with residues in the β5-β6 loop contribute to I's binding potency and selectivity.  Evidence suggests that I specifically attenuates the SHP2-dependent signaling inside the cell.  Moreover, I blocks growth factor mediated Erk1/2 and Akt activation and exhibits excellent antiproliferative activity in lung cancer and breast cancer as well as leukemia cell lines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3ko-q4-PSXbVg90H21EOLACvtfcHk0ljF44iI7L6diQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFajtrvO&md5=ac8e5359387e614782c95c02f32fd97d</span></div><a href="/servlet/linkout?suffix=cit21b&amp;dbid=16384&amp;doi=10.1021%2Fjm5006176&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5006176%26sid%3Dliteratum%253Aachs%26aulast%3DZeng%26aufirst%3DL.%2BF.%26aulast%3DZhang%26aufirst%3DR.%2BY.%26aulast%3DYu%26aufirst%3DZ.%2BH.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DGunawan%26aufirst%3DA.%2BM.%26aulast%3DLane%26aufirst%3DB.%2BS.%26aulast%3DMali%26aufirst%3DR.%2BS.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DChan%26aufirst%3DR.%2BJ.%26aulast%3DKapur%26aufirst%3DR.%26aulast%3DWells%26aufirst%3DC.%2BD.%26aulast%3DZhang%26aufirst%3DZ.%2BY.%26atitle%3DTherapeutic%2520Potential%2520of%2520Targeting%2520the%2520Oncogenic%2520SHP2%2520Phosphatase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D6594%26epage%3D6609%26doi%3D10.1021%2Fjm5006176" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit21c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Bunda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrell, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heir, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alamsahebpour, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kano, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raught, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zadeh, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohh, M.</span></span> <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">8859</span>, <span class="refDoi"> DOI: 10.1038/ncomms9859</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=10.1038%2Fncomms9859" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=26617336" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFWksLbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Bunda%2C+S.%3B+Burrell%2C+K.%3B+Heir%2C+P.%3B+Zeng%2C+L.%3B+Alamsahebpour%2C+A.%3B+Kano%2C+Y.%3B+Raught%2C+B.%3B+Zhang%2C+Z.+Y.%3B+Zadeh%2C+G.%3B+Ohh%2C+M.+Nat.+Commun.+2015%2C+6%2C+8859%2C+10.1038%2Fncomms9859"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21cR"><div class="casContent"><span class="casTitleNuber">21c</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of SHP2-mediated dephosphorylation of Ras suppresses oncogenesis</span></div><div class="casAuthors">Bunda, Severa; Burrell, Kelly; Heir, Pardeep; Zeng, Lifan; Alamsahebpour, Amir; Kano, Yoshihito; Raught, Brian; Zhang, Zhong-Yin; Zadeh, Gelareh; Ohh, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">8859</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Ras is phosphorylated on a conserved tyrosine at position 32 within the switch I region via Src kinase.  This phosphorylation inhibits the binding of effector Raf while promoting the engagement of GTPase-activating protein (GAP) and GTP hydrolysis.  Here we identify SHP2 as the ubiquitously expressed tyrosine phosphatase that preferentially binds to and dephosphorylates Ras to increase its assocn. with Raf and activate downstream proliferative Ras/ERK/MAPK signalling.  In comparison to normal astrocytes, SHP2 activity is elevated in astrocytes isolated from glioblastoma multiforme (GBM)-prone H-Ras(12V) knock-in mice as well as in glioma cell lines and patient-derived GBM specimens exhibiting hyperactive Ras.  Pharmacol. inhibition of SHP2 activity attenuates cell proliferation, soft-agar colony formation and orthotopic GBM growth in NOD/SCID mice and decelerates the progression of low-grade astrocytoma to GBM in a spontaneous transgenic glioma mouse model.  These results identify SHP2 as a direct activator of Ras and a potential therapeutic target for cancers driven by a previously 'undruggable' oncogenic or hyperactive Ras.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhWi25AJiphrVg90H21EOLACvtfcHk0li6rO_Dm2no0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFWksLbP&md5=8524ad9cc6f2e85abaff6b07c698f464</span></div><a href="/servlet/linkout?suffix=cit21c&amp;dbid=16384&amp;doi=10.1038%2Fncomms9859&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms9859%26sid%3Dliteratum%253Aachs%26aulast%3DBunda%26aufirst%3DS.%26aulast%3DBurrell%26aufirst%3DK.%26aulast%3DHeir%26aufirst%3DP.%26aulast%3DZeng%26aufirst%3DL.%26aulast%3DAlamsahebpour%26aufirst%3DA.%26aulast%3DKano%26aufirst%3DY.%26aulast%3DRaught%26aufirst%3DB.%26aulast%3DZhang%26aufirst%3DZ.%2BY.%26aulast%3DZadeh%26aufirst%3DG.%26aulast%3DOhh%26aufirst%3DM.%26jtitle%3DNat.%2520Commun.%26date%3D2015%26volume%3D6%26spage%3D8859%26doi%3D10.1038%2Fncomms9859" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scott, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sebti, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span> <span> </span><span class="NLM_article-title">Targeting Protein Tyrosine Phosphatases for Anticancer Drug Discovery</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1843</span>– <span class="NLM_lpage">1862</span>, <span class="refDoi"> DOI: 10.2174/138161210791209027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=10.2174%2F138161210791209027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=20337577" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADC%252BC3cXot1ClsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=1843-1862&author=L.+M.+Scottauthor=H.+R.+Lawrenceauthor=S.+M.+Sebtiauthor=N.+J.+Lawrenceauthor=J.+Wu&title=Targeting+Protein+Tyrosine+Phosphatases+for+Anticancer+Drug+Discovery&doi=10.2174%2F138161210791209027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting protein tyrosine phosphatases for anticancer drug discovery</span></div><div class="casAuthors">Scott, Latanya M.; Lawrence, Harshani R.; Sebti, Said M.; Lawrence, Nicholas J.; Wu, Jie</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1843-1862</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Protein tyrosine phosphatases (PTPs) are a diverse family of enzymes encoded by 107 genes in the human genome.  Together with protein tyrosine kinases (PTKs), PTPs regulate various cellular activities essential for the initiation and maintenance of malignant phenotypes.  While PTK inhibitors are now used routinely for cancer treatment, the PTP inhibitor development field is still in the discovery phase.  In this article, the suitability of targeting PTPs for novel anticancer drug discovery is discussed.  Examples are presented for PTPs that have been targeted for anticancer drug discovery as well as potential new PTP targets for novel anticancer drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHuBrNeSP0n7Vg90H21EOLACvtfcHk0li6rO_Dm2no0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXot1ClsLY%253D&md5=17813d1fba0225fd5e54692b1159bc4a</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.2174%2F138161210791209027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161210791209027%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DL.%2BM.%26aulast%3DLawrence%26aufirst%3DH.%2BR.%26aulast%3DSebti%26aufirst%3DS.%2BM.%26aulast%3DLawrence%26aufirst%3DN.%2BJ.%26aulast%3DWu%26aufirst%3DJ.%26atitle%3DTargeting%2520Protein%2520Tyrosine%2520Phosphatases%2520for%2520Anticancer%2520Drug%2520Discovery%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2010%26volume%3D16%26spage%3D1843%26epage%3D1862%26doi%3D10.2174%2F138161210791209027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Gilmartin, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faitg, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richter, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seefeld, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darcy, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Federowicz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minthorn, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaworski, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaber, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martens, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNulty, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinnamon, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkpatrick, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nevins, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pietrak, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diaz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heerding, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, R.</span></span> <span> </span><span class="NLM_article-title">Allosteric WIP1 Phosphatase Inhibition Through Flap-Subdomain Interaction</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">181</span>– <span class="NLM_lpage">187</span>, <span class="refDoi"> DOI: 10.1038/nchembio.1427</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=10.1038%2Fnchembio.1427" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=24390428" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADC%252BC2cXis1egsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=181-187&author=A.+G.+Gilmartinauthor=T.+H.+Faitgauthor=M.+Richterauthor=A.+Groyauthor=M.+A.+Seefeldauthor=M.+G.+Darcyauthor=X.+Pengauthor=K.+Federowiczauthor=J.+Yangauthor=S.+Y.+Zhangauthor=E.+Minthornauthor=J.+P.+Jaworskiauthor=M.+Schaberauthor=S.+Martensauthor=D.+E.+McNultyauthor=R.+H.+Sinnamonauthor=H.+Zhangauthor=R.+B.+Kirkpatrickauthor=N.+Nevinsauthor=G.+Cuiauthor=B.+Pietrakauthor=E.+Diazauthor=A.+Jonesauthor=M.+Brandtauthor=B.+Schwartzauthor=D.+A.+Heerdingauthor=R.+Kumar&title=Allosteric+WIP1+Phosphatase+Inhibition+Through+Flap-Subdomain+Interaction&doi=10.1038%2Fnchembio.1427"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23aR"><div class="casContent"><span class="casTitleNuber">23a</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric Wip1 phosphatase inhibition through flap-subdomain interaction</span></div><div class="casAuthors">Gilmartin, Aidan G.; Faitg, Thomas H.; Richter, Mark; Groy, Arthur; Seefeld, Mark A.; Darcy, Michael G.; Peng, Xin; Federowicz, Kelly; Yang, Jingsong; Zhang, Shu-Yun; Minthorn, Elisabeth; Jaworski, Jon-Paul; Schaber, Michael; Martens, Stan; McNulty, Dean E.; Sinnamon, Robert H.; Zhang, Hong; Kirkpatrick, Robert B.; Nevins, Neysa; Cui, Guanglei; Pietrak, Beth; Diaz, Elsie; Jones, Amber; Brandt, Martin; Schwartz, Benjamin; Heerding, Dirk A.; Kumar, Rakesh</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">181-187</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Although therapeutic interventions of signal-transduction cascades with targeted kinase inhibitors are a well-established strategy, drug-discovery efforts to identify targeted phosphatase inhibitors have proven challenging.  Herein we report a series of allosteric, small-mol. inhibitors of wild-type p53-induced phosphatase (Wip1), an oncogenic phosphatase common to multiple cancers.  Compd. binding to Wip1 is dependent on a 'flap' subdomain located near the Wip1 catalytic site that renders Wip1 structurally divergent from other members of the protein phosphatase 2C (PP2C) family and that thereby confers selectivity for Wip1 over other phosphatases.  Treatment of tumor cells with the inhibitor GSK2830371 increases phosphorylation of Wip1 substrates and causes growth inhibition in both hematopoietic tumor cell lines and Wip1-amplified breast tumor cells harboring wild-type TP53.  Oral administration of Wip1 inhibitors in mice results in expected pharmacodynamic effects and causes inhibition of lymphoma xenograft growth.  To our knowledge, GSK2830371 is the first orally active, allosteric inhibitor of Wip1 phosphatase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-jXZXKTKTL7Vg90H21EOLACvtfcHk0li6rO_Dm2no0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXis1egsA%253D%253D&md5=47524caa70df233fb152a2d683417e7d</span></div><a href="/servlet/linkout?suffix=cit23a&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1427&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1427%26sid%3Dliteratum%253Aachs%26aulast%3DGilmartin%26aufirst%3DA.%2BG.%26aulast%3DFaitg%26aufirst%3DT.%2BH.%26aulast%3DRichter%26aufirst%3DM.%26aulast%3DGroy%26aufirst%3DA.%26aulast%3DSeefeld%26aufirst%3DM.%2BA.%26aulast%3DDarcy%26aufirst%3DM.%2BG.%26aulast%3DPeng%26aufirst%3DX.%26aulast%3DFederowicz%26aufirst%3DK.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DS.%2BY.%26aulast%3DMinthorn%26aufirst%3DE.%26aulast%3DJaworski%26aufirst%3DJ.%2BP.%26aulast%3DSchaber%26aufirst%3DM.%26aulast%3DMartens%26aufirst%3DS.%26aulast%3DMcNulty%26aufirst%3DD.%2BE.%26aulast%3DSinnamon%26aufirst%3DR.%2BH.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DKirkpatrick%26aufirst%3DR.%2BB.%26aulast%3DNevins%26aufirst%3DN.%26aulast%3DCui%26aufirst%3DG.%26aulast%3DPietrak%26aufirst%3DB.%26aulast%3DDiaz%26aufirst%3DE.%26aulast%3DJones%26aufirst%3DA.%26aulast%3DBrandt%26aufirst%3DM.%26aulast%3DSchwartz%26aufirst%3DB.%26aulast%3DHeerding%26aufirst%3DD.%2BA.%26aulast%3DKumar%26aufirst%3DR.%26atitle%3DAllosteric%2520WIP1%2520Phosphatase%2520Inhibition%2520Through%2520Flap-Subdomain%2520Interaction%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2014%26volume%3D10%26spage%3D181%26epage%3D187%26doi%3D10.1038%2Fnchembio.1427" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit23b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Chio, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bishop, A. C.</span></span> <span> </span><span class="NLM_article-title">Rational Design of Allosteric-Inhibition Sites in Classical Protein Tyrosine Phosphatases</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">2828</span>– <span class="NLM_lpage">2838</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2015.03.027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=10.1016%2Fj.bmc.2015.03.027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=25828055" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADC%252BC2MXkvVWhs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=2828-2838&author=C.+M.+Chioauthor=X.+Yuauthor=A.+C.+Bishop&title=Rational+Design+of+Allosteric-Inhibition+Sites+in+Classical+Protein+Tyrosine+Phosphatases&doi=10.1016%2Fj.bmc.2015.03.027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23bR"><div class="casContent"><span class="casTitleNuber">23b</span><div class="casTitle"><span class="NLM_cas:atitle">Rational design of allosteric-inhibition sites in classical protein tyrosine phosphatases</span></div><div class="casAuthors">Chio, Cynthia M.; Yu, Xiaoling; Bishop, Anthony C.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2828-2838</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Protein tyrosine phosphatases (PTPs), which catalyze the dephosphorylation of phosphotyrosine in protein substrates, are crit. regulators of metazoan cell signaling and have emerged as potential drug targets for a range of human diseases.  Strategies for chem. targeting the function of individual PTPs selectively could serve to elucidate the signaling roles of these enzymes and would potentially expedite validation of the therapeutic promise of PTP inhibitors.  Here we report a novel strategy for the design of non-natural allosteric-inhibition sites in PTPs; these sites, which can be introduced into target PTPs through protein engineering, serve to sensitize target PTPs to potent and selective inhibition by a biarsenical small mol.  Building on the recent discovery of a naturally occurring cryptic allosteric site in wild-type Src-homol.-2 domain contg. PTP (Shp2) that can be targeted by biarsenical compds., we hypothesized that Shp2's unusual sensitivity to biarsenicals could be strengthened through rational design and that the Shp2-specific site could serve as a blueprint for the introduction of non-natural inhibitor sensitivity in other PTPs.  Indeed, we show here that the strategic introduction of a cysteine residue at a position removed from the Shp2 active site can serve to increase the potency and selectivity of the interaction between Shp2's allosteric site and the biarsenical inhibitor.  Moreover, we find that 'Shp2-like' allosteric sites can be installed de novo in PTP enzymes that do not possess naturally occurring sensitivity to biarsenical compds.  Using primary-sequence alignments to guide our enzyme engineering, we have successfully introduced allosteric-inhibition sites in four classical PTPs-PTP1B, PTPH-1, FAP-1, and HePTP-from four different PTP subfamilies, suggesting that our sensitization approach can likely be applied widely across the classical PTP family to generate biarsenical-responsive PTPs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwDXbkv2RdC7Vg90H21EOLACvtfcHk0ljt1-7QIdolxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXkvVWhs7s%253D&md5=14a48e70c722a586a2e3ccb3fa9006ae</span></div><a href="/servlet/linkout?suffix=cit23b&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2015.03.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2015.03.027%26sid%3Dliteratum%253Aachs%26aulast%3DChio%26aufirst%3DC.%2BM.%26aulast%3DYu%26aufirst%3DX.%26aulast%3DBishop%26aufirst%3DA.%2BC.%26atitle%3DRational%2520Design%2520of%2520Allosteric-Inhibition%2520Sites%2520in%2520Classical%2520Protein%2520Tyrosine%2520Phosphatases%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2015%26volume%3D23%26spage%3D2828%26epage%3D2838%26doi%3D10.1016%2Fj.bmc.2015.03.027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit23c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beumer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simard, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grutter, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rauh, D.</span></span> <span> </span><span class="NLM_article-title">Selective Detection of Allosteric Phosphatase Inhibitors</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>135</i></span>,  <span class="NLM_fpage">6838</span>– <span class="NLM_lpage">6841</span>, <span class="refDoi"> DOI: 10.1021/ja4030484</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja4030484" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmtlWhtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=135&publication_year=2013&pages=6838-6841&author=R.+Schneiderauthor=C.+Beumerauthor=J.+R.+Simardauthor=C.+Grutterauthor=D.+Rauh&title=Selective+Detection+of+Allosteric+Phosphatase+Inhibitors&doi=10.1021%2Fja4030484"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23cR"><div class="casContent"><span class="casTitleNuber">23c</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Detection of Allosteric Phosphatase Inhibitors</span></div><div class="casAuthors">Schneider, Ralf; Beumer, Claudia; Simard, Jeffrey R.; Gruetter, Christian; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">135</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6838-6841</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Normal cellular function, such as signal transduction, is largely controlled by the reversible phosphorylation of cellular proteins catalyzed by two major classes of enzymes, kinases and phosphatases.  A misbalance in this complex and dynamic interplay leads to a variety of severe diseases, such as cancer, inflammation, or autoimmune diseases.  This makes kinases as well as phosphatases equally attractive targets for therapeutic manipulation by small mols.  While the development of kinase inhibitors has resulted in several blockbuster drugs, such as imatinib, with remarkable success in the clinic and sales of many billions of U.S. dollars per yr, not a single phosphatase inhibitor has yet been approved for clin. use.  Similar to the kinase world, substrate-competitive phosphatase inhibitors have been developed but were not suitable for further development into clin. candidates due to their charge and limited selectivity.  Research efforts, therefore, have shifted to the exploitation of allosteric sites that can regulate phosphatase activity and may enable the discovery of novel modulators of phosphatase activity with much improved pharmacol. properties.  However, assay systems, which enable the straightforward discovery of these inhibitor types, are missing.  Here, we present a novel binding assay capable of detecting ligands of an allosteric pocket of the protein tyrosine phosphatase 1B.  This assay is suitable for high-throughput screening and selectively detects ligands which bind to this unique site with a clear discrimination from substrate-competitive ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMMpcm8RfGWrVg90H21EOLACvtfcHk0ljt1-7QIdolxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmtlWhtbk%253D&md5=49a980ad7f749718803f1afe1d8d1a04</span></div><a href="/servlet/linkout?suffix=cit23c&amp;dbid=16384&amp;doi=10.1021%2Fja4030484&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja4030484%26sid%3Dliteratum%253Aachs%26aulast%3DSchneider%26aufirst%3DR.%26aulast%3DBeumer%26aufirst%3DC.%26aulast%3DSimard%26aufirst%3DJ.%2BR.%26aulast%3DGrutter%26aufirst%3DC.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DSelective%2520Detection%2520of%2520Allosteric%2520Phosphatase%2520Inhibitors%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2013%26volume%3D135%26spage%3D6838%26epage%3D6841%26doi%3D10.1021%2Fja4030484" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.-N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaMarche, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fekkes, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Fortanet, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acker, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonakos, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. H.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooke, V. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobson, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fei, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Firestone, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fodor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fridrich, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grunenfelder, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, H.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacob, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsiao, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, Z. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karki, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larrow, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La Bonte, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenoir, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majumdar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palermo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quinn, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shakya, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shultz, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slisz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkatesan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warmuth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramsey, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keen, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellers, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stams, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fortin, P. D.</span></span> <span> </span><span class="NLM_article-title">Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinase</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>535</i></span>,  <span class="NLM_fpage">148</span>– <span class="NLM_lpage">152</span>, <span class="refDoi"> DOI: 10.1038/nature18621</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=10.1038%2Fnature18621" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=27362227" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVOns7bI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=535&publication_year=2016&pages=148-152&author=Y.-N.+P.+Chenauthor=M.+J.+LaMarcheauthor=H.+M.+Chanauthor=P.+Fekkesauthor=J.+Garcia-Fortanetauthor=M.+G.+Ackerauthor=B.+Antonakosauthor=C.+H.-T.+Chenauthor=Z.+Chenauthor=V.+G.+Cookeauthor=J.+R.+Dobsonauthor=Z.+Dengauthor=F.+Feiauthor=B.+Firestoneauthor=M.+Fodorauthor=C.+Fridrichauthor=H.+Gaoauthor=D.+Grunenfelderauthor=H.-X.+Haoauthor=J.+Jacobauthor=S.+Hoauthor=K.+Hsiaoauthor=Z.+B.+Kangauthor=R.+Karkiauthor=M.+Katoauthor=J.+Larrowauthor=L.+R.+La+Bonteauthor=F.+Lenoirauthor=G.+Liuauthor=S.+Liuauthor=D.+Majumdarauthor=M.+J.+Meyerauthor=M.+Palermoauthor=L.+Perezauthor=M.+Puauthor=E.+Priceauthor=C.+Quinnauthor=S.+Shakyaauthor=M.+D.+Shultzauthor=J.+Sliszauthor=K.+Venkatesanauthor=P.+Wangauthor=M.+Warmuthauthor=S.+Williamsauthor=G.+Yangauthor=J.+Yuanauthor=J.-H.+Zhangauthor=P.+Zhuauthor=T.+Ramseyauthor=N.+J.+Keenauthor=W.+R.+Sellersauthor=T.+Stamsauthor=P.+D.+Fortin&title=Allosteric+inhibition+of+SHP2+phosphatase+inhibits+cancers+driven+by+receptor+tyrosine+kinase&doi=10.1038%2Fnature18621"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases</span></div><div class="casAuthors">Chen, Ying-Nan P.; LaMarche, Matthew J.; Chan, Ho Man; Fekkes, Peter; Garcia-Fortanet, Jorge; Acker, Michael G.; Antonakos, Brandon; Chen, Christine Hiu-Tung; Chen, Zhouliang; Cooke, Vesselina G.; Dobson, Jason R.; Deng, Zhan; Fei, Feng; Firestone, Brant; Fodor, Michelle; Fridrich, Cary; Gao, Hui; Grunenfelder, Denise; Hao, Huai-Xiang; Jacob, Jaison; Ho, Samuel; Hsiao, Kathy; Kang, Zhao B.; Karki, Rajesh; Kato, Mitsunori; Larrow, Jay; La Bonte, Laura R.; Lenoir, Francois; Liu, Gang; Liu, Shumei; Majumdar, Dyuti; Meyer, Matthew J.; Palermo, Mark; Perez, Lawrence; Pu, Minying; Price, Edmund; Quinn, Christopher; Shakya, Subarna; Shultz, Michael D.; Slisz, Joanna; Venkatesan, Kavitha; Wang, Ping; Warmuth, Markus; Williams, Sarah; Yang, Guizhi; Yuan, Jing; Zhang, Ji-Hu; Zhu, Ping; Ramsey, Timothy; Keen, Nicholas J.; Sellers, William R.; Stams, Travis; Fortin, Pascal D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">535</span>
        (<span class="NLM_cas:issue">7610</span>),
    <span class="NLM_cas:pages">148-152</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The non-receptor protein tyrosine phosphatase SHP2, encoded by PTPN11, has an important role in signal transduction downstream of growth factor receptor signalling and was the first reported oncogenic tyrosine phosphatase.  Activating mutations of SHP2 have been assocd. with developmental pathologies such as Noonan syndrome and are found in multiple cancer types, including leukemia, lung and breast cancer and neuroblastoma.  SHP2 is ubiquitously expressed and regulates cell survival and proliferation primarily through activation of the RAS-ERK signalling pathway2,3.  It is also a key mediator of the programmed cell death 1 (PD-1) and B- and T-lymphocyte attenuator (BTLA) immune checkpoint pathways.  Redn. of SHP2 activity suppresses tumor cell growth and is a potential target of cancer therapy.  Here we report the discovery of a highly potent (IC50 = 0.071 μM), selective and orally bioavailable small-mol. SHP2 inhibitor, SHP099, that stabilizes SHP2 in an auto-inhibited conformation.  SHP099 concurrently binds to the interface of the N-terminal SH2, C-terminal SH2, and protein tyrosine phosphatase domains, thus inhibiting SHP2 activity through an allosteric mechanism.  SHP099 suppresses RAS-ERK signalling to inhibit the proliferation of receptor-tyrosine-kinase-driven human cancer cells in vitro and is efficacious in mouse tumor xenograft models.  Together, these data demonstrate that pharmacol. inhibition of SHP2 is a valid therapeutic approach for the treatment of cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBs_e02S0Sp7Vg90H21EOLACvtfcHk0ljt1-7QIdolxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVOns7bI&md5=ec8a4b612d5008a2519bd846d45ce019</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1038%2Fnature18621&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature18621%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DY.-N.%2BP.%26aulast%3DLaMarche%26aufirst%3DM.%2BJ.%26aulast%3DChan%26aufirst%3DH.%2BM.%26aulast%3DFekkes%26aufirst%3DP.%26aulast%3DGarcia-Fortanet%26aufirst%3DJ.%26aulast%3DAcker%26aufirst%3DM.%2BG.%26aulast%3DAntonakos%26aufirst%3DB.%26aulast%3DChen%26aufirst%3DC.%2BH.-T.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DCooke%26aufirst%3DV.%2BG.%26aulast%3DDobson%26aufirst%3DJ.%2BR.%26aulast%3DDeng%26aufirst%3DZ.%26aulast%3DFei%26aufirst%3DF.%26aulast%3DFirestone%26aufirst%3DB.%26aulast%3DFodor%26aufirst%3DM.%26aulast%3DFridrich%26aufirst%3DC.%26aulast%3DGao%26aufirst%3DH.%26aulast%3DGrunenfelder%26aufirst%3DD.%26aulast%3DHao%26aufirst%3DH.-X.%26aulast%3DJacob%26aufirst%3DJ.%26aulast%3DHo%26aufirst%3DS.%26aulast%3DHsiao%26aufirst%3DK.%26aulast%3DKang%26aufirst%3DZ.%2BB.%26aulast%3DKarki%26aufirst%3DR.%26aulast%3DKato%26aufirst%3DM.%26aulast%3DLarrow%26aufirst%3DJ.%26aulast%3DLa%2BBonte%26aufirst%3DL.%2BR.%26aulast%3DLenoir%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DMajumdar%26aufirst%3DD.%26aulast%3DMeyer%26aufirst%3DM.%2BJ.%26aulast%3DPalermo%26aufirst%3DM.%26aulast%3DPerez%26aufirst%3DL.%26aulast%3DPu%26aufirst%3DM.%26aulast%3DPrice%26aufirst%3DE.%26aulast%3DQuinn%26aufirst%3DC.%26aulast%3DShakya%26aufirst%3DS.%26aulast%3DShultz%26aufirst%3DM.%2BD.%26aulast%3DSlisz%26aufirst%3DJ.%26aulast%3DVenkatesan%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DWarmuth%26aufirst%3DM.%26aulast%3DWilliams%26aufirst%3DS.%26aulast%3DYang%26aufirst%3DG.%26aulast%3DYuan%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DJ.-H.%26aulast%3DZhu%26aufirst%3DP.%26aulast%3DRamsey%26aufirst%3DT.%26aulast%3DKeen%26aufirst%3DN.%2BJ.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DStams%26aufirst%3DT.%26aulast%3DFortin%26aufirst%3DP.%2BD.%26atitle%3DAllosteric%2520inhibition%2520of%2520SHP2%2520phosphatase%2520inhibits%2520cancers%2520driven%2520by%2520receptor%2520tyrosine%2520kinase%26jtitle%3DNature%26date%3D2016%26volume%3D535%26spage%3D148%26epage%3D152%26doi%3D10.1038%2Fnature18621" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garcia
Fortanet, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. H.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.-N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Firestone, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fekkes, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fodor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fortin, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fridrich, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grunenfelder, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, Z. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karki, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaBonte, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larrow, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenoir, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majumdar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palermo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramsey, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellers, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shultz, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stams, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Towler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaMarche, M. J.</span></span> <span> </span><span class="NLM_article-title">Allosteric Inhibition of SHP2: Identification of a Potent, Selective, and Orally Efficacious Phosphatase Inhibitor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">7773</span>– <span class="NLM_lpage">7782</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00680</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00680" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVKju7fP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=7773-7782&author=J.+Garcia%0AFortanetauthor=C.+H.-T.+Chenauthor=Y.-N.+P.+Chenauthor=Z.+Chenauthor=Z.+Dengauthor=B.+Firestoneauthor=P.+Fekkesauthor=M.+Fodorauthor=P.+D.+Fortinauthor=C.+Fridrichauthor=D.+Grunenfelderauthor=S.+Hoauthor=Z.+B.+Kangauthor=R.+Karkiauthor=M.+Katoauthor=N.+Keenauthor=L.+R.+LaBonteauthor=J.+Larrowauthor=F.+Lenoirauthor=G.+Liuauthor=S.+Liuauthor=F.+Lombardoauthor=D.+Majumdarauthor=M.+J.+Meyerauthor=M.+Palermoauthor=L.+Perezauthor=M.+Puauthor=T.+Ramseyauthor=W.+R.+Sellersauthor=M.+D.+Shultzauthor=T.+Stamsauthor=C.+Towlerauthor=P.+Wangauthor=S.+L.+Williamsauthor=J.-H.+Zhangauthor=M.+J.+LaMarche&title=Allosteric+Inhibition+of+SHP2%3A+Identification+of+a+Potent%2C+Selective%2C+and+Orally+Efficacious+Phosphatase+Inhibitor&doi=10.1021%2Facs.jmedchem.6b00680"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric Inhibition of SHP2: Identification of a Potent, Selective, and Orally Efficacious Phosphatase Inhibitor</span></div><div class="casAuthors">Garcia Fortanet, Jorge; Chen, Christine Hiu-Tung; Chen, Ying-Nan P.; Chen, Zhouliang; Deng, Zhan; Firestone, Brant; Fekkes, Peter; Fodor, Michelle; Fortin, Pascal D.; Fridrich, Cary; Grunenfelder, Denise; Ho, Samuel; Kang, Zhao B.; Karki, Rajesh; Kato, Mitsunori; Keen, Nick; LaBonte, Laura R.; Larrow, Jay; Lenoir, Francois; Liu, Gang; Liu, Shumei; Lombardo, Franco; Majumdar, Dyuti; Meyer, Matthew J.; Palermo, Mark; Perez, Lawrence; Pu, Minying; Ramsey, Timothy; Sellers, William R.; Shultz, Michael D.; Stams, Travis; Towler, Christopher; Wang, Ping; Williams, Sarah L.; Zhang, Ji-Hu; LaMarche, Matthew J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7773-7782</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">SHP2 is a nonreceptor protein tyrosine phosphatase (PTP) encoded by the PTPN11 gene involved in cell growth and differentiation via the MAPK signaling pathway.  SHP2 also purportedly plays an important role in the programmed cell death pathway (PD-1/PD-L1).  Because it is an oncoprotein assocd. with multiple cancer-related diseases, as well as a potential immunomodulator, controlling SHP2 activity is of significant therapeutic interest.  Recently in our labs., a small mol. inhibitor of SHP2 was identified as an allosteric modulator that stabilizes the autoinhibited conformation of SHP2.  A high throughput screen was performed to identify progressable chem. matter, and X-ray crystallog. revealed the location of binding in a previously undisclosed allosteric binding pocket.  Structure-based drug design was employed to optimize for SHP2 inhibition, and several new protein-ligand interactions were characterized.  These studies culminated in the discovery of 6-(4-amino-4-methylpiperidin-1-yl)-3-(2,3-dichlorophenyl)pyrazin-2-amine (SHP099, 1), a potent, selective, orally bioavailable, and efficacious SHP2 inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6RT7zfZnvfLVg90H21EOLACvtfcHk0lhiQpPHajS-4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVKju7fP&md5=dfe43b5253e172576386f86797087f7b</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00680&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00680%26sid%3Dliteratum%253Aachs%26aulast%3DGarcia%2BFortanet%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DC.%2BH.-T.%26aulast%3DChen%26aufirst%3DY.-N.%2BP.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DDeng%26aufirst%3DZ.%26aulast%3DFirestone%26aufirst%3DB.%26aulast%3DFekkes%26aufirst%3DP.%26aulast%3DFodor%26aufirst%3DM.%26aulast%3DFortin%26aufirst%3DP.%2BD.%26aulast%3DFridrich%26aufirst%3DC.%26aulast%3DGrunenfelder%26aufirst%3DD.%26aulast%3DHo%26aufirst%3DS.%26aulast%3DKang%26aufirst%3DZ.%2BB.%26aulast%3DKarki%26aufirst%3DR.%26aulast%3DKato%26aufirst%3DM.%26aulast%3DKeen%26aufirst%3DN.%26aulast%3DLaBonte%26aufirst%3DL.%2BR.%26aulast%3DLarrow%26aufirst%3DJ.%26aulast%3DLenoir%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DLombardo%26aufirst%3DF.%26aulast%3DMajumdar%26aufirst%3DD.%26aulast%3DMeyer%26aufirst%3DM.%2BJ.%26aulast%3DPalermo%26aufirst%3DM.%26aulast%3DPerez%26aufirst%3DL.%26aulast%3DPu%26aufirst%3DM.%26aulast%3DRamsey%26aufirst%3DT.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DShultz%26aufirst%3DM.%2BD.%26aulast%3DStams%26aufirst%3DT.%26aulast%3DTowler%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DWilliams%26aufirst%3DS.%2BL.%26aulast%3DZhang%26aufirst%3DJ.-H.%26aulast%3DLaMarche%26aufirst%3DM.%2BJ.%26atitle%3DAllosteric%2520Inhibition%2520of%2520SHP2%253A%2520Identification%2520of%2520a%2520Potent%252C%2520Selective%252C%2520and%2520Orally%2520Efficacious%2520Phosphatase%2520Inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D7773%26epage%3D7782%26doi%3D10.1021%2Facs.jmedchem.6b00680" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span> <span> </span><span class="NLM_article-title">SHP2 Inhibition Triggers Anti-tumor Immunity and Synergizes with PD-1 Blockade</span>. <i>Acta Pharm. Sin. B</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">304</span>– <span class="NLM_lpage">315</span>, <span class="refDoi"> DOI: 10.1016/j.apsb.2018.08.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=10.1016%2Fj.apsb.2018.08.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=30972278" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A280%3ADC%252BB3M%252FktFKktw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=304-315&author=M.+Zhaoauthor=W.+Guoauthor=Y.+Wuauthor=C.+Yangauthor=L.+Zhongauthor=G.+Dengauthor=Y.+Zhuauthor=W.+Liuauthor=Y.+Guauthor=Y.+Luauthor=L.+Kongauthor=X.+Mengauthor=Q.+Xuauthor=Y.+Sun&title=SHP2+Inhibition+Triggers+Anti-tumor+Immunity+and+Synergizes+with+PD-1+Blockade&doi=10.1016%2Fj.apsb.2018.08.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">SHP2 inhibition triggers anti-tumor immunity and synergizes with PD-1 blockade</span></div><div class="casAuthors">Zhao Mingxia; Guo Wenjie; Yang Chenxi; Deng Guoliang; Zhu Yuyu; Liu Wen; Kong Lingdong; Meng Xiangbao; Xu Qiang; Sun Yang; Wu Yuanyuan; Lu Yin; Zhong Liang; Meng Xiangbao; Gu Yanhong</div><div class="citationInfo"><span class="NLM_cas:title">Acta pharmaceutica Sinica. B</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">304-315</span>
        ISSN:<span class="NLM_cas:issn">2211-3835</span>.
    </div><div class="casAbstract">Tyrosine phosphatase SHP2 is a promising drug target in cancer immunotherapy due to its bidirectional role in both tumor growth promotion and T-cell inactivation.  Its allosteric inhibitor SHP099 is known to inhibit cancer cell growth both in vitro and in vivo.  However, whether SHP099-mediated SHP2 inhibition retards tumor growth in vivo via anti-tumor immunity remains elusive.  To address this, a CT-26 colon cancer xenograft model was established in mice since this cell line is insensitive to SHP099.  Consequently, SHP099 minimally affected CT-26 tumor growth in immuno-deficient nude mice, but significantly decreased the tumor burden in CT-26 tumor-bearing mice with intact immune system.  SHP099 augmented anti-tumor immunity, as shown by the elevated proportion of CD8(+)IFN-γ(+) T cells and the upregulation of cytotoxic T-cell related genes including Granzyme B andPerforin, which decreased the tumor load.  In addition, tumor growth in mice with SHP2-deficient T-cells was markedly slowed down because of enhanced anti-tumor responses.  Finally, the combination of SHP099 and anti-PD-1 antibody showed a higher therapeutic efficacy than either monotherapy in controlling tumor growth in two colon cancer xenograft models, indicating that these agents complement each other.  Our study suggests that SHP2 inhibitor SHP099 is a promising candidate drug for cancer immunotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSB60VxKgx5l_h3YQQtAhNufW6udTcc2ea8Ui8wFzp9urntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M%252FktFKktw%253D%253D&md5=759babe45705b88551f6ac62cb3cee2e</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.apsb.2018.08.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.apsb.2018.08.009%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DM.%26aulast%3DGuo%26aufirst%3DW.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DC.%26aulast%3DZhong%26aufirst%3DL.%26aulast%3DDeng%26aufirst%3DG.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DGu%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DKong%26aufirst%3DL.%26aulast%3DMeng%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DSun%26aufirst%3DY.%26atitle%3DSHP2%2520Inhibition%2520Triggers%2520Anti-tumor%2520Immunity%2520and%2520Synergizes%2520with%2520PD-1%2520Blockade%26jtitle%3DActa%2520Pharm.%2520Sin.%2520B%26date%3D2019%26volume%3D9%26spage%3D304%26epage%3D315%26doi%3D10.1016%2Fj.apsb.2018.08.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27a"><span><span class="NLM_label">(a) </span> OECD guidelines, <i>In Vitro</i> 3T3 NRU
Phototoxicity
Test. <a href="https://ntp.niehs.nih.gov/iccvam/suppdocs/feddocs/oecd/oecdtg432-508.pdf" class="extLink">https://ntp.niehs.nih.gov/iccvam/suppdocs/feddocs/oecd/oecdtg432-508.pdf</a> (accessed Aug 19, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+OECD+guidelines%2C+In+Vitro+3T3+NRU%0APhototoxicity%0ATest.+https%3A%2F%2Fntp.niehs.nih.gov%2Ficcvam%2Fsuppdocs%2Ffeddocs%2Foecd%2Foecdtg432-508.pdf+%28accessed+Aug+19%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit27b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Schumann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boudon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulrich, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loll, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaffner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Streich, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kittel, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, D.</span></span> <span> </span><span class="NLM_article-title">Integrated Preclinical Photosafety Testing Strategy for Systemically Applied Pharmaceuticals</span>. <i>Toxicol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>139</i></span>,  <span class="NLM_fpage">245</span>– <span class="NLM_lpage">256</span>, <span class="refDoi"> DOI: 10.1093/toxsci/kfu026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=10.1093%2Ftoxsci%2Fkfu026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=24519524" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A280%3ADC%252BC2cvjvF2huw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=139&publication_year=2014&pages=245-256&author=J.+Schumannauthor=S.+Boudonauthor=P.+Ulrichauthor=N.+Lollauthor=D.+Garciaauthor=R.+Schaffnerauthor=J.+Streichauthor=B.+Kittelauthor=D.+Bauer&title=Integrated+Preclinical+Photosafety+Testing+Strategy+for+Systemically+Applied+Pharmaceuticals&doi=10.1093%2Ftoxsci%2Fkfu026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27bR"><div class="casContent"><span class="casTitleNuber">27b</span><div class="casTitle"><span class="NLM_cas:atitle">Integrated preclinical photosafety testing strategy for systemically applied pharmaceuticals</span></div><div class="casAuthors">Schumann Jens; Boudon Stephanie; Ulrich Peter; Loll Nathalie; Garcia Deborah; Schaffner Rene; Streich Jeannine; Kittel Birgit; Bauer Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological sciences : an official journal of the Society of Toxicology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">139</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">245-56</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Phototoxic properties of systemically applied pharmaceuticals may be the cause of serious adverse drug reactions.  Therefore, a reliable preclinical photosafety assessment strategy, combining in vitro and in vivo approaches in a quantitative manner, is important and has not been described so far.  Here, we report the establishment of an optimized modified murine local lymph node assay (LLNA), adapted for phototoxicity assessment of systemically applied compounds, as well as the test results for 34 drug candidates in this in vivo photo-LLNA.  The drug candidates were selected based on their ability to absorb ultraviolet/visible light and the photo irritation factors (PIFs) determined in the well-established in vitro 3T3 neutral red uptake phototoxicity test.  An in vivo phototoxic potential was identified for 13 of these drug candidates.  The use of multiple dose levels in the described murine in vivo phototoxicity studies enabled the establishment of no- and/or lowest-observed-adverse-effect levels (NOAELs/LOAELs), also supporting human photosafety assessment.  An in vitro-in vivo correlation demonstrated that a drug candidate classified as "phototoxic" in vitro is not necessarily phototoxic in vivo.  However, the probability for a drug candidate to cause phototoxicity in vivo clearly correlated with the magnitude of the phototoxicity identified in vitro.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTPHAsrez4GpyXXDYhVZBdlfW6udTcc2eZxy8U2wJjMsrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cvjvF2huw%253D%253D&md5=9d638c7064af0765e7f1ab93165f42c6</span></div><a href="/servlet/linkout?suffix=cit27b&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2Fkfu026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252Fkfu026%26sid%3Dliteratum%253Aachs%26aulast%3DSchumann%26aufirst%3DJ.%26aulast%3DBoudon%26aufirst%3DS.%26aulast%3DUlrich%26aufirst%3DP.%26aulast%3DLoll%26aufirst%3DN.%26aulast%3DGarcia%26aufirst%3DD.%26aulast%3DSchaffner%26aufirst%3DR.%26aulast%3DStreich%26aufirst%3DJ.%26aulast%3DKittel%26aufirst%3DB.%26aulast%3DBauer%26aufirst%3DD.%26atitle%3DIntegrated%2520Preclinical%2520Photosafety%2520Testing%2520Strategy%2520for%2520Systemically%2520Applied%2520Pharmaceuticals%26jtitle%3DToxicol.%2520Sci.%26date%3D2014%26volume%3D139%26spage%3D245%26epage%3D256%26doi%3D10.1093%2Ftoxsci%2Fkfu026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Canon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rex, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saiki, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohr, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooke, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagal, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaida, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holt, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knutson, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koppada, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanman, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rapaport, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">San Miguel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortiz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osgood, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarter, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volak, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houk, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fakih, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Neil, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falchook, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Govindan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouyang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henary, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arvedson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cee, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipford, J.R.</span></span> <span> </span><span class="NLM_article-title">The Clinical KRAS(G12C) Inhibitor AMG510 Drives Anti-Tumour Immunity</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>575</i></span>,  <span class="NLM_fpage">217</span>– <span class="NLM_lpage">223</span>, <span class="refDoi"> DOI: 10.1038/s41586-019-1694-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=10.1038%2Fs41586-019-1694-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=31666701" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitV2hsb7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=575&publication_year=2019&pages=217-223&author=J.+Canonauthor=K.+Rexauthor=A.+Y.+Saikiauthor=C.+Mohrauthor=K.+Cookeauthor=D.+Bagalauthor=K.+Gaidaauthor=T.+Holtauthor=C.+G.+Knutsonauthor=N.+Koppadaauthor=B.+A.+Lanmanauthor=J.+Wernerauthor=A.+S.+Rapaportauthor=T.+San+Miguelauthor=R.+Ortizauthor=T.+Osgoodauthor=J.+R.+Sunauthor=X.+Zhuauthor=J.+D.+McCarterauthor=L.+P.+Volakauthor=B.+E.+Houkauthor=M.+G.+Fakihauthor=B.+H.+O%E2%80%99Neilauthor=T.+J.+Priceauthor=G.+S.+Falchookauthor=J.+Desaiauthor=J.+Kuoauthor=R.+Govindanauthor=D.+S.+Hongauthor=W.+Ouyangauthor=H.+Henaryauthor=T.+Arvedsonauthor=V.+J.+Ceeauthor=J.R.+Lipford&title=The+Clinical+KRAS%28G12C%29+Inhibitor+AMG510+Drives+Anti-Tumour+Immunity&doi=10.1038%2Fs41586-019-1694-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28aR"><div class="casContent"><span class="casTitleNuber">28a</span><div class="casTitle"><span class="NLM_cas:atitle">The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity</span></div><div class="casAuthors">Canon, Jude; Rex, Karen; Saiki, Anne Y.; Mohr, Christopher; Cooke, Keegan; Bagal, Dhanashri; Gaida, Kevin; Holt, Tyler; Knutson, Charles G.; Koppada, Neelima; Lanman, Brian A.; Werner, Jonathan; Rapaport, Aaron S.; San Miguel, Tisha; Ortiz, Roberto; Osgood, Tao; Sun, Ji-Rong; Zhu, Xiaochun; McCarter, John D.; Volak, Laurie P.; Houk, Brett E.; Fakih, Marwan G.; O'Neil, Bert H.; Price, Timothy J.; Falchook, Gerald S.; Desai, Jayesh; Kuo, James; Govindan, Ramaswamy; Hong, David S.; Ouyang, Wenjun; Henary, Haby; Arvedson, Tara; Cee, Victor J.; Lipford, J. Russell</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">575</span>
        (<span class="NLM_cas:issue">7781</span>),
    <span class="NLM_cas:pages">217-223</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">KRAS is the most frequently mutated oncogene in cancer and encodes a key signalling protein in tumors1,2.  The KRAS(G12C) mutant has a cysteine residue that has been exploited to design covalent inhibitors that have promising preclin. activity3-5.  Here we optimized a series of inhibitors, using novel binding interactions to markedly enhance their potency and selectivity.  Our efforts have led to the discovery of AMG 510, which is, to our knowledge, the first KRAS(G12C) inhibitor in clin. development.  In preclin. analyses, treatment with AMG 510 led to the regression of KRASG12C tumors and improved the anti-tumor efficacy of chemotherapy and targeted agents.  In immune-competent mice, treatment with AMG 510 resulted in a pro-inflammatory tumor microenvironment and produced durable cures alone as well as in combination with immune-checkpoint inhibitors.  Cured mice rejected the growth of isogenic KRASG12D tumors, which suggests adaptive immunity against shared antigens.  Furthermore, in clin. trials, AMG 510 demonstrated anti-tumor activity in the first dosing cohorts and represents a potentially transformative therapy for patients for whom effective treatments are lacking.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTHdBftQfnhbVg90H21EOLACvtfcHk0lg-Ry43h8Idaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitV2hsb7F&md5=3819175980905976ba87ff545b9506e1</span></div><a href="/servlet/linkout?suffix=cit28a&amp;dbid=16384&amp;doi=10.1038%2Fs41586-019-1694-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41586-019-1694-1%26sid%3Dliteratum%253Aachs%26aulast%3DCanon%26aufirst%3DJ.%26aulast%3DRex%26aufirst%3DK.%26aulast%3DSaiki%26aufirst%3DA.%2BY.%26aulast%3DMohr%26aufirst%3DC.%26aulast%3DCooke%26aufirst%3DK.%26aulast%3DBagal%26aufirst%3DD.%26aulast%3DGaida%26aufirst%3DK.%26aulast%3DHolt%26aufirst%3DT.%26aulast%3DKnutson%26aufirst%3DC.%2BG.%26aulast%3DKoppada%26aufirst%3DN.%26aulast%3DLanman%26aufirst%3DB.%2BA.%26aulast%3DWerner%26aufirst%3DJ.%26aulast%3DRapaport%26aufirst%3DA.%2BS.%26aulast%3DSan%2BMiguel%26aufirst%3DT.%26aulast%3DOrtiz%26aufirst%3DR.%26aulast%3DOsgood%26aufirst%3DT.%26aulast%3DSun%26aufirst%3DJ.%2BR.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DMcCarter%26aufirst%3DJ.%2BD.%26aulast%3DVolak%26aufirst%3DL.%2BP.%26aulast%3DHouk%26aufirst%3DB.%2BE.%26aulast%3DFakih%26aufirst%3DM.%2BG.%26aulast%3DO%25E2%2580%2599Neil%26aufirst%3DB.%2BH.%26aulast%3DPrice%26aufirst%3DT.%2BJ.%26aulast%3DFalchook%26aufirst%3DG.%2BS.%26aulast%3DDesai%26aufirst%3DJ.%26aulast%3DKuo%26aufirst%3DJ.%26aulast%3DGovindan%26aufirst%3DR.%26aulast%3DHong%26aufirst%3DD.%2BS.%26aulast%3DOuyang%26aufirst%3DW.%26aulast%3DHenary%26aufirst%3DH.%26aulast%3DArvedson%26aufirst%3DT.%26aulast%3DCee%26aufirst%3DV.%2BJ.%26aulast%3DLipford%26aufirst%3DJ.R.%26atitle%3DThe%2520Clinical%2520KRAS%2528G12C%2529%2520Inhibitor%2520AMG510%2520Drives%2520Anti-Tumour%2520Immunity%26jtitle%3DNature%26date%3D2019%26volume%3D575%26spage%3D217%26epage%3D223%26doi%3D10.1038%2Fs41586-019-1694-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit28b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hallin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engstrom, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hargis, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calinisan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aranda, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Briere, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sudhakar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowcut, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baer, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burkard, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fell, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vigers, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gatto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez-Banet, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavlicek, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velastagui, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierobon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baldelli, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patricoin, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cassidy, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marx, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rybkin, I. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, S.-H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lito, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papadopoulos, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, J. G.</span></span> <span> </span><span class="NLM_article-title">The KRASG12C Inhibitor, MRTX849, Provides Insight Toward Therapeutic Susceptibility of KRAS Mutant Cancers in Mouse Models and Patients</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">54</span>– <span class="NLM_lpage">71</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-19-1167</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=10.1158%2F2159-8290.CD-19-1167" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=31658955" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtleitbfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2020&pages=54-71&author=J.+Hallinauthor=L.+D.+Engstromauthor=L.+Hargisauthor=A.+Calinisanauthor=R.+Arandaauthor=D.+M.+Briereauthor=N.+Sudhakarauthor=V.+Bowcutauthor=B.+R.+Baerauthor=J.+A.+Ballardauthor=M.+R.+Burkardauthor=J.+B.+Fellauthor=J.+P.+Fischerauthor=G.+P.+Vigersauthor=Y.+Xueauthor=S.+Gattoauthor=J.+Fernandez-Banetauthor=A.+Pavlicekauthor=K.+Velastaguiauthor=R.+C.+Chaoauthor=J.+Bartonauthor=M.+Pierobonauthor=E.+Baldelliauthor=E.+F.+Patricoinauthor=D.+P.+Cassidyauthor=M.+A.+Marxauthor=I.+I.+Rybkinauthor=M.+L.+Johnsonauthor=S.-H.+I.+Ouauthor=P.+Litoauthor=K.+P.+Papadopoulosauthor=P.+A.+J%C3%A4nneauthor=P.+Olsonauthor=J.+G.+Christensen&title=The+KRASG12C+Inhibitor%2C+MRTX849%2C+Provides+Insight+Toward+Therapeutic+Susceptibility+of+KRAS+Mutant+Cancers+in+Mouse+Models+and+Patients&doi=10.1158%2F2159-8290.CD-19-1167"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28bR"><div class="casContent"><span class="casTitleNuber">28b</span><div class="casTitle"><span class="NLM_cas:atitle">The KRASG12C inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients</span></div><div class="casAuthors">Hallin, Jill; Engstrom, Lars D.; Hargis, Lauren; Calinisan, Andrew; Aranda, Ruth; Briere, David M.; Sudhakar, Niranjan; Bowcut, Vickie; Baer, Brian R.; Ballard, Joshua A.; Burkard, Michael R.; Fell, Jay B.; Fischer, John P.; Vigers, Guy P.; Xue, Yaohua; Gatto, Sole; Fernandez-Banet, Julio; Pavlicek, Adam; Velastagui, Karen; Chao, Richard C.; Barton, Jeremy; Pierobon, Mariaelena; Baldelli, Elisa; Patricoin, Emanuel F., III; Cassidy, Douglas P.; Marx, Matthew A.; Rybkin, Igor I.; Johnson, Melissa L.; Ou, Sai-Hong Ignatius; Lito, Piro; Papadopoulos, Kyriakos P.; Janne, Pasi A.; Olson, Peter; Christensen, James G.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">54-71</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Despite decades of research, efforts to directly target KRAS have been challenging.  MRTX849 was identified as a potent, selective, and covalent KRASG12C inhibitor that exhibits favorable drug-like properties, selectively modifies mutant cysteine 12 in GDP-bound KRASG12C, and inhibits KRAS-dependent signaling.  MRTX849 demonstrated pronounced tumor regression in 17 of 26 (65%) KRASG12C-pos. cell line- and patient-derived xenograft models from multiple tumor types, and objective responses have been obsd. in patients with KRASG12C-pos. lung and colon adenocarcinomas.  Comprehensive pharmacodynamic and pharmacogenomic profiling in sensitive and partially resistant nonclin. models identified mechanisms implicated in limiting antitumor activity including KRAS nucleotide cycling and pathways that induce feedback reactivation and/or bypass KRAS dependence.  These factors included activation of receptor tyrosine kinases (RTK), bypass of KRAS dependence, and genetic dysregulation of cell cycle.  Combinations of MRTX849 with agents that target RTKs, mTOR, or cell cycle demonstrated enhanced response and marked tumor regression in several tumor models, including MRTX849-refractory models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxAUhi3n75ULVg90H21EOLACvtfcHk0lg-Ry43h8Idaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtleitbfL&md5=48f4c34e757385eed89b47f19cbb10db</span></div><a href="/servlet/linkout?suffix=cit28b&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-19-1167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-19-1167%26sid%3Dliteratum%253Aachs%26aulast%3DHallin%26aufirst%3DJ.%26aulast%3DEngstrom%26aufirst%3DL.%2BD.%26aulast%3DHargis%26aufirst%3DL.%26aulast%3DCalinisan%26aufirst%3DA.%26aulast%3DAranda%26aufirst%3DR.%26aulast%3DBriere%26aufirst%3DD.%2BM.%26aulast%3DSudhakar%26aufirst%3DN.%26aulast%3DBowcut%26aufirst%3DV.%26aulast%3DBaer%26aufirst%3DB.%2BR.%26aulast%3DBallard%26aufirst%3DJ.%2BA.%26aulast%3DBurkard%26aufirst%3DM.%2BR.%26aulast%3DFell%26aufirst%3DJ.%2BB.%26aulast%3DFischer%26aufirst%3DJ.%2BP.%26aulast%3DVigers%26aufirst%3DG.%2BP.%26aulast%3DXue%26aufirst%3DY.%26aulast%3DGatto%26aufirst%3DS.%26aulast%3DFernandez-Banet%26aufirst%3DJ.%26aulast%3DPavlicek%26aufirst%3DA.%26aulast%3DVelastagui%26aufirst%3DK.%26aulast%3DChao%26aufirst%3DR.%2BC.%26aulast%3DBarton%26aufirst%3DJ.%26aulast%3DPierobon%26aufirst%3DM.%26aulast%3DBaldelli%26aufirst%3DE.%26aulast%3DPatricoin%26aufirst%3DE.%2BF.%26aulast%3DCassidy%26aufirst%3DD.%2BP.%26aulast%3DMarx%26aufirst%3DM.%2BA.%26aulast%3DRybkin%26aufirst%3DI.%2BI.%26aulast%3DJohnson%26aufirst%3DM.%2BL.%26aulast%3DOu%26aufirst%3DS.-H.%2BI.%26aulast%3DLito%26aufirst%3DP.%26aulast%3DPapadopoulos%26aufirst%3DK.%2BP.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DOlson%26aufirst%3DP.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26atitle%3DThe%2520KRASG12C%2520Inhibitor%252C%2520MRTX849%252C%2520Provides%2520Insight%2520Toward%2520Therapeutic%2520Susceptibility%2520of%2520KRAS%2520Mutant%2520Cancers%2520in%2520Mouse%2520Models%2520and%2520Patients%26jtitle%3DCancer%2520Discovery%26date%3D2020%26volume%3D10%26spage%3D54%26epage%3D71%26doi%3D10.1158%2F2159-8290.CD-19-1167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Altman, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shafir, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lichtor, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchwald, S. A.</span></span> <span> </span><span class="NLM_article-title">An Improved Cu-Based Catalyst System for the Reactions of Alcohols with Aryl Halides</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">284</span>– <span class="NLM_lpage">286</span>, <span class="refDoi"> DOI: 10.1021/jo702024p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo702024p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlOgsrjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2008&pages=284-286&author=R.+A.+Altmanauthor=A.+Shafirauthor=A.+Choiauthor=P.+A.+Lichtorauthor=S.+A.+Buchwald&title=An+Improved+Cu-Based+Catalyst+System+for+the+Reactions+of+Alcohols+with+Aryl+Halides&doi=10.1021%2Fjo702024p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">An Improved Cu-Based Catalyst System for the Reactions of Alcohols with Aryl Halides</span></div><div class="casAuthors">Altman, Ryan A.; Shafir, Alexandr; Choi, Alice; Lichtor, Phillip A.; Buchwald, Stephen L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">284-286</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The use of 3,4,7,8-tetramethyl-1,10-phenanthroline (Me4Phen) as a ligand improves the Cu-catalyzed cross-coupling reactions of aryl iodides and bromides with primary and secondary aliph., benzylic, allylic, and propargylic alcs to give products, e.g., I, in good yields.  Most importantly, by employing this catalyst system, the need to use an excessive quantity of the alc. coupling partner is alleviated.  The relatively mild conditions, short reaction times, and moderately low catalyst loading allow for a wide array of functional groups to be tolerated on both the electrophilic and nucleophilic coupling partners.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpy2UxAcp1pOrVg90H21EOLACvtfcHk0ljkksyIkzVfEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlOgsrjF&md5=a99d7184c0f34e2ca688ba0796c95b70</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fjo702024p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo702024p%26sid%3Dliteratum%253Aachs%26aulast%3DAltman%26aufirst%3DR.%2BA.%26aulast%3DShafir%26aufirst%3DA.%26aulast%3DChoi%26aufirst%3DA.%26aulast%3DLichtor%26aufirst%3DP.%2BA.%26aulast%3DBuchwald%26aufirst%3DS.%2BA.%26atitle%3DAn%2520Improved%2520Cu-Based%2520Catalyst%2520System%2520for%2520the%2520Reactions%2520of%2520Alcohols%2520with%2520Aryl%2520Halides%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2008%26volume%3D73%26spage%3D284%26epage%3D286%26doi%3D10.1021%2Fjo702024p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mispelaere-Canivet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spindler, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrio, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beslin, P.</span></span> <span> </span><span class="NLM_article-title">Pd<sub>2</sub>(dba)<sub>3</sub>/Xantphos-Catalyzed Cross-Coupling of Thiols and Aryl Bromides/Triflates</span>. <i>Tetrahedron</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">5253</span>– <span class="NLM_lpage">5259</span>, <span class="refDoi"> DOI: 10.1016/j.tet.2005.03.078</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=10.1016%2Fj.tet.2005.03.078" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADC%252BD2MXktFWgs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2005&pages=5253-5259&author=C.+Mispelaere-Canivetauthor=J.+F.+Spindlerauthor=S.+Perrioauthor=P.+Beslin&title=Pd2%28dba%293%2FXantphos-Catalyzed+Cross-Coupling+of+Thiols+and+Aryl+Bromides%2FTriflates&doi=10.1016%2Fj.tet.2005.03.078"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Pd2(dba)3/Xantphos-catalyzed cross-coupling of thiols and aryl bromides/triflates</span></div><div class="casAuthors">Mispelaere-Canivet, Clotilde; Spindler, Jean-Francis; Perrio, Stephane; Beslin, Pierre</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">5253-5259</span>CODEN:
                <span class="NLM_cas:coden">TETRAB</span>;
        ISSN:<span class="NLM_cas:issn">0040-4020</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The cross-coupling of aliph. and arom. thiols and aryl halides or triflates mediated by a Pd2(dba)3/Xantphos catalytic system in refluxing xylene afforded the corresponding aryl thioethers in good to excellent yields.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfbcJkhwf7l7Vg90H21EOLACvtfcHk0ljkksyIkzVfEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXktFWgs7k%253D&md5=54027b2333f6deb1df375bd85b36ea71</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.tet.2005.03.078&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tet.2005.03.078%26sid%3Dliteratum%253Aachs%26aulast%3DMispelaere-Canivet%26aufirst%3DC.%26aulast%3DSpindler%26aufirst%3DJ.%2BF.%26aulast%3DPerrio%26aufirst%3DS.%26aulast%3DBeslin%26aufirst%3DP.%26atitle%3DPd2%2528dba%25293%252FXantphos-Catalyzed%2520Cross-Coupling%2520of%2520Thiols%2520and%2520Aryl%2520Bromides%252FTriflates%26jtitle%3DTetrahedron%26date%3D2005%26volume%3D61%26spage%3D5253%26epage%3D5259%26doi%3D10.1016%2Fj.tet.2005.03.078" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Becht, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mioskowski, C.</span></span> <span> </span><span class="NLM_article-title">Facile Introduction of SH Group on Aromatic Substrates via Electrophilic Substitution Reactions</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">5758</span>– <span class="NLM_lpage">5761</span>, <span class="refDoi"> DOI: 10.1021/jo034013h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo034013h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADC%252BD3sXktlGqsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2003&pages=5758-5761&author=J.+M.+Bechtauthor=A.+Wagnerauthor=C.+Mioskowski&title=Facile+Introduction+of+SH+Group+on+Aromatic+Substrates+via+Electrophilic+Substitution+Reactions&doi=10.1021%2Fjo034013h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Facile Introduction of SH Group on Aromatic Substrates via Electrophilic Substitution Reactions</span></div><div class="casAuthors">Becht, Jean-Michel; Wagner, Alain; Mioskowski, Charles</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5758-5761</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A mild and efficient two-step procedure to introduce a thiol group on arom. substrates was developed.  First, reaction of arenes RH [R = Ph, 4-MeOC6H4, 4-Me2NC6H4, 2,4,6-Me3C6H2, etc.] with activated sulfoxide (MeO2CCH2CH2)2SO resulted in the corresponding arylsulfonium salt intermediates, which on treatment in situ with Et3N underwent dealkylation to give aryl sulfides RSCH2CH2CO2Me (I) in 53-95% yields.  The second β-elimination-based dealkylation reaction of I afforded the desired arylthiols RSH in good to excellent yields (71-97%).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosTB3voA8x-7Vg90H21EOLACvtfcHk0ljkksyIkzVfEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXktlGqsLo%253D&md5=6a377e8ecf56d2392b18f989c507f6d9</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fjo034013h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo034013h%26sid%3Dliteratum%253Aachs%26aulast%3DBecht%26aufirst%3DJ.%2BM.%26aulast%3DWagner%26aufirst%3DA.%26aulast%3DMioskowski%26aufirst%3DC.%26atitle%3DFacile%2520Introduction%2520of%2520SH%2520Group%2520on%2520Aromatic%2520Substrates%2520via%2520Electrophilic%2520Substitution%2520Reactions%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2003%26volume%3D68%26spage%3D5758%26epage%3D5761%26doi%3D10.1021%2Fjo034013h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dess, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, J. C.</span></span> <span> </span><span class="NLM_article-title">Readily Accessible 12-I-5 Oxidant for the Conversion of Primary and Secondary Alcohols to Aldehydes and Ketones</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1983</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">4155</span>– <span class="NLM_lpage">4156</span>, <span class="refDoi"> DOI: 10.1021/jo00170a070</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo00170a070" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADyaL3sXlslCqsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=1983&pages=4155-4156&author=D.+B.+Dessauthor=J.+C.+Martin&title=Readily+Accessible+12-I-5+Oxidant+for+the+Conversion+of+Primary+and+Secondary+Alcohols+to+Aldehydes+and+Ketones&doi=10.1021%2Fjo00170a070"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Readily accessible 12-I-5 oxidant for the conversion of primary and secondary alcohols to aldehydes and ketones</span></div><div class="casAuthors">Dess, D. B.; Martin, J. C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">1983</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">4155-6</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    </div><div class="casAbstract">Oxidn. of 2-IC6H4CO2H with KBrO3 in aq. H2SO4, followed by treatment of the oxidn. product with Ac2O gave 87% periodinane I, a 10-I-5 species (i.e., 10 valence electrons are formally involved in binding 5 ligands to the central iodine atom).  I reacted rapidly with primary or secondary alcs. at room temp. to give the corresponding aldehydes or ketones in high yield.  Excess I does not further oxidize the aldehyde or ketone under the reaction conditions.  The reaction is strongly catalyzed by excess alc. or strong acid, but is unaffected by pyridine.  I oxidizes benzylic alcs. selectively in the presence of satd. alcs.  Procedures for sepg. the carbonyl product from the reaction mixt. are mild and simple.  Cryst. I is stable at room temp. in the absence of moisture.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAtQbosBW467Vg90H21EOLACvtfcHk0ljMvK1mQG9wkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3sXlslCqsro%253D&md5=31b4835cd94c04773221d921e76231d1</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fjo00170a070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo00170a070%26sid%3Dliteratum%253Aachs%26aulast%3DDess%26aufirst%3DD.%2BB.%26aulast%3DMartin%26aufirst%3DJ.%2BC.%26atitle%3DReadily%2520Accessible%252012-I-5%2520Oxidant%2520for%2520the%2520Conversion%2520of%2520Primary%2520and%2520Secondary%2520Alcohols%2520to%2520Aldehydes%2520and%2520Ketones%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1983%26volume%3D48%26spage%3D4155%26epage%3D4156%26doi%3D10.1021%2Fjo00170a070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ellman, J. A.</span></span> <span> </span><span class="NLM_article-title">Applications of <i>Tert</i>-Butanesulfinamide in the Asymmetric Synthesis of Amines</span>. <i>Pure Appl. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>75</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">39</span>– <span class="NLM_lpage">46</span>, <span class="refDoi"> DOI: 10.1351/pac200375010039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=10.1351%2Fpac200375010039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADC%252BD3sXit1Sisr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2003&pages=39-46&issue=1&author=J.+A.+Ellman&title=Applications+of+Tert-Butanesulfinamide+in+the+Asymmetric+Synthesis+of+Amines&doi=10.1351%2Fpac200375010039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Applications of tert-butanesulfinamide in the asymmetric synthesis of amines</span></div><div class="casAuthors">Ellman, Jonathan A.</div><div class="citationInfo"><span class="NLM_cas:title">Pure and Applied Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">39-46</span>CODEN:
                <span class="NLM_cas:coden">PACHAS</span>;
        ISSN:<span class="NLM_cas:issn">0033-4545</span>.
    
            (<span class="NLM_cas:orgname">International Union of Pure and Applied Chemistry</span>)
        </div><div class="casAbstract">A review.  Tert-Butanesulfinamide (2-methyl-2-propanesulfinamide) is prepd. using catalytic enantioselective methods in two steps from the extremely inexpensive oil waste byproduct, tert-Bu disulfide.  Direct condensation of tert-butanesulfinamide with aldehydes and ketones provides tert-butanesulfinyl imines in uniformly high yields.  The tert-butanesulfinyl group activates the imines for the addn. of many different classes of nucleophiles, serves as a powerful chiral directing group, and after nucleophilic addn. is readily cleaved by treatment with acid.  A wide range of highly enantioenriched amines, including a-branched and α,α-dibranched amines, α- and β-amino acids, 1,2- and 1,3-amino alcs. and α-trifluoromethyl amines are efficiently synthesized using this methodol.  A review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreXHI36VE2U7Vg90H21EOLACvtfcHk0ljMvK1mQG9wkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXit1Sisr8%253D&md5=d4f9b92b02e94084e0ca0285ecb30af3</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1351%2Fpac200375010039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1351%252Fpac200375010039%26sid%3Dliteratum%253Aachs%26aulast%3DEllman%26aufirst%3DJ.%2BA.%26atitle%3DApplications%2520of%2520Tert-Butanesulfinamide%2520in%2520the%2520Asymmetric%2520Synthesis%2520of%2520Amines%26jtitle%3DPure%2520Appl.%2520Chem.%26date%3D2003%26volume%3D75%26issue%3D1%26spage%3D39%26epage%3D46%26doi%3D10.1351%2Fpac200375010039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Bagdanoff, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dore, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Firestone, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fodor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fortanet, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hentemann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koenig, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaBonte, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohseni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ntaganda, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarver, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sendzik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stams, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spence, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Towler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaMarche, M. J.</span></span> <span> </span><span class="NLM_article-title">Optimization of Fused Bicyclic Allosteric SHP2 Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">1781</span>– <span class="NLM_lpage">1792</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01725</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01725" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFKjtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=1781-1792&author=J.+T.+Bagdanoffauthor=Z.+Chenauthor=M.+Ackerauthor=Y.+Chenauthor=H.+Chanauthor=M.+Doreauthor=B.+Firestoneauthor=M.+Fodorauthor=J.+Fortanetauthor=M.+Hentemannauthor=M.+Katoauthor=R.+Koenigauthor=L.+R.+LaBonteauthor=S.+Liuauthor=M.+Mohseniauthor=R.+Ntagandaauthor=P.+Sarverauthor=T.+Smithauthor=M.+Sendzikauthor=T.+Stamsauthor=S.+Spenceauthor=C.+Towlerauthor=H.+Wangauthor=P.+Wangauthor=S.+L.+Williamsauthor=M.+J.+LaMarche&title=Optimization+of+Fused+Bicyclic+Allosteric+SHP2+Inhibitors&doi=10.1021%2Facs.jmedchem.8b01725"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34aR"><div class="casContent"><span class="casTitleNuber">34a</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of Fused Bicyclic Allosteric SHP2 Inhibitors</span></div><div class="casAuthors">Bagdanoff, Jeffrey T.; Chen, Zhouliang; Acker, Michael; Chen, Ying-Nan; Chan, Homan; Dore, Michael; Firestone, Brant; Fodor, Michelle; Fortanet, Jorge; Hentemann, Murphy; Kato, Mitsunori; Koenig, Robert; La Bonte, Laura R.; Liu, Shumei; Mohseni, Movarid; Ntaganda, Rukundo; Sarver, Patrick; Smith, Troy; Sendzik, Martin; Stams, Travis; Spence, Stan; Towler, Christopher; Wang, Hongyun; Wang, Ping; Williams, Sarah L.; La Marche, Matthew J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1781-1792</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">SHP2 is a nonreceptor protein tyrosine phosphatase within the mitogen-activated protein kinase (MAPK) pathway controlling cell growth, differentiation, and oncogenic transformation.  SHP2 also participates in the programed cell death pathway (PD-1/PD-L1) governing immune surveillance.  Small-mol. inhibition of SHP2 has been widely investigated, including in our previous reports describing SHP099 (2), which binds to a tunnel-like allosteric binding site.  To broaden our approach to allosteric inhibition of SHP2, we conducted addnl. hit finding, evaluation, and structure-based scaffold morphing.  These studies, reported here in the first of two papers, led to the identification of multiple 5,6-fused bicyclic scaffolds that bind to the same allosteric tunnel as 2.  We demonstrate the structural diversity permitted by the tunnel pharmacophore and culminated in the identification of pyrazolopyrimidinones (e.g., SHP389, 1) that modulate MAPK signaling in vivo.  These studies also served as the basis for further scaffold morphing and optimization, detailed in the following manuscript.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGra2OF_vrNnP7Vg90H21EOLACvtfcHk0ljMvK1mQG9wkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFKjtbo%253D&md5=e810a8a6bd1d1fb7bfadc5bc1448ff22</span></div><a href="/servlet/linkout?suffix=cit34a&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01725&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01725%26sid%3Dliteratum%253Aachs%26aulast%3DBagdanoff%26aufirst%3DJ.%2BT.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DAcker%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DChan%26aufirst%3DH.%26aulast%3DDore%26aufirst%3DM.%26aulast%3DFirestone%26aufirst%3DB.%26aulast%3DFodor%26aufirst%3DM.%26aulast%3DFortanet%26aufirst%3DJ.%26aulast%3DHentemann%26aufirst%3DM.%26aulast%3DKato%26aufirst%3DM.%26aulast%3DKoenig%26aufirst%3DR.%26aulast%3DLaBonte%26aufirst%3DL.%2BR.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DMohseni%26aufirst%3DM.%26aulast%3DNtaganda%26aufirst%3DR.%26aulast%3DSarver%26aufirst%3DP.%26aulast%3DSmith%26aufirst%3DT.%26aulast%3DSendzik%26aufirst%3DM.%26aulast%3DStams%26aufirst%3DT.%26aulast%3DSpence%26aufirst%3DS.%26aulast%3DTowler%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DWilliams%26aufirst%3DS.%2BL.%26aulast%3DLaMarche%26aufirst%3DM.%2BJ.%26atitle%3DOptimization%2520of%2520Fused%2520Bicyclic%2520Allosteric%2520SHP2%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D1781%26epage%3D1792%26doi%3D10.1021%2Facs.jmedchem.8b01725" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit34b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Sarver, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagdanoff, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Firestone, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fodor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fortanet, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hentemann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koenig, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaBonte, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNeill, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohseni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sendzik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stams, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spence, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamez, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tichkule, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Towler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaMarche, M. J.</span></span> <span> </span><span class="NLM_article-title">6-Amino-3-methylpyrimidinones as Potent, Selective, and Orally Efficacious SHP2 Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">1793</span>– <span class="NLM_lpage">1802</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01726</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01726" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFKisLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=1793-1802&author=P.+Sarverauthor=M.+Ackerauthor=J.+T.+Bagdanoffauthor=Z.+Chenauthor=Y.+Chenauthor=H.+Chanauthor=B.+Firestoneauthor=M.+Fodorauthor=J.+Fortanetauthor=H.+Haoauthor=M.+Hentemannauthor=M.+Katoauthor=R.+Koenigauthor=L.+R.+LaBonteauthor=G.+Liuauthor=S.+Liuauthor=C.+Liuauthor=E.+McNeillauthor=M.+Mohseniauthor=M.+Sendzikauthor=T.+Stamsauthor=S.+Spenceauthor=V.+Tamezauthor=R.+Tichkuleauthor=C.+Towlerauthor=H.+Wangauthor=P.+Wangauthor=S.+L.+Williamsauthor=B.+Yuauthor=M.+J.+LaMarche&title=6-Amino-3-methylpyrimidinones+as+Potent%2C+Selective%2C+and+Orally+Efficacious+SHP2+Inhibitors&doi=10.1021%2Facs.jmedchem.8b01726"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34bR"><div class="casContent"><span class="casTitleNuber">34b</span><div class="casTitle"><span class="NLM_cas:atitle">6-Amino-3-methylpyrimidinones as Potent, Selective, and Orally Efficacious SHP2 Inhibitors</span></div><div class="casAuthors">Sarver, Patrick; Acker, Michael; Bagdanoff, Jeffrey T.; Chen, Zhouliang; Chen, Ying-Nan; Chan, Homan; Firestone, Brant; Fodor, Michelle; Fortanet, Jorge; Hao, Huaixiang; Hentemann, Murphy; Koenig, Robert; Kato, Mitsunori; LaBonte, Laura R.; Liu, Gang; Liu, Shumei; Liu, Chen; McNeill, Eric; Mohseni, Morvarid; Sendzik, Martin; Stams, Travis; Spence, Stan; Tamez, Victoriano; Tichkule, Ritesh; Towler, Christopher; Wang, Hongyun; Wang, Ping; Williams, Sarah L.; Yu, Bing; LaMarche, Matthew J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1793-1802</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Protein tyrosine phosphatase SHP2 is an oncoprotein assocd. with cancer as well as a potential immune modulator because of its role in the programmed cell death PD-L1/PD-1 pathway.  In the preceding manuscript, we described the optimization of a fused, bicyclic screening hit for potency, selectivity, and physicochem. properties in order to further expand the chem. diversity of allosteric SHP2 inhibitors.  In this manuscript, we describe the further expansion of our approach, morphing the fused, bicyclic system into a novel monocyclic pyrimidinone scaffold through our understanding of SAR and use of structure-based design.  These studies led to the identification of SHP394 (1), an orally efficacious inhibitor of SHP2, with high lipophilic efficiency, improved potency, and enhanced pharmacokinetic properties.  We also report other pyrimidinone analogs with favorable pharmacokinetic and potency profiles.  Overall, this work improves upon our previously described allosteric inhibitors and exemplifies and extends the range of permissible chem. templates that inhibit SHP2 via the allosteric mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaRey6_uE0ULVg90H21EOLACvtfcHk0lhsoM_16MuY4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFKisLs%253D&md5=29c357236b7ff51596385e3e256320a5</span></div><a href="/servlet/linkout?suffix=cit34b&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01726&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01726%26sid%3Dliteratum%253Aachs%26aulast%3DSarver%26aufirst%3DP.%26aulast%3DAcker%26aufirst%3DM.%26aulast%3DBagdanoff%26aufirst%3DJ.%2BT.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DChan%26aufirst%3DH.%26aulast%3DFirestone%26aufirst%3DB.%26aulast%3DFodor%26aufirst%3DM.%26aulast%3DFortanet%26aufirst%3DJ.%26aulast%3DHao%26aufirst%3DH.%26aulast%3DHentemann%26aufirst%3DM.%26aulast%3DKato%26aufirst%3DM.%26aulast%3DKoenig%26aufirst%3DR.%26aulast%3DLaBonte%26aufirst%3DL.%2BR.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DMcNeill%26aufirst%3DE.%26aulast%3DMohseni%26aufirst%3DM.%26aulast%3DSendzik%26aufirst%3DM.%26aulast%3DStams%26aufirst%3DT.%26aulast%3DSpence%26aufirst%3DS.%26aulast%3DTamez%26aufirst%3DV.%26aulast%3DTichkule%26aufirst%3DR.%26aulast%3DTowler%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DWilliams%26aufirst%3DS.%2BL.%26aulast%3DYu%26aufirst%3DB.%26aulast%3DLaMarche%26aufirst%3DM.%2BJ.%26atitle%3D6-Amino-3-methylpyrimidinones%2520as%2520Potent%252C%2520Selective%252C%2520and%2520Orally%2520Efficacious%2520SHP2%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D1793%26epage%3D1802%26doi%3D10.1021%2Facs.jmedchem.8b01726" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="note"><p class="first last">Novartis SHP2 patents:</p></div><div class="NLM_citation" id="rightTab-cit35a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span>; <span class="NLM_string-name">Fortanet, J. G.</span>; <span class="NLM_string-name">Grunenfelder, D.</span>; <span class="NLM_string-name">Karki, R.</span>; <span class="NLM_string-name">Kato, M.</span>; <span class="NLM_string-name">LaMarche, M. J.</span>; <span class="NLM_string-name">Perez, L. B.</span>; <span class="NLM_string-name">Stams, T. M.</span>; <span class="NLM_string-name">Williams, S.</span></span> <span> </span><span class="NLM_article-title">1-Pyridazine-/triazine-3-yl-piper(-azine)idine/pyrolidine Derivatives and Compositions Thereof for Inhibiting the Activity of SHP2</span>. Patent <span class="NLM_patent">WO2015107493</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=Z.+Chen&author=J.+G.+Fortanet&author=D.+Grunenfelder&author=R.+Karki&author=M.+Kato&author=M.+J.+LaMarche&author=L.+B.+Perez&author=T.+M.+Stams&author=S.+Williams&title=1-Pyridazine-%2Ftriazine-3-yl-piper%28-azine%29idine%2Fpyrolidine+Derivatives+and+Compositions+Thereof+for+Inhibiting+the+Activity+of+SHP2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DZ.%26atitle%3D1-Pyridazine-%252Ftriazine-3-yl-piper%2528-azine%2529idine%252Fpyrolidine%2520Derivatives%2520and%2520Compositions%2520Thereof%2520for%2520Inhibiting%2520the%2520Activity%2520of%2520SHP2%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit35b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span>; <span class="NLM_string-name">Dore, M.</span>; <span class="NLM_string-name">Fortanet, J. G.</span>; <span class="NLM_string-name">Karki, R.</span>; <span class="NLM_string-name">Kato, M.</span>; <span class="NLM_string-name">LaMarche, M. J.</span>; <span class="NLM_string-name">Perez, L. B.</span>; <span class="NLM_string-name">Williams, S.</span>; <span class="NLM_string-name">Sendzik, M.</span></span> <span> </span><span class="NLM_article-title">1-(Triazin-3-yl/pyridazine-3-yl)-piper(-azine)idine Derivatives and Compositions Thereof for Inhibiting the Activity of SHP2</span>. Patent <span class="NLM_patent">WO2015107494</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=Z.+Chen&author=M.+Dore&author=J.+G.+Fortanet&author=R.+Karki&author=M.+Kato&author=M.+J.+LaMarche&author=L.+B.+Perez&author=S.+Williams&author=M.+Sendzik&title=1-%28Triazin-3-yl%2Fpyridazine-3-yl%29-piper%28-azine%29idine+Derivatives+and+Compositions+Thereof+for+Inhibiting+the+Activity+of+SHP2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DZ.%26atitle%3D1-%2528Triazin-3-yl%252Fpyridazine-3-yl%2529-piper%2528-azine%2529idine%2520Derivatives%2520and%2520Compositions%2520Thereof%2520for%2520Inhibiting%2520the%2520Activity%2520of%2520SHP2%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit35c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. H.</span>; <span class="NLM_string-name">Chen, Z.</span>; <span class="NLM_string-name">Dore, M.</span>; <span class="NLM_string-name">Fortanet, J. G.</span>; <span class="NLM_string-name">Karki, R.</span>; <span class="NLM_string-name">Kato, M.</span>; <span class="NLM_string-name">LaMarche, M. J.</span>; <span class="NLM_string-name">Perez, L. B.</span>; <span class="NLM_string-name">Smith, T.</span>; <span class="NLM_string-name">Williams, S.</span>; <span class="NLM_string-name">Toure, B. B.</span>; <span class="NLM_string-name">Sendzik, M.</span></span> <span> </span><span class="NLM_article-title"><i>N</i>-azaspirocycloalkane Substituted <i>N</i>-heteroaryl Compounds and Compositions for Inhibiting the Activity of SHP2</span>. Patent <span class="NLM_patent">WO2015107495</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=C.+H.+Chen&author=Z.+Chen&author=M.+Dore&author=J.+G.+Fortanet&author=R.+Karki&author=M.+Kato&author=M.+J.+LaMarche&author=L.+B.+Perez&author=T.+Smith&author=S.+Williams&author=B.+B.+Toure&author=M.+Sendzik&title=N-azaspirocycloalkane+Substituted+N-heteroaryl+Compounds+and+Compositions+for+Inhibiting+the+Activity+of+SHP2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DC.%2BH.%26atitle%3DN-azaspirocycloalkane%2520Substituted%2520N-heteroaryl%2520Compounds%2520and%2520Compositions%2520for%2520Inhibiting%2520the%2520Activity%2520of%2520SHP2%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit35d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Bagdanoff, J. T.</span>; <span class="NLM_string-name">Chen, Z.</span>; <span class="NLM_string-name">Dore, M.</span>; <span class="NLM_string-name">Fortanet, J. G.</span>; <span class="NLM_string-name">Kato, M.</span>; <span class="NLM_string-name">LaMarche, M. J.</span>; <span class="NLM_string-name">Sarver, P. J.</span>; <span class="NLM_string-name">Shultz, M.</span>; <span class="NLM_string-name">Smith, T. D.</span>; <span class="NLM_string-name">Williams, S.</span></span> <span> </span><span class="NLM_article-title">Compounds and Compositions for Inhibiting the Activity of SHP2</span>. Patent <span class="NLM_patent">WO2016203404</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=J.+T.+Bagdanoff&author=Z.+Chen&author=M.+Dore&author=J.+G.+Fortanet&author=M.+Kato&author=M.+J.+LaMarche&author=P.+J.+Sarver&author=M.+Shultz&author=T.+D.+Smith&author=S.+Williams&title=Compounds+and+Compositions+for+Inhibiting+the+Activity+of+SHP2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBagdanoff%26aufirst%3DJ.%2BT.%26atitle%3DCompounds%2520and%2520Compositions%2520for%2520Inhibiting%2520the%2520Activity%2520of%2520SHP2%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit35e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span>; <span class="NLM_string-name">Fortanet, J. G.</span>; <span class="NLM_string-name">LaMarche, M. J.</span>; <span class="NLM_string-name">Sendzik, M.</span>; <span class="NLM_string-name">Tamez, V.</span>; <span class="NLM_string-name">Yu, B.</span></span> <span> </span><span class="NLM_article-title">Compounds and Compositions for Inhibiting the Activity of SHP2</span>. Patent <span class="NLM_patent">WO2016203405</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=Z.+Chen&author=J.+G.+Fortanet&author=M.+J.+LaMarche&author=M.+Sendzik&author=V.+Tamez&author=B.+Yu&title=Compounds+and+Compositions+for+Inhibiting+the+Activity+of+SHP2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35e&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DZ.%26atitle%3DCompounds%2520and%2520Compositions%2520for%2520Inhibiting%2520the%2520Activity%2520of%2520SHP2%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit35f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span>; <span class="NLM_string-name">Fortanet, J. G.</span>; <span class="NLM_string-name">Jouk, A.</span>; <span class="NLM_string-name">Karki, R.</span>; <span class="NLM_string-name">LaMarche, M. J.</span>; <span class="NLM_string-name">Liu, G.</span>; <span class="NLM_string-name">Palermo, M.</span>; <span class="NLM_string-name">Perez, L. B.</span>; <span class="NLM_string-name">Sarver, P. J.</span>; <span class="NLM_string-name">Shultz, M. D.</span>; <span class="NLM_string-name">Sendzik, M.</span>; <span class="NLM_string-name">Toure, B. B.</span>; <span class="NLM_string-name">Yu, B.</span></span> <span> </span><span class="NLM_article-title">Compounds and Compositions for Inhibiting the Activity of SHP2</span>. Patent <span class="NLM_patent">WO2016203406</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=Z.+Chen&author=J.+G.+Fortanet&author=A.+Jouk&author=R.+Karki&author=M.+J.+LaMarche&author=G.+Liu&author=M.+Palermo&author=L.+B.+Perez&author=P.+J.+Sarver&author=M.+D.+Shultz&author=M.+Sendzik&author=B.+B.+Toure&author=B.+Yu&title=Compounds+and+Compositions+for+Inhibiting+the+Activity+of+SHP2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35f&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DZ.%26atitle%3DCompounds%2520and%2520Compositions%2520for%2520Inhibiting%2520the%2520Activity%2520of%2520SHP2%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit35g"><span><span class="NLM_label">(g) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span>; <span class="NLM_string-name">Fortanet, J. G.</span>; <span class="NLM_string-name">Karki, R.</span>; <span class="NLM_string-name">LaMarche, M. J.</span>; <span class="NLM_string-name">Majumdar, D.</span>; <span class="NLM_string-name">Perez, L. B.</span>; <span class="NLM_string-name">Sendzik, M.</span>; <span class="NLM_string-name">Smith, T. D.</span>; <span class="NLM_string-name">Yang, F.</span>; <span class="NLM_string-name">Yu, B.</span></span> <span> </span><span class="NLM_article-title">Compounds and Compositions for Inhibiting the Activity of SHP2</span>. Patent <span class="NLM_patent">WO2017216706</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=Z.+Chen&author=J.+G.+Fortanet&author=R.+Karki&author=M.+J.+LaMarche&author=D.+Majumdar&author=L.+B.+Perez&author=M.+Sendzik&author=T.+D.+Smith&author=F.+Yang&author=B.+Yu&title=Compounds+and+Compositions+for+Inhibiting+the+Activity+of+SHP2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35g&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DZ.%26atitle%3DCompounds%2520and%2520Compositions%2520for%2520Inhibiting%2520the%2520Activity%2520of%2520SHP2%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Czako, B.</span>; <span class="NLM_string-name">Jones, P.</span>; <span class="NLM_string-name">Cross, P.</span>; <span class="NLM_string-name">Leonard, P.</span></span> <span> </span><span class="NLM_article-title">Heterocyclic Inhibitors of PTPN11</span>. Patent <span class="NLM_patent">WO2017156397</span>, <span class="NLM_year">2017</span> (University of Texas).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=B.+Czako&author=P.+Jones&author=P.+Cross&author=P.+Leonard&title=Heterocyclic+Inhibitors+of+PTPN11"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCzako%26aufirst%3DB.%26atitle%3DHeterocyclic%2520Inhibitors%2520of%2520PTPN11%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit36b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span>; <span class="NLM_string-name">Gu, S.</span>; <span class="NLM_string-name">Si, X.</span>; <span class="NLM_string-name">Xie, J.</span>; <span class="NLM_string-name">Shen, J.</span></span> <span> </span><span class="NLM_article-title"><i>N</i>-heterocyclic Ring Compound, and Intermediate, Preparation Method, Medicine Composition and Application Thereof</span>. Patent <span class="NLM_patent">CN107286150</span>, <span class="NLM_year">2017</span> (Shanghai Organic Institute).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=J.+Zhu&author=S.+Gu&author=X.+Si&author=J.+Xie&author=J.+Shen&title=N-heterocyclic+Ring+Compound%2C+and+Intermediate%2C+Preparation+Method%2C+Medicine+Composition+and+Application+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DJ.%26atitle%3DN-heterocyclic%2520Ring%2520Compound%252C%2520and%2520Intermediate%252C%2520Preparation%2520Method%252C%2520Medicine%2520Composition%2520and%2520Application%2520Thereof%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit36c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Jones, P.</span>; <span class="NLM_string-name">Czako, B.</span>; <span class="NLM_string-name">Cross, P.</span>; <span class="NLM_string-name">Leonard, P.</span>; <span class="NLM_string-name">Mseeh, F.</span></span> <span> </span><span class="NLM_article-title">Heterocyclic Inhibitors of PTPN11</span>. <span class="NLM_patent">WO2017210134</span>, <span class="NLM_year">2017</span> (University of Texas).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=P.+Jones&author=B.+Czako&author=P.+Cross&author=P.+Leonard&author=F.+Mseeh&title=Heterocyclic+Inhibitors+of+PTPN11"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DP.%26atitle%3DHeterocyclic%2520Inhibitors%2520of%2520PTPN11%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit36d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Jones, P.</span>; <span class="NLM_string-name">Cross, P.</span>; <span class="NLM_string-name">Burke, J.</span>; <span class="NLM_string-name">Mcafoos, T.</span>; <span class="NLM_string-name">Kang, Z.</span></span> <span> </span><span class="NLM_article-title">Substituted Heterocyclic Inhibitors of PTPN11</span>. Patent <span class="NLM_patent">WO2019213318</span>, <span class="NLM_year">2019</span> (University of Texas).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=P.+Jones&author=P.+Cross&author=J.+Burke&author=T.+Mcafoos&author=Z.+Kang&title=Substituted+Heterocyclic+Inhibitors+of+PTPN11"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DP.%26atitle%3DSubstituted%2520Heterocyclic%2520Inhibitors%2520of%2520PTPN11%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit36e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Jones, P.</span>; <span class="NLM_string-name">Czako, B.</span>; <span class="NLM_string-name">Carroll, C.</span>; <span class="NLM_string-name">Mandal, P.</span>; <span class="NLM_string-name">Cross, P.</span></span> <span> </span><span class="NLM_article-title">6-(4-Amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(2,3-dichlorophenyl)-2-methylpyrimidine-4(3H)-one Derivatives and Related Compounds as PTPN11 (SHP2) Inhibitors for Treating Cancer</span>. Patent <span class="NLM_patent">WO2020033828</span>, <span class="NLM_year">2019</span> (University of Texas).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=P.+Jones&author=B.+Czako&author=C.+Carroll&author=P.+Mandal&author=P.+Cross&title=6-%284-Amino-3-methyl-2-oxa-8-azaspiro%5B4.5%5Ddecan-8-yl%29-3-%282%2C3-dichlorophenyl%29-2-methylpyrimidine-4%283H%29-one+Derivatives+and+Related+Compounds+as+PTPN11+%28SHP2%29+Inhibitors+for+Treating+Cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36e&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DP.%26atitle%3D6-%25284-Amino-3-methyl-2-oxa-8-azaspiro%255B4.5%255Ddecan-8-yl%2529-3-%25282%252C3-dichlorophenyl%2529-2-methylpyrimidine-4%25283H%2529-one%2520Derivatives%2520and%2520Related%2520Compounds%2520as%2520PTPN11%2520%2528SHP2%2529%2520Inhibitors%2520for%2520Treating%2520Cancer%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, C.</span>; <span class="NLM_string-name">Gao, P.</span>; <span class="NLM_string-name">Chu, J.</span>; <span class="NLM_string-name">Wu, X.</span>; <span class="NLM_string-name">Wen, C.</span>; <span class="NLM_string-name">Kang, D.</span>; <span class="NLM_string-name">Bai, J.</span>; <span class="NLM_string-name">Pei, X.</span></span> <span> </span><span class="NLM_article-title">Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors</span>. Patent <span class="NLM_patent">WO2017211303</span>, <span class="NLM_year">2017</span> (Jacobio).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=C.+Ma&author=P.+Gao&author=J.+Chu&author=X.+Wu&author=C.+Wen&author=D.+Kang&author=J.+Bai&author=X.+Pei&title=Novel+Heterocyclic+Derivatives+Useful+as+SHP2+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DC.%26atitle%3DNovel%2520Heterocyclic%2520Derivatives%2520Useful%2520as%2520SHP2%2520Inhibitors%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit37b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, C.</span>; <span class="NLM_string-name">Gao, P.</span>; <span class="NLM_string-name">Hu, S.</span>; <span class="NLM_string-name">Xu, Z.</span>; <span class="NLM_string-name">Han, H.</span>; <span class="NLM_string-name">Wu, X.</span>; <span class="NLM_string-name">Kang, D.</span>; <span class="NLM_string-name">Long, W.</span></span> <span> </span><span class="NLM_article-title">Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors</span>. Patent <span class="NLM_patent">WO2018172984</span>, <span class="NLM_year">2018</span> (Jacobio).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=C.+Ma&author=P.+Gao&author=S.+Hu&author=Z.+Xu&author=H.+Han&author=X.+Wu&author=D.+Kang&author=W.+Long&title=Novel+Heterocyclic+Derivatives+Useful+as+SHP2+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DC.%26atitle%3DNovel%2520Heterocyclic%2520Derivatives%2520Useful%2520as%2520SHP2%2520Inhibitors%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit37c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Han, H.</span>; <span class="NLM_string-name">Gao, P.</span>; <span class="NLM_string-name">Ma, C.</span>; <span class="NLM_string-name">Kang, D.</span></span> <span> </span><span class="NLM_article-title">Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors</span>. Patent <span class="NLM_patent">WO2020063760</span>, <span class="NLM_year">2019</span> (Jacobio).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=H.+Han&author=P.+Gao&author=C.+Ma&author=D.+Kang&title=Novel+Heterocyclic+Derivatives+Useful+as+SHP2+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DH.%26atitle%3DNovel%2520Heterocyclic%2520Derivatives%2520Useful%2520as%2520SHP2%2520Inhibitors%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit37d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Jogalekar, A.</span>; <span class="NLM_string-name">Won, W.</span>; <span class="NLM_string-name">Koltun, E. S.</span>; <span class="NLM_string-name">Gill, A.</span>; <span class="NLM_string-name">Mellem, K.</span>; <span class="NLM_string-name">Aay, N.</span>; <span class="NLM_string-name">Buckl, A.</span>; <span class="NLM_string-name">Semko, C.</span>; <span class="NLM_string-name">Kiss, G.</span></span> <span> </span><span class="NLM_article-title">2,5-Disubstituted 3-Methyl Pyrazines and 2,5,6-Trisubstituted 3-Methyl Pyrazines as Allosteric SHP2 Inhibitors</span>. Patent <span class="NLM_patent">WO2018013597</span>, <span class="NLM_year">2017</span> (Revolution Medicines).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=A.+Jogalekar&author=W.+Won&author=E.+S.+Koltun&author=A.+Gill&author=K.+Mellem&author=N.+Aay&author=A.+Buckl&author=C.+Semko&author=G.+Kiss&title=2%2C5-Disubstituted+3-Methyl+Pyrazines+and+2%2C5%2C6-Trisubstituted+3-Methyl+Pyrazines+as+Allosteric+SHP2+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DJogalekar%26aufirst%3DA.%26atitle%3D2%252C5-Disubstituted%25203-Methyl%2520Pyrazines%2520and%25202%252C5%252C6-Trisubstituted%25203-Methyl%2520Pyrazines%2520as%2520Allosteric%2520SHP2%2520Inhibitors%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit37e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Gill, A.</span>; <span class="NLM_string-name">Aay, N.</span>; <span class="NLM_string-name">Mellem, K.</span>; <span class="NLM_string-name">Buckyl, A.</span>; <span class="NLM_string-name">Koltun, E. S.</span>; <span class="NLM_string-name">Semko, C.</span>; <span class="NLM_string-name">Kiss, G.</span></span> <span> </span><span class="NLM_article-title">Pyridine Compounds as Allosteric SHP2 Inhibitors</span>. Patent <span class="NLM_patent">WO2018136264</span>, <span class="NLM_year">2018</span> (Revolution Medicines).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=A.+Gill&author=N.+Aay&author=K.+Mellem&author=A.+Buckyl&author=E.+S.+Koltun&author=C.+Semko&author=G.+Kiss&title=Pyridine+Compounds+as+Allosteric+SHP2+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37e&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGill%26aufirst%3DA.%26atitle%3DPyridine%2520Compounds%2520as%2520Allosteric%2520SHP2%2520Inhibitors%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit37f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Blank, B. R.</span>; <span class="NLM_string-name">Pitzen, J.</span>; <span class="NLM_string-name">Wang, G.</span>; <span class="NLM_string-name">Won, W. S.</span>; <span class="NLM_string-name">Tzitzilonis, C.</span>; <span class="NLM_string-name">Li, J. J.</span>; <span class="NLM_string-name">Koltun, E. S.</span>; <span class="NLM_string-name">Aay, N.</span>; <span class="NLM_string-name">Buckyl, A.</span>; <span class="NLM_string-name">Mellem, K.</span>; <span class="NLM_string-name">Semko, C.</span>; <span class="NLM_string-name">Jogalekar, A.</span>; <span class="NLM_string-name">Kiss, G.</span>; <span class="NLM_string-name">Gill, A.</span></span> <span> </span><span class="NLM_article-title">Bicyclic Compounds as Allosteric SHP2 Inhibitors</span>. Patent <span class="NLM_patent">WO2018136265</span>, <span class="NLM_year">2018</span> (Revolution Medicines).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=B.+R.+Blank&author=J.+Pitzen&author=G.+Wang&author=W.+S.+Won&author=C.+Tzitzilonis&author=J.+J.+Li&author=E.+S.+Koltun&author=N.+Aay&author=A.+Buckyl&author=K.+Mellem&author=C.+Semko&author=A.+Jogalekar&author=G.+Kiss&author=A.+Gill&title=Bicyclic+Compounds+as+Allosteric+SHP2+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37f&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBlank%26aufirst%3DB.%2BR.%26atitle%3DBicyclic%2520Compounds%2520as%2520Allosteric%2520SHP2%2520Inhibitors%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit37g"><span><span class="NLM_label">(g) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Albrecht, B. K.</span>; <span class="NLM_string-name">Giordanetto, F.</span>; <span class="NLM_string-name">Greisman, J. B.</span>; <span class="NLM_string-name">Maragakis, P.</span>; <span class="NLM_string-name">Taylor, A. M.</span>; <span class="NLM_string-name">Walters, W. P.</span></span> <span> </span><span class="NLM_article-title">SHP2 Phosphatase Inhibitors and Methods of Use Thereof</span>. Patent <span class="NLM_patent">WO2018057884</span>, <span class="NLM_year">2017</span> (Relay Therapeutics).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=B.+K.+Albrecht&author=F.+Giordanetto&author=J.+B.+Greisman&author=P.+Maragakis&author=A.+M.+Taylor&author=W.+P.+Walters&title=SHP2+Phosphatase+Inhibitors+and+Methods+of+Use+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37g&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAlbrecht%26aufirst%3DB.%2BK.%26atitle%3DSHP2%2520Phosphatase%2520Inhibitors%2520and%2520Methods%2520of%2520Use%2520Thereof%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit37h"><span><span class="NLM_label">(h) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Giordanetto, F.</span>; <span class="NLM_string-name">Greisman, J. B.</span>; <span class="NLM_string-name">Maragakis, P.</span>; <span class="NLM_string-name">Taylor, A. M.</span>; <span class="NLM_string-name">Dipietro, L. V.</span>; <span class="NLM_string-name">Kelley, E. H.</span>; <span class="NLM_string-name">Lescarbeau, A.</span>; <span class="NLM_string-name">Murcko, M. A.</span>; <span class="NLM_string-name">Pierce, L. C. T.</span>; <span class="NLM_string-name">Shortsleeves, K. C.</span>; <span class="NLM_string-name">Walters, W. P.</span>; <span class="NLM_string-name">Bhat, S.</span>; <span class="NLM_string-name">Therrien, E.</span>; <span class="NLM_string-name">Dahlgren, M. K.</span></span> <span> </span><span class="NLM_article-title">Pyrazolo[3,4-b]pyrazine Derivatives as SHP2 Phosphatase Inhibitors</span>. Patent <span class="NLM_patent">WO2018081091</span>, <span class="NLM_year">2017</span> (Relay Therapeutics).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=F.+Giordanetto&author=J.+B.+Greisman&author=P.+Maragakis&author=A.+M.+Taylor&author=L.+V.+Dipietro&author=E.+H.+Kelley&author=A.+Lescarbeau&author=M.+A.+Murcko&author=L.+C.+T.+Pierce&author=K.+C.+Shortsleeves&author=W.+P.+Walters&author=S.+Bhat&author=E.+Therrien&author=M.+K.+Dahlgren&title=Pyrazolo%5B3%2C4-b%5Dpyrazine+Derivatives+as+SHP2+Phosphatase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37h&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGiordanetto%26aufirst%3DF.%26atitle%3DPyrazolo%255B3%252C4-b%255Dpyrazine%2520Derivatives%2520as%2520SHP2%2520Phosphatase%2520Inhibitors%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit37i"><span><span class="NLM_label">(i) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, A. M.</span>; <span class="NLM_string-name">Lescarbeau, A.</span>; <span class="NLM_string-name">Kelley, E. H.</span>; <span class="NLM_string-name">Shortsleeves, K. C.</span>; <span class="NLM_string-name">Dipietro, L. V.</span>; <span class="NLM_string-name">Walters, W. P.</span>; <span class="NLM_string-name">Murcko, M. A.</span>; <span class="NLM_string-name">Pierce, L. C.</span>; <span class="NLM_string-name">Tang, Y.</span>; <span class="NLM_string-name">Giordanetto, F.</span>; <span class="NLM_string-name">Greisman, J. B.</span>; <span class="NLM_string-name">Maragakis, P.</span>; <span class="NLM_string-name">Bhat, S.</span>; <span class="NLM_string-name">Dahlgeren, M. K.</span>; <span class="NLM_string-name">Therrien, E.</span></span> <span> </span><span class="NLM_article-title">Pyrazolo[3,4-b]pyrazine Derivatives as SHP2 Phosphatase Inhibitors</span>. Patent <span class="NLM_patent">WO2018218133</span>, <span class="NLM_year">2018</span> (Relay Therapeutics).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=A.+M.+Taylor&author=A.+Lescarbeau&author=E.+H.+Kelley&author=K.+C.+Shortsleeves&author=L.+V.+Dipietro&author=W.+P.+Walters&author=M.+A.+Murcko&author=L.+C.+Pierce&author=Y.+Tang&author=F.+Giordanetto&author=J.+B.+Greisman&author=P.+Maragakis&author=S.+Bhat&author=M.+K.+Dahlgeren&author=E.+Therrien&title=Pyrazolo%5B3%2C4-b%5Dpyrazine+Derivatives+as+SHP2+Phosphatase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37i&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DTaylor%26aufirst%3DA.%2BM.%26atitle%3DPyrazolo%255B3%252C4-b%255Dpyrazine%2520Derivatives%2520as%2520SHP2%2520Phosphatase%2520Inhibitors%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit37j"><span><span class="NLM_label">(j) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Nichols, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haderk, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahlhut, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulze, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hemmati, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wildes, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tzitzilonis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mordec, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marquez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olivas, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCoach, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blakely, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiss, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koltun, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gill, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldsmith, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J. A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bivona, T. G.</span></span> <span> </span><span class="NLM_article-title">RAS Nucleotide Cycling Underlies the SHP2 Phosphatase Dependence of Mutant BRAF-, NF1- and RAS-Driven Cancers</span>. <i>Nat. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1064</span>, <span class="refDoi"> DOI: 10.1038/s41556-018-0169-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37j&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=10.1038%2Fs41556-018-0169-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37j&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=30104724" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37j&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsV2isLnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2018&pages=1064&author=R.+J.+Nicholsauthor=F.+Haderkauthor=C.+Stahlhutauthor=C.+J.+Schulzeauthor=G.+Hemmatiauthor=D.+Wildesauthor=C.+Tzitzilonisauthor=K.+Mordecauthor=A.+Marquezauthor=J.+Romeroauthor=T.+Hsiehauthor=A.+Zamanauthor=V.+Olivasauthor=C.+McCoachauthor=C.+M.+Blakelyauthor=Z.+Wangauthor=G.+Kissauthor=E.+S.+Koltunauthor=A.+L.+Gillauthor=M.+Singhauthor=M.+A.+Goldsmithauthor=J.+A.+M.+Smithauthor=T.+G.+Bivona&title=RAS+Nucleotide+Cycling+Underlies+the+SHP2+Phosphatase+Dependence+of+Mutant+BRAF-%2C+NF1-+and+RAS-Driven+Cancers&doi=10.1038%2Fs41556-018-0169-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37jR"><div class="casContent"><span class="casTitleNuber">37j</span><div class="casTitle"><span class="NLM_cas:atitle">RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers</span></div><div class="casAuthors">Nichols, Robert J.; Haderk, Franziska; Stahlhut, Carlos; Schulze, Christopher J.; Hemmati, Golzar; Wildes, David; Tzitzilonis, Christos; Mordec, Kasia; Marquez, Abby; Romero, Jason; Hsieh, Tientien; Zaman, Aubhishek; Olivas, Victor; McCoach, Caroline; Blakely, Collin M.; Wang, Zhengping; Kiss, Gert; Koltun, Elena S.; Gill, Adrian L.; Singh, Mallika; Goldsmith, Mark A.; Smith, Jacqueline A. M.; Bivona, Trever G.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Cell Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1064-1073</span>CODEN:
                <span class="NLM_cas:coden">NCBIFN</span>;
        ISSN:<span class="NLM_cas:issn">1465-7392</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Oncogenic alterations in the RAS/RAF/MEK/ERK pathway drive the growth of a wide spectrum of cancers.  While BRAF and MEK inhibitors are efficacious against BRAFV600E-driven cancers, effective targeted therapies are lacking for most cancers driven by other pathway alterations, including non-V600E oncogenic BRAF, RAS GTPase-activating protein (GAP) NF1 (neurofibromin 1) loss and oncogenic KRAS.  Here, we show that targeting the SHP2 phosphatase (encoded by PTPN11) with RMC-4550, a small-mol. allosteric inhibitor, is effective in human cancer models bearing RAS-GTP-dependent oncogenic BRAF (for example, class 3 BRAF mutants), NF1 loss or nucleotide-cycling oncogenic RAS (for example, KRASG12C).  SHP2 inhibitor treatment decreases oncogenic RAS/RAF/MEK/ERK signalling and cancer growth by disrupting SOS1-mediated RAS-GTP loading.  Our findings illuminate a crit. function for SHP2 in promoting oncogenic RAS/MAPK pathway activation in cancers with RAS-GTP-dependent oncogenic BRAF, NF1 loss and nucleotide-cycling oncogenic KRAS.  SHP2 inhibition is a promising mol. therapeutic strategy for patients with cancers bearing these oncogenic drivers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2gVKE5Juu_LVg90H21EOLACvtfcHk0lgIb5v1Gc6ZDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsV2isLnP&md5=05e84e5c0d51d501c229e118f44aa6cd</span></div><a href="/servlet/linkout?suffix=cit37j&amp;dbid=16384&amp;doi=10.1038%2Fs41556-018-0169-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41556-018-0169-1%26sid%3Dliteratum%253Aachs%26aulast%3DNichols%26aufirst%3DR.%2BJ.%26aulast%3DHaderk%26aufirst%3DF.%26aulast%3DStahlhut%26aufirst%3DC.%26aulast%3DSchulze%26aufirst%3DC.%2BJ.%26aulast%3DHemmati%26aufirst%3DG.%26aulast%3DWildes%26aufirst%3DD.%26aulast%3DTzitzilonis%26aufirst%3DC.%26aulast%3DMordec%26aufirst%3DK.%26aulast%3DMarquez%26aufirst%3DA.%26aulast%3DRomero%26aufirst%3DJ.%26aulast%3DHsieh%26aufirst%3DT.%26aulast%3DZaman%26aufirst%3DA.%26aulast%3DOlivas%26aufirst%3DV.%26aulast%3DMcCoach%26aufirst%3DC.%26aulast%3DBlakely%26aufirst%3DC.%2BM.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DKiss%26aufirst%3DG.%26aulast%3DKoltun%26aufirst%3DE.%2BS.%26aulast%3DGill%26aufirst%3DA.%2BL.%26aulast%3DSingh%26aufirst%3DM.%26aulast%3DGoldsmith%26aufirst%3DM.%2BA.%26aulast%3DSmith%26aufirst%3DJ.%2BA.%2BM.%26aulast%3DBivona%26aufirst%3DT.%2BG.%26atitle%3DRAS%2520Nucleotide%2520Cycling%2520Underlies%2520the%2520SHP2%2520Phosphatase%2520Dependence%2520of%2520Mutant%2520BRAF-%252C%2520NF1-%2520and%2520RAS-Driven%2520Cancers%26jtitle%3DNat.%2520Cell%2520Biol.%26date%3D2018%26volume%3D20%26spage%3D1064%26doi%3D10.1038%2Fs41556-018-0169-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit37k"><span><span class="NLM_label">(k) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Zou, H.</span>; <span class="NLM_string-name">Li, Z.</span>; <span class="NLM_string-name">Wang, Y.</span>; <span class="NLM_string-name">Yu, J.</span>; <span class="NLM_string-name">Zhu, W.</span></span> <span> </span><span class="NLM_article-title">Pyrimidine and Five-membered Nitrogen Heterocycle Derivative, Preparation Method Therefor, and Medical Uses Thereof</span>. Patent <span class="NLM_patent">WO2020108590</span>, <span class="NLM_year">2020</span> (Tuojie Biotech Co., Ltd.).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=H.+Zou&author=Z.+Li&author=Y.+Wang&author=J.+Yu&author=W.+Zhu&title=Pyrimidine+and+Five-membered+Nitrogen+Heterocycle+Derivative%2C+Preparation+Method+Therefor%2C+and+Medical+Uses+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37k&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DZou%26aufirst%3DH.%26atitle%3DPyrimidine%2520and%2520Five-membered%2520Nitrogen%2520Heterocycle%2520Derivative%252C%2520Preparation%2520Method%2520Therefor%252C%2520and%2520Medical%2520Uses%2520Thereof%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit37l"><span><span class="NLM_label">(l) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J.</span>; <span class="NLM_string-name">Babiss, L. E.</span></span> <span> </span><span class="NLM_article-title">SHP2 Inhibitors and Uses Thereof</span>. Patent <span class="NLM_patent">WO2019182960</span>, <span class="NLM_year">2019</span> (Synblia Therapeutics, Inc.).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=J.+Xie&author=L.+E.+Babiss&title=SHP2+Inhibitors+and+Uses+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37l&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DXie%26aufirst%3DJ.%26atitle%3DSHP2%2520Inhibitors%2520and%2520Uses%2520Thereof%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit37m"><span><span class="NLM_label">(m) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Zou, B.</span>; <span class="NLM_string-name">Fu, X.</span>; <span class="NLM_string-name">Zhang, R.</span>; <span class="NLM_string-name">Ma, S.</span>; <span class="NLM_string-name">Xu, S.</span>; <span class="NLM_string-name">Fu, W.</span>; <span class="NLM_string-name">Liu, L.</span></span> <span> </span><span class="NLM_article-title">Pyrimidine-fused Cyclic Compound, Preparation Method Therefor, and Application Thereof</span>. Patent <span class="NLM_patent">WO2019158019</span>, <span class="NLM_year">2019</span> (Shanghai Blueray BioPharma Co. Ltd.).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=B.+Zou&author=X.+Fu&author=R.+Zhang&author=S.+Ma&author=S.+Xu&author=W.+Fu&author=L.+Liu&title=Pyrimidine-fused+Cyclic+Compound%2C+Preparation+Method+Therefor%2C+and+Application+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37m&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DZou%26aufirst%3DB.%26atitle%3DPyrimidine-fused%2520Cyclic%2520Compound%252C%2520Preparation%2520Method%2520Therefor%252C%2520and%2520Application%2520Thereof%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit37n"><span><span class="NLM_label">(n) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, C. N.</span>; <span class="NLM_string-name">Buck, I. M.</span>; <span class="NLM_string-name">Chessari, G.</span>; <span class="NLM_string-name">Day, J. E. H.</span>; <span class="NLM_string-name">Fujiwara, H.</span>; <span class="NLM_string-name">Hamlett, C. C. F.</span>; <span class="NLM_string-name">Hiscock, S. D.</span>; <span class="NLM_string-name">Holvey, R. S.</span>; <span class="NLM_string-name">Howard, S.</span>; <span class="NLM_string-name">Liebeschuetz, J. W.</span>; <span class="NLM_string-name">Palmer, N. J.</span>; <span class="NLM_string-name">St Denis, J. D.</span>; <span class="NLM_string-name">Twigg, D. G.</span>; <span class="NLM_string-name">Woodehead, A. J.</span></span> <span> </span><span class="NLM_article-title">Pharmaceutical Compounds</span>. Patent <span class="NLM_patent">WO2019167000</span>, <span class="NLM_year">2019</span> (Otsuka Pharmaceutical Co. Ltd., Taiho Pharmaceutical Co. Ltd.).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=C.+N.+Johnson&author=I.+M.+Buck&author=G.+Chessari&author=J.+E.+H.+Day&author=H.+Fujiwara&author=C.+C.+F.+Hamlett&author=S.+D.+Hiscock&author=R.+S.+Holvey&author=S.+Howard&author=J.+W.+Liebeschuetz&author=N.+J.+Palmer&author=J.+D.+St+Denis&author=D.+G.+Twigg&author=A.+J.+Woodehead&title=Pharmaceutical+Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37n&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DC.%2BN.%26atitle%3DPharmaceutical%2520Compounds%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit37o"><span><span class="NLM_label">(o) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Shimamura, T.</span>; <span class="NLM_string-name">Kato, R.</span>; <span class="NLM_string-name">Miura, R.</span>; <span class="NLM_string-name">Mita, T.</span>; <span class="NLM_string-name">Ogawa, T.</span>; <span class="NLM_string-name">Sagara, Y.</span>; <span class="NLM_string-name">Johnson, C. N.</span>; <span class="NLM_string-name">Howard, S.</span>; <span class="NLM_string-name">Day, J. E. H.</span>; <span class="NLM_string-name">St Denis, J. D.</span>; <span class="NLM_string-name">Liebeschuetz, J. W.</span></span> <span> </span><span class="NLM_article-title">Heterocyclic Compounds for Inhibiting the Activity of SHP2</span>. Patent <span class="NLM_patent">WO2020022323</span>, <span class="NLM_year">2019</span> (Otsuka Pharmaceutical Co. Ltd., Taiho Pharmaceutical Co. Ltd.).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=T.+Shimamura&author=R.+Kato&author=R.+Miura&author=T.+Mita&author=T.+Ogawa&author=Y.+Sagara&author=C.+N.+Johnson&author=S.+Howard&author=J.+E.+H.+Day&author=J.+D.+St+Denis&author=J.+W.+Liebeschuetz&title=Heterocyclic+Compounds+for+Inhibiting+the+Activity+of+SHP2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37o&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DShimamura%26aufirst%3DT.%26atitle%3DHeterocyclic%2520Compounds%2520for%2520Inhibiting%2520the%2520Activity%2520of%2520SHP2%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit37p"><span><span class="NLM_label">(p) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Fu, J.</span>; <span class="NLM_string-name">Lou, Y.</span>; <span class="NLM_string-name">He, Y.</span></span> <span> </span><span class="NLM_article-title">Fused Tricyclic Ring Derivatives as SRC Homology-2 Phosphatase Inhibitors</span>. Patent <span class="NLM_patent">WO2020061103</span>, <span class="NLM_year">2019</span> (Nikang Therapeutics, Inc.).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=J.+Fu&author=Y.+Lou&author=Y.+He&title=Fused+Tricyclic+Ring+Derivatives+as+SRC+Homology-2+Phosphatase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37p&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFu%26aufirst%3DJ.%26atitle%3DFused%2520Tricyclic%2520Ring%2520Derivatives%2520as%2520SRC%2520Homology-2%2520Phosphatase%2520Inhibitors%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit37q"><span><span class="NLM_label">(q) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Volkmann, R.</span>; <span class="NLM_string-name">Marfat, A.</span>; <span class="NLM_string-name">Nelson, F.</span>; <span class="NLM_string-name">Zagouras, P.</span></span> <span> </span><span class="NLM_article-title">Octahydrocyclopenta[c]pyrrole Allosteric Inhibitors of SHP2</span>. Patent <span class="NLM_patent">WO2019051469</span>, <span class="NLM_year">2018</span> (Krouzon Pharmaceuticals, Inc.).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=R.+Volkmann&author=A.+Marfat&author=F.+Nelson&author=P.+Zagouras&title=Octahydrocyclopenta%5Bc%5Dpyrrole+Allosteric+Inhibitors+of+SHP2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37q&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DVolkmann%26aufirst%3DR.%26atitle%3DOctahydrocyclopenta%255Bc%255Dpyrrole%2520Allosteric%2520Inhibitors%2520of%2520SHP2%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">LaMarche, M. J.</span>; <span class="NLM_string-name">Chen, J.</span></span> Unpublished results.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=LaMarche%2C+M.+J.%3B+Chen%2C+J.+Unpublished+results."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dunpublished%26sid%3Dliteratum%253Aachs%26aulast%3DLaMarche%26aufirst%3DM.%2BJ." title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fodor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Argintaru, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glick, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koenig, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaRochelle, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNeill, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majumdar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishiguchi, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paris, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quinn, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramsey, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sendzik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shultz, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stams, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blacklow, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acker, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaMarche, M. J.</span></span> <span> </span><span class="NLM_article-title">Dual Allosteric Inhibition of SHP2 Phosphatase</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">647</span>– <span class="NLM_lpage">656</span>, <span class="refDoi"> DOI: 10.1021/acschembio.7b00980</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.7b00980" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjslOgtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=647-656&author=M.+Fodorauthor=E.+Priceauthor=P.+Wangauthor=H.+Luauthor=A.+Argintaruauthor=Z.+Chenauthor=M.+Glickauthor=H.+Haoauthor=M.+Katoauthor=R.+Koenigauthor=J.+R.+LaRochelleauthor=G.+Liuauthor=E.+McNeillauthor=D.+Majumdarauthor=G.+A.+Nishiguchiauthor=L.+B.+Perezauthor=G.+Parisauthor=C.+M.+Quinnauthor=T.+Ramseyauthor=M.+Sendzikauthor=M.+D.+Shultzauthor=S.+L.+Williamsauthor=T.+Stamsauthor=S.+C.+Blacklowauthor=M.+G.+Ackerauthor=M.+J.+LaMarche&title=Dual+Allosteric+Inhibition+of+SHP2+Phosphatase&doi=10.1021%2Facschembio.7b00980"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Dual allosteric inhibition of SHP2 phosphatase</span></div><div class="casAuthors">Fodor, Michelle; Price, Edmund; Wang, Ping; Lu, Hengyu; Argintaru, Andreea; Chen, Zhouliang; Glick, Meir; Hao, Huai-Xiang; Kato, Mitsunori; Koenig, Robert; La Rochelle, Jonathan R.; Liu, Gang; McNeill, Eric; Majumdar, Dyuti; Nishiguchi, Gisele A.; Perez, Lawrence B.; Paris, Gregory; Quinn, Christopher M.; Ramsey, Timothy; Sendzik, Martin; Shultz, Michael David; Williams, Sarah L.; Stams, Travis; Blacklow, Stephen C.; Acker, Michael G.; LaMarche, Matthew J.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">647-656</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">SHP2 is a cytoplasmic protein tyrosine phosphatase encoded by the PTPN11 gene and is involved in cell proliferation, differentiation, and survival.  Recently, we reported an allosteric mechanism of inhibition that stabilizes the auto-inhibited conformation of SHP2.  SHP099 (1) was identified and characterized as a moderately potent, orally bioavailable, allosteric small mol. inhibitor, which binds to a tunnel-like pocket formed by the confluence of three domains of SHP2.  In this report, we describe further screening strategies that enabled the identification of a second, distinct small mol. allosteric site.  SHP244 (2) was identified as a weak inhibitor of SHP2 with modest thermal stabilization of the enzyme.  X-ray crystallog. revealed that 2 binds and stabilizes the inactive, closed conformation of SHP2, at a distinct, previously unexplored binding site-a cleft formed at the interface of the N-terminal SH2 and PTP domains.  Derivatization of 2 using structure-based design resulted in an increase in SHP2 thermal stabilization, biochem. inhibition, and subsequent MAPK pathway modulation.  Downregulation of DUSP6 mRNA, a downstream MAPK pathway marker, was obsd. in KYSE-520 cancer cells.  Remarkably, simultaneous occupation of both allosteric sites by 1 and 2 was possible, as characterized by cooperative biochem. inhibition expts. and X-ray crystallog.  Combining an allosteric site 1 inhibitor with an allosteric site 2 inhibitor led to enhanced pharmacol. pathway inhibition in cells.  This work illustrates a rare example of dual allosteric targeted protein inhibition, demonstrates screening methodol. and tactics to identify allosteric inhibitors, and enables further interrogation of SHP2 in cancer and related pathologies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWdw7pTS6sOLVg90H21EOLACvtfcHk0lgIb5v1Gc6ZDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjslOgtg%253D%253D&md5=8e4de4c353b9fc196c81e1cb51e367df</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Facschembio.7b00980&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.7b00980%26sid%3Dliteratum%253Aachs%26aulast%3DFodor%26aufirst%3DM.%26aulast%3DPrice%26aufirst%3DE.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DLu%26aufirst%3DH.%26aulast%3DArgintaru%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DGlick%26aufirst%3DM.%26aulast%3DHao%26aufirst%3DH.%26aulast%3DKato%26aufirst%3DM.%26aulast%3DKoenig%26aufirst%3DR.%26aulast%3DLaRochelle%26aufirst%3DJ.%2BR.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DMcNeill%26aufirst%3DE.%26aulast%3DMajumdar%26aufirst%3DD.%26aulast%3DNishiguchi%26aufirst%3DG.%2BA.%26aulast%3DPerez%26aufirst%3DL.%2BB.%26aulast%3DParis%26aufirst%3DG.%26aulast%3DQuinn%26aufirst%3DC.%2BM.%26aulast%3DRamsey%26aufirst%3DT.%26aulast%3DSendzik%26aufirst%3DM.%26aulast%3DShultz%26aufirst%3DM.%2BD.%26aulast%3DWilliams%26aufirst%3DS.%2BL.%26aulast%3DStams%26aufirst%3DT.%26aulast%3DBlacklow%26aufirst%3DS.%2BC.%26aulast%3DAcker%26aufirst%3DM.%2BG.%26aulast%3DLaMarche%26aufirst%3DM.%2BJ.%26atitle%3DDual%2520Allosteric%2520Inhibition%2520of%2520SHP2%2520Phosphatase%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2018%26volume%3D13%26spage%3D647%26epage%3D656%26doi%3D10.1021%2Facschembio.7b00980" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><a href="https://Clinicaltrials.gov" class="extLink">https://Clinicaltrials.gov</a> (accessed Aug 19, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2FClinicaltrials.gov+%28accessed+Aug+19%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kabsch, W.</span></span> <span> </span><span class="NLM_article-title">XDS</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>D66</i></span>,  <span class="NLM_fpage">125</span>– <span class="NLM_lpage">132</span>, <span class="refDoi"> DOI: 10.1107/S0907444909047337</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=10.1107%2FS0907444909047337" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1SisLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=D66&publication_year=2010&pages=125-132&author=W.+Kabsch&title=XDS&doi=10.1107%2FS0907444909047337"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Software XDS for image rotation, recognition and crystal symmetry assignment</span></div><div class="casAuthors">Kabsch, Wolfgang</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">125-132</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">The usage and control of recent modifications of the program package XDS for the processing of rotation images are described in the context of previous versions.  New features include automatic detn. of spot size and reflecting range and recognition and assignment of crystal symmetry.  Moreover, the limitations of earlier package versions on the no. of correction/scaling factors and the representation of pixel contents have been removed.  Large program parts have been restructured for parallel processing so that the quality and completeness of collected data can be assessed soon after measurement.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpv5AyUw00DYbVg90H21EOLACvtfcHk0lj69k7oMUYrOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1SisLc%253D&md5=1aa9a38aeb3ce95af4ffb7d8b8a142bd</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1107%2FS0907444909047337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444909047337%26sid%3Dliteratum%253Aachs%26aulast%3DKabsch%26aufirst%3DW.%26atitle%3DXDS%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2010%26volume%3DD66%26spage%3D125%26epage%3D132%26doi%3D10.1107%2FS0907444909047337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bricogne, G.</span>; <span class="NLM_string-name">Blanc, E.</span>; <span class="NLM_string-name">Brandl, M.</span>; <span class="NLM_string-name">Flensburg, C.</span>; <span class="NLM_string-name">Keller, P.</span>; <span class="NLM_string-name">Paciorek, W.</span>; <span class="NLM_string-name">Roversi, P.</span>; <span class="NLM_string-name">Smart, O. S.</span>; <span class="NLM_string-name">Vonrhein, C.</span>; <span class="NLM_string-name">Womack, T. O.</span></span> <i>BUSTER</i>, version <span class="NLM_edition">2.8.0</span>; <span class="NLM_publisher-name">Global Phasing Ltd.</span>, <span class="NLM_publisher-loc">Cambridge, U.K.</span>, <span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=G.+Bricogne&author=E.+Blanc&author=M.+Brandl&author=C.+Flensburg&author=P.+Keller&author=W.+Paciorek&author=P.+Roversi&author=O.+S.+Smart&author=C.+Vonrhein&author=T.+O.+Womack&title=BUSTER"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26aulast%3DBricogne%26aufirst%3DG.%26jtitle%3DBUSTER%26pub%3DGlobal%2520Phasing%2520Ltd%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Emsley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lohkamp, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowtan, K.</span></span> <span> </span><span class="NLM_article-title">Features and Development of Coot</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>D66</i></span>,  <span class="NLM_fpage">486</span>– <span class="NLM_lpage">501</span>, <span class="refDoi"> DOI: 10.1107/S0907444910007493</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=10.1107%2FS0907444910007493" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;key=1%3ACAS%3A528%3ADC%252BC3cXksFKisb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=D66&publication_year=2010&pages=486-501&author=P.+Emsleyauthor=B.+Lohkampauthor=W.+G.+Scottauthor=K.+Cowtan&title=Features+and+Development+of+Coot&doi=10.1107%2FS0907444910007493"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Features and development of Coot</span></div><div class="casAuthors">Emsley, P.; Lohkamp, B.; Scott, W. G.; Cowtan, K.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">486-501</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Coot is a mol.-graphics application for model building and validation of biol. macromols.  The program displays electron-d. maps and at. models and allows model manipulations such as idealization, real-space refinement, manual rotation/translation, rigid-body fitting, ligand search, solvation, mutations, rotamers and Ramachandran idealization.  Furthermore, tools are provided for model validation as well as interfaces to external programs for refinement, validation and graphics.  The software is designed to be easy to learn for novice users, which is achieved by ensuring that tools for common tasks are 'discoverable' through familiar user-interface elements (menus and toolbars) or by intuitive behavior (mouse controls).  Recent developments have focused on providing tools for expert users, with customisable key bindings, extensions and an extensive scripting interface.  The software is under rapid development, but has already achieved very widespread use within the crystallog. community.  The current state of the software is presented, with a description of the facilities available and of some of the underlying methods employed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAKBKszbqb_7Vg90H21EOLACvtfcHk0lj69k7oMUYrOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXksFKisb8%253D&md5=67262cbfc60004de5ef962d5c043c910</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1107%2FS0907444910007493&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444910007493%26sid%3Dliteratum%253Aachs%26aulast%3DEmsley%26aufirst%3DP.%26aulast%3DLohkamp%26aufirst%3DB.%26aulast%3DScott%26aufirst%3DW.%2BG.%26aulast%3DCowtan%26aufirst%3DK.%26atitle%3DFeatures%2520and%2520Development%2520of%2520Coot%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2010%26volume%3DD66%26spage%3D486%26epage%3D501%26doi%3D10.1107%2FS0907444910007493" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EHP" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EHP','PDB','5EHP'); return false;">PDB: 5EHP</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6MDD" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6MDD','PDB','6MDD'); return false;">PDB: 6MDD</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7JVN" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7JVN','PDB','7JVN'); return false;">PDB: 7JVN</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7JVM" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7JVM','PDB','7JVM'); return false;">PDB: 7JVM</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2SHP" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2SHP','PDB','2SHP'); return false;">PDB: 2SHP</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i34"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01170">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_28238"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01170?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01170</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Selectivity data, histopathology, X-ray data tables, and chemistry experimental details (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01170/suppl_file/jm0c01170_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings and some data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01170/suppl_file/jm0c01170_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01170/suppl_file/jm0c01170_si_001.pdf">jm0c01170_si_001.pdf (1.65 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01170/suppl_file/jm0c01170_si_002.csv">jm0c01170_si_002.csv (1.7 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">PDB codes are <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7JVM">7JVM</a> for SHP2 in complex with compound <b>1</b> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7JVN">7JVN</a> for SHP2 in complex with compound <b>24</b>. Authors will release the atomic coordinates data upon article publication.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c01170&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c01170%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-22" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c01170" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                5MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-b425991822a79ada59b3.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-fb88834b824b41b135ad.js"></script>

<script type="text/javascript" src="/wro/ke1q~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"66798436dd2ad1c3","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.6.0","si":10}'></script>
</body>
</html>
